<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/220956-pyrrolopyridazine-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 10:10:24 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 220956:PYRROLOPYRIDAZINE DERIVATIVES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PYRROLOPYRIDAZINE DERIVATIVES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to compound of the formula (I) or its salt, in which R&lt;SUP&gt;1&lt;/SUP&gt; R&lt;SUP&gt;2&lt;/SUP&gt;, R&lt;SUP&gt;3&lt;/SUP&gt; and R&lt;SUP&gt;4&lt;/SUP&gt; are as defined in the description, and to the process for their preparation.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
This invention relates to new pyrrolopyridazine derivatives and pharmaceuticalLY acceptable salts thereof which inhibit enzymatic activity of phosphodiesterase IV (PDE IV) and production of tumor necrosis factor-α (TNF-a).<br>
BACKGROUND ART<br>
Cyclic adenosine monophosphate (adenosine 3, 5'-cyclic monophosphate, "cAMP" or "cyclic AMP") is known as an intracellular second messenger, which is intermediated by a first messenger (hormone, neurotransmitter or autacoid) and the cellar responses.   The first messenger stimulates the enzyme responsible for synthesis of cAMP. and then the cAMP intervenes in many functions such as metabolic, contractile or secretory. The effect of cAMP end when it is degraded by cyclic nucleotide phosphodiesterases, in particular phosphosieslerase-4 (PDE4 or PDE-IV), which is specific for cAMP. PDE-IV have been identified in many tissues including the central nervous systems, the heart, vascular smooth muscle, airway smooth muscle, myeloid lines, lymphoid, and the like. Evaluation of cAMP level by using the PDE-IV inhibitor would produce beneficial effect on inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells.<br>
A major concern with the use of PDE-IV inhibitors is the side effect of emesis which has been observed for several candidate compounds as described in CBumouf et al, (Ann. Rep. In Med. Chem., 33:91-109(1998)). Burnouf describe the wide variation of the severity of the undesirable side effects exhibited by various compounds.<br>
Some condensed heterocyclic derivatives having the inhibitory activity of PDE-IV have been known, for example in WO03/016279, WO03/018579, WO03/000679 and the like. However, there remains a need for novel compounds that inhibit PDE-IV with minimal side effects. Although some pyrrolopyridazine derivatives having the inhibitory activity of hydroxymethylglutaryl (HMG) CoA reductase have been known, for example, in WO91/18903, pyrrolopyridazine derivatives having the inhibitory activity of PDE-IV have not been known.<br><br>
DISCLOSURE OF INVENTION<br>
This invention relates to new pyrrolopyridazine derivatives.<br>
The compounds of this invention inhibit cAMP phosphodiesterase enzyme  m particular phosphodiesterase-4 enzyme, and also inhibit the production of tumor nu factor-α (TNF-α), a serum glycoprotein.<br>
Accordingly, one object of this invention is to provide the new and useful pyrrolopyridazine derivatives and pharmaceutically acceptable salts thereof which possess a strong phosphodicstcrase-4 (PDE lV)-inhibitory activity and a strong in activity on the production of tumor necrosis factor (TNF).<br>
Another object of this invention is to provide processes for preparation pyrrolopyridazine derivatives and salts thereof.<br>
A further object of this invention is to provide a pharmaceutical compos comprising said pyrrolopyridazine derivatives or a pharmaceutically acceptable sal' thereof.<br>
Still further object of this invention is to provide a use of said pyrrolopyridazine derivatives or a pharmaceutically acceptable sail as a medicament for prophylactic and therapeutic treatment of PDE-IV and TNI mediated diseases such as chronic inflammatory diseases, specific autoimmune  ,r es, sepsis-induced organ injury, and the like in human being and animals.<br>
The object pyrrolopyridazine derivatives of the present invention arecan be represented by the following general formula (I):<br><br><br><br>
is optionally interrupted by amino or sulfonyl and optionally fuse with benzene ring, and also is optionally substituted by the group consisting of lower alky], hydroxy, oxo and lower alkoxy,<br><br><br>
Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).<br>
The "prodrug" means the derivatives of the object compound (I) having a chemically or metabolically degradable group, which became pharmaceutically active after chemo- or biotransformation.<br><br><br>
in which<br>
R1 is    (1) carboxy or esterified carboxy (more preferably, ethoxycarbonyl),<br>
(2)	-CONR5R6 [whei ein R' and R1 each independently represents lower alky], or alternatively R5 and R, together with nitrogen atom to which they are attached represents saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s).] (more preferably, dimethylcarbamoyl or 1-pyrrolidinylcarbonyl),<br>
(3)	hydroxy or lower alkoxy,<br>
(4)	amino, cyclo(lower)alkylamino, or mono- or di(Iower)alkylamino optionally substituted by lower alkoxy,<br>
(5)	trihalo(lower)alkyl,<br>
(6)	trihalo(lower)alkylsulfonyloxy or arylsulfonylarnino,<br>
(7)	lower alkyl optionally substituted by (i) halogen; (ii) carboxy; (iii) protected carboxy; (iv) cyano; (v)'carbamoyl; (vi) -OCONR15R16) [wherein R15 and R16 each independently represents hydrogen, aryl or lower alkyl optionally substituted by aryl, or R15 and R16, together with the nitrogen atom to which they are attached, represents saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom.] (more preferably, dimethylcarbamoyloxy, methyl-phenylcarbamoyloxy, morpholinylcarbonyloxy orpyrrolidinylcarnbonyloxy); (vii) lower alkylthio; (viii) lower alkylsulfonyl; (ix) lower alkylsulfonyloxy; (x) lower alkylsulfonylamino; (xi) mono- or di(lower)alkylamino optionally substituted by hydroxy, lower alkoxy, aryloxy, or substituted or unsubstituted aryl; (xii) amino; (xiii) acylamino (more preferably, lower alkanoylamino such as acetylamino, aroylamino such as benzoylamino, or heterocycliccarbonylamino such as pyrazinylcarbonylamino); (xiv) protected amino such as phthalimide, benzylamino or lower alkoxycarbonylamino; (xv) hydorxy; (xvi) acyloxy (more preferably, lower alkanoyloxy such as acetyloxy); (xvii) cyclo(lower)alkyloxy; (xviii) aryloxy; (xix) substituted or unsubstituted aryl (more preferably, phenyl); (xx) saturated or unsaturated 5- or 6-membered heteromonocyclic group containing 1 to<br><br>
3 nitrogen atom(s) and also optionally containing oxygen atom or sulfur atom (more preferably, pipcrazinyl, morpholinyl, oxazolidinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl or iriazolyl) optionally substituted by lower alkyl, hydroxy(lower)alkyl, aryl or oxo; or (xxi) lower alkoxy optionally substituted by carboxy, protected carboxy, hydroxy, protected hydroxy, lower alkoxy, cyclo(lower)alkyl, substituted or unsubstituted aryl (more preferably, phenyl optionally substituted by cyano, carboxy, protected carboxy or carbamoyl), saturated or unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) (more preferably, pyridinyl, pyrazinyl or piperazinyl) optionally substituted by lower alky], or -CONR13R14 [wherein R13 and R14 each independently represents hydrogen or lower alkyl optionally substituted by aryl, or R13 and Ri4, together with the nitrogen atom to which they are attached, represents saturated 5- or 6-rnembered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom.] (more preferably, carbamoyl, metbylcarbamoyl, benzylcarbamoyl or morpholinylcarbonyl),<br>
(8)	aryl (more preferably, phenyl) optionally substituted by the<br>
substituent(s) selected from the group consisting of halogen, or<br>
(9)	saturated or unsaturated 5- or 6-membered heteromonocyclic group<br>
(more preferably, pyrrolidinyl, pyrrolyl, oxazolyl, isooxazolyl,<br><br><br>
R7 is<br>
(1)	hydrogen,<br>
(2)	aryl (more preferably, phenyl) optionally substituted by lower alkoxy,<br>
(3)	unsaturated heteromonocyclic group containing 1 to 2 nitrogen atom(s).<br>
(more preferably, pyridinyl),<br>
(4)	carboxy, esterified carboxy (more preferably, lower alkoxycarbonyl) or -<br>
CONR10Rn [wherein R10 and R11 each independently represents hydrogen,<br>
lower alkylsulfonyh unsaturated heteromonocyclic group containing 1 to 2<br>
nitrogen atom(s) such as pyridinyl or lower alkyl optionally substituted by<br>
hydroxy, alkoxy, carboxy, protected carboxy, sulfo or -R17, or alternatively<br>
R10 and R11, together with the nitrogen atom to which they are attached,<br>
represents saturated 5- or 6-membered heteromonocyclic group containing 1<br>
to 2 nitrogen atom(s) and also optionally containing oxygen atom such as<br>
morpholinyl.],<br>
(5)	acyl (e.g. lower alkanoyl such as formyl or acetyl, and heterocycliccarbonyl<br>
such as pyridinylcarbonyl) or halocarbonyl,<br>
(6)	cyano,<br>
(7)	amino, protected amino such as lower alkoxycarbonylamino, or mono- or di(lower)alkylamino,<br>
(8)	hydroxy, aryloxy, acyloxy or lower alkoxy optionally substituted by hydroxy<br>
or acyloxy (e.g. lower alkanoyloxy),<br>
(9)	lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl, or<br>
(10)	-O-R12,<br>
or<br>
R and R2are combined together to form lower alkylene or lower alkenylen group which is optionally interrupted by amino or sulfonyl and also is optionally substituted by the group consisting of lower alkyl, hydroxy, oxo and lower alkoxy,<br><br><br><br>
R3 is (1) aryl (more preferably, phenyl or naphthyl) optionally substituted by at least one substituent(s) selected from the group consisting of (i) halogen, (ii) carboxy, (iii) protected carboxy, (iv) cyano, (v) -CONR!5R16 [wherein R15 and R16 each independently represents hydrogen, lower alkyl optionally substituted by hydroxy], (vi) lower alkyl, (vii) cyclo(lower)alkyl, (viii) hydroxy(lower)alkyl, (ix) lower alkoxy, (x) trihalo(lower)alkyl, (xi) unsaturated 5- or 6-membered heterornonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 2 nitrogen atom(s) such as oxazolyl, (xii) lower alkylsulfonyl, (xiii) nitro, (xiv) sulfamoyl, and (xv) protected sulfamoyl; or (2) heterocyclic group selected from the group consisting of pyridinyl, pyrazinyl, oxazolyl, isooxazolyl, furanyl, thienyl, quinolyl, benzofuranyl and benzothienyl, wherein said heterocyclic group is optionally substituted by at least one substituent(s) selected from the group consisting of (i) lower alkyl, (ii)<br><br>
cyclo()ower)alkyl, (iii) lower alkoxy, (iv) acyl such as lower alkanoyl, (v) amino, (vi) mono- or di(lowcr)alky]amino, (vii) protected amino such as lower alkoxycarbonylamino, (viii) cyano, (ix) carboxy, (x) protected carboxy such as ethoxycarbonyl or methoxycarbonyl, (xi) -CONR15R16 [wherein RI5andR16 each independently represents hydrogen, lower alkyl optionally substituted by hydroxy], (xii) lower alkenyl optionally substituted by lower alkoxy, (xiii) halogen, (xiv) lower alkylthio and (xv) hydroxy; R4 is hydrogen, halogen, cyano, carbamoyl, lower alkanoyl, thiocyanate, lower alkylthio, lower alkenyl, hydroxyl(Jower)alkyl, trihalo(lower)alkyl or lower alkyl, and<br>
1 *)	1 "7<br>
R " and R   are each independently a group derived from protected or unprotected sugar<br>
such as galactose by removal of the hydroxy group therefrom, or a pharmaceutically acceptable salt thereof.<br>
More preferred compounds of formula (I) are those in which: R1 is    (1) mono- or di(lower)aIkylamino,<br>
(2)	aryl such as phenyl,<br>
(3)	satulated or unsaturated 5 to 6 membered heteromonocyclic group containing 1 to 2 hetero atom(s) selected from nitrogen, oxygen or sulfur atom(s) (more preferably, pyrrolidinyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, furanyl, thienyl, pyridinyl,elc), or<br>
(4)	lower alkyl optionally substituted by lower alkoxy or saturated 5- or 6-rnembered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom (more preferably, piperazinyl or morpholinyl), wherein lower alkoxy is optionally substituted by cyclo(lower)alkyl or unsaturated 5 to 6 membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) (more preferably, pyridinyl),<br>
R2 is R7 or -A2-R7, wherein<br>
A2 is -(CH,)n- or -(CH=CH)m- [wherein n is integer which may range 2 to 6 and<br>
m is integer of 1 or 2, and<br>
R7 is hydrogen, lower alkylsulfonyl, carboxy, protected carboxy or unsaturated 5<br>
to 6 membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) (more<br>
preferably, pyridinyl), R3 is (1) aryl optionally substituted by lower alkyl, cyclo(lower)alkyl, halogen, cyano or<br><br>
carbamoyl; or (2) unsaturated condensed heterocyclic group containing 1 to 2 nitrogen atom(s) (more preferably, quinolinyl); or unsaturated 5 to 6 membered heteromonocyclic group containing at least one nitrogen atom(s) (more preferably, 3-pyridinyl and 4-pyridinyl) substituted by lower alkyl, cyclo(lower)alky! or halogen, and R4 is lower alkyl.<br>
Most preferred compounds of formula (I) are those in which: R1 is phenyl, satulated or unsaturated 5 to 6 membered heteromonocyclic group<br>
containing 1 to 2 hetero atom(s) selected from nitrogen, oxygen or sulfur atom(s) (more preferably, pyrrolyl, isooxazolyl, furanyl, thienyl, etc.) or lower alkyl optionally substituted by lower alkoxy or saturated or saturated 5- or 6-rnembered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom (more preferably, piperazinyl or morpholinyl), wherein lower alkoxy is optionally substituted by cyclo(lower)alkyl or unsaturated 5 to 6 membered heteromonocyclic group containing at least one nitrogen atom(s) (more preferably, pyridinyl),<br>
	"7	"7<br>
R2 is -(CH2)n-R , wherein n is integer which may range 2 to 5, and R is carboxy or protected carboxy,<br>
R3 is (1) phenyl optionally substituted by lower alkyl, cyclo(lower)alkyl, lower alkoxy, halogen, cyano or carbamoyl; or (2) unsaturated 5 to 6 membered heteromonocyclic group containing at least one nitrogen atom(s) (more preferably, 3-pyridinyl and 4-pyridinyl) substituted by lower alkyl, cyclo(lower)alkyl, lower<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Both of the above tautomeric isomers are included within the scope of the present invention, and in the present specification and claims, however, the object compound (I) is represented for convenience' sake by one expression of the possible tautomeric forms of pyrrolopyridazine ring.<br>
In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.<br>
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.<br>
Suitable "lower alkyl" and "lower alkyl moiety" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-penlyl, hexyl, and the like, and in which more preferable example may be C1-C4 alkyl.<br>
Suitable "lower alkenyl" may include vinyl(ethenyl), l-(or 2-)propenyl, l-(or 2- or 3-)butenyl, l-(or 2- or 3- or4-)pentenyl, l-(or 2- or 3- or 4-or 5-)hexenyl, 1-methylvinyl, 1-ethylvinyl, l-(or 2-)rnethy]-l-(or 2-)propenyl, l-(or 2-)ethyl-1-(or 2-)propenyl, l-(or 2-or 3-)rnethyI-l-(or 2- or 3-)butenyl, and the like, in which more preferable example may be C2-C4 alkenyl.<br>
Suitable "lower alkynyl" may include ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, ] or 2 or 3-bulynyl, 1 or 2 or 3 or4-pentynyl, 1 or 2 or 3 or 4 or 5-hexynyl, and the like.<br><br>
Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, ethylethylene, propylene, and the like, in which more preferable example may be C1-C4 alkylene and the most preferable one may be methylene.<br>
Example of hydroxy(C1-C2)alkylene is hydroxymethylene, (hydroxymethyl)methylene or l-(or 2-)hydroxyethylene.<br>
Suitable "lower alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy,t-pentyloxy, hexyloxy and the like.<br>
Suitable "halogen" and "halogen moiety" may include fluorine, bromine, chlorine and iodine.<br>
Suitable "trihalo(lower)alkyl" may include trichloromethyl, trifluoromethyl, trichloroethyl, tribromoethyl, and the like.<br>
Suitable "mono- or di(lower)alkylamino" may include amino group substituted by one or two lower alkyl such as methylamino, ethylamino, dimethylamino, and the like.<br>
Example of "mono- or di(lower)alkylamino substituted by lower alkoxy" may be methoxymetylamino,methoxyethylamino,methoxyethyl(methyl)amino, methoxyethyl(ethyl)amino,di(methoxyethyl)amino,ethoxymethylamino, ethoxyethylamino, and the like.<br>
Suitable "lower alkylthio" may include conventional ones such as methylthio, ethylthio, propylthio, butylthio, and the like.<br>
Suitable "lower alkylsulfinyl" may include conventional ones such as rnethylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, and the like.<br>
Suitable "lower alkylsulfonyl" may include conventional ones such as methylsulfonyl, ethylsulfonyl, propylsulfonyl,bytylsulfonyl, and the like.<br>
Suitable "trihalo(lower)alkylsulfonyloxy"may include sulfonyloxy group substituted by trihalo(lower)alkyl such as trifluoromethylsulfonyloxy, trifluoroethylsulfonyloxy, trichloromethylsulfonyloxy, and the like.<br>
Suitable "protected carboxy" and "protected carboxy moiety" may include esterified carboxy and the like.<br>
And suitable example of said ester may be the ones such as lower alkyl ester (e.g., methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, l-pentyl ester, hexyl ester, etc.); lower alkenyl ester (e.g., vinyl ester, allyl ester, etc.);<br><br>
lower alkyny] ester (e.g. elbynyl ester, propynyl ester, etc.);<br>
i<br>
lower alkoxy(lower)alkyl ester (e.g., methoxymelhyl ester, elhoxymethyl ester,<br>
isopropoxymethyl ester, 1-melhoxyethy] ester, 1-elhoxyethy) ester, etc.);<br>
lower alkylthio(lower)alkyl ester (e.g., methylthiometbyl ester, ethylthiomelhyl ester,<br>
ethyllhioethyl ester, isopropoxythiomethyl ester, etc.);<br>
mono(or di or lri)halo(lower)alkyl ester (e.g., 2-iodoethyl ester, 2,2,2-trichloroethyl ester,<br>
etc.);<br>
lower alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester, propionyloxymethyl ester,<br>
butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester,<br>
hexanoyloxymethyl ester, 1-acetoxyethyl ester, 2-acetoxyethyl ester, 2-propionyloxyethyl<br>
ester, etc.);<br>
lower alkoxycarbonyloxy(lower)alkyl ester (e.g., methoxycarbonyloxymethyl ester,<br>
ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, l-(or2-)-<br>
[methoxycarbonyloxy]ethyl ester, l-(or 2-)-[ethoxycarbonyloxy]ethyl ester, l-(or 2-)-<br>
[propoxycarbonyloxyjethyl ester, l-(or 2-)-[isopropoxycarbonyloxy]ethyl ester, etc.);<br>
lower alkanesuIfonyl(lower)alkyl ester (e.g., mesylmethyl ester, 2-mesylethyJ ester, etc.);<br>
lower alkoxycarbonyloxy(lower)alkyl ester (e.g., methoxycarbonyloxymethyl ester,<br>
ethoxycarbonyloxymethyl ester, propoxycarbonyloxymethyl ester, t-butoxycarbonyl-<br>
oxymethy] ester, l-(or 2-)methoxycarbonyloxyethyl ester, l-(or2-<br>
)ethoxycarbonyloxyethyl ester, l-(or 2-)-isopropoxycarbonyloxyethyl ester, etc.);<br>
phthalidylidene(lower)alkyl ester;<br>
(5-lower alkyl-2-oxo-l,3-dioxoI-4-yI)(lower)alkyl ester [e.g., (5-methyl-2-oxo-l,3-<br>
dioxol-4-yl)methyl ester, (5-ethyl-2-oxo-l,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-<br>
l,3-dioxol-4-yl)ethyl ester, etc.];<br>
mono(or di or tri)aryl(lower)alkyl ester, for example, mono(or di or<br>
tri)phenyl(lower)alkyl ester which may have one or more suitable substituent(s) (e.g.,<br>
benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester,<br>
benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyI ester, 4-<br>
hydroxy-3,5-di-t-butylbenzyl ester, etc.);<br>
aryl ester which may have one or more suitable substituent(s) such as substituted or<br>
unsubstituted phenyl ester (e.g., phenyl ester, tolyl ester, t-butylphenyl ester, xylyl ester,<br>
mesityl ester, cumenyl ester, 4-chlorophenyl ester, 4-methoxyphenyl ester, etc.);<br>
tri(lower)alkylsilyl ester (e.g. trimethylsilyl ester, triethylsilyl ester, etc.);<br><br>
tri(lowcr)alkyIsilyI(lower)alkyl ester (e.g. 2-lrimethylsilylethyl ester, etc.);<br>
and the like, in which more preferable example may be lower alkyl ester, i.e., lower<br>
alkoxycarbonyl (e.g. ethoxycarbonyl, etc.).<br>
The term "protected amino" means an amino group bonded to the amino-protecting group. Example of such amino-protectnig group include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, etc.); lower alkenyloxycarbonyl (e.g. vinyloxycarbonyl, allyloxycarbonyl, etc.); optionally substituted aryl(lower)alkoxycarbonyl (e.g. benzyloxycarbonyl, etc.); phthalimide; and the like. Further example of amino-protecting group are well-known in organic synthesis and are described by T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis," Second Edition, John Wiley and Sons, New York, N.Y., which is herein incorporated by reference.<br>
The term "protected sulfamoyl" means sulfamoyl group having the amino-protecting group mentioned above on the nitrogen atom. A preferred amino-protecting group is aryl(lower)alkoxycarbonyl (e.g. benzyloxycarbonyl, etc.); and the like.<br>
Suitable "acyl" and "acyl moiety" may include aliphatic acyl group, and acyl group containing an aromatic ring, which is referred to as aromatic acyl, or heterocyclic ring, which is referred to as heterocyclic acyl.<br>
Suitable example of said acyl may be illustrated as follows: Aliphatic acyl such as<br>
lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoy], decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoy], etc.); in which preferable "lower alkanoyl" may include straight or branched one such as formyl, acetyl, propionyl, butyryl, and the like, lower or higher alkenoyl (e.g., acryloyl, 2-(or 3-)-butenoyl, 2-(or 3- or 4-)pentenoyl, 2-(or<br>
3- or 4- or 5-)-bexenoyl, etc.); lower alkadienoyl (e.g., heptadienoyl, hexadienoyl, etc.); cyclo(lower)alkylcarbonyl (e.g., cyclopropylcarbonyl, cyclopenlylcarbonyl,<br>
cyclohexylcarbonyl, etc.); lower alkylglyoxyloyl (e.g., methylglyoxyloyl, ethylglyoxyloyl, propylglyoxyloyl, etc.); lower alkoxyglyoxyloyl (e.g., methoxyglyoxyloyl, ethoxyglyoxyloyl, propoxyglyoxyloyl,<br><br>
etc.);<br>
or the like;<br>
Aromatic acyl such as<br>
aroy] (e.g., benzoyl, toluoyl,naphthoyl,etc.);<br>
ar(lower)alkanoyl [e.g.,phenyI(lower)alkanoyl (e.g.,phenylacetyl, phenylpropanoyl,<br>
phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.),<br>
naphthyl(lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl,<br>
etc.), etc.]; ar(lower)alkenoyl [e.g., pheny](lower)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl,<br>
phenylmethacryloyl, phenylpenlenoyl, phenylhexenoyl, etc.), naphthy](lower)alkenoyl<br>
(e.g., naphthylpropenoyl, naphtbylbutenoyl, etc.), etc.]; aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.); heterocyclic acyl such as heterocycliccarbonyl; heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl,<br>
heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.); heterocyclic(lower)alkenoyl(e.g., heterocyclicpropenoyl,heterocyclicbutenoyl,<br>
heterocyclicpentenoy], heterocyclichexenoyl, etc.); heterocyclicglyoxyloyl; heterocyclicoxycarbonyl; or the like;<br>
in which suitable "heterocyclic moiety" may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like, as mentioned below and preferable "heterocyclic¬carbonyl" may include carbonyl group substituted by heterocyclic group as mentioned below such as pyrrolidinylcarbonyl, pyridinylcarbonyl, pyrazinylcarbonyl, and the like..<br>
Syitable "halocarbonyl" may include chlorocarbonyl, bromocarbonyl, and the like. Suitable "cyclo(lower)alkyl" and "cyclo(lower)alkyl moeity" may include one having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.<br>
Suitable "aryl" and "aryl moiety" may include C6-C10 aryl such as phenyl,<br>
naphthyl and the like.<br>
Suitable "heterocyclic moiety" may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen,<br><br>
sulfur, nitrogen atom and the like.<br>
Preferable heterocyclic group may be heterocyclic group such as<br>
(1)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 4 nitrogen alom(s),for example, pyrrolyl, pyrrolinyl, imidazolyl,<br>
pyrazoly], pyridinyl, dihydropyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl<br>
tetrazolyl (e.g., lH-tetrazolyl, 2H-tetrazolyI, etc.), etc.;<br>
(2)	saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 4 nitrogen atom(s),for example, pyrrolidinyl, imidazolidinyl,<br>
piperidyl, piperazinyl, etc.;<br>
(3)	unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for<br>
example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl,<br>
tetrahydroquinolyl (e.g., 1,2,3,4-tetrahydroquinolyl, etc.), isoquinolyl, indazolyl,<br>
benzotriazolyl, benzopyrimidinyl (e.g., benzo[b]pyrimidinyl, etc.), etc.;<br>
(4)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example,<br>
oxazolyl,isoxazolyl,oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-<br>
oxadiazolyl, etc.), etc.;<br>
(5)	saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example,<br>
rnorpholinyl, sydnonyl, etc.;<br>
(6)	unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3<br>
nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;<br>
(7)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example,<br>
thiazolyl,isothiazolyl,thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-<br>
thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;<br>
(8)	saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example,<br>
thiazolidinyl,etc;<br>
(9)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic<br>
group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl,<br>
dihydrodilhionyl, etc.;<br><br>
(10)	unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;<br>
(11)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furanyl, etc.;<br>
(12)	unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s), for example, benzodioxolyl (e.g. methylenedioxyphenyl, etc.), benzofuranyl, etc.;<br>
(13)	unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;<br>
(14)	unsaturated condensed heterocyclic group containing 1 to 2 sulfur alom(s), for example,benzothienyl (e.g., benzo[b]thienyl, etc.), benzodithiinyl, etc.;<br>
(15)	unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like.<br>
Suitable "heterocyclic group" and "heterocyclic moiety" in the terms "heterocycliccarbonyl" can be referred to the ones as mentioned above.<br>
Suitable "N-containing heterocyclic group" and "N-containing heterocyclic moiety" can be referred to the ones as mentioned above, wherein the heterocyclic group is containing at least one nitrogen atom such as l-pyrrolidinyl, morpholinyl and the like.<br>
A group derived from a sugar may be the group derived from, for example, glyceraldehydes; an aldose such as erythrose, threose, arabinose, ribose, xylose, lyxose, glucose, mannose or galactose; a ketose such as fructose or sorbose; or a discccharide such as maltose, lactose or sucrose.<br>
Protecting groups for the hydroxy group of the above-mentioned sugars are an aliphatic acyl group, such as formyl, or acetyl; a cyclic ether group such as tetrahydro-2-furanyl ortetrahydro-2-pyranyl; a 1-alkoxyethyl group such as 1-melhoxyethyl or 1-ethoxyethyl; and a silyl group such as trimethylsilyl, triethylsilyl or t-butyldimethylsilyl.<br>
Suitable "substituted or unsubstituted lower alkyl" for R1 may include straight or branched lower alkyl (e.g. methyl, isopropyl, neopentyl, etc.) optionally substituted by; (1) halogen (e.g. fluoro, bromo, etc.), (2) carboxy, (3) protected carboxy (e.g. esterified carboxy such as ethoxycarbonyl, etc.), (4) cyano, (5) carbamoyl, (6) -OCONR  R [wherein R15 and R16 each independently represents hydrogen, aryl or lower alkyl optionally substituted by aryl, or R " and R  , together with the nitrogen atom to which<br><br>
they are attached, represents saturated 5- or 6-membcred heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom.] (more preferably, dimethylcarbamoyloxy,meUiyl-phenylcarbamoyloxy, morpholinylcarbonyloxy, pyrrolidinylcarnbonyloxy, etc); (7) lower alkylthio (e.g. methylthio, etc.), (8) lower alkylsulfonyl (e.g. methylsulfonyl, etc.), (9) lower alkylsulfonyloxy (e.g. methylsulfonyoxyl, etc.), (10) lower alkylsulfonylamino (e.g. methylsulfonylamino, etc.), (11) mono- or di(lower)alkylamino optionally substituted by hydroxy, lower alkoxy, acyloxy (e.g. phenoxy, etc.), or substituted or unsubstituted aryl (e.g. benzylamino, etc.), (12) amino; (13) acylamino (more preferably, lower alkanoylamino such as acetylamino, aroylamino such as benzoylamino, or heterocycliccarbonylamino such as pyrazinylcarbonylarnino, or the like), (14) protected amino (e.g., methoxycarbonylamino, phthalimide, etc.), (15) hydroxy, (16) acyloxy (more preferably, lower alkanoyloxy such as acetyloxy, or the like), (17) cyclo(lower)alkyloxy, (18) aryloxy (e.g. phenoxy, etc.) (19) substituted or unsubstituted aryl (more preferably, phenyl), (20) saturated or unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 3 nitrogen atom(s) and also optionally containing oxygen atom or sulfur atom (more preferably, piperazinyl, rnorpholinyl, oxazolidinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl or triazolyl) optionally substituted by lower alkyl, hydroxy(lower)alkyl, aryl or oxo, (21) lower alkoxy (e.g. methoxy, ethoxy, iso-propoxy, etc.) optionally substituted by carboxy, protected carboxy (e.g. tert-butoxycarbonyl, etc.), hydroxy, protected hydroxy (e.g. tetrahydro-2H-pyran-2-yloxy, etc.), cyclo(lower)alkyl (e.g. cyclopropyl, cyclohexyl, etc.), substituted or unsubstituted aryl (e.g. phenyl optionally substituted by cyano, carboxy, protected carboxy or carbamoyl, such as phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-carboxyphenyl, 2-, 3- or 4-(methoxycarbonyl)phenyl, 2-, 3- or 4-carbamoylphenyl, etc.), saturated or unsaturated 5- or 6-membered heterocyclic group containing 1 to 2 nitrogen atom(s) optionally substituted by lower (more preferably, 2-, 3- or 4-pyridinyl, pyrazinyl or 4-methylpiperazinyl)(e.g. 2-, 3- or 4-pyridinyl, pyrazinyl, etc.), or -CONR R   [wherein R  and R   each independently hydrogen or lower alkyl optionally substituted by aryl, or R13 and R14, together with the nitrogen atom to which they are attached, represents N-containing heterocyclic group] (e.g. morpholinocarbonyl, dimethylcarbamoyl, etc.), and the like.<br>
Suitable "substituted or unsubstituted aryl" may include <br>
phenyl, naphthyl, etc.) optionally substituted by the substituent(s) selected from the group<br><br>
consisting of (1) halogen (e.g. fluoro, chloro, etc.), (2) carboxy, (3) protected carboxy, cyano, (5) -CONR15Ru [wherein R15 and R16 are each independently represents hydrogen, lower alkyl optionally substituted by hydroxy] (e.g. carbamoyl, hydroxyethylcarbamoyl, etc.), (6) lower alkyl (e.g. methyl, etc.), (7) cyclo(Iower)alkyl (e.g. cyclopropyl, etc) (8) lower alkoxy (e.g. methoxy, etc.), (9) trihalo(Iower)alkyl (e.g. trifluoromethyl, etc.), (10) heterocyclic group such as oxazolyl, (11) lower alkylsulfonyl (e.g. methylsulfonyl, etc.), (12) nitro, (13) amino, (14) sulfamoyl, and (15) protected sulfamoyl such as ar(lower)alkoxycarbonyl$ulfamoyl, and the like.<br>
In which, preferable example of "substituted or unsubstituted aryl" for R1 is aryl optionally substituted by the substituent(s) selected from the group consisting of halogen (e.g. phenyl, 4-fluorophenyl, etc.);<br>
preferable example of "substituted or unsubstituted aryl" for R3 is aryl optionally substituted by the substituent(s) selected from the group consisting of (1) halogen, (2) carboxy, (3) protected carboxy such as esterified carboxy (e.g. benzyloxycarbonyl, etc,), (4) cyano, (5) --CONR15R16 [wherein R15 and R36 are each independently represents hydrogen, lower alkyl optionally substituted by hydroxy], (6) lower alkyl, (7) cyclo(lower)alkyl, (8) lower alkoxy, (9) trihalo(lower)alkyl, (10) heterocyclic group, (11) lower alkyl sulfonyl, (12) nitro, (13) amino, (14) sulfamoyl, and (15) protected sulfamoyl, and the like. (e.g. phenyl, 2-naphthyl, 2- or 3-chlorophenyl, 2,3-, 2,4-, 3,4- or 3,5-dichlorophenyl, 3- or 4-fluorophenyl, 3- or 4-cyanophenyl, 3- or 4-carbamoylphenyl, 4-sulfamoylphenyl, 4-(benzyloxycarbonylsulfamoyl)phenyl, 3-carboxyphenyl, 3-(N-(2-hydroxyethyl)carbamoyl)phenyl, 3-nitrophenyl, 3-irifluoromethylphenyl, 3-methylsulfonylphenyl, 3-(5-oxazolyl)phenyl, 3-methoxyphenyl, 3-methylphenyl, etc.); and<br>
•7<br>
preferable example of "substituted or unsubstituted aryl" for R is aryl optionally substituted by lower alkoxy (e.g. phenyl, 2-, 3- or 4-methoxyphenyl, etc.).<br>
Suitable "substituted or unsubstituted heterocyclic group" may include heterocyclic group mentioned above (more preferably, pyridinyl, pyrazinyl, oxazolyl, isooxazolyl, furanyl, thienyl, quinolinyl, benzofuranyl and benzothienyl), which is optionally substituted by the substituent(s) selected from the group consisting of (1) lower alkyl (e.g. methyl, etc.), (2) cyclo(lower)alkyl (e.g. cyclopropyl, etc.) (3) lower alkoxy (e.g. methoxy, etc.), (4) acyl (e.g. lower alkanoyl such as acetyl, etc.), (5) amino,<br><br>
(6) mono- or di(lower)alkylamino (e.g. dimethylamino, etc.), (7) protected amino (e.g. lower alkoxycarbonylamino such as tert-butoxycarbonylamino, etc.), (8) cyano, (9) carboxy, (10) protected carboxy (e.g. benzyloxycarbonyl, etc.), (11) -CONR15R16 [wherein R15 and R16 are each independently represents hydrogen, lower alkyl optionally substituted by hydroxy] (e.g. carbamoyl, hydroxyethylcarbamoyl, etc.), (12) lower alkenyl optionally substituted by lower alkoxy (e.g. vinyl, 1-ethoxyvinyl, etc.), (13) halogen (e.g. chloro, bromo, etc.), (14) lower alkylthio, (15) hydroxy, and the like.<br>
In which, preferable example of "substituted or unsubstituted heterocyclic group" for R1 is heterocyclic group optionally substituted by lower alkyl or halogen (e.g. 2-pyridinyl, 5-blomo-3-pyridinyl, l-methyl-2-pyrrolyl, 1-pyrrolyl, l-pyrrolidinyl,3-methyl-2-thienyl, 2-thienyl, 2- or 3-furanyl, 2-thiazolyl, 5-oxazolyl, 5-methyl-isooxazolyl, 3,5-dimethyl-4-isoxazolyl, etc.); and<br>
preferable example of "substituted or unsubstituted heterocyclic group" for R3 is heterocyclic group optionally substituted by at least one substituent(s) selected from the group consisting of (1) lower alkyl, (2) cyclo(lower)alkyl, (3) lower alkoxy, (4) acy] such as lower alkanoyl, (5) amino, (6) mono- or di(lower)alkylamino, (7) protected amino such as lower alkoxycarbonylamino, (8) cyano, (9) carboxy, (10) protected carboxy such as esterified carboxy (e.g. benzyloxycarbonyl), (11) carbamoyl, (12) lower alkenyl optionally substituted by lower alkoxy, (13) halogen, (14) lower alkylthio, and (15) hydroxy (e.g. 3- or 4-pyridyl, 2-pyrazinyl, 6-methoxy-2-pyrazinyl, 4- or 5-oxazolyl, 2-benzofuranyl, 2-benzothienyl, 3- or 6-quinolinyl, 2-chloro-4-pyridyl, 5-bromo-3-pyridyl, 5-chloro-2-thienyl, 5,6-dichloro-2-pyridyl, 4-chloro-2-pyridyl, 5-cyano-3-pyridyl, 5-carboxy-3-pyridinyl, 5-carbamoyl-3-pyridyl, 5-(benzyloxycarbonyl)-3-pyridyl, 5-(tert-butoxycarbonylamino)-3-pyridinyl, 5-amino-3-pyridinyl, 2-methoxy-4-pyridyl, 3-rnethoxy-5-isoxazolyl, 2-methylthio-4-pyridinyl, 2-hydroxy-4-pyridyl, 5-methyl-3-pyridyl, 5-ethyl-3-pyridyl, 5-methyl-3-isoxazolyl, 5-vinyl-3-pyridyl, 2-vinyl-4-pyridyl, 5-acetyl-3-pyridyl, 2-dimethylamino-4-pyridyl, 5-(l-ethoxyvinyl)-3-pyridyl, 2-oxo-l,2-dihydro-4-pyridyl, or 2-methylthio-4-pyridyl, etc.).<br>
R] and R2 are combined together to form lower alkylene or lower alkenylen group which is optionally interrupted by amino or sulfonyl and also is optionally substituted by the group consisting of lower alkyl, hydroxy, oxo and lower alkoxy, which is represented<br><br><br>
Suitable "leaving group" may include acid residue, lower alkoxy as exemplified above, and the like.<br>
The above Processes can be earned out according to a conventional manner such<br><br>
as the one described in Preparations and/or Examples, or in a similar manner thereto. Among the above Processes, fused heterocyclic ring forming processes (such as Process "1 and Process 12) are important for carrying out of this invention and are explained in more detail.<br>
According to the Process 1, pyrrolopyridazine derivatives (I) can be prepared by reacting the l-amino-2-acylpyrrole derivative (II) or a salt thereof and the compound (III) or a sail thereof in the presence of a catalytic amount of acid catalyst in an inert solvent, preferably with concomitant removal of the water being produced by physical (e.g. Dean-Stark trap) or chemical (e.g. molecular sieves) means. Suitable acid catalyst is, for example p-toluenesulfonic acid, rnethanesulfonic acid, hydrochloric acid, trifluoroacetic acid and so on. Suitable inert solvent is, for example, benzene, toluene, tetrahydrofuran and the like.<br>
Another ring forming process is descried in Process 12, in this process pyrrolopyridazine derivatives (I) can be also prepared reacting 1-aminopyrole derivative (V) or a salt thereof and (3-diketone derivative or a salt thereof under the similar condition before mentioned Process 1, and therefore the reaction conditions can be referred to those of the Process 1.<br>
The compounds of the present invention can be purified by any conventional purification methods employed for purifying organic compounds, such as re-crystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography and the like. The compounds can be identified by conventional methods such as NMR spectrography, mass spectrography, IR spectrography, elemental analysis, and measurement of melting point.<br>
Suitable salts of the object and the starting compounds in Processes 1 to 40 can be referred to the ones as exemplified for the compound (I).<br>
The new pyrrolopyridazine derivatives (I) and pharmaceutically acceptable salts thereof hardly possess a strong inhibitory activity against phosphodiesterase 111 (PDE III), but possess a strong inhibitory activity against phosphodiesterase IV (PDE IV) and a strong inhibitory activity on the tumor necrosis factor (TNF).<br>
That is, the pyrrolopyridazine derivatives (I) and pharmaceutically acceptable salts thereof are selective inhibitors of phosphodiesterase IV (PDE IV) and inhibitors on<br><br>
the production of tumor necrosis factor (TNF).<br>
Accordingly, the new pyrrolopyridazine derivatives (]) and a pharmaceutically acceptable salt thereof can be used for prophylactic and therapeutic treatment of PDE-IV and TNF mediated diseases such as chronic inflammatory diseases (e.g., rheumatoid arthrilis, osteoarthritis, emphysema, chronic bronchiolitis, allergic rhinitis, etc.), 3Steoporosis, rejection by transplantation, asthma, chronic obstructive pulmonary disease (COPD), eosinophilia, fibrotic disease (e.g., cystic fibrosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, etc.), (viral alcoholic, drug-induced) acute and fulminant hepatitis, hepatic steatosis (alcoholic and non-alcoholic steato-hepatitis), chronic (viral and non-viral) hepatitis, hepatic cirrhosis, autoimmune hepatitis, pancreatitis, nephritis, endotoxin shock, specific autoimmune diseases [e.g., ankylosing spondylitis, autoimmune encephalomyelitis, autoimmune hematological disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, etc.), systemic lupus erythematosus (SLE), polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis (Wilson's disease, etc.), myasthenia gravis, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, etc.), endocrine ophthalmopathy, Grave's disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non infection uveitis, autoimmune keratitis (e.g., keratoconjunctivitis sicca, vernal keratoconjunctivitis, etc.), interstitial lung fibrosis, psoriatic arthritis, etc.], dermatological disorders associated with PDE-IV enzyme (such as psoriasis and other benign or malignant proliferative skin diseases, atopic dermatitis, and urticaria), neurodegenerative disorders such as Parkinson disease, Alzheimer's disease, acute and chronic multiple sclerosis, cancer cachexia, viral infection, AIDS cachexia, thrombosis, and the like.<br>
For therapeutic administration, the compound (I), or its prodrug, or a salt thereof can be administered alone or in the form of a mixture, preferably, with a pharmaceutical vehicle or carrier.<br>
The active ingredient of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains a compound (I), as an active ingredient, in admixture with an organic or<br><br>
inorganic carrier or excipient suitable for external (topical), enteral, intravenous, intramuscular, parenteral or intra-mucous applications. The active ingredient can be formulated, for example, with the conventional non-toxic, pharmaceutically acceptable carriers for ointment, cream, plaster, tablets, pellets, capsules, suppositories, solution (saline, for example), emulsion, suspension (olive oil, for example), aerosols, pills, powders, syrups, injections, troches, cataplasms, aromatic waters, lotions, buccal tablets, sublingual tablets, nasal drops and any other form suitable for use. The carriers which can be used are water, wax, glucose, lactose, gum acacia, gelatin, mannitol, starch paster, magnesium trisilicate, talc, corn starch, keratin, paraffin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The active compound is included in a pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the diseases.<br>
The active ingredient can be formulated into, for example, preparations for oral application, preparations for injection, preparations for external application, preparations for inhalation, and preparations for application to mucous membranes.<br>
Further, the compound of this invention can be used in combination with other therapeutic compounds. In particular, the combinations of the PDE4 inhibiting compound of this invention can be advantageously used in combination with i) Leukotriene receptor antagonists, ii) Leukotriene biosynthesis inhibitors, iii) COX-2 selective inhibitors, iv) statins, v) NSAlDs, vi) M2/M3 antagonists, vii) corticosteroids, viii) Hi (histamine) receptor antagonists, ix) beta 2 adrenoceptor agonist, x) interferon, xi) antiviral drugs for hepatitis C virus (HCV) such as protease inhibitor, helicase inhibitor, polymerase inhibitor, or the like, xii) antiviral drug for hepatitis B virus such as lamivudine, xiii) ursodesoxycholic acid, xiv) glycyrrhizin, xv) human grouth factor (HGF), xvi) aminosalicylic acid such as salazosulfapyridine, mesalazin, or the like, xvii) steroids such as prednisolone farnesylate, xviii) immunosuppressant such as azathioprine, 6-mercaptopurine, tacrolimus, and the like.<br>
Mammals which may be treated by the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and<br><br>
humans, preferably humans.<br>
While the dosage of therapeutically effective amount of the compound (I) will vary depending upon the age and condition of each individual patient, an average single dose to a human patient of about 0.01 mg, 0 1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg of the compound (1) may be effective for treating the above-mentioned diseases. In general, amounts between 0.01 mg/body and about 1,000 mg/body may be administered per day.<br>
In order to show the utilities of the pyrrolopyridazine derivatives (I) and a pharmaceutically acceptable salt thereof of the present invention, pharmacological test data of the representative compound of the pyrrolopyridazine derivatives (I) are illustrated in the following.<br><br>
1.        Test method:<br>
Cultured U937 cells were washed twice and harvested with phosphate-buffered saline (PBS) by cell-scraper. After centrifugation, the cell pellet was suspended in homogenizing buffer (0.5 % deoxycholate [DOC], 5 mM 2-mercaptoetbanol, 1 -iM leupeptin, 100 -M PMSF, 20µm p-tosyl-L-lysine-chloromethyl ketone [TLCK] in PBS). The cell suspension was then sonicated for a couple of minutes and homogenized by a glass-Teflon homogenizer with twenty strokes. The homogenate was centrifuged at 200g for 30 minutes, and the supernatant was further ultra-centrifuged at 100,000 x g for 90 minutes (4°C). The final supernatant was dialyzed against dialysis buffer, which was the same component as homogenizing buffer without DOC. The dialysate of enzyme preparation was stored at -20°C until assay.<br>
PDE4, activity was estimated with a Phosphodiesterase [ H]cAMP SPA Enzyme Assay System (Amersham Pharmacia Biotech), using a 96 well Opti-plate. Reactions were initiated by addition of 0.025 -Ci/well of [3H]cAMP to the enzyme mixture containing 50 mM Tris-HCl (pH 7.5), 8.3 mM MgCl2 ,1.7 mM EGTA, and various concentrations of the test compound or vehicle. CI-930 (10µm in final), a specific PDE3, inhibitor, was also added in the reaction mixture. After incubation at 30°C for 15 minutes, 50 µl of SPA beads suspension was added to each well. The well-plate was then shaken<br><br>
for 20 minutes by a plate mixer. Radio-activity in each well was counted by a Top Counter.<br>
Test compounds were dissolved in 100% dimethylsulfoxide (DMSO) and diluted into respective concentrations with the final solution containing ] % v/v of DMSO.<br>
JC50 values of test compounds for the enzyme activity of PDE4 was determined from regression analysis for log-logit conversion values of percent inhibition in the compound-treated tubes compared to that of the control. Percent inhibition was calculated with the following equation: Inhibition (%) = {1-(C-B)/(A-B)} x 100; in which A, B and C means mean values of radio-activity counts (dpm) of control, blank and the compound-treated tubes, respectively.<br>
2. Test results<br>
The following table illustrates the inhibitory activity on PDE-IV of the representative compound of formula (I):<br><br>
(b)      Inhibition on TNF-αlpha production in human mononuclear cells<br>
l.Test method<br>
(1) Human peripheral blood mononuclear cells (PBMCs) preparation<br>
Blood (30 ml for each person) was collected from the median cubital vein of healthy volunteer was divided 15 mLeach in heparin containing conical tube and the same volume of RPMI1640 was added to each tube. Diluted blood was then piled up to 20 mLof Ficoll-Paque PLUS (Amersham Pharmacia Biotech) in polystyrene centrifuge tube. After centrifugation at 1 ,600rpm for 30 minutes, cells gathering in the center area of the gradient were collected by capillary and washed with 40 mL of RPMI1640 in several times with centrifugation at 1,200 rpm for 10 minutes. PBMC finally precipitated were suspended in RPMI1640 containing 1% fetal bovine serum and antibiotics. After cell counting, final suspension at 3 x 106cells/mL in culture medium was prepared.<br><br>
(2) TNF-αlpha production from stimulated PBMCs<br>
Human PBMCs prepared by the density gradient method using Ficoll-Paque PLUS were suspended in the culture medium mentioned above with the concentration of 3 x 106 cells/mL and 0.5 mL of the suspension was sowed into each well of a 24-well culture plate. Cells were incubated in the CO2 incubator for 24 hours with 0.25 mLof LPS in addition of 0.25 mL of concentrations of drugs or vehicle at the start of the incubation. Final concentration of LPS in the incubation medium was 1 fxg/mL. After 24 hours, the supernatant of each well by centrifugation at 1,700 rpm for 10 minutes was stored at -80°C until assay. TNF-αlpha levels in the medium were measured by ELISA.<br>
The IC50 values of drugs on cytokine productions in LPS stimulated PBMC were estimated by the regression analysis for the relative values of cytokine level in the drug-treated wells compared to those of the vehicle-treated ones.<br><br><br>
Best Mode for carrying out the Invention<br>
The following examples are provided to further illustrate details for the preparation of the compounds of the present invention. The examples are not intended to be limitations on the scope of the instant invention in any way, and they should not be so construed. Furthermore, the compounds described in the following examples are not to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.<br>
The starting materials and intermediates are prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.<br><br>
Preparation 1<br>
To a suspension of 2-pyridinethiol (17 g) in tetrahydrofuran (200 mL) was added triethylamine (15.5 g) in an ice-water bath under N2. To this was added a solution of 4-cyanobenzoyl chloride (25.3 g) in tetrahydrofuran (80 mL) below 10°C over 30 minutes. After 15 minutes, the bath was removed and the mixture was stirred overnight at ambient temperature. The mixture was concentrated in vacuo. The residue was partitioned between chloroform and water. The organic layer was washed with saturated sodium<br><br>
bicarbonate and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue (38 g) was triturated with isopropy] ether to give S-(2-pyridinyl) 4-cyanobenzenecarbothioale (32.5 g) as a pale brown solid.<br>
S-(2-Pyridinyl)4-cyanobenzenecarbothioate<br>
NMR (CDC13,5): 7.38 (1H, t, J=7Hz), 7.72 (1H, d, J=8Hz), 7.75-7.87 (3H, m), 8.1 J<br>
(2H, d, J=8Hz); 8.71 (1H, d, J=2Hz) MS(ESI+):m/z241 (M+H)<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 1.<br>
Preparation 2<br>
S-(2-Pyridinyl) 2-chloro-4-pyridinecarbothioate<br>
NMR (CDCI3,5): 7.40 (1H, m), 7.65-7.75 (2H, m), 7.75-7.90 (2H, m), 8.62 (1H, d,<br>
J=5Hz),8.70(lH,m)<br>
Preparation 4<br>
S-(2-Pyridinyl) 3-cyanobenzenecarbothioate<br>
NMR (CDCI3, 5): 7.39 (1H, m), 7.66 (1H, t, J=8Hz), 7.72 (1H, t, J=8Hz), 7.83 (1H,<br>
m), 7.91 (1H, d, J=8Hz), 8.24 (1H, d, J=8Hz), 8.29 (1H, s), 8.71 (1H, m) MS (ESI+): m/z 241 (M+H)<br>
Preparation 5 S-(2-Pyridinyl)3-methoxybenzenecarbothioate<br>
NMR (CDCI3, 5): 3.87 (3H, s), 7.16 (1H, m), 7.32-7.44 (2H, m), 7.51 (1H, m), 7.63<br>
(1H, d, J=8Hz), 7.71-7.83 (2H, m), 8.69 (1H, m)<br>
Preparation 6<br>
S-(2-Pyridinyl) 4-pyridinecarbothioate<br>
NMR (CDCI3, 5): 7.35-7.43 (1H, m), 7.73 (1H, d, J=8Hz), 7.77-7.88 (3H5 m), 8.70<br>
(1H, d, J=7Hz), 8.85 (2H, d, J=8Hz)<br><br>
MS(ESD:m/z217<br>
Preparation 7<br>
S-(2-Pyridinyl) 2-pyrazinecarbothioate<br>
NMR (CDCI3, 8): 7.38 (1H, m), 7.71 (1H, d, J=8Hz), 7.82 (1H, m), 8.73 (2H, m),<br>
8.86 (lH,m), 9.17 (lH,s)<br>
Preparation 8<br>
S-(2-Pyridinyl) 3-pyridinecarbothioate<br>
NMR (CDCI3,8): 7.37 (1H, m), 7.46 (1H, m), 7.73 (1H, m), 7.83 (1H, m), 8.27 (1H,<br>
m), 8.68 (1H, m), 8.84 (1H, m), 9.23 (1H, m)<br>
Preparation 9<br>
To a solution of 2-ethyl-lH-pyrrole in toluene (120 mL) was added dropwise 1M methylmagnesium bromide in tetrahydrofuran (170 mL) in a dry ice-acetone bath below -60°C over 30 minutes. Then the mixture was stirred in an ice-water bath for 40 minutes. To this reaction mixture was added S-(2-pyridinyl) 4-cyanobenzenecarbothioate (15.2 g) portionwise over 10 minutes in a dryice-acetone bath. After 1.5 hours stirring, saturated ammonium chloride (100 mL) was added therein and the reaction mixture was allowed to ambient temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with IN sodium hydroxide (100 mL) twice, water, and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was triturated with isopropyl ether to give 4-[(5-ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile (12.7 g) as a pale yellow solid.<br>
4-[(5-Ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile<br>
NMR (CDC13, 8): 1.32 (3H, t, J=8Hz), 2.75 (2H, q, J=8Hz), 6.11 (1H, d, J=5Hz),<br>
6.76 (1H, d, J=5Hz), 7.77 (2H, d, J=8Hz), 7.94 (2H, d, J=8Hz), 9.49 (1H, br s) MS (ESI+): m/z 225 (M+H)<br>
The following compound was obtained in substantially the same manner as that of Preparation 9.<br><br>
Preparation 10 (2E)-l-(5-Elhy]-lH-pyrrol-2-y])-3-phenyl-2-propen-l-one<br>
NMR(CDC)3,5): 1.31 (3H, t,J=7Hz), 2.73 (2H,q,J=7Hz), 6,10(1 H,m), 7.02 (1H,<br>
m), 7.27 (1H, d, J=16Hz), 7.35-7.43 (3H, m), 7.63 (2H, m), 7.79 (1H, d, J=16Hz)<br>
MS(ESI+):m/z226(M+H)<br>
Preparation 11<br>
To a solution of 4-[(5-elhyl-lH-pyrrol-2-yl)carbonyl]-benzonilrile (12.5 g) in N,N-dimetbylformamide (63 rnL) was added 60% sodium hydride in oil (2.68 g) in an ice-water bath under N2, After 30 minutes, to the mixture was added l-(aminooxy)-2,4-<br>
dinitrobenzene (13.3 g). After 2 hours, the mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with water (100 mL) 3 times, IN sodium hydroxide (100 mL), and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 500 mL) eluted with hexane-chloroform = 1-2,1-5, and 1-10 followed by triturated with isopropyl ether to give 4-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile (8.1 g, 60.7%) as an yellow solid. The mixed fraction and the mother layer (7 g) were repurified by flash silica gel chromatography (silica gel, 200 mL) eluted with hexane-chloroform = 2-1 and 1-1 followed by triturated with isopropyl ether to give 4-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile (2.0 g, 15%) as a pale yellow solid.<br>
4-[(l-Amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]-benzonitrile<br>
NMR (CDC13, 5): 1.29 (3H, t, J=8Hz), 2.77 (2H, q, J=8Hz), 5.75 (2H7 br s), 5.94 (1H,<br>
d, J=5Hz), 6.59 (1H, d, J=5Hz), 7.76 (2H, d, J=8Hz), 7.85 (2H, d, J=8Hz) MS (ES1+): m/z 240 (M+H)<br>
The following compounds were obtained in substantially the same manner as that<br>
of Preparation 11.<br>
Preparation 12 (l-Amino-5-ethyl-lH-pyrrol-2-yl)(2-chloro-4-pyridinyl)methanone<br>
NMR(CDCl3,5):1.29(3H,t,J=7Hz))2.77(2H,q,J=7Hz),5.71(2H,s),5.96(lH,d,<br><br>
J=4Hz), 6.63 (1H, d, J=4Hz), 7.50 (1H, d, J=4Hz), 7.61 (1H, s), 8.52 (1H, d, J=4Hz) MS: (m/z) 250 (M+H)<br>
Preparation .13<br>
3-[(l -Aniino-5-ethyl-l H-pyrrol-2-y])carbonyl]-benzoni(rile<br>
NMR (CDC13,6): 1.29 (3H, t, J=7Hz), 2.77 (2H, q, J=7Hz), 5.74 (2H, s), 5.94 (1H, d,<br>
J=5Hz), 6.59 (1H, d, J=5Hz), 7.59 (1H, t, J=8Hz), 7.82 (1H, d, J=8Hz), 8.00 (1H, d,J=8Hz),8.06(lH,s)<br>
Preparation 14 (2E)-l-(l-Amino-5-ethyl-lH-pyrrol-2-y])-3-phenyl-2-propen-l-one<br>
NMR (CDCI3, 5): 1.28 (3H, t, J=7Hz), 2.73 (2H, q, J=7Hz), 5.93 (1H, d, J=5Hz),<br>
6.99 (1H, d, J=5Hz), 7.30 (1H, d, J=16Hz), 7.37-7.43 (3H, m), 7.62 (2H, m), 7.74 (lH,d,J=16Hz) MS (ESI+): m/z 241 (M+H)<br>
Preparation 15 (l-Amino-5-ethyl-lH-pyrrol-2-yl)(3-methoxyphenyl)-rnethanone<br>
NMR (CDCI3,8): 1.26 (3H, I, J=7Hz), 2.75 (2H, q, J=7Hz), 3.86 (3H, s), 5.79 (2H, s),<br>
5.89 (1H, d, J=4Hz), 6.67 (1H, d, J=4Hz), 7.07 (1H, m), 7.29-7.40 (3H, m) MS (ESI+): m/z 245<br>
Preparation 16 (l-Amino-5-ethyl-lH-pyrrol-2-y])(4-pyridiny])methanone<br>
NMR (CDCI3,5): 1.29 (3H, t, J=7Hz), 2.77 (2H, q, J=7Hz), 5.76 (2H, s), 5.94 (1H, d,<br>
J=4Hz), 6.63 (1H, d, J=4Hz), 7.58 (2H, d, J=7Hz), 8.75 (2H, d, J=7Hz) MS(ESl+):m/z216<br>
Preparation 17 (l-Amino-5-ethyi-lH-pyrrol-2-yl)(2-pyrazinyl)methanone<br>
NMR (CDCI3, 8): 1.29 (3H, t, J=7Hz), 2.77 (2H, q, J=7Hz), 5.79 (2H, s), 5.98 (1H, d,<br><br>
J=4Hz), 7.27 (1H, d, J=4Hz), 8.63 (1H, m), 8.71 (1H, m), 9.17 (1H, m)<br>
Preparation 18 (l-Amino-5-ethy]-lH-pyrro]-2-yl)(3-pyridinyl)melhanone<br>
NMR (CDC13,5): 1.29 (3H, t, J=7Hz), 2.77 (2H, q, J=7Hz), 5.78 (2H, s), 5.94 (1H, d,<br>
J=4Hz), 6.65 (1H, d, J=4Hz), 7.39 (1H, m), 8.06 (1H, m), 8.74 (1H, m), 8.99 (1H, m)<br>
Preparation 19 (l-Amino-5-ethyl-lH-pyrrol-2-yl)(5-bromo-3-pyridinyl)-methanone<br>
NMR (CDCI3, 5): 1.29 (3H, t, J=7Hz), 2.76 (2H, q, J=7Hz), 5.72 (2H, s), 5.96 (1H,<br>
m), 6.65 (1H, m), 8,19 (1H, m), 8.70 (1H, m), 8.89 (1H, m)<br>
Preparation 20<br>
To a solution of tert-butyl 3-oxobutanoate (20.0 g) in tetrahydrofuran (200 mL) was added 60% sodium hydride in oil (5.56 g) portionwise over 20 minutes in an ice-water bath under N2. After 40 minutes, to the mixture was added ethyl 5-iodopentanoate<br>
(35.6 g) at the temperature. After 15 minutes, the mixture was stirred at ambient temperature. After 1 hour, the reaction mixture was heated at 50°C for 24 hours. The cooled mixture was partitined between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 1 L) eluting with hexarie-ethyl acetate = 50-1,20-1,10-1, and 8-1 to give 1-tert-butyl 7-elhyl 2-acetylheptanedioate (27.3 g, 75.4%) as colorless oil.<br>
1-tert-Butyl 7-ethyl 2-acetylheptanedioate<br>
NMR (CDCI3, 8): 1.20-138 (5H, m), 1.46 (9H, s), 1.54-1.71 (2H, m), 1.75-1.87 (2H,<br>
m), 2.12 (3H, s), 2.30 (2H, t, J=8Hz), 3.30 (12H, t, J=8Hz), 4.11 (2H, q, J=8Hz)<br>
The following compounds were obtained in substantially the same manner as that of Preparation 20.<br><br>
Preparation 21<br>
1-tert-Butyl 9-ethyl 2-acetylnonanedioate<br>
NMR (CDCI3, 5): 1.23-133 (9H, m), 1.46 (9H, s), 1.55 (2H, m), 1.77 (2H, m), 2.21<br>
(3H, s), 2.28 (2H, t, J=7Hz), 3.27 (1H, I, J=7Hz), 4.12 (2H, q, J=7Hz) MS(ESI+):m/2 315(M+H)<br>
Preparation 22<br>
tert-Butyl 2-acetylhexanoate<br>
NMR (CDCI3,8): 0.90 (3H, t, J=8Hz), 1.28-1.40 (4H, m), 1.46 (9H, s), 1.73-1.89<br>
(2H, m), 2.22 (3H, s), 330 (1H, t, J=8Hz)<br>
Preparation 23<br>
1-tert-Butyl 8-ethyl 2-acetyloctanedioate<br>
NMR (CDCI3, 5): 1.21-133 (7H, m), 1.46 (9H, s), 1.54-1.69 (2H, m), 1.74-1.85 (2H,<br>
m), 2.21 (3H, s), 2.28 (2H, t, J=8Hz), 3.29 (1H, t, J=8Hz), 4.12 (2H, q, J=8Hz)<br>
Preparation 24<br>
To a suspension of magnesium chloride (133 g) in dichloromethane (40 mL) was added 1-tert-butyl 7-ethyl 2-acetylheptanedioate (4.0 g) at ambient temperature under N2.<br>
To this mixture was added dropwise pyridine (2.26 mL) in an ice-water bath. Then the mixture was stirred at ambient temperature for 40 minutes. To the reaction mixture was added a solution of 3-cyanobenzoyl chloride (3.01 g) in dichloromethane (6 mL) dropwise over 2 minutes. The reaction mixture was stirred at ambient temperature for 2 hours. To the mixture was added IN hydrogen chloride and ethyl acetate in an ice-water bath. The organic layer was washed with IN hydrogen chloride, water, and brine, dried over magnesium sulfate, and evaporated in vacuo to give a solid. The residue was purified by flash silica gel chromatography (silica gel, 300 mL) eluting with hexane-ethyl acetate = 10-1,8-1,5-1, and 3-1 to give 1-tert-butyl 7-ethyl 2-acetyl-2-(3-cyanobenzoyl)heptanedioate (4.23 g, 72.9%) as colorless oil.<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3-cyanobenzoyl)-heptanedioate<br>
NMR (CDCI3, 5): 1.25 (3H,t,J=8Hz), 1.28-1.40 (HH,m), 1.63-1.75 (2H,m), 2.19-<br><br>
2.28 (2H, m), 2.32 (2H, I, J=8Hz), 2.45 (3H, s), 4.11 (2H, q, J=8Hz), 7.56 (1H, t, J=8Hz), 7.80 (2H, dd, J=8,1Hz), 7.95 (2H, dd, J=8,1Hz), 8.06 (1H, br s) MS(ESI+):m/z416(M+H)<br>
The following compounds were obtained in substantially the same manner as that of Preparation 24. Preparation 25 Ethyl 2-isobutyryl-4-methyl-3-oxopentanoate<br>
NMR (300 MHz, CDC13,5): 1.10-1.23 (12H, m), 1.30-1.43 (3H, m), 2.91-3.10 (2H,<br>
m),4.21-4.36(2H,m)<br>
Preparation 26<br>
Ethyl 2-(2-chlorobenzoyl)-4-methyl-3-oxopentanoate<br>
NMR (300 MHz, CDCI3, 5): 0.79 (3H, t, J=7.5Hz),1.22 (6H, d, J=7.5Hz), 3.36-3.54<br>
(1H, m), 3.88 (2H, q, J=7.5Hz), 7.26-7.44 (4H, m)<br>
Preparation 27<br>
Ethyl 4-methyl-2-(2-naphthoyl)-3-oxopentanoate<br>
NMR (300 MHz,CDCl3,6): 0.76-1.03 (3H,m), 1.10-1.30 (6H,m), 2.56-2.71 (1/2H,<br>
m), 2.88-3.04 (1/6H, m), 3.20-3.35 (1/3H, m), 3.72-4.336 (3H, m), 7.50-7.68 (2+1/3H, m), 7.82-8.01 (3+2/3H, m), 8.09 (1/3H, s), 8.35 (1/2H, s), 8.41 (1/6H, s) MS (ES+):m/e 313.45<br>
Preparation 28<br>
1 -tert-Butyl 7-ethyl 2-acetyl-2-[3-(trifluoromethyl)benzoyl1Heptanedioate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.32 (9H, s), 1.36-1.75 (4H, m), 2.15-2.36<br>
(4H, m), 2.45 (3H, s), 4.11 (2H, q, J=7Hz), 7.56 (1H, t, J=8Hz), 7.79 (1H, d, J=8Hz), 7.93 (1H, d, J=8Hz), 8.04 (1H, s)<br>
Preparation 29<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(5-methyl-3-pyridinyl)carbonyl1Heplanedioate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.27-1.42 (2H, m), 1.34 (9H, s), 1.65-1.77<br><br>
(2H, m), 2.16-2.35 (4H, m), 2.39 (3H, s), 2.43 (3H, s), 4.10 (2H, q, J=7Hz), 7.87 (1 H,s), 8.56 (lH,s), 8.73 (lH,s) MS (ESI+): m/z 406 (M+H)<br>
Preparation 30<br>
1-tert-Bulyl 7-ethyl 2-(melhoxyacetyI)-2-[(3-melhoxy-<br>
5isoxazolyl)carbonyl1Heptanedioate<br>
NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.39 (9H, s), 1.35-1.50 (2H, m), 1.64-1.75<br>
(2H, m), 2.15-2.23 (2H, m), 2.32 (2H, t, J=7Hz), 3.40 (3H, s), 4.01 (3H, s), 4.12 (2H, q, J=7Hz), 4.57 (2H, s), 6.54 (1H, s)<br>
Preparation 31<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[3-(l ,3-oxazol-5-yl)benzoyl1Heptanedioate<br>
NMR (CDCI3, 8): 1.23 (3H, t, J=7Hz), 1.33 (9H, s), 1.30-1.43 (2H, m), 1.62-1.76<br>
(2H, m), 2.17-2.35 (4H, m), 2.44 (3H, s), 4.09 (2H, q, J=7Hz), 7.42 (1H, s), 7.48 (1H, t, J=8Hz), 7.69 (1H, d, J=8Hz), 7.82 (1H, d, J=8Hz), 7.94 (1H, s), 8.09 (1H, m)<br>
Preparation 32<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3,4-dichlorobenzoyl)heptanedioate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.35 (9H, s), 1.63-1.74<br>
(2H, m), 2.15-2.34 (4H, m), 2.41 (3H, s), 4.10 (2H, q, J=7Hz), 7.48 (1H, d, J=8Hz), 7.56 (1H, dd, J=2,8Hz), 7.88 (1H, d, J=2Hz)<br>
Preparation 33<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(4-chloro-2-pyridinyl)carbonyl1Heptanedioate<br>
NMR (CDCI3, 8): 1.23-1.30 (3H, m), 1.25 (9H, s), 1.40-1.58 (2H, m), 1.65-1.77 (2H,<br>
m), 2.10-2.21 (2H, m), 2.35 (2H, t, J=7Hz), 2.61 (3H, s), 4.12 (2H, q, J=7Hz), 7.39 (1H, m), 8.04 (1H, m), 8.43 (1H, d, J=5Hz) MS (ES1+): m/z 426 (M+H)<br>
Preparation 34<br><br>
1-tert-Butyl 7-elhyl 2-[(5-chloro-2-thieny])carbonyl]-2-(methoxyacetyl)heptanec3ioale NMR (CDC13,5): 1.23 (3H, t, J=7Hz), 1.25-1.40 (2H,m), 1.41 (9H,s), 1.62-1.74<br>
(2H, m), 2.26-2.37 (4H, m), 3.37 (3H, s), 4.11 (2H, q, J=7Hz), 4.30 (1H, d, J=17Hz), 4.42 (1H, d, J=17Hz), 6.92 (1H, d, J=4Hz), 7.39 (1H, d, J=4Hz)<br>
Preparation 35<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(6-methoxy-2-pyrazinyl)carbonyl1Heptanedioale NMR (CDC13, 5): 1.24 (3H, t, J=7Hz), 1.26 (9H, s), 1.38-1.49 (2H, m), 1.66-1.80<br>
(2H, m), 2.14-2.26 (2H, m), 2.33 (2H, t, J=7Hz), 2.57 (3H, s), 3.90 (3H, s), 4.12 (2H, q, J=7Hz), 8.37 (1H, s), 8.83 (1H, s)<br>
Preparation 36<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(l-benzofuran-2-ylcarbonyl)heptanedioate<br>
NMR (CDCI3, 8): 1.23 (3H, t, J=7Hz), 1.33 (9H, s), 1.38-1.55 (2H, m), 1.64-1.77<br>
(2H, m), 2.23-2.36 (4H, m), 2.49 (3H, s), 4.08 (2H, q, J=7Hz), 7.32 (1H, m), 7.46 (2H, m), 7.54 (1H, s), 7.71 (1H, d, J=8Hz)<br>
Preparation 37<br>
1 -tert-Butyl 7-ethyl 2-acetyl-2-(l -benzothien-2-ylcarbonyl)heptanedioate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.30-1.45 (2H, m), 1.39 (9H, s), 1.62-1.75<br>
(2H, m), 2.25-2.38 (4H, m), 2.40 (3H, s), 4.10 (2H, q, J=7Hz), 7.36-7.51 (2H, m), 7.76 (lH,s), 7.82-7.88 (2H,m)<br>
Preparation 38<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(l ,3-oxazol-5-ylcarbonyl)heptanedioate<br>
NMR(CDC13,6): 1.24 (3H,t, J=7Hz), 1.30-1.45 (2H,m), 1.38 (9H, s), 1.63-1.77<br>
(2H, m), 2.15-2.27 (2H, m), 2.30 (2H, t, J=7Hz), 2.43 (3H, s), 4.10 (2H, q, J=7Hz), 7.80 (1H, s), 7.93 (1H, s)<br>
Preparation 39<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-benzoylheptanedioate<br>
NMR (CDCI3,5): 1.26 (3H, t, J=7Hz), 1.20-1.40 (2H, m), 1.32 (9H, s), 1.60-1.73<br><br>
(2H, m), 2.26-2.38 (4H, m), 2.40 (3H, s), 4.12 (2H, q, J=7Hz), 7.36-7.78 (5H, m)<br>
Preparation 40<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(6-quinolinylcarbonyl)heptanedioate<br>
NMR (CDC13, 5): 1.21 (3H,t, J=7Hz), 1.30 (9H, s), 1.32-1.47 (2H, m), ] .64-1.77<br>
(2H, m), 2.26-2.38 (4H, m), 2.46 (3H, s), 4.08 (2H, q, J=7Hz), 7.48 (1H, m), 8.04 (1H, dd, J=2 Hz, 8Hz), 8.13 (1H, d, J=8Hz), 8.23 (1H, d, J=8Hz), 8.28 (1H, d, J=2Hz),9.00(lH,m) MS (ESI+): m/z 442 (M+H)<br>
Preparation 41<br>
1-tert-Butyl 9-ethyl 2-acetyl-2-[4-({[(benzyloxy)carbonyl]amino}sulfonyl)benzoyl]-<br>
nonanedioate<br>
NMR (CDC13, 8): 1.23-1.37 (HH,m), 1.60 (9H, s), 2.15-2.31 (4H, m), 2.46 (3H, s),<br>
4.12 (2H, q, J=7Hz), 5.10 (2H, s), 7.26-7.40 (5H, m), 7.65 (1H, s, br), 7.84 (2H, d, J=9Hz),8.06(2H,d,J=9Hz)<br>
Preparation 42<br>
1 -tert-Butyl 7-ethyl 2-acetyl-2-(2-chloroisonicotinoyl)heptanedioate<br>
NMR (CDCI3, 5): 1.20-1.40 (14H, m), 1.61-1.75 (2H, m), 2.19-2.28 (2H, m), 2.20<br>
(2H, t, J=8Hz), 2.31 (2H, t, J=8Hz), 2.46 (3H, s), 4.11 (2H, q, J=8Hz), 7.41 (1H, dd, J =7,1Hz), 7.55 (1H, d, J=lHz), 8.50 (1H, d, J=7Hz)<br>
Preparation 43<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[3-(methylsulfonyl)benzoyl1Heptanedioate<br>
NMR (CDC13, 8): 1.24 (3H, t, J=8Hz), 1.27-1.40 (11H, m), 1.61-1.75 (2H, m), 2.19-<br>
2.35 (4H, m), 2.46 (3H, s), 3.07 (3H, s), 4.10 (2H, q, J=8Hz), 7.65 (1H, t, J=8Hz), 7.99 (1H, dd, J=8,1Hz), 8.09 (2H, br d, J=8Hz), 8.34 (1H, br s)<br>
Preparation 44<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3-nitrobenzoyl)heptanedioate<br>
NMR (CDCI3, 8): 1.30-1.39 (12H, m), 1.61-1.75 (2H, m), 2.19-2.35 (4H, m),<br><br>
2.47(3H, s), 4.10 (2H, q, J=8Hz), 7.63 (1H, t, J=8Hz), 8.09 (1H, br d, J=8Hz), 8.39 (1H, br d, J=8Hz), 8.60 (1H, br s)<br>
Preparation 45<br>
tert-Buty] 2-acetyl-2-(4-cyanobenzoyl)hexanoate<br>
NMR (CDC13,5): 0.90 (3H, 1, J=8Hz), 1.20-1.44 (13H, m), 2.15-2.25 (2H, m), 2.45<br>
(3H, s), 7.70 (2H, d, J=8Hz), 7.83 (2H, d, J=8Hz)<br>
Preparation 46<br>
1-tert-Butyl 7-ethy] 2-acetyl-2-[(5-bromo-3-pyridinyl)carbonyl1Heptanedioate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.36 (9H, s), 1.32-1.45 (2H, m), 1.65-1.77<br>
(2H, m), 2.18-2.28 (2H, m), 2.32 (2H, t, J=7Hz), 2.45 (3H, s), 4.11 (2H, q, J=7Hz), 8.20 (1H, m), 8.80 (2H, m) MS: (m/z) 470,472 (M+H)<br>
Preparation 47<br>
1 -tert-Butyl 7-ethyl 2-(2-chloroisonicotinoyl)-2-[(methylthio)acetyl1Heptanedioate NMR(CDC13,8): 1.24 (3H, t, J=7Hz), 1.37 (9H,s), 1.23-1.45 (2H,m), 1.63-1.77<br>
(2H, m), 2.05 (3H, s), 2.16-2.28 (2H, m), 2.32 (2H, t, J=7Hz), 3.16 (1H, d, J=17Hz), 4.07 (1H, d, J=17Hz), 4.11 (2H, q, J=7Hz), 7.68 (1H, d, J=5Hz), 7.87 (lH,s),8.49(lH,d,J=5Hz)<br>
Preparation 48<br>
Ethyl 2-(4-fluorobenzoyl)-3-oxobutanoate<br>
NMR (CDCI3, 8): (mixture of tautomers) 0.97 and 1.02 (3H, t, J=7Hz), 2.07 and 2.42 -<br>
(3H, s), 4.01 and 4.13 (2H, q, J=7Hz), 7.06-7.18,7.56, and 7.85 (4H, m) MS (ESI+): m/z 275 (M+H)<br>
Preparation 49<br>
1-tert-Butyl 8-ethyl 2-acety]-2-(3-cyanobenzoyl)octanedioate<br>
NMR (CDCI3,8): 1.21-1.46 (16H, m), 1.56-1.70 (2H, m), 2.15-2.25 (2H, m), 2.29<br>
(2H, t, J=8Hz), 2.45 (3H, s), 4.12 (2H, q, J=8Hz), 7.56 (1H, t, J=8Hz), 7.80 (2H,<br><br>
dd, J=8, 1 Hz), 7.95 (2H, dd, J=8,1Hz), 8.05 (1H, br s)<br>
Preparation 50<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(6-chloro-2-pyridinyl)carbonyl1Heplanedioate<br>
NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.27 (9H, s), 1.20-1.78 (4H, m), 2.08 (2H, t,<br>
J=7Hz), 2.26-2.40 (2H, m), 2.69 (3H, s), 4.12 (2H, q, J=7Hz), 7.43 (1H, d, J=8Hz), 7.81 (1H, t, J=8Hz), 7.96 (1H, d, J=8Hz) MS (ES1+): m/z 426<br>
Preparation 51<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3-methoxybenzoyl)heptanedioate<br>
NMR (CDC13, 5): 1.25 (3H, m), 1.34 (9H, s), 1.20-1.92 (4H, m), 2.10-2.38 (4H, m),<br>
2.41 (3H, s), 3.84 (3H, s), 4.04-4.22 (2H, m), 7.08 (1H, br), 7.23-7.40 (3H, m)<br>
Preparation 52<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3,5-dich]orobenzoyl)heptanedioate<br>
NMR (CDC13, 5): 1.24 (3H, t, J=7Hz), 1.26-1.40 (2H, m), 1.36 (9H, s), 1.63-1.76<br>
(2H, m), 2.15-2.36 (4H, m), 2.43 (3H, s), 4.10 (2H, q, J=7Hz), 7.51 (1H, m), 7.60 (2H, m)<br>
Preparation S3<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(5-chloro-2-thienyl)carbonyl1Heptanedioate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.40 (9H, s), 1.30-1.90 (4H, m), 2.20-2.35<br>
(4H, m), 2.38 (3H, s), 4.11 (2H, q, J=7Hz), 6.91 (1H, d, J=4Hz), 7.32 (1H, d, J=4Hz)<br>
Preparation 54<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-(3-fluorobenzoyl)heptanedioate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.35 (9H, s), 1.35-1.45 (2H,m), 1.64-1.74<br>
(2H, m), 2.16-2.35 (4H, m), 2.42 (3H, s), 4.09 (2H, q, J=7Hz), 7.24 (1H, m), 7.35-7.43 (1H, m), 7.46-7.53 (2H, m)<br><br>
Preparation 55<br>
1-tert-Butyl 7-ethyl 2-acety]-2-(3-quino]iny]carbonyl)heptanedioate<br>
NMR (CDCI3, 8): 1.22 (3H, t, J=7Hz), 1.33 (9H, s), 1.33-1.53 (2H, m), 1.65-1.78<br>
(2H, m), 2.25-2.43 (4H, m), 2.47 (3H, s), 4.08 (2H, q, J=7Hz), 7.63 (1H, t, J=8Hz), 7.81-7.87 (lH,t,J=8Hz), 7.91 (lH,d, J=8Hz), 8.56 (lH,m), 9.24 (1H, m) MS (ES1+): m/z 442<br>
reparation 56<br>
-tert-Butyl 7-ethyl 2-acetyl-2-isonicotinoylheptanedioate<br>
NMR (CDCI3, 8): 1.23 (3H, t, J=7Hz), 1.31 (9H, s), 1.30-1.45 (2H, m), 1.65-1.76<br>
(2H, m), 2.18-2.28 (2H, m), 2.31 (2H, t, J=7Hz), 2.45 (3H, s), 4.10 (2H, q, J=7Hz), 7.52 (2H, d, J=7Hz), 8.75 (2H, d, J=7Hz)<br>
preparation 57<br>
L-tert-Butyl 7-ethyl 2-acetyl-2-[(3-methoxy-5-isoxazolyl)carbonyl1Heptanedioate NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.39 (9H, s), 1.35-1.50 (2H, m), 1.62-1.75<br>
(2H, m), 2.11-2.23 (2H, m), 2.33 (2H, t, J=7Hz), 2.49 (3H, s), 4.01 (3H, s), 4.11 (2H,q,J=7Hz),6.53(lH,s)<br>
Preparation 58<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(5-methyl-3-isoxazolyl)carbonyl1Heptanedioate<br>
NMR (CDCI3, 8): 1.24 (3H,t, J=7Hz), 1.31-1.48 (2H,m), 1.37 (9H, s), 1.63-1.75<br>
(2H, m), 2.18-2.26 (2H, m), 2.31 (2H, t, J=7Hz), 2.47 (3H, s), 2.50 (3H, s), 4.11 (2H,q,J=7Hz),6.38(lH,s)<br>
Preparation 59<br>
1-tert-Butyl 7-ethyl 2-(2-chloroisonicotinoyl)-2-(methoxyacetyl)heptanedioate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.32-1.45 (2H, m), 1.36 (9H, s), 1.64-1.78<br>
(2H, m), 2.16-2.28 (2H, m), 2.31 (2H, t, J=7Hz), 3.36 (3H, s), 4.11 (2H, q, J=7Hz), 4.25 (1H, d, J=17Hz), 4.39 (1H, d, J=17Hz), 7.39 (1H, d, J=5Hz), 7.54 (lH,s),8.50(lH,d,J=5Hz)<br><br>
MS(ES]+):m/z456<br>
Preparation 60<br>
I-tcrt-Butyl 7-elhyl 2-(methoxyacetyl)-2-(3-methoxybenzoyl)heplaneclioate<br>
NMR (CDCJ3,5): 1.22 (3H, t, J=7Hz), 1.25-1.33 (2H, m), 1.34 (9H, s), 1.60-1.75<br>
(2H, m), 2.15-2.40 (4H, m), 3.38 (3H, s), 3.83 (3H, s), 4.08 (2H, q, J=7Hz), 4.39 (1H, d, J=17Hz), 4.55 (1H, d, J=17Hz), 7.07 (1H, m), 7.26-7.34 (3H, m) MS (ESI+): m/z 451<br>
Preparation 61<br>
1 -tert-Butyl 7-ethyl 2-(methoxyacetyl)-2-(6-quinolinylcarbonyl)heptanedioate<br>
NMR (CDC13,5): 1.25 (3H, t, J=7Hz), 1.32 (9H, s), 1.30-1.50 (2H, m), 1.65-1.78<br>
(2H, m), 2.26-2.44 (4H, m), 3.38 (3H, s), 4.11 (2H, q, J=7Hz), 4.38 (1H, d, J=17Hz), 4.57 (1H, d, J=17Hz), 7.47 (1H, m), 8.03 (1H, d, J=8Hz), 8.13 (1H, d, J=8Hz), 8.28 (1H, d, J=8Hz), 8.27 (1H, s), 9.01 (1H, m) MS(ESI+):m/z472<br>
Preparation 62<br>
1 -tert-Butyl 7-ethyl 2-(methoxyacetyl)-2-(3-pyridinylcarbonyl)heptanedioate<br>
NMR (CDC13, 5): 1.23 (3H, t, J=7Hz), 1.30-1.47 (2H, m), 1.35 (9H, s), 1.63-1.78<br>
(2H, m), 2.22-2.38 (4H, m), 3.37 (3H, s), 4.10 (2H, q, J=7Hz), 4.32 (1H, d, J=17Hz), 4.45 (1H, d, J=17Hz), 7.37 (1H, m), 8.03 (1H, m), 8.73 (1H, m), 8.92 (lH,m)<br>
Preparation 63<br>
1 -tert-Butyl 7-ethyl 2-(3-chlorobenzoyl)-2-(methoxyacetyl)heptanedioate<br>
NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.35 (9H, s), 1.20-1.50 (2H, m), 1.60-1.73<br>
(2H, m), 2.25-2.35 (4H, m), 3.37 (3H, s), 4.12 (2H, q, J=7Hz), 4.35 (1H, d, J=17Hz), 4.50 (1H, d, J=17Hz), 7.34 (1H, m), 7.48 (1H, d, J=8Hz), 7.59 (1H, d, J=8Hz),7.73(lH,m)<br>
Preparation 64<br><br>
1-tert-Butyl 7-ethyl 2-acely]-2-(3-methylbenzoyl)heptanedioale<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.30-1.40 (2H, m), 1.33 (9H, s), 1.60-1.72<br>
(2H, m), 2.10-2.38 (4H, m), 2.21 (3H, s), 2.39 (3H, s), 4.10 (2H, q, J=7Hz), 7.26-7.36 (2H, m), 7.48-7.62 (2H, m) MS (ESI+): m/z 405<br>
Preparation 67<br>
1 -tert-Buly] 7-ethyl 2-(methoxyacetyl)-2-[(5-methyl-3-pyridinyl)carbonyl1Heptanedioale NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.36 (9H, s), 1.30-1.45 (2H, m), 1.62-1.76<br>
(2H, m), 2.20-2.36 (4H, m), 2.40 (3H, s), 3.38 (3H, s), 4.10 (2H, q, J=7Hz), 4.34 (1H, d, J=17Hz), 4.49 (1H, d, J=17Hz), 7.86 (1H, s), 8.56 (1H, s), 8.73 (1H, s) MS(ESl+):m/z436<br>
Preparation 68<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(5-bromo-3-pyridinyl)carbonyl1Heptanedioate<br>
NMR(CDCl3,8):1.25(3H,t,J=7Hz),1.36(9H,s), 1.32-1.45 (2H,m), 1.65-1.77<br>
(2H, m), 2.18-2.28 (2H, m), 2.32 (2H, t, J=7Hz), 2.45 (3H, s), 4.11 (2H, q, J=7Hz), 8.20 (1H, m), 8.80 (2H, m) MS (ESI+): m/z 470,472<br>
Preparation 69<br>
1-tert-Butyl 7-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(methoxyacetyl)heptanedioate NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1.30-1.44 (2H, m), 1.37 (9H, s), 1.65-1.77<br>
(2H, m), 2.18-2.36 (4H, m), 3.36 (3H, s), 4.10 (2H, q, J=7Hz), 4.28 (1H, d, J=17Hz), 4.40 (1H, d, J=17Hz), 8.18 (1H, m), 8.80 (2H, m) MS (ESI): m/z 500,502<br>
Preparation 70<br>
1-tert-Butyl 7-ethyl 2-acetyl-2-[(5,6-dichloro-3-pyridiny])carbonyl1Heptanedioate NMR (CDCI3,8): 1.24 (3H, t, J=7Hz), 1.25-1.40 (2H, m), 1.38 (9H, s), 1.65-1.75<br>
(2H, m), 2.18-2.27 (2H, m), 2.28-2.37 (2H, m), 2.44 (3H, s), 4.12 (2H, q, J=7Hz), 8.13 (1H, d, J=2Hz), 8.57 (1H, d, J=2Hz)<br><br>
Preparation 71<br>
1-lert-Buty] 6-elhy] 2-(methoxyacety])-2-[(5-methyl-3-pyridinyl)carbonyl1Hexanedioate NMR (CDCI3, 5): 1.24 (3H, 1, J=7Hz), 1.36 (9H, s), 1.60-1.80 (2H, m), 2.20-2.45<br>
(4H, m), 2.39 (3H, s), 3.38 (3H, s), 4.12 (2H, q, J=7Hz), 4.38 (1H, d, J=18Hz), 4.50 (1H, d, J=18Hz), 7.87 (1H, s), 8.55 (1H, s), 8.73 (1H, s) MS (ESI+): m/z 422<br>
Preparation 72<br>
1-tert-Butyl 5-ethyl 2-(methoxyacetyl)-2-[(5-methy]-3-pyridinyl)carbonyl]pentanedioate NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.37 (9H, s), 2.23-2.70 (4H, m), 2.39 (3H, s),<br>
3.37 (3H, s), 4.12 (2H, q, J=7Hz), 4.32 (1H, d, J=18Hz), 4.43 (1H, d, J=18Hz), 7.84 (1H, s), 8.55 (1H, s), 8.73 (1H, s) MS (ESI+): m/z 408<br>
Preparation 73<br>
1 -tert-Butyl 6-ethyl 2-acetyl-2-[(5-methyl-3-pyridinyl)carbonyl1Hexanedioate<br>
NMR (CDCI3, 6): 1.24 (3H, t, J=7Hz), 1.34 (9H, s), 1.60-1.75 (2H, m), 2.20-2.39<br>
(4H, m), 2.39 (3H, s), 2.46 (3H, s), 4.11 (2H, q, J=7Hz), 7.87 (1H, s), 8.56 (1H, s),<br>
8.73	OH, s)<br>
MS (ESI+): m/z 392<br>
Preparation 74<br>
1-tert-Butyl 5-ethyl 2-acetyl-2-[(5-methyl-3-pyridinyl)carbonyl]pentanedioate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.36 (9H, s), 2.39 (3H, s), 2.44 (3H, s), 2.35-<br>
2.47 (2H, m), 2.56-2.70 (2H, m), 4.11 (2H, q, J=7Hz), 7.88 (1H, s), 8.56 (1H, s),<br>
8.74	OH, s)<br>
MS (ES1+): m/z 378<br>
Preparation 75<br>
1 -tert-Butyl 5-ethyl 2-acelyl-2-[(5-bromo-3-pyridinyl)carbonyl]pentanedioate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.37 (9H, s), 2.40 (2H, t, J=7Hz), 2.59 (2H, t,<br><br>
J=7Hz), 2.46 (3H, s), 4.13 (2H, q, J=7Hz), 8.20 (1H, t, J=3Hz), 8.81 (2H, dd, .1=7, 3Hz)<br>
Preparation 76<br>
1-lert-Butyl 7-ethyl 2-(3-cyanobenzoyl)-2-(methoxyacetyl)heptanedioate<br>
NMR(CDC13,5): 1.20-1.41 (14H,m), 1.60-1.74 (2H, m), 2.27-2.34 (4H,m), 3.37<br>
(83H, s), 4.10 (2H, q, J=8Hz), 4.29 (1H, d, J=16Hz), 4.46 (1H, d, J=16Hz), 7.55 (1H, t, J=8Hz), 7.80 (1H, dd, J=8,1Hz), 7.93 (1H, dd, J=8,1Hz), 8.04 (1H, br s)<br>
Preparation 77<br>
1-tert-Butyl 7-ethyl 2-[(acetyloxy)acetyl]-2-[(5-bromo-3-<br>
pyridinyl)carbonyl1Heptanedioate<br>
NMR (CDC13,5): 1.22-1.28 (5H, m), 1.36 (9H, s), 1.68 (2H, m), 2.14 (3H, s), 2.32<br>
(2H, m), 4.11 (2H, q, J=7Hz), 5.07 (1H, d, J=18Hz), 5.34 (1H, d, J=18Hz), 8.21 (lH,m),8.81(2H,m)<br>
Preparation 78<br>
To 1-tert-butyl 7-ethyl 2-acetyl-2-(3-cyanobenzoyl)-heptanedioate (4.2 g) was added trifluoroacetic acid (20 mL) in an ice-water bath. After 30 minutes, the bath was removed and the reaction mixture was stirred at ambient temperature. After 1 hour, the mixture was concentrated. The residue was dissolved in toluene and was evaporated in vacuo to give ethyl 6-(3-cyanobenzoyl)-7-oxooctanoate (3.20 g, 100.4%) as colorless oil.<br>
Ethyl 6-(3-cyanobenzoyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=8Hz), 1.28-1.40 (2H, m), 1.60-1.74 (2H, m), 1.91-<br>
2.14 (2H, m), 2.17 (3H, s), 2.31 (2H, t, J=8Hz), 4.11 (2H, q, J=8Hz), 4.39 (1H, t, J=8Hz), 7.64 (1H, t, J=8Hz), 7.87 (2H, dd, J=8,1Hz), 8.20 (2H, dd, J=8,1Hz), 8.26(lH,brs) MS(ESr):m/z314(M-H)<br>
The following compounds were obtained in substantially the same manner as that<br><br>
of Preparation 78.<br>
Preparation 79<br>
Ethyl 7-oxo-6-[3-(trifluoromethyl)benzoyl]octanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1.32-1.43 (2H, in), 1.62-1.77 (2H, m), 1.96-<br>
2.17 (2H, m), 2.17 (3H, s), 2.30 (2H, t, J=7Hz), 4.J1 (2H, q, J=7Hz), 4.44 (1H, t, J=7Hz), 7.64 (1H, t, J=8Hz), 7.86 (1H, d, J=8Hz), 8.15 (1H, d, J=8Hz), 8.24 (1H, s)<br>
Preparation 80<br>
Ethyl 6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3, 5): 1.26 (3H, t, J=7Hz), 1.27-1.44 (2H, m), 1.65-1.75 (2H, m), 1.90-<br>
2.12 (2H, m), 2.17 (3H, s), 2.25-2.34 (2H, m), 2.43 (3H, s), 4.10 (2H, q, J=7Hz), 4.42 (1H, t, J=7Hz), 8.03 (1H, s), 8.63 (1H, s), 8.98 (1H, s) MS (ES1+): m/z 306 (M+H)<br>
Preparation 81<br>
Ethyl 8-methoxy-6-[(3-methoxy-5-isoxazolyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.34-1.47 (2H, m), 1.65-1.74 (2H, m), 1.83-<br>
2.03 (2H, m), 2.29 (2H, t, J=7Hz), 3.31 (3H, s), 4.05 (5H, s), 4.11 (2H, q, J=7Hz), 4.51 (lH,t,J=7Hz), 6.56 (lH,s)    . MS (ES1+): m/z 342 (M+H)<br>
Preparation 82<br>
Ethyl 6-[3-(l ,3-oxazol-5-yl)benzoyl]-7-oxooctanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.33-1.46 (2H, m), 1.63-1.77 (2H, m), 1.95-<br>
2.17 (2H, m), 2.17 (3H, s), 2.30 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.46 (1H, t, J=7Hz), 7.47 (1H, s), 7.56 (1H, t, J=8Hz), 7.85-7.96 (2H, m), 7.98 (1H, s), 8.27 (lH,m)<br>
Preparation 83<br>
Ethyl 6-(3,4-dichlorobenzoyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.60-1.74 (2H, m), 1.91-<br><br>
2.14 (2H, m), 2.14 (3H, s), 2.30 (2H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 4.34 (1H, t, J=7Hz), 7.57 (1H, d, J=8Hz), 7.78 (1H, dd, J=2,8Hz), 8.06 (1H, d, J=2Hz)<br>
Preparation 84<br>
Ethyl 6-[(4-chloro-2-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDC13, 5): 1.25 (3H, t, J=7Hz), 1.34-] .48 (2H, m), 1.62-1.77 (2H, m), 1.80-<br>
2.10 (2H, m), 2.31 (2H, t, J=7Hz), 2.34 (3H, s), 4.12 (2H, q, J=7Hz), 4.83-4.92 (1H, m), 7.49 (1H, dd, J=2 Hz, 5Hz), 8.04 (1H, d, J=2Hz), 8.57 (1H, d, J=5Hz) MS (ESI+): m/z 326 (M+H)<br>
Preparation 85<br>
Ethyl 6- [(5 -chloro-2-thienyl)carbonyl] -8-methoxy-7-oxooctanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1321.42 (2H, m), 1.60-1.73 (2H, m), 1.84-<br>
2.06 (2H, m), 2.28 (2H, t, J=7Hz), 3.30 (3H, s), 3.97 (1H, d, J=17Hz), 4.06 (1H, d, J=17Hz), 4.11 (2H, q, J=7Hz), 4.40 (1H, t, J=7Hz), 6.99 (1H, d, J=4Hz), 7.56 (1H, d,J=4Hz)<br>
Preparation 86<br>
Ethyl 6-[(6-methoxy-2-pyrazinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.34-1.48 (2H, m), 1.60-1.78 (2H, m), 1.88-<br>
2.08 (2H, m), 2.31 (3H, s), 2.32 (2H, t, J=7Hz), 4.01 (3H, s), 4.11 (2H, q, J=7Hz), 4.62 (1H, t, J=7Hz), 8.44 (1H, s), 8.81 (1H, s) MS (ESI+): m/z 323 (M+H)<br>
Preparation 87<br>
Ethyl 6-(l-benzofuran-2-ylcarbonyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.34-1.48 (2H, m), 1.62-1.76 (2H, m), 1.93-<br>
2.19 (2H, m), 2.24 (3H, s), 2.30 (2H, t, J=7Hz), 4.10 (2H, q, J=7Hz), 4.37 (1H, t,<br>
J=7Hz), 7.34 (1H, t, J=8Hz), 7.51 (1H, t, J=8Hz), 7.56-7.65 (2H, m), 7.73 (1H, d,<br>
1	J=8Hz)<br>
MS (ESI+): m/z 895 (M+H)<br><br>
Preparation 88<br>
Ethyl 6-(l-benzothien-2-ylcarbony])-7-oxooctanoate<br>
NMR (CDC13,5): 1.23 (3H, t, J=7Hz), 1.35-1.48 (2H,m), 1.60-1.80 (2H,m), 1.95-<br>
2.17	(2H, m), 2.19 (3H, s), 2.30 (2H, t, J=7Hz), 4.10 (2H, q, J=7Hz), 4.36 (1H, t,<br>
J=7Hz), 7.38-7.53 (2H, m), 7.82-7.93 (2H, m), 8.05 (1H, s)<br>
Preparation 89<br>
Ethyl 6-(l ,3-oxazol-5-ylcarbonyl)-7-oxooctanoate<br>
NMR (CDC13,5): 1.25 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.65-1.78 (2H, ra), 1.92-<br>
2.10 (2H, m), 2.21 (3H, s), 2.32 (2H, t, J=7Hz), 4.11 (3H, m), 7.88 (1H, s), 8.05 (lH,s)<br>
Preparation 90<br>
Ethyl 6-benzoyl-7-oxooctanoate<br>
NMR(CDC13,6): 1.24(3H,t,J=7Hz), 1.29-1.42(2H,m), 1.60-1.75 (2H,m), 1.92-<br>
2.12 (2H, m), 2.14 (3H, s), 2.29 (2H, t, J=7Hz), 4.10 (2H, q, J=7Hz), 4.43 (1H, t, J=7Hz), 7.42-7.53 (2H, m), 7.55-7.64 (1H, m), 7.98 (2H, d, J=8Hz)<br>
Preparation 91<br>
Ethyl 7-oxo-6-(6-quinolinylcarbonyl)octanoate<br>
NMR (CDC13, 5): 1.23 (3H31, J=7Hz), 1.36-1.48 (2H, m), 1.65-1.78 (2H, m), 2.00-<br>
2.18	(2H, m), 2.18 (3H, s), 2.30 (2H, t, J=7Hz), 4.10 (2H, q, J=7Hz), 4.58 (1H, t,<br>
J=8Hz), 7.54 (1H, m), 8.18 (1H, d, J=8Hz), 8.28 (1H, dd, J=2 Hz, 8Hz), 8.32 (1H,<br>
d, J=8Hz), 8.51 (1H, d, J=2Hz), 9.05 (1H, m)<br>
MS (ESI+): m/z 342 (M+H)<br>
Preparation 92<br>
Ethyl 8-[4-({[(benzyloxy)carbonyl]amino}sulfonyl)benzoyl]-9-oxodecanoate<br>
NMR (CDC13,5): 1.23-1.37 (9H, m), 1.55-1.68 (11H, s), 2.01 (2H, m), 2.18 (3H, s),<br>
2.29 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.39 (1H, t, J=7Hz), 5.11 (2H, s), 7.30-7.49 (5H, m), 7.74 (1H, s, br), 8.04-8.13 (4H, m) MS (ESP): m/z 530 (M-H)<br><br>
Preparation 93<br>
Ethyl 7-(l ,3-oxazol-5-yl)-7-oxoheptanoate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.41 (2H, m), 1.76 (2H, m), 2.03 (2H, m),<br>
2.31 (2H, m), 3.20 (2H, m), 4.10 (2H, q, J=7Hz), 7.94 (1H, s), 8.10 (1H, s)<br>
Preparation 94<br>
Ethyl 6-[3-(methylsulfonyl)benzoyl]-7-oxooctanoate<br>
NMR (CDCI3,8): 1.24 (3H, t, J=8Hz), 1.59-1.64 (2H, m), 1.91-2.15 (2H, m), 2.18<br>
(3H, s), 2.30 (2H, t, J=8Hz), 3.11 (3H, s), 4.10 (2H, q, J=8Hz), 4.45 (1H, t, J=8Hz), 7.23 (1H, t, J=8Hz), 8.17 (1H, dd, J=8,1Hz), 8.25 (2H, br d, J=8Hz), 8.53(lH,brs) MS (ESI+): m/z 369 (M+H)<br>
Preparation 95<br>
Ethyl 6-(2-chloroisonicotinoyl)-7-oxooctanoate<br>
NMR(CDC13,8): 1.25 (3H,t,J=8Hz), 1.30-1.40 (2H,m), 1.60-1.71 (2H,m), 1.90-<br>
2.14 (2H, m), 2.27 (3H, s), 2.25-2.74 (2H, m), 4.11 (2H, q, J=8Hz), 4.32 (1H, t, J=8Hz), 7.15 (1H, dd, J=7,1Hz), 7.76 (1H, d, J=lHz), 8.09 (1H, d, J=7Hz) MS (ES1+): m/z 326 (M+H)<br>
Preparation 96<br>
Ethyl 6-(3-nitrobenzoyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=8Hz), 1.29-1.41 (2H, m), 1.60-1.74 (2H, m), 1.91-<br>
2.16 (2H, m), 2.19 (3H, s), 2.30 (2H, t, J=8Hz), 4.11 (2H, q, J=8Hz), 4.46 (1H, t, J=8Hz), 7.71 (1H, t, J=8Hz), 8.30 (1H, br d, J=8Hz), 8.45 (4H, br d, J=8Hz), 8.80 (lH,brs) MS (ES1+): m/z 337 (M+H)<br>
Preparation 97 4-(2-Acetylhexanoyl)benzonitrile<br>
NMR (CDC13,8): 0.90 (3H, t, J=8Hz), 1.18-1.44 (4H, m), 1.90-2.12 (2H, m), 2.17<br><br>
(3H, s), 4.40 (1H, t, J=8Hz), 7.80 (2H, d, J=8Hz), 8.08 (2H, d, J=8Hz) MS (ESI"): m/z 242 (M-H)<br>
Preparation 98<br>
Ethyl 6-[(5-bromo-3-pyridinyl)carbony]]-7-oxooctanoate<br>
NMR(CDC13,5): 1.25 (3H, t, J=7Hz), 1.32-1.43 (2H,m), 1.60-1.76 (2H,m), 1.96-<br>
2.15 (2H, m), 2.19 (3H, s), 2.30 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.36 (1H, t, J=7Hz), 8.37 (1H, s), 8.87 (1H, br), 9.07 (1H, br) MS: (m/z) 370,372 (M+H)<br>
Preparation 99<br>
Ethyl 6-(2-chloroisonicotinoyl)-8-(methylthio)-7-oxooctanoate<br>
NMR (CDC13,5): 1.24 (3H, t, J=7Hz), 1.34-1.47 (2H, m), 1.60-1.77 (2H, m), 1.92<br>
(3H, s), 1.93-2.05 (2H, m), 2.30 (2H, t, J=7Hz), 3.19 (1H, d, J=17Hz), 3.26 (1H, d, J=17Hz), 4.11 (2H, q, J=7Hz), 4.68 (1H, t, J=7Hz), 7.72 (1H, d, J=5Hz), 7.86 (1H, s), 8.57 (1H, d, J=5Hz) MS: (m/z) 370 (M-H), 372 (M+H)<br>
Preparation 100<br>
Ethyl 7-(3-cyanobenzoyl)-8-oxononanoate<br>
NMR (CDCI3,8): 1.21-1.44 (7H, m), 1.55-1.69 (2H, m), 1.89-2.15 (2H, m), 2.17 (3H,<br>
s), 2.29 (2H, t, J=8Hz), 4.12 (2H, q, J=8Hz), 4.39 (1H, t, J=8Hz), 7.64 (1H, t, J=8Hz), 7.87 (1H, dd, J=8,1Hz), 8.20 (1H, dd, J=8,1Hz), 8.27 (1H, br s) MS (ESI+): m/z 330 (M+H)<br>
Preparation 101<br>
Ethyl 6-[(6-chloro-2-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3, 5): 1.26 (3H, t, J=7Hz), 1.36-1.52 (2H, m), 1.63-1.75 (2H, m), 1.77-<br>
2.06 (2H, m), 2.29 (2H, t, J=7Hz), 2.45 (3H, s), 4.12 (2H, q, J=7Hz), 4.82 (1H, t, J=7Hz), 7.51 (1H, d, J=8Hz), 7.82 (1H, t, J=8Hz), 7.97 (1H, d, J=8Hz) MS (ESI+): m/z 326<br><br>
Preparation 102<br>
Ethyl 6-(3-methoxybenzoyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.60-1.77 (2H,m), 1.92-<br>
2.12 (2H, m), 2.15 (3H, s), 2.31 (2H, t, J=7Hz), 3.88 (3H, s), 4.12 (2H, q, J=7Hz), 4.42 (1H, t, J=7Hz), 7.14 (1H, dd, J=2Hz, 8Hz), 7.40 (1H, t, J=8Hz), 7.46-758 (2H,m) MS (ESI+): m/z 321<br>
Preparation 103<br>
Ethyl 6-(3,5-dichlorobenzoyl)-7-oxooctanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.32-1.42 (2H, m), 1.63-1.75 (2H, m), 1.90-<br>
2.12 (2H, m), 2.16 (3H, s), 2.30 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.32 (1H, t, J=7Hz), 7.58 (1H, m), 7.82 (2H, m)<br>
Preparation 104<br>
Ethyl 6-[(5-chloro-2-thienyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3,8): 1.24 (3H, t, J=7Hz), 1.30-1.40 (2H, m), 1.62-1.74 (2H, m), 1.90-<br>
2.12	(2H, m), 2.16 (3H, s), 2.29 (2H, t, J=7Hz), 4.13 (2H, q, J=7Hz), 4.14 (1H, m),<br>
6.98 (1H, d, J=4Hz), 158 (1H, d, J=4Hz)<br>
Preparation 105<br>
Ethyl 6-(3-fluorobenzoyl)-7-oxooctanoate<br>
NMR (CDCI3, 5): 1.24 (3H, t, J=7Hz), 1.28-1.42 (2H, m), 1.60-1.75 (2H, m), 1.90-<br>
2.13	(2H, m), 2.14 (3H, s), 2.29 (2H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 4.37 (1H, t,<br>
J=7Hz), 7.26-7.33 (1H, m), 7.43-7.52 (1H, m), 7.63-7.68 (1H, m), 7.76 (1H, d,<br>
J=8Hz)<br>
MS (ESI+): m/z 309<br>
Preparation 106<br>
Ethyl 7-oxo-6-(3-quinolinylcarbonyl)octanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.35-1.47 (2H, m), 1.63-1.77 (2H, m), 1.98-<br>
2.18 (2H, m), 2.20 (3H, s), 2.31 (2H, t, J=7Hz), 4.10 (2H, q, J=7Hz), 4.55 (1H, t,<br><br>
J=7Hz), 7.66 (1H, t, J=8Hz), 7.87 (1H, t, J=8Hz), 7.97 (1H, d, J=8Hz), 8.18 (1H, d, J=8Hz), 8.78 (1H, d, J=2Hz), 9.43 (1H, d, J=2Hz) MS (ESI+): m/z 342<br>
Preparation 107<br>
Ethyl 6-isonicotinoyl-7-oxooctanoate<br>
NMR (CDC13,5): 1.24 (3H, t, J=7Hz), 1.26-1.45 (2H, m), 1.60-1.75 (2H,m), 1.94- -<br>
2.07 (2H, m), 2.17 (3H, s), 2.27-2.35 (2H, m), 4.11 (2H, q, J=7Hz), 4.38 (1H, t, J=7Hz), 7.74 (2H, m), 8.83 (2H, m)<br>
Preparation 108<br>
Ethyl 6-[(3-methoxy-5-isoxazolyl)carbonyl]-7-oxooctanoate<br>
NMR (CDC13,6): 1.25 (3H, t, J=7Hz), 1.33-1.45 (2H, m), 1.60-1.80 (2H, m), 1.88-<br>
2.05 (2H, m), 2.28 (3H, s), 2.30-2.45 (2H, m), 4.03 (3H, s), 4.11 (2H, q, J=7Hz), 4.33 (1H, t, J=7Hz), 6.56 (1H, s) MS (ESI4): m/z 312<br>
Preparation 109<br>
Ethyl 6-[(5-methyl-3-isoxazolyl)carbonyl]-7-oxooctanoate<br>
NMR (CDC13,5): 1.24 (3H, t, J=7Hz), 1.32-1.44 (2H,m), 1.61-1.74 (2H,m), 1.85-<br>
2.07 (2H, m), 2.26-2.38 (2H, m), 2.29 (3H, s), 2.49 (3H, s), 4.11 (2H, q, J=7Hz), 4.64 (lH,m), 6.39 (lH,s) MS (ESI+): m/z 296<br>
Preparation 110<br>
Ethyl 6-(2-chloroisonicotinoyl)-8-methoxy-7-oxooctanoate<br>
NMR (CDC13,8): 1.24 (3H, t, J=7Hz), 1.28-1.43 (2H, m), 1.66 (2H, t, J=7Hz), 1.73-<br>
1.86 (1H, m), 1.93-2.07 (1H, m), 2.73 (2H, t, J=7Hz), 3.23 (3H, s), 3.89 (1H, d, J=17Hz), 4.00 (1H, d, J=17Hz), 4.10 (2H, q, J=7Hz), 4.58 (1H, t, J=7Hz), 7.66 (1H, d, J=5Hz), 7.78 (1H, s), 8.60 (1H, d, J=5Hz) MS (ES1+): m/z 356, MS (ESI"): m/z 354<br><br>
Preparation 111<br>
Ethyl 8-methoxy-6-(3-methoxybenzoyl)-7-oxooctanoate<br>
NMR (CDCI3, 5): 1.24 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.60-1.73 (2H, m), 1.79-<br>
2.04 (2H, m), 2.28 (2H, t, J=7Hz), 3.27 (3H, s), 3.87 (3H, s), 4.00 (2H, m), 4.12 (2H, q, J=7Hz), 4.66 (1H, t, J=7Hz), 7.13 (1H, m), 7.39 (1H, m), 7.45-7.55 (2H, m)<br>
Preparation 112<br>
Ethyl 8-methoxy-7-oxo-6-(6-quinolinylcarbonyl)octanoate<br>
NMR (CDCI3,6): 1.24 (3H, t, J=7Hz), 1.34-1.47 (2H, m), 1.60-1.75 (2H, m), 1.86-<br>
2.10 (2H, m), 2.27 (2H, t, J=7Hz), 3.24 (3H, s), 4.02-4.10 (2H, m), 4.12 (2H, q, J=7Hz), 4.83 (1H, t, J=7Hz), 7.48-7.55 (1H, m), 8.16-8.33 (3H, m), 8.49 (1H, m), 9.02 (1H, m) MS (ESI+): m/z 372<br>
Preparation 113<br>
Ethyl 8-methoxy-7-oxo-6-(3-pyridinylcarbonyl)octanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.31-1.45 (2H, m), 1.60-1.73 (2H, m), 1.75-<br>
2.08 (2H, m), 2.28 (2H, t, J=7Hz), 3.24 (3H, s), 3.94 (1H, d, J=17Hz), 4.00 (1H, d, J=17Hz), 4.10 (2H, q, J=7Hz), 4.67 (1H, t, J=7Hz), 7.44 (1H, m), 8.22 (1H, m), 8.81 (1H, d, J=5Hz), 9.18 (1H, m) MS (ESI+): m/z 322<br>
Preparation 114<br>
Ethyl 6-(3-chlorobenzoyl)-8-methoxy-7-oxooctanoate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.30-1.44 (2H, m), 1.60-1.74 (2H, m), 1.75-<br>
1.92 (1H, m), 1.94-2.10 (1H, m), 2.28 (2H, 1, J=7Hz), 3.25 (3H, s), 3.93 (1H, d, J=17Hz), 4.02 (1H, d, J=17Hz), 4.12 (2H, q, J=7Hz), 4.63 (1H, t, J=7Hz), 7.43 (1H, I, J=8Hz), 7.57 (1H, d, J=8Hz), 7.83 (1H, d, J=8Hz), 7.94 (1H, s)<br>
Preparation 115<br>
Ethyl 6-(3-methylbenzoyl)-7-oxooctanoate<br><br>
NMR (CDCI3,6): 1.24 (3H, t, J=7Hz), 1.29-1.42 (2H, m), 1.60-1.73 (2H, m), 1.90-<br>
2.06 (2H, m), 2.13 (3H, s), 2.28 (2H, t, J=7Hz), 2.42 (3H, s), 4.10 (2H, q, J=7Hz), 4.42 (1H, t, J=7Hz), 7.31-7.43 (2H, m), 7.73-7.78 (2H, m)<br>
Preparation 118<br>
Ethyl 8-methoxy-6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.30-1.47 (2H, m), 1.60-1.74 (2H, m), 1.75-<br>
1.93 (1H, m), 1.93-2.08 (1H, m), 2.26 (2H, t, J=7Hz), 2.43 (3H, s), 3.25 (3H, s), 3.95 (1H, d, J=17Hz), 4.03 (1H, d, J=17Hz), 4.12 (2H, q, J=7Hz), 4.67 (1H, 1, J=7Hz), 8.03 (1H, s), 8.63 (1H, s), 8.98 (1H, s) MS (ES1+): m/z 336<br>
Preparation 119<br>
Ethyl 6-[(5-bromo-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.32-1.43 (2H, m), 1.60-1.76 (2H, m), 1.96-<br>
2.15 (2H, m), 2.19 (3H, s), 2.30 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.36 (1H, t, J=7Hz), 8.37 (1H, s), 8.87 (1H, br), 9.07 (1H, br) MS (ES1+): m/z 370,372<br>
Preparation 120<br>
Ethyl 6-[(5-bromo-3-pyridinyl)carbonyl]-8-methoxy-7-oxooctanoate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.30-1.47 (2H, m), 1.60-1.72 (2H, m), 1.75-<br>
1.93 (1H, m), 1.95-2.08 (1H, m), 2.27 (2H, t, J=7Hz), 3.25 (3H, s), 3.93 (1H, d, J=17Hz), 4.02 (1H, d, J=17Hz), 4.10 (2H, q, J=7Hz), 4.63 (1H, t, J=7Hz), 8.38 (1H, m), 8.88 (1H, m), 9.07 (1H, m) MS (ESI+): m/z 400,402<br>
Preparation 121<br>
Ethyl 6-[(5,6-dichloro-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3,8): 1.24 (3H, t, J=7Hz), 1.30-1.43 (2H, m), 1.60-1.77 (2H, m), 1.95-<br>
2.17 (2H, m), 2.19 (3H, s), 2.30 (2H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 4.32 (1H, t, J=7Hz), 8.31 (1H, d, J=2Hz), 8.82 (1H, d, J=2Hz)<br><br>
Preparation 122<br>
Ethyl 7-methoxy-5-[(5-methyl-3-pyridinyl)carbony]]-6-oxoheptanoate<br>
NMR (CDGI3,5): 1.23 (3H, t,J=7Hz), 1.60-1.75 (2H,m), 1.78-1.95 (1H, m), 1.95-<br>
2.12 (1H, m), 2.32 (2H, t, J=7Hz), 2.44 (3H, s), 3.25 (3H, s), 3.94 (1H, d, J=18Hz), 4.02 (1H, d, J=18Hz), 4.12 (2H, q, J=7Hz), 4.69 (1H, t, J=7Hz), 8.04 (1H, s), 8.63 (1H, s), 9.00 (1H, s) MS (ES1+): m/z 322<br>
Preparation 123<br>
Ethyl 6-methoxy-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
NMR (CDCI3,6): 1.24 (3H, t, J=7Hz), 2.08-255 (4H, m), 2.44 (3H, s), 3.23 (3H, s),<br>
3.94 (1H, d, J=18Hz), 4.01 (1H, d, J=18Hz), 4.12 (2H, q, J=7Hz), 4.88 (1H, m),<br>
8.12	(1H, s), 8.64 (1H, s), 9.04 (1H, s)<br>
MS (ESI+): m/z 308<br>
Preparation 124<br>
Ethyl 5-[(5-methyl-3-pyridinyl)carbonyl]-6-oxoheptanoate<br>
NMR (CDCI3, 8): 1.25 (3H, t, J=7Hz), 1.60-1.75 (2H,m), 1.96-2.13 (2H,m), 2.18<br>
(3H, s), 2.36 (2H, t, J=7Hz), 2.43 (3H, s), 4.12 (2H, q, J=7Hz), 4.43 (1H, t, J=7Hz), 8.04 (1H, s), 8.63 (1H, s), 8.97 (1H, s) MS (ESI4): m/z 292<br>
Preparation 125<br>
Ethyl 4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
NMR (CDCI3,6): 1.25 (3H, t, J=7Hz), 2.20 (3H, s), 2.26-2.48 (4H, m), 2.43 (3H, s),<br>
4.13	(2H, q, J=7Hz), 4.62 (1H, t, J=7Hz)5 8.08 (1H, s), 8.64 (1H, s), 9.02 (1H, s)<br>
MS (ES1+): m/z 278<br>
Preparation 126<br>
Ethyl 4-[(5-bromo-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
NMR (CDCI3,8): 1.25 (3H, t, J=7Hz), 2.26 (3H, s), 2.30 (2H, t, J=7Hz), 2.43 (2H, t,<br><br>
J=7Hz), 4.15 (2H, q, J=7Hz), 8.65(1H, s), 8.94 (1H, s), 9.22(1H, s)<br>
Preparation 127<br>
Ethyl 6-(3-cyanobenzoyl)-8-methoxy-7-oxooctanoate<br>
NMR (CDC13,6): 1.19-1.43 (12H, m), 1.57-1.70 (2H, m), 1.80 (1H, m), 1.99 (1H, m),<br>
2.28 (2H, t, J=8Hz), 3.24 (3H, s), 3.91 (1H, d, J=16Hz), 4.01 (1H, d, J=16Hz), 4.09 (2H, q, J=8Hz), 4.65 (1H, t, J=8Hz), 7.64 (1H, t, J=8Hz), 7.87 (1H, dd, J=8, 1Hz), 8.18 (1H, dd, J=8,1Hz), 8.25 (1H, br s)<br>
Preparation 128<br>
Ethyl 8-(acetyloxy)-6-[(5-bromo-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=7Hz), 1.37 (2H, m), 1.67 (2H, m), 1.98-2.06 (5H, m),<br>
2.30 (2H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 4.47 (1H, t, J=7Hz), 4.66 (d, J=17Hz), 4.74 (d, J=17Hz), 8.37 (1H, m), 8.88 (1H, m), 9.06 (1H, m)<br>
Preparation 129<br>
To a solution of Meldrum's acid (30 g, 0.208 mol) in dichloromethane (420 mL) was added pyridine (33.7 mL, 0.416 mol) over 3 minutes in an ice-methanol bath under nitrogen atmosphere (-9°C). To this mixture was added dropwise a solution of methoxyacetyl chloride (24.8 g) in dichloromethane (180 mL) over 1 hour period at the temperature. After addition, the reaction mixture was stirred at the temperature for 1 hour and at ambient temperature for 2 hours. The mixture was quenched with IN hydrochoric acid (600 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane. The combined organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give 5-(methoxyacetyl)-2,2-dimethyl-l,3-dioxane-4,6-dione as dark orange oil (38.1 g, 84.7%).<br>
5-(Methoxyacetyl)-2,2-dimethyl-l,3-dioxane-4,6-dione NMR (CDCI3,5): 1.75 (6H, s), 3.53 (3H, s), 4.87 (2H, s)<br>
Preparation 130<br>
A solution of 5-(methoxyacetyl)-2,2-dimethyl-l,3-dioxane-4,6-dione (38 g) in<br><br>
tert-butanol (120 mL) and toluene (120 mL) was refluxed for 2 hours under nitrogen atmosphere. The mixture was evaporated in vacuo to give brown oil (32.5 g). The residue was dissolved in hexane-ethyl acetate = 2-1 (200 mL) and was added silica gel (65 g) therein. After stirring for 30 minutes at ambient temperature, the mixture was filtered and washed with hexane-ethyl acetate = 2-1 (200 mL). The filtrate was concentrated in vacuo to give tert-butyl 4-methoxy-3-oxobutanoate as pale yellow oil (30.1 g, 91.0%).<br>
tert-Butyl 4-methoxy-3-oxobutanoate<br>
NMR(CDC13,5): 1.50 (9H,s),3.41 (2H, s), 3.43 (3H,s), 4.08 (2H,s)<br>
Preparation 131<br>
To a mixture of 3-formylbenzoic acid (500 mg) and p-toluenesulfonylmethyl isocyanide (715 mg) in methanol (20 mL) was added potassium carbonate (1.38 g) and the mixture was heated under reflux for 2 hours. After evaporation of solvent, the residue was partitioned between ethyl acetate and water. The aqueous layer was separated and acidified with IN hydrochloric acid. The resulting precipitates were collected and washed with water, methanol and ether to give 3-(l,3-oxazol-5-yl)benzoic acid as a colorless amorphous powder (484 mg).<br>
3-(l,3-OxazoL5-yl)benzoic acid<br>
NMR (DMSO-d6,5): 7.63 (1H, t, J=8Hz), 7.84 (1H, s), 7.89-8.02 (2H, m), 8.25 (1H,<br>
m), 8.50 (lH,s), 13.22 (lH,br) MS(ESI+):m/zl88(M-H)<br>
Preparation 132<br>
A mixture of l-(3-chlorophenyl)-l,3-butanedione (500 mg), 5-(iodomethyl)-2,2-dimethyl-l,3-dioxane (716 mg), and potassium carbonate (351 mg) in dimethylsulfoxide (2.5 mL) was stirred for 14 hours at room temperature and 7 hours at 40°C. The mixture was partitioned between ethyl acetate (20 mL) and water (10 mL). The organic layer was washed with water (10 x 2 mL) and brine, dried over magnesium sulfate, and evaporated to give a brown oil. Flash silica gel column chromatography eluling with ethyl acetate-hexane = 1-10 to 2-5 afforded l-(3-chloroDhenvl)-2-f(2,2-dimethvl-13-dioxan-5-<br><br>
yl)methyl]-l,3-butanedione as an yellow oil (614 mg).<br>
1 -(3-Chlorophenyl)-2-[(2,2-dimethyl-l ,3-dioxan-5-yl)methyl]-l ,3-bulanedione<br>
NMR (CDCI3, 5): 1.39 (6H, s), 1.70 (1H, m), 1.91-2.15 (2H, m), 2.16 (3H, s), 3.61<br>
(2H, m), 3.88 (2H, m), 4.46 (1H, t, J=7Hz), 7.44 (1H, t, J=9Hz), 7.57 (1H, m), 7.86 (1H, d, J=9Hz), 7.96 (1H, m)<br>
The following compounds were obtained in substantially the same manner as that of Preparation 132. Preparation 133 1-tert-Butyl 7-ethyl 2-(l,3-oxazol-5-ylcarbonyl)heptanedioate<br>
NMR (CDC13, 8): 1.26 (3H, t, J=7Hz), 1.32-1.38 (11H, m), 1.67 (2H, m), 1.97 (2H,<br>
m), 2.30 (2H, m), 3.86 (1H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 7.86 (1H, s), 8.03 (1H, s)<br>
Preparation 134<br>
1-tert-Butyl 7-ethyl 2-[(3,5-dimethyl-4-isoxazolyl)carbonyl1Heptanedioate<br>
NMR (CDC13, 5): 1.25 (3H, t, J=7Hz), 1.33-1.41 (11H, m), 1.64 (2H, m), 1.93 (2H,<br>
m), 2.30 (2H, m), 2.47 (3H5 s), 2.69 (2H, s), 3.79 (1H, t, J=7Hz), 4.12 (2H, q, J=7Hz)<br>
Preparation 135<br>
To a suspensin of magnesium chloride (1.46 g) in tetrahydrofuran (10 ml) was added a solution of ethyl 3-oxo-4-phenylbutanoate (2.0 g) in tetrahydrofuran (10 ml) and the mixture was cooled to 0°C, then pyridine (2.5 ml) was added. The mixture was stirred at 20°C for 30 minutes, then a solution of 4-fluorobenzoyl chloride (2.44 g) in tetrahydrofuran (10 ml) was added at 0°C. After stirring at 20°C for 2 hours, the mixure was partitoned between 0.5N hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluling with a mixture of ethyl acetate and hexane (1:5) to give ethyl 2-(4-fluorobenzoyl)-3-oxo-4-phenylbutanoate (2.15 g) as an oil.<br><br>
Ethyl 2-(4-fluorobenzoyl)-3-oxo-4-phenylbutanoate<br>
(mixture of jautomers, too complicated to be assigned)<br>
Preparation 136<br>
A mixture of l-(4-fluorophenyl)butane-l,3-dione Q .0 g), potassium carbonate (3.42 g), and tetrabulylammonium bromide (20 mg) in toluene (10 ml) was refluxed for 3 hours. After cooling to 20°C, ethyl bromoacetate (0.74 ml) was added to the mixture. After being allowed to stand at 20°C overnight, the mixture was partitoned between ethyl acetate and 0.5N hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give ethyl 3-(4-fluorobenzoyl)-4-oxopentanoate (964 mg) as an oil.<br>
Ethyl 3-(4-fIuorobenzoyl)-4-oxopentanoate<br>
NMR (CDC13,8): 1.23 (3H, t, J=7Hz), 2.18 (3H, s), 3.01 (2H, d, J=7Hz), 4.12 (2H, q,<br>
J=7Hz), 4.95 (1H, d, J=7Hz), 7.18 (2H, dt, J=2,7Hz), 8.07 (2H, ddd, J=2,5,7Hz)<br>
Preparation 137<br>
A mixture of l-(4-fluorophenyl)butane-l,3-dione (1.0 g), potassium carbonate (3.84 g), and tetrabutylammonium bromide (90 mg) in toluene (20 ml) was refluxed for 3 hours, then ethyl 6-bromohexanoate (1.18 ml) was added. After stirring at 100°C for 3 hours, the mixture was partitoned between ethyl acetate and 0.5N hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give ethyl 7-(4-fluorobenzoyl)-8-oxononanoate (983 mg) as an oil.<br>
Ethyl 7-(4-fluorobenzoyl)-8-oxononanoate<br>
NMR (CDC13,8): 1.24 (3H, t, J=7Hz), 1.25-1.45 (4H, m), 155-1.70 (2H, m), 1.90-<br>
2.10 (2H, m), 2.13 (3H, s), 2.27 (2H, t, J=7Hz), 4.11 (2H, q, J=7Hz), 4.37 (1H, t, J=7Hz), 7.16 (2H, t, J=9Hz), 8.02 (2H, dd, J=5,9Hz)<br>
Preparation 138<br><br>
A mixture of pentane-2,4-dione (5.0 g), ethyl 7-bromoheptanoate (11.1 g), potassium carbonate (13.8 g), and cesium carbonate (1.63 g) in a mixture of acetonitrile (150 ml) and dimethylsulfoxide (30 ml) was stirred at 20°C overnight, then pentane-2,4-dione (5 g) was added. After stirring at 20°C overnight, the mixture was partitoned between ethyl acetate and 0.5N hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give ethyl 8-acetyl-9-oxodecanoate (5.5 g) as an oil.<br>
Ethyl 7-acetyl-8-oxononanoate<br>
(mixture of tautomers, too complicated to be assigned)<br>
Preparation 139<br>
To a mixture of ethyl 7-acetyl-8-oxononanoate (4.0 g) and magnesium chloride (1.27 g) in dichloromethane (70 ml) was added pyridine (2.15 ml) at 0°C. The mixture was stirred at 20°C for 1 hour, then a solution of 4-cyanobenzoyI chloride (2.87 g) in dichloromethane (10 ml) was added. After stirring for 3 hours at 20°C, the mixture was partitioned between ether and IN hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give ethyl 7-acetyl-7-(4-cyanobenzoyl)-8-oxononanoate (3.52 g) as an oil.<br>
1-tert-Butyl 8-ethyl 2-acetyl-2-(4-cyanobenzoyl)octanedioate<br>
NMR(CDCl3,8):1.24(3H,t,J=7Hz),1.25-1.45(4H,m),130(9H,s)&gt;1.55-1.70<br>
(2H, m), 2.20 (2H, t, J=7Hz), 2.28 (2H, t, J=7Hz), 2.44 (3H, s), 4.12 (2H5 q, J=7Hz), 7.72 (2H, t, J=9Hz), 7.83 (2H, d, J=9Hz)<br>
Preparation 140<br>
Ethyl 7-acetyl-7-(4-cyanobenzoyl)-8-oxononanoate (3.5 g) was dissolved in trifluoroacetic acid (12.6 ml) and the mixture was stirred at 20°C for 15 minutes. The mixture was partitoned between ethyl acetate and water. The organic layer was separated, washed with water, aqueous sodium bicarbonate and brine, dried over MgSC&gt;4 (magnesium sulfate), and evaporated to give ethyl 7-(4-cyanobenzoyl)-8-oxononanoate<br><br>
(2.25 g) as an oil.<br>
Ethyl 7-(4-cyanobenzoyl)-8-oxononanoate NMR (CDCJ3, 5): 1.25 (3H, t, J=7Hz), 1.25-1.45 (4H, m), 1.55-1.70 (2H, m), 1.80-<br>
2.10 (2H, m), 2.16 (3H, s), 2.28 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 4.40 (1H, I, J=7Hz), 7.80 (2H, t, J=9Hz), 8.07 (2H, d, J=9Hz)<br>
Preparation 141<br>
A mixture of methyl 4-(arninosulfonyl)benzoate (5.10 g) and potassium carbonate (6.55 g) in dimethoxyethane (50 mL) was refluxed for 5 minutes. After cooling the mixture, a solution of benzyl chloridocarbonate (5.25 g) in dimethoxyethane (30 mL), and the resulting mixture was refluxed for 1 hour. The reaction was quenched by adding IN hydrochloric acid (100 mL). The mixture was extracted with ethyl acetate (200 mL), and the organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give a pale yellow oil, which was solidified upon standing. The solid was triturated in diisopropyl ether (30 mL) to give methyl 4-({[(benzyloxy)carbonyl]amino}sulfonyl)benzoate as a white powder (3.38 g).<br>
Methyl 4-({[(benzyloxy)carbonyl]amino}sulfonyl)benzoate<br>
NMR (CDC13, 5): 3.98 (3H, s), 5.10 (2H, s), 7.22 (2H, m), 7.34 (3H, m), 7.64 (1H, s,<br>
br), 8.08 (2H, d, J=9Hz), 8.16 (2H, d, J=9Hz)<br>
Preparation 142<br>
A suspension of methyl 4-({[(benzyloxy)carbonyl]amino}-sulfonyl)benzoate (3.38 g) and 85% pottasium hydroxide (1.28 g) in methanol (40 mL) was stirred for 35 minutes. Methanol was evaporated off, and to the mixture was added IN hydrochloric acid (20 mL). A white crystal was formed, which was collected by filtration and washed with water and diisopropyl ether, and dried under vacuum. 4-({[(Benzyloxy)carbonyl]amino}sulfonyl)benzoic acid was obtained as a white crystal (2.92 g).<br>
4-({[(Benzyloxy)carbonyl]amino}sulfonyl)benzoic acid<br><br>
NMR (DMSO-d6,8): 5.06 (2H, s), 7.25 (2H, m), 7.33 (3H, m), 8.00 (2H, d, J=9Hz),<br>
8.15(2H,d,J=9Hz)<br>
MS(ESI"):m/z334(M-H)<br>
Preparation 143<br>
To a suspension of S-(2-pyridinyl) 3-cyanobenzenecarbothioate (2.40 g) in toluene (10 mL) was added titanium chloride (1.99 g) under an ice-methanol bath over 5 minutes (-7 to -2°C). After stirring for 10 minutes, a solution of 2-ethyl-lH-pyrrole (1.00 g) in toluene (10 mL) was added over 5 minutes (-4 to 0°C). The resulting heterogeneous mixture was stirred for 1.5 hours at room temperature. Ethyl acetate (20 mL) and water (20 mL) were added, and the mixture was filtered through celite. The filtrate was diluted with ethyl acetate (80 mL) and water (30 mL), and organic extract was washed with water (30 mL), IN sodium hydroxide (50 mL), and brine (50 mL), dried over magnesium sulfate, and evaporated to give a dark colored crystal (2.46 g). The crystal was triturated in diisopropyl ether (10 mL) to give 3-[(5-ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile as a brown crystal (1.57 g, 70.1%).<br>
3-[(5-Ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile<br>
NMR (CDC13,5): 1.33 (3H, t, J=7Hz), 2.75 (2H, q, J=7Hz), 6.12 (1H, m), 6.78 (1H,<br>
m), 7.60 (1H, t, J=8Hz), 7.82 (1H, d, J=8Hz), 8.07 (1H, d, J=8Hz), 8.14 (1H, s), 9.50(lH,s,br)<br>
Preparation 144<br>
To a suspension of magnesium chloride (3.01 g) in tetrahydrofuran (30 mL) was added tert-butyl 3-oxobutanoate (5.00 g). The mixture was cooled under an ice-bath. Then, pyridine (5.00 g) was added over 15 minutes. After stirring for 1 hour at room temperature, the resulting mixture was cooled under the ice-bath. A solution of 2-chlorobenzoyl chloride (4.98 g) in tetrahydrofuran (30 mL) was added over 15 minutes. The mixture was stirred for 1 hour at room temperature. The reaction was quenched by adding IN hydrochloric acid (65 mL). The mixture was filtered, and the solvent was evaporated off. The residue was extracted with ethyl acetate (150 mL). The extract was washed with water (100 mL), saturated sodium bicarbonate (100 mL), and brine, dried over magnesium sulfate, and evaporated lo give tert-butyl 2-(3-chlorobenzoyl)-3-<br><br>
oxobutanoate as an yellow oil (8.82 g).<br>
terl-Butyl 2-(3-chlorobenzoyl)-3-oxobutanoate<br>
NMR (CDCI3, 5): mixture of tautomers: 1.20 and 1.27 (9H, s), 2.16 and 2.44 (3H, s),<br>
7.33-7.71 (4H,m), 13.66 (lH,s)<br>
Preparation 145<br>
A solution of tert-butyl 2-(3-chlorobenzoyl)-3-oxobutanoate (8.82 g) in trifluoroacetic acid (40 mL) was stirred for 1 hour under an ice-bath. The volatile was removed in vacuo, and the residue was partitioned between ethyl acetate (150 mL) and saturated sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give l-(3-chlorophenyl)-l,3-butanedione as a pale orange crystal (5.33 g).<br>
l-(3-Chlorophenyl)-l ,3-butanedione<br>
NMR (CDCI3, 5): 2.21 (3H, s), 6.14 (1H, s), 7.38 (1H, t, J=9Hz), 7.48 (1H, d, J=9Hz),<br>
7.75 (1H, d, J=9Hz), 7.85 (1H, s)<br>
Preparation 146<br>
To a mixture of 2-(trimethylsilyl)ethanol (20.5 g) and pyridine (18.7 g) in dichloromethane (40 mL) was added a solution of ethanedioyl dichloride (10.0 g) in dichloromethane (20 mL) over 30 minutes under an ice-bath (6 to 20°C). The bath was removed, and the mixture was stirred for 0.5 hour. The mixture was filtered, and the filtrate was partitioned between ethyl acetate (200 mL) and IN hydrochloric acid (200 mL). The organic layer was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, and evaporated to give bis[2-(trimethylsilyl)ethyl] oxalate as a pale yellow oil (25.1 g).<br>
bis[2-(Trimethylsilyl)ethyl]oxalate<br>
NMR (CDCI3, 6): 0.08 (18H, s), 1.12 (4H, m), 4.38 (4H, m)<br>
Preparation 147<br><br>
To a suspension of dimethyl sulfone (7.00 g) in diethyl ether (50 mL) was added potassium tert-butoxide (8.76 g). To the resulting mixture was added bis[2-(trimetbylsilyl)-<br>
ethyljoxalate (23.8 g). The resulting mixture was stirred for 36 hours at room temperature. The mixture was partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (50 mL). The organic layer was washed with brine, dried over magnesium sufate, and evaporated to give a dark orange oil. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-25 to 8-5 afforded 2-(trimethylsilyl)ethyl 3-(methylsulfonyl)-2-oxopropanoate as a pale brown oil (8.37 g).<br>
2-(Trimethylsilyl)ethyl 3-(methylsulfonyl)-2-oxopropanoate<br>
NMR (CDC13,5): 0.08 (9H, s), 1.14 (2H, m), 3.11 (3H, s), 4.43 (4H, m), 4.56 (2H, s)<br>
MS (ESI): m/z 265 (M-H)<br>
Preparation 148<br>
A mixture of 4-oxo-4-phenylbutanoic acid (5.00 g), ethanol (2.59 g), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.46 g), and 4-(dimethylamino)pyridine (171 mg) in N,N-dimethylformamide (25 mL) was stirred for 1.5 hours at room temperature. The mixture was partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (75 mL), and the organic layer was washed with water (75 x 3 mL), saturated sodium bicarbonate (75 mL), and brine (75 mL), dried over magnesium sulfate, and evaporated to give ethyl 4-oxo-4-phenylbutanoate as a colorless oil (4.19 g).<br>
Ethyl 4-oxo-4-phenylbutanoate<br>
NMR (CDCI3,5): 1.27 (3H, t, J=7Hz), 2.76 (2H, t, J=7Hz), 3.32 (2H, t, J=7Hz), 4.16<br>
(2H, q, J=7Hz), 7.47 (2H, t, J=9Hz), 7.55 (1H, d, J=9Hz), 7.98 (2H, d, J=9Hz) MS (ESI+): Hi'2 207 (M+H)<br>
The following compound was obtained in substantially the same manner as thai of Preparation 148.<br><br>
Preparation 149<br>
Elhy] 5-oxo-5-phenylpentanoate<br>
NMR (CDCI3, 5): 1.26 (3H, t, J=7Hz), 2.08 (2H, m), 2.44 (2H, t, J=7Hz), 3.06 (2H, t,<br>
J=7Hz), 4.14 (2H, q, J=7Hz), 7.46 (2H, t, J-9Hz), 7.56 (1H, d, J=9Hz), 7.97 (2H, d,J=9Hz) MS(ESI+):m/2 221(M+H)<br>
Preparation 150<br>
A mixture of 2-benzoylcyclohexanone (1.00 g), sodium ethoxide (404 mg) in ethanol (5 mL) was stirred for 3.5 hours at room temperature. The reaction was quenched by adding IN hydrochloric acid (1 mL). The solvent was evaporated off, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give ethyl 7-oxo-7-phenylheptanoate as a brown oil (133 g).<br>
Ethyl 7-oxo-7-phenylheptanoate<br>
NMR (CDC13,6): 1.25 (3H, t, J=7Hz), 1.42 (2H, m), 1.63-1.81 (4H, m), 2.32 (2H, t,<br>
J=7Hz), 2.98 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 7.47 (2H, t, J=9Hz), 7.54 (1H, d, J=7Hz), 7.95 (2H, d, J=9Hz)<br>
Preparation 151<br>
To a solution of ethyl 7-chloro-7-oxoheptanoate (1.31 g) in dichloromethane (25 mL) was added a solution of 2-(trirnethylsilyl)-l,3-thiazole (500 mg) in dichloromethane (5 mL) under nitrogen. After stirring for 3 hours, the reaction was quenched by adding saturated sodium bicarbonate (5 mL). The mixture was partitioned between ethyl acetate (30 mL) and saturated sodium bicarbonate (30 mL), and the organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give a colorless oil. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-10 to 2-5 afforded ethyl 7-oxo-7-(l,3-thiazol-2-yl)heptanoate as a colorless oil (778 mg).<br>
Ethyl 7-oxo-7-(l ,3-thiazol-2-yl)heptanoate<br>
NMR (CDC13, 8): 1.25 (3H, t, J=7Hz), 1.44 (2H, m), 1.64-1.85 (4H, m), 2.32 (2H, t,<br><br>
J=7Hz), 3.17 (2H, 1, J=7Hz), 4.12 (2H, q, J=7Hz), 7.66 (1H, d, J=3Hz), 8.00 (1H, d,J=3Hz) MS(ESI+):m/z256(M+H)<br>
Preparation 152<br>
To a solution of 7-methoxy-7-oxoheptanoic acid (1.00 g) in dichloromethane (10 mL) was added a solution of trifluoroacetic anhydride (1.33 g) in dichloromethane (2 mL). After stirring for 0.5 hour, a solution of 1-methyl-lH-pyrrole (1.49 g) in dichloromethane (2 mL) was added. The mixture was stirred for 2 hours 40 minutes at room temperature and 2 hours at 35°C. The mixture was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give a brmown oil. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-20 to 4-5 afforded methyl 7-(l-methyl-lH-pyrrol-2-yl)-7-oxoheptanoate as a colorless oil (615 mg).<br>
Methyl 7-(l-methyl-lH-pyrrol-2-yl)-7-oxoheptanoate<br>
NMR (CDC13&gt; 5): 1.34 (2H, m), 1.61-1.77 (4H, m), 2.32 (2H, t, J=7Hz), 2.77 (2H, t,<br>
J=7Hz), 3.66 (3H, s), 3.94 (3H, s), 6.13 (1H, m), 6.79 (1H, m), 6.93 (1H, m) MS (ES1+): m/z 238 (M+H)<br>
Preparation 153<br>
To a suspension of 4-({[(benzyloxy)carbonyl]amino}-sulfonyl)benzoic acid (2.90 g) in dichloromethane (30 mL) was added N,N-dimethylformamide (19.0 mg) and followed by oxalyl chloride (1.15 g) under an ice-bath. The mixture was stirred for 0.5 hour at room temperature and refluxed for 1 hour. The resulting mixture was refluxed further for 5 minutes after adding oxalyl chloride (439 mg). The volatile was evaporated off to give a white solid. The solid was triturated in diisopropyl ether to give benzyl [4-(chlorocarbonyl)phenyl]sulfonylcarbamate as a white powder (2.40 g), which was used for the next reaction without further purification.<br>
Benzyl [4-(chlorocarbonyI)phenyl]sulfonylcarbamate<br>
Preparation 154<br><br>
To a solution of lerl-butyl 4-(methylthio)-3-oxobutanoate (5.00 g) and potassium carbonate (3.72 g) in dimethylformamide (25 mL) was added ethyl 5-iodopentanoate (6.89 g) and the mixture was stirred at ambient temperature for 15 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of bexane and ethyl acetate (20:1 -10:1) to give 1-tert-butyl 7-ethyl 2-[(methylthio)acetyl1Heptanedioate as colorless oil (5.88 g),<br>
1-tert-butyl 7-ethyl 2-[(methylthio)acetyl1Heptanedioate<br>
NMR(CDC13,5): 1.25 (3H,t, J=7Hz), 130-1.42 (2H,m), 1.45 (9H,s), 1.63-1.74<br>
(2H, m), 1.81-1.93 (2H, m), 2.05 (3H, s), 2.30 (2H, t, J=7Hz), 3.23 (1H, d, ]=17Hz), 3.38 (1H, d, J=17Hz), 3.74 (1H, t, J=7Hz), 4.11 (2H, q, J=7Hz)<br>
Preparation 155<br>
To a suspension of hydroxylamine hydrochloride (29.4 g) in dichloromethane (200 mL) was added diisopropylethylamine (54.6 g) over 3 minutes in a methanol-ice bath under a nitrogen atmosphere. A white precipitate was formed upon the addition. After stirring for 1 hour under the bath, a solution of diphenylphosphinic chloride (20.0 g) in dichloromethane (20 mL) was added over 60 minutes. A white crystal was formed upon the addition. The mixture was warmed to 0°C over 1 hour with stirring. The reaction was quenched by adding water (200 mL) over 3 minutes. After stirring the mixture for 0.5 hour, the crystal was collected by filtration. The crystal was washed with water (50 x 3 mL) followed by diisopropyl ether (50 x 3 mL). The collected crystal was dried overnight in the air and 3 hours under a reduced pressure with slight warming (4°C) to give a crude product. The crude product was triturated in EtOH (ethanol) to give (aminooxy)(diphenyl)phosphine oxide as a white crystal (15.3 g).<br>
(Aminooxy)(dipheny])phosphine oxide<br>
NMR (CDC13,5): 7.54-7.58 (6H, m), 7.74-7.83 (4H, m), 8.20-8.33 (2H, m)<br>
Preparation 156<br><br>
To a solution of l-(lH-pyrrol-2-yl)ethanone (5.00 g) in telrahydrofuran (100 mL) was added potassium tert-butoxide (6.17 g) in a water bath under a nitrogen atmosphere. After stirring for 1 hour, (aminooxy)(diphenyl)phosphine oxide (12.8 g) was added over 2 hours. After stirring for 2 hours at room temperature, water (4 mL) was added over 3 minutes to give a clear solution. The solvent was evaporated off, and the residue was partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (25 x 5 mL), and the combined organic extract was washed with brine, dried over anhydrous magnesium sulfate, and evaporated to give a brown oil (6.01 g). The oil was dissolved in diisopropyl ether (30 mL), and to the solution was added hexane (15 mL) to afford a pale yellow crystal. After stirring for 1 hour, the crystal was removed by filtration. The filtrate was evaporated to give a brown oil (5.69 g). The oil was dissolved in ethyl acetate (45.5 mL), the solution was cooled under an ice-bath. To the cooled solution was added 4N hydrogen chloride in ethyl acetate (11.5 mL) over 15 minutes to afford a pale brown precipitate. After stirring the mixture for 0.5 hour under the bath, the precipitate was collected by filtration and washed with ethyl acetate (5x3 mL) to give a pale brown powder (5.33 g). The powder was suspended in ethyl acetate (37 mL) and warmed to 3°C. The suspension was stirred for 1 hour at room temperature. The powder was collected by filtration and washed with ethyl acetate (5x3 mL) to give l-(l-amino-lH-pyrrol-2-yl)ethanone hydrochloride as a pale brown powder (5.25 g).<br>
l-(l-Amino-lH-pyrrol-2-yl)ethanohe hydrochloride<br>
NMR (CDC13,5): 2.37 (3H, s), 5.22 (2H, s, br), 6.07 (1H, m), 6.99 (1H, m), 7.15 (1H,<br>
m)<br>
Preparation 157<br>
Under a nitrogen atmosphere, hydrazine monohydrate (530 g) was added to ethanol (1.7 L) over 55 minutes. To the mixture was added l-(l-amino-lH-pyrrol-2-yl)ethanone hydrochloride (170 g) over 20 minutes. The mixture was stirred for 10 minutes at room temperature and heated to refluxing temperature over 55 minutes, and refluxed for 15 minutes. After cooling the mixture under a water bath, water (1.7 L) was added to the mixture (30 to 31°C). Ethanol was evaporated off, and the resulting mixture was extracted with chloroform (0.85 x 4 mL). The combined organic extract was washed<br><br>
with brine (1.3 L). The brine was extracted with chloroform (0.85 L). The combined rganic extract was dried over anhydrous magnesium sulfate, and evaporated to give lE)-l-(l-amino-lH-pyrrol-2-yl)ethanone hydrazone as a brown crystal (112 g).<br>
lE)"l-(l-Amino-lH-pyrrol-2-yl)ethanone hydrazone<br>
NMR (CDC13,5): 2.10 (3H,s), 5.11 (2H,s,br), 5.83 (2H,s,br), 5.98 (lH,m), 6.25<br>
(lH,m),6.79(lH,m) MS (ESI+): m/z 139 (M+H)<br>
-reparation 158<br>
To a suspension of (lE)-l-(l-amino-lH-pyrrol-2-yl)ethanone hydrazone (110 g) n toluene (1.1 L) was added potassium tert-butoxide (93.8 g) over 5 minutes under a litrogen atmosphere, and the mixture was heated to refluxing temperature over 45 ninutes. After refluxing for 15 minutes, the mixture was cooled to room temperature and partitioned between ethyl acetate (1.1 L) and water (1.1 L). The aqueous layer was extracted with ethyl acetate (1.1 L) again. The combined organic extract was was washed with brine (1.1 L), and the brine was extracted with ethyl acetate (0.5 L). All the organic layer was combined, dried over anhydrous magnesium sulfate, and evaporated to give 2-sthyl-lH-pyrrol-1-amine as a brown oil (94.4 g).<br>
2-Ethyl-lH-pyrrol-l-amine<br>
NMR (CDCI3,8): 1.26 (3H, t, J=7Hz), 21.62 (2H, q, J=7Hz), 4.53 (2H, s, br), 5.80<br>
(1H, m), 5.99 (1H, m), 6.67 (1H, m)<br>
Preparation 159<br>
To a suspension of tert-butyl 4-methoxy-3-oxobutanoate (3.09 g) and potassium carbonate (2.50 g) in dimethylformamide (20 mL) was added ethyl 5-iodopentanoate (4.62 g) and the mixture was stirred at ambient temperature for 15 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (20:1 - 5:1) to give 1-tert-butyl 7-ethyl 2-(methoxyacetyl)heptanedioate as colorless oil (4.33 g).<br><br>
1-tert-Buly] 7-ethyl 2-(melhoxyacetyl)heptanedioate<br>
NMR(CDC13,5): 1.25 (3H,t,J=7Hz), 1.30-1.44 (2H, m), 1.45 (9H,s), 1.60-1.73<br>
(2H, m), 1.80-1.93 (2H, m), 2.29 (2H, t, J=7Hz), 3.41 (3H, s), 3.47 (1H, t, J=7Hz), 4.02 (4H,m) MS:(m/z)317(M+H)<br>
The following compounds were obtained in substantially the same manner as that of Preparation 159. Preparation 160 1-tert-Butyl 6-ethyl 2-(methoxyacetyl)hexanedioate<br>
NMR(CDC13, 8): 1.25 (3H,t, J=7Hz), 1.46 (9H,s), 1.52-1.73 (2H,m), 1.82-1.94<br>
(2H, m), 2.33 (2H, t, J=7Hz), 3.42 (3H, s), 3.50 (1H, t, J=7Hz), 4.10 (2H, s), 4.12 (2H,q,J=7Hz)<br>
Preparation 161<br>
1-tert-Buty] 5-ethyl 2-(methoxyacetyl)pentanedioate<br>
NMR (CDC13, 8): 1.26 (3H, t, J=7Hz), 1.47 (9H, s), 2.10-2.25 (2H, m), 2.37 (2H51,<br>
J=7Hz), 3.42 (3H, s), 3.62 (1H, t, J=7Hz), 4.12 (2H, s), 4.13 (2H, q, J=7Hz)<br>
Preparation 162<br>
1-tert-Butyl 6-ethyl 2-acetylhexanedioate<br>
NMR (CDCI3, 8): 1.26 (3H, t, J=7Hz), 1.47 (9H, s), 1.57-1.75 (2H, m), 1.79-1.93<br>
(2H, m), 2.23 (3H, s), 2.33 (2H, t, J=7Hz), 3.33 (1H, t, J=7Hz), 4.12 (2H, q, J=7Hz) MS (ES1+): m/z 273<br>
Preparation 163<br>
1-tert-Butyl 5-ethyl 2-acetylpentanedioate<br>
NMR (CDCI3,8): 1.26 (3H, t, J=7Hz), 1.47 (9H, s), 2.08-2.22 (2H, m), 2.24 (3H, s),<br>
2.33-2.42 (2H, m), 3.45 (1H, t, J=7Hz), 4.13 (2H, q, J=7Hz)<br><br>
Preparation 164<br>
To a solution of 2-ethyl-lH-pyrrole (7.00 g) in tetrahydrpfuran (14 mL) was added 0.93 M ethyl magnesium bromide (198 mL) under an ice-bath. The mixture was stirred for 1 hour at room temperature. Then the resulting solution was added to a suspension of 5-bromonicotinoyl chloride (22.3 g) in tetrahydrofuran (110 mL) over 50 minutes under an ice-bath. After stirring for 15 minutes under the bath, the reaction was quenched by adding saturated ammonium chloride (30 mL). The mixture was partitioned between ethyl acetate (350 mL) and water (350 mL). The organic layer was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, and evaporated to give a dark colored gum (33.9 g). The gum was dispersed in ethyl acetate-exane (1:3, 150 mL) in the presence of silica gel (150 mL). The mixture was filtered, and the filtrate was concentrated to give an yellow crystal (20.6 g). Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-20 to 4-5 afforded (5-bromo-3-pyridinyl)(5-ethyl-lH-pyrrol-2-yl)methanone as a pale yellow solid (7.11 g).<br>
(5-Bromo-3-pyridinyl)(5-ethyl-lH-pyrrol-2-yl)methanone<br>
NMR (CDC13,5): 1.33 (3H, t, J=7Hz), 2.75 (2H, q, J=7Hz), 6.14 (1H, m), 6.83 (1H,<br>
m), 8.27 (1H, m), 8.82 (1H, m), 8.98 (1H, m) MS(ESl+):m/z279(M+H)<br>
Preparation 165<br>
To a solution of tert-butyl 4-(acetyloxy)-3-oxobutanoate (30.0 g) and ethyl 5-iodopentanoate (35.5 g) in N,N-dimethylformamide (150 mL) was added potassium carbonate (19.2 g) at room temperature. After stirring for 4 hours, the mixture was quenched by adding IN hydrochloric acid (140 mL) under an ice-bath. The mixture was partitioned between ethyl acetate (450 mL) and water (300 mL). The organic extract was washed with water (500 mL, three times) and brine, dried over magnesium sulfate, and evaporated to give a brown oil containing 1-tert-butyl 7-ethyl 2-[(acetyloxy)acetyl1Heptanedioate (63.4 g, 43% wt purity).<br>
1-tert-Butyl 7-ethyl 2-[(acetyloxy)acetyl1Heptanedioate<br>
NMR (CDC13,8): 1.20-1.37 (5H,m), 1.46 (9H, s), 1.63 (2H,m), 1.85 (2H,m), 2.17<br>
(3H, s), 2.30 (2H, t, J=7Hz), 3.39 (1H, t, J=7Hz), 4.11 82H, q, J=7Hz), 4.73 (1H,<br><br>
d, J=17Hz), 4.82 (1H, d, J=17Hz)<br>
Preparation 166<br>
To a solution of ethyl thiophene (2.00 g) and ethyl 7-chloro-7-oxoheptanoate (5.39 g) in dichloromethane (20 mL) was added 1 M tin chloride in dichloromethane (38.9 mL) over 0.5 hour under an ice-bath (5 to 8°C). After stirring for 0.5 hour, the mixture was stirred for 0.5 hour at room temperature. The mixture was poured into ice-water (100 mL), and extracted with ethyl acetate (100 mL). The organic extract was washed with water (100 mL) and brine, dried over magnesium sulfate, and evaporated to give a brown oil. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-10 to 3-10 afforded ethyl 7-oxo-7-(2-thienyl)heptanoate as a brown oil (5.79<br>
g&gt;-<br>
Ethyl 7-oxo-7-(2-thienyl)heptanoate<br>
NMR (CDC13,8): 1.25 (3H, t, J=7Hz), 1.42 (2H, m), 1.63-1.72 (4H, m), 2.31 (2H, t,<br>
J=7Hz), 2.91 (2H, t, J=7Hz), 4.12 (2H, q, J=7Hz), 7.13 (1H, m), 7.612 (1H, m), 7.70 (lH,m)<br>
The following compounds were obtained in substantially the same manner as those of Preparations 129 and 130. Preparation 167 tert-Butyl 3-(3,5-dimethyl-4-isoxazolyl)-3-oxopropanoate<br>
NMR (CDCI3,5): 1.47 (9H, s), 2.46 (3H, s), 2.68 (3H, s), 3.68 (2H, s)<br>
Preparation 168<br>
Ethyl 4-methyl-3-oxopentanoate<br>
NMR (CDCI3,5): 1.14 (6H, d, J=7Hz), 1.28 (3H, t, J=7Hz), 2.71 (1H, quintet,<br>
J=7Hz), 3.50 (s, 2H), 4.19 (2H, q, J=7Hz), 7.06-7.18,7.56, and 7.85 (4H, m) Preparation 169<br><br>
tert-Butyl 4-(methylthio)-3-oxobutanoate<br>
NMR (CDCI3, 5): 1.47 (9H, s), 2.07 (3H, s), 3.31 (2H, s), 3.58 (2H, s)<br>
Preparation 170<br>
tert-Butyl 3-(l ,3-oxazol-5-yl)-3-oxopropanoate<br>
NMR (CDCI3, 6): (a mixture of keto- and enol-form); keto-form: 1.45 (9H, s), 3.77<br>
(2H, s), 7.85 (1H, s), 8.04 (1H, s); enol-form: d 1.45 (9H, s), 5.54 (1H, s), 7.53 (1H,S),7.91(1H,S)<br>
The following compounds were obtained in substantially the same manner as that of Preparation 143. Preparation 171 (2-Chloro-4-pyridinyl)(5-ethyl-lH-pyrrol-2-yl)methanone<br>
NMR (CDCI3, 5): 1.32 (3H, t, J=7Hz), 2.74 (2H, q, J=7Hz), 6.13 (1H, m), 6.79 (1H,<br>
m), 7.56 (1H, d, J=5Hz), 7.69 (1H, s), 8.54 (1H, d, J=5Hz), 9.40 (lH,br)<br>
Preparation 172 (5 -Ethyl-1 H-py rrol-2-yl)(3-methoxypheny l)methanone<br>
NMR (CDCI3, 5): 1.32 (3H, t, J=7Hz), 2.74 (2H, q, J=7Hz), 3.87 (3H, s), 6.08 (1H,<br>
m), 6.83 (1H, m), 7.08 (1H, dd, J=2 Hz, 8Hz), 7.33-7.42 (2H, m), 7.47 (1H, d, J=8Hz),9.58(lH,br) MS (ESI+): m/z 230<br>
Preparation 173 (5-Ethyl-lH-pyrrol-2-yl)(4-pyridinyl)methanone<br>
NMR (CDCI3, 5): 1.32 (3H, t, J=7Hz), 2.72 (2H, q, J=7Hz), 6.13 (1H, m), 6.81 (1H,<br>
m), 7.65 (2H, d, J=7Hz), 8.77 (2H, d, J=7Hz), 9.39 (1H, br)<br>
Preparation 174<br>
(5 -Ethyl -1 H-py rrol -2-yl)(2-py razinyl)methanone<br>
NMR (CDCI3, 5): 1.33 (3H, t, J=7Hz), 2.77 (2H, q, J=7Hz), 6.14 (1H, m), 7.51 (1H,<br>
m), 8.65 (1H, m), 8.74 (1H, m), 9.36 (1H, br)<br><br>
Preparation 175 (5-Ethyl-lH-pyrrol-2-yl)(3-pyridinyl)methanone<br>
NMR (CDCI3,5): 133 (3H, t, J=7Hz), 2.76 (2H, q, J=7Hz), 6.12 (1H, m), 6.81 (1H,<br>
m), 7.42 (1H, m), 8.13 (1H, m), 8.76 (1H, m), 9.08 (1H, m), 9.36 (1H, br)<br>
Preparation 176<br>
A mixture of 3-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyI]benzonitriIe (300 mg), methanesulfonylacetic acid (208 mg), l-(3-dimethylaminopropy])-3-ethylcarbodiimide hydrochloride (361 mg), and 1-hydroxybenzotriazole (254 mg) in N,N-dimethylformamide (1 mL) was stirred for 15 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water two times, saturated sodium bicarbonate, and brine, dried over magnesium sulfate, and evaporated to give a pale brown solid. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1/2 to 1/0 afforded N-[2-(3-cyanobenzoyl)-5-ethyl-lH-pyrrol-l-yl]-2-(methylsulfonyl)acetamide as a pale brown foam, which was solidified upon standing (505 mg).<br>
N-[2-(3-Cyanobenzoyl)-5-ethyl-lH-pyrrol-l-yl]-2-(methylsulfonyl)acetamide<br>
NMR (CDC13,8): 1.29 (3H, t, J=7Hz), 2.62 (2H, q, J=7 Hz,), 3.28 (3H, s), 4.15 (2H,<br>
s), 6.12 (1H, d, J=5Hz), 6.75 (1H, d, J=5Hz), 7.58 (1H, t, J=9Hz), 7.82 (1H, d, J=9Hz), 8.01 (1H, d, J=9Hz), 8.06 (1H, s)<br><br>
The following compound was obtained in substantially the same manner as that of Preparation 176. Preparation 177 Ethyl 3-{[2-(4-cyanobenzoyl)-5-ethyl-lH-pyrrol-l-yl]ammo}-3-oxopropanoate<br>
NMR (CDCI3, 5): 1.20-1.37 (6H, m), 2.56 (2H, q, J=7Hz), 3.57 (2H, s), 4.30 (2H, q,<br>
J=7Hz), 6.06 (1H, d, J=5Hz), 6.68 (1H, d, J=5Hz), 7.54 (2H, d, J=9Hz), 7.84 (2H, d,J=9Hz)<br>
Example 1<br><br>
To a solution of 4-[(l-amino-5-ethyl-lH-pyrrol-2-yI)carbonyl]benzonitri]e (100 mg) in toluene (1 rnL) were added l-(4-methoxyphenyl)acetone (103 mg) and p-toluene-sulfonic acid monohydrate (16 mg) at ambient temperature. The reaction mixture was heated at 80°C for 3 hours. The mixture was evaporated in vacuo. The residue was purified by flash silica gel column chromatography eluting with hexane-ethyl acetate = 20-1 and 15-1 to give 4-[7-ethyl-3-(4-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile (31 mg, 20.2%) as an yellow solid.<br>
4-[7-Ethyl-3-(4-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-4»yl]benzonitrile<br>
NMR (CDC13,5): 1.40 (3H, t, J=8Hz), 2.31 (3H, s), 3.16 (2H, q, J=8Hz), 3.77 (3H, s),<br>
6.10 (1H, d, J=5Hz), 6.60 (1H, d, J=5Hz), 6.75 (2H, d, J=8Hz), 6.93 (2H, d5 J=8Hz), 7.33 (2H, d, J=8Hz), 7.53 (2H, d, J=8Hz) MS (ESI+): m/z 368 (M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 1. Example 2<br>
Ethyl 4-(4-cyanophenyl)-2-(2-ethoxy-2-oxoethyl)-7-ethylpyrrolo[ 1,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3,5): 0.84 (3H, t, J=7Hz), 1.28 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 3.04<br>
(2H, q, J=7Hz), 3.93 (2H, q, J=7Hz), 4.13 (3H, s), 4.19 (2H, q, J=7Hz), 6.24 (1H, d, J=5Hz)&gt; 6.62 (1H, d, J=5Hz), 7.13 (2H, d, J=9Hz), 7.76 (2H, d, J=9Hz)<br>
.    Example 3<br>
Ethyl 4-(4-cyanophenyl)-7-ethyl-2-(trifluoromethyl)pyrrolo[ 1 ,2-b]pyridazine-3-carboxylate<br>
NMR(CDC13,5): 1.08 (3H, t,J=7Hz), 1.41 (3HSt, J=7Hz),3.11 (2H,q,J=7Hz),4.11<br>
(2H, q, J=7Hz), 6.43 (1H, d, J=5Hz), 6.93 (1H, d, J=5Hz), 7.62 (2H, d, J=9Hz), 7.80(2H,d,J=9Hz)<br>
Example 4 4-[7-Ethyl-2-methyl-3-(3-pyridinylcarbonyl)pyrrolo[l)2-b]pyridazin-4-yl]benzonitrile<br><br>
NMR (CDCI3,5): 1.43 (t, J=7 Hz, 3H), 2.47 (s, 3H), 3.09 (q, J=7 Hz, 2 H), 6.35 (d,<br>
J=5 Hz, 1H), 6.74 (d, J=5 Hz, 1H), 7.23 (1H, m), 7.48 (2H, d, J=9Hz), 7.55 (2H, d, J=9Hz), 7.93 (1H, m), 8.62 (1H, m), 8.74 (1H, m)<br>
Example 5 3-[7-Ethyl-2-methyl-3-(4-pyridinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDCJ3,8): 1.42 (3H, t, J=7Hz), 2.32 (3H, s), 3.08 (2H, q, J=7Hz), 6.15 (1H, d,<br>
J=5Hz), 6.67 (1H, d, J=5Hz), 7.00 (2H, d, J=9Hz), 7.37 (2H, m), 7.57 (2H, m), 8.50(2H,d,J=9Hz)<br>
Example 6 4-(3-Benzyl-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl)benzonitrile<br>
NMR (CDCI3,5): 1.40 (3H, t, J=8Hz), 2.35 (3H, s), 3.04 (2H, q, J=8Hz), 3.83 (3H, s),<br>
5.94 (1H, d, J=5Hz), 6.57 (1H, d, J=5Hz), 6.98 (2H, d, J=8Hz), 7.14-7.30 (3H, m), 7.46 (2H, d, J=8Hz), 7.68 (2H, d, J=8Hz) MS (ESI+): m/z 352 (M+H)<br>
Example 7 4-(3-Chlorophenyl)-7-e(hyl-2-phenylpyrrolo[l,2-b]pyridazine-3-carbonitrile<br>
mp: 172-173°C<br>
NMR(CDCI3,8): 1.41 (3H, t,J=8Hz), 3.10 (2H,q,J=8Hz), 6.65 (lH,d, J=5Hz), 6.88 (1H, d, J=5Hz), 7.47-7.64 (6H, m), 7.70 (1H, br s), 7.81-7.90 (2H, m)<br>
Example 8<br>
3-(3-Ethyl-7,7,9,9-tetramethyl-6,7,8,9-tetrahydropyrrolo[l,2-b]cinnolin-10-<br>
yl)benzonitrile<br>
NMR (CDCI3,8): 1.00-1.15 (12H, m), 1.37 (3H, 1, J=8Hz), 2.81 (3H, s), 3.00 (2H, q,<br>
J=8Hz), 3.82 (2H, t, J=5Hz), 5.46 (1H, d, J=5Hz), 6.46 (1H, d, J=5Hz),7.50-7.65 (3H,m),7.72(lH,m)<br>
Example 9 3-(3-Ethyl-9-oxo-6,7,8,9-tetrahydropyrrolo[l,2-b]cinnolin-10-yI)benzonitrile<br><br>
NMR (CDCI3,5): 1.40 (3H, t, J=8Hz), 2.08-2.22 (2H, m), 2.60 (2H, I, J=7Hz), 3.00-<br>
3.15 (4H, m), 6.26 (1H, d, J=5Hz), 6.74 (1H, d, J=5Hz), 7.49-7.61 (3H, m), 7.74 (lH.m) MS(ESI+):m/z316(M+H)<br>
Example 10<br>
3-(6-Ethyl-l-oxo-2,3-dihydro-lH-cyclopenta[e]pyrrolo[l,2-b]pyridazin-9-yl)benzonitrile mp: 150-154°C<br>
NMR (CDC13,5): 1.43 (3H, t, J=8Hz), 2.75 (2H, t, J=7Hz), 3.10 (2H, q, J=8Hz), 3.24 (2H, t, J=7Hz), 6.67 (1H, d, J=5Hz), 6.87 (1H, d, J=5Hz), 7.60 (1H, 1, J=8Hz), 7.75-7.90 (3H,m) MS (ES1+): m/z 324 (M+Na)<br>
Example 11 3-(7-Ethyl-2-neopentylpyirolo[l,2-b]pyridazin-4-yl)benzonitrile<br>
NMR (CDCI3, 6): 1.05 (9H, s), 1.39 (3H, t, J=8Hz), 2.68 (2H, s), 3.04 (2H, q, J=8Hz),<br>
6.36 (1H, s), 6.48 (1H, d, J=5Hz), 6.67 (1H, d, J=5Hz), 7.51 (1H, t, J=8Hz), 7.75 (1H, br d, J=8Hz), 7.92-8.01 (2H, m) MS (ES1+): m/z 318 (M+H)<br>
Example 12 3-[7-Ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDCI3, 5): 1.44 (3H, t, J=8Hz), 3.11 (2H, q, J=8Hz), 6.52-6.60 (2H, m), 6.74<br>
(1H, d, J=5Hz), 6.98 (1H, s), 7.09 (1H, d, J=5Hz), 7.56-7.68 (2H, m), 7.78 (1H, dd, J=8,1Hz), 7.96-8.08 (2H, m) MS (ESI+): m/z 314 (M+H)<br>
Example 13 4-[7-Ethyl-2-methyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDCI3,8): 1.38 (3H, t, J=8Hz), 2.89 (3H, s), 3.00-3.11 (5H, m), 6.09 (1H, d,<br>
J=5Hz), 6.73 (1H, d, J=5Hz), 7.45 (2H, d, J=8Hz), 7.76 (2H, d, J=8Hz) MS (ES1+): m/z 340 (M+H)<br><br>
Example 13-2 4-{7-Ethyl-2-[(melhylsu]fony])iriethyl]pyrro]o[l,2-]pyridazin-4-yl}benzonitrile<br>
NMR (CDCI3,5): 1.39 (3H, t, J=8Hz), 2.96-3.09 (5H, m), 4.44 (2H, s), 6.63 (1H, d,<br>
J=5Hz), 6.71 (1H, s), 6.8J (1H, d, J=5Hz), 7.79 (2H, d, J=8Hz), 7.85 (2H, d, J=8Hz) MS (ES1+): m/z 340 (M+H)<br>
Example 15 3-[7-Ethyl-2-methy]-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDCI3, 5): 1.39 (3H, t, J=SHz), 2.89 (3H, s), 3.00-3.11 (5H, m), 6.09 (1H, d,<br>
J=5Hz), 6.73 (1H, d, J=5Hz), 7.54-7.63 (3H, m), 7.77 (1H, m)<br>
Example 16<br>
To a solution of 4-[7-ethyl-3-(4-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile (22 mg) in N,N-dimethylformamide (1 mL) were added IN sodium hydroxide (0.12 mL) and 30% hydrogen peroxide (0.07 mL) at ambient temperature. After 1 hour stirring, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water three times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel column chromatography (silica gel, 30 mL) eluting with hexane-ethyl acetate = 5-1 and 0-1 to give 4-[7-ethyl-3-(4-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzamide (18 mg, 78.0%) as an yellow solid.<br>
4-[7-Ethyl-3-(4-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzamide<br>
NMR (CDCI3, 5): 1.41 (3H, t, J=8Hz), 2.31 (3H, s), 3.17 (2H, q, J=8Hz), 3.77 (3H, s),<br>
5.61 (0.2H, br s), 6.02 (0.4H, br s), 6.13 (1H, d, J=5Hz), 6.60 (1H, d, J=5Hz), 6.75 (2H, d, J=8Hz), 6.95 (2H, d, J=8Hz), 7.31 (2H, d, J=8Hz), 7.68 (2H, d, J=8Hz)<br>
MS(ESI+):m/z386(M+H)<br>
The following compound was obtained in substantially the same manner as that of Example 16.<br><br>
Example 17<br>
3-[2-(Dimethylai"nino)-7-ethyl-3-(mcthylsu]fonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzamide NMR (CDCI3, 5): 1.32 (3H, t, J=7Hz), 2.90 (6H, s), 2.95 (2H, q, J=7Hz), 3.36 (3H, s),<br>
6.21 (1H, d, J=5Hz), 6.79 (1H, d, J=5Hz), 7.44 (1H, s, br), 7.52-7.56 (2H, m), 7.90 (1H, s), 7.94-8.06 (2H, m) MS (ES1+): m/z 387 (M+H)<br>
Example 18 3-(7-Ethyl-2-neopentylpyrrolo[l,2-b]pyridazin-4-yl)benzamide<br>
NMR (CDCI3, 5): 1.05 (9H, s), 1.39 (3H, t, J=8Hz), 2.68 (2H, s), 3.04 (2H, q, J=8Hz),<br>
5.70 (1H, br s), 6.11 (1H, br s), 6.41 (1H, s), 6.52 (1H, d, J=5Hz), 6.65 (1H, d, J=5Hz), 7.59 (1H, t, J=8Hz), 7.85-7.93 (2H, m), 8.15 (1H, br s) MS (ES1+): m/z 336 (M+H)<br>
Example 19 3-[7-Ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-yl]benzamide<br>
NMR (CDCI3, 8): 1.43 (3H, t, J=8Hz), 3.10 (2H, q, J=8Hz), 5.70 (1H, br s), 6.13 (1H,<br>
br s), 6.53-6.60 (2H, m), 6.71 (1H, d, J=5Hz), 7.02 (1H, s), 7.06 (1H, d, J=5Hz), 7.55-7.65 (2H, m), 7.79-7.98 (2H, m), 8.02 (1H, br s) MS(ESI+):m/z332(M+H)<br>
Example 20<br>
5-[2-({[4-(Aminocarbonyl)benzyl]oxy}methyl)-4-(5-bromo-3-pyridinyl)-7-<br>
ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (DMSO-d6,5): 1.27-1.45 (7H, m), 1.99 (2H, m), 2.96 (2H, m), 3.40 (2H, m), 4.67 (2H, s), 4.72 (2H, s), 5.88 (1H, d, J=5Hz), 6.67 (1H, d, J=5Hz), 7.35 (1H, s, br), 7.44 (2H, d, J=8Hz), 7.86 (2H, d, J=8Hz), 7.96 (1H, s, br), 8.21 (1H, m), 8.60 (lH,m),8.86(lH,m)<br>
Example 21<br>
To a solution of ethyl 6-(3-cyanobenzoyl)-7-oxooctanoate (3.18 g) in toluene (30 mL) was added 2-ethyl-lH-pyrrol-l-amine (1.17 g) and p-toluenesulfonic acid<br><br>
monohydrate (96 mg) at ambient temperature. The reaction mixture was refluxed for 1 hour. The mixture was evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 200 mL) eluting with hexane-ethyl acetate = 20-1, 15-1, and 10-1 to give ethyl 5-[4-(3-cyanophenyl)-7-ethy]-2-methy]pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (3.29 g, 83.8%) as an yellow oil.<br>
Ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l)2-b]pyridazin-3-yl]pentanoate NMR (CDC13,5); 1.23 (3H, l, J=8Hz), 1.32-1.58 (7H, m), 2.18 (2H, t, J=8Hz), 2.35-<br>
2.45 (2H,m), 3.01 (2H,q, J=8Hz),4.1()(2H,q, J=8Hz),5J9 (lH,d, J=5Hz), 6.51 (1H, d, J=5Hz), 7.57-7.67 (3H, m), 7.75 (1H, m)<br>
The following compounds were obtained in substantially the same manner as that of Example 21. Example 22 Ethyl 2,4-diisopropylpyrrolo[l,2-b]pyridazine-3-carboxylale<br>
NMR (300 MHz, CDCI3, 8): 1.32 (6H, d, J=7.5Hz), 1.39 (3H, t, J=7.5Hz), 1.46 (6H,<br>
d, J=7.5Hz), 2.91-3.05 (1H, m), 3.05-3.20 (1H, m), 4.38 (2H, q, J=7.5Hz), 6.64-6.68 (1H, m), 6.76-6.80 (1H, m), 7.65-7.68 (1H, m) MS(ES+)m/e275.33<br>
Example 23<br>
■<br>
Ethyl 4-(2-chlorophenyl)-2-isopropylpyiTOlo[ 1,2-b]pyridazine-3-carboxylate<br>
NMR (300 MHz, CDCI3, §): 0.89 (3H, t, J=7.5Hz), 1.30-1.40 (6H, m), 3.36-3.51 (1H,<br>
m), 4.00 (2H, q, J=7.5Hz), 6.10-6.18 (1H, m), 6.75-6.84 (1H, m), 7.28-7.45 (3H, m), 7.45-7.55 (1H, m), 7.75-7.81 (1H, m)<br>
Example 24<br>
Ethyl 2-isopropyl-4-(2-naphthyl)pyrrolo[l ,2-b]pyridazine-3-carboxylate<br>
NMR (300 MHz, CDCI3, 5): 0.78 (3H, t, J=7.5Hz), 1.38 (6H, d, J=7.5Hz), 3.24-3.35<br>
(lH,m), 3.95 (2H,q,J=7.5Hz), 6.36-6.40 (lH,m), 6.80-6.85 (lH,m), 7.50-7.54 (3H, m), 7.78-7.82 (1H, m), 7.82-8.00 (4H, m) MS (ES+) m/e 359.56<br><br>
Example 25<br>
Ethyl 5-{7-ethyl-2-methyl-4-[3-(trifluoromethyl)phenyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br>
NMR (CDCI3,5): 1.22 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.59 (4H, m), 2.14<br>
(2H, t, J=7Hz), 2.38-2.46 (2H, m), 2.55 (3H, s), 3.01 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.83 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.53-7.64 (3H, m), 7.71 (1H, d, J=8Hz) MS (ES1+): m/z 433 (M+H)<br>
Example 26<br>
Ethyl 5-[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pynolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.38-1.60 (4H, m), 2.18<br>
(2H, t, J=7Hz), 2.42 (3H, s), 2.38-2.50 (2H, m), 2.55 (3H, s), 3.00 (2H, q, J=7Hz), 4.09 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.50 (1H, s), 8.39 (lH,s),8.53(lH,s) MS (ES1+): m/z 380 (M+H)<br>
Example 27<br>
Ethyl 5-[7-ethyl-4-(3-methoxy-5-isoxazolyl)-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]pentanoate<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.55-1.64 (2H, m), 1.64-<br>
1.80 (2H, m), 2.33 (2H, t, J=7Hz), 2.74-2.85 (2H, m), 3.03 (2H, q, J=7Hz), 3.43 (3H, s), 4.08 (3H, s), 4.12 (2H, q, J=7Hz), 4.62 (2H, s), 6.28 (1H, s), 6.38 (1H, d, J=4Hz),6.65(lH,d,J=4Hz) MS (ES1+): m/z 416 (M+H)<br>
Example 28<br>
Ethyl 5-{7-ethyl-2-methyl-4-[3-(l,3-oxazol-5-yl)phenyl]pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3, 5): 1.20 (3H, t, J=7Hz), 1.35 (3H, t, J=7Hz), 1.40-1.63 (4H, m), 2.17<br><br>
(2H, 1, J=7Hz), 2.44-2.57 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 4.05 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.50 (1H, d, J=4Hz), 7.33 (1H, d, J=8Hz), 7.39 (1H, s), 7.53 (1H, t, J=8Hz), 7.66 (1H, m), 7.74 (1H, d, J=8Hz), 7.93 (1H, s)<br>
Example 29<br>
Ethyl 5-[4-(3,4-dichlorophenyl)-7-ethyl-2-melhylpyrrolo[l,2-b]pyridazin-3-yl]penlanoate NMR (CDC13,5): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.38-1.48 (2H, m), 1.50-<br>
1.65 (2H, m), 2.20 (2H, t, J=7Hz), 2.38-2.47 (2H, m), 2.54 (3H, s), 3.00 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.19 (1H, dd, J=2 Hz, 8Hz), 7.46 (1H, d, J=2Hz), 7.56 (1H, d, J=8Hz) MS (ESI+): m/z 433 (M+H)<br>
Example 30<br>
Ethyl 5-[4-(4-chloro-2-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.44-1.67 (4H, m), 2.15-<br>
2.26 (2H, m), 2.42-2.56 (2H, m), 2.56 (3H, s), 3.01 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.95 (1H, d, J=3Hz), 6.54 (1H, d, J=3Hz), 7.40 (1H, dd, J=2 Hz, 4Hz), 7.54 (1H, d, J=2Hz), 8.67 (1H, d, J=4Hz) MS (ES1+): m/z 400 (M+H)<br>
Example 31<br>
Ethyl 5-[4-(5-chloro-2-thienyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.48-1.74 (4H, m), 2.28<br>
(2H, t, J=7Hz), 2.68-2.77 (2H, m), 3.02 (2H, q, J=7Hz), 3.44 (3H, s), 4.12 (2H, q, J=7Hz), 4.60 (2H, s), 6.25 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 6.97 (2H, m) MS (ES1+): m/z 435 (M+H)<br>
Example 32<br>
Ethyl 5-[7-ethyl-4-(6-methoxy-2-pyrazinyl)-2-methylpyrrolo[l52-b]pyridazin-3-<br>
yl]pentanoate<br><br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), J .37 (3H, t, J=7Hz), 1.52-1.68 (4H, m), 2.23<br>
(2H, t, J=7Hz), 2.48-2.55 (2H, m), 2.56 (3H, s), 3.(32 (2H, q, J=7Hz), 3.98 (3H, s), 4.09 (2H, q, J=7Hz), 6.03 (1H, d, J=4Hz), 6.55 (1H, d, J=4Hz), 8.30 (1H, s), 8.33 (lH,s) MS (ESI+): m/z 397 (M+H)<br>
Example 33<br>
Ethyl 5-[4-(l-benzofuran-2-yl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.62-1.83 (4H, m), 2.33<br>
(2H, t, J=7Hz), 2.57 (3H, s), 2.69-2.78 (2H, m), 3.03 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 6.48 (1H, d, J=4Hz), 6.59 (1H, d, J=4Hz), 7.15 (1H, s), 7.26-7.42 (2H, m), 7.57 (1H, d, J=8Hz), 7.68 (1H, d, J=8Hz) MS (ESI+): m/z 405 (M+H)<br>
Example 34<br>
Ethyl 5-[4-(l-benzothien-2-yl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3, 5): 1.21 (3H, t, J=7Hz), 1.35 (3H, t, J=7Hz), 1.52-1.69 (4H, m), 2.23<br>
(2H, t, J=7Hz), 2.56 (3H, s), 2.61-2.70 (2H, m), 3.02 (2H, q, J=7Hz), 4.07(2H, q, J=7Hz), 6.21 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.35-7.43 (3H, m), 7.81-7.92 (2H,m)<br>
Example 35<br>
Ethyl 5-[7-ethyl-2-methyl-4-(l,3-oxazol-5-yl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.53-1.66 (2H, m), 1.66-<br>
1.83 (2H, m), 2.34 (2H, t, J=7Hz), 2.56 (3H, s), 2.62-2.73 (2H, m), 3.02 (2H, q, J=7Hz), 4.13 (2H, q, J=7Hz), 6.42 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.50 (1H,<br>
s),8.10(lH,s)<br>
MS(ESl+):m/z356(M+H)<br>
Example 36<br>
Ethyl 5-(7-ethyl-2-methyl-4-phenylpyrrolo[l,2-b]pyridazin-3-yl)penlanoate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.15<br><br>
(2H, t, J=7Hz), 2.41-2.48 (2H, m), 2.55 (3H, s), 3.02 (2H, q, J=7Hz), 4.08 (2H, q, J=7Hz), 5.88 (1H, d, J=4Hz), 6.48 (1H, d, J=4Hz), 7.31-7.34 (2H, m), 7.40-7.49 (3H,m) MS(ESl+):m/z365(M+H)<br>
Example 37<br>
Elhyl 5-[7-ethyl-2-methyl-4-(6-quinolinyl)pyrrolo[l,2-b]pyridazin-3-yl]penlanoale NMR (CDCI3,8): 1.18 (3H, t, J=7Hz), 1.39 (3H, t, J=7Hz), 1.39-1.55 (4H, m), 2.14<br>
(2H, d, J=7Hz), 2.44-2.55 (2H, m), 2.58 (3H, s), 3.03 (2H, q, J=7Hz), 4.03 (2H, q, J=7Hz), 5.86 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.45-7.52 (1H, m), 7.69 (1H, dd, J=2Hz, 8Hz), 7.84 (1H, d, J=2Hz), 8.20 (2H, d, J=8Hz), 9.00 (1H, m)<br>
Example 38<br>
Ethyl 7-{4-[4-({[(benzyloxy)carbonyl]amino}sulfonyl)phenyl]-7-ethyl-2-<br>
methylpyrrolo[l,2-b]pyridazin-3-yl}heptanoate<br>
NMR (CDC13,5): 1.12-1.23 (7H,m), 1.33-1.51 (7H,s), 2.17 (2H,t, J=7Hz), 2.35<br>
(2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 4.11 (2H, q, J=7Hz), 5.17 (2H, s), 5.78 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.29-7.38 (5H, m), 7.49 (2H, d, J=9Hz), 7.87 (1H, s.br), 8.11 (2H, d, J=9Hz)<br>
MS (ESI+): m/z 606 (M+H)<br>
MS (ESI"): m/z 604 (M-H)<br>
Example 39<br>
2-{[4-(3-Chlorophenyl)-7-ethy]-2-methylpyrrolo[l,2-b]pyridazJn-3-y]]methyl}-l,3-<br>
propanediol<br>
NMR (CDCI3,8): 1.26 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.64-1.82 (3H, m), 2.59<br>
(3H, s), 3.02 (2H, q, J=7Hz), 3.45 (2H, m), 3.63 (2H, m), 4.12 (2H, q, J=7Hz), 5.93 (1H, d), J=5Hz), 6.53 (1H, d, J=5Hz), 7.28 (1H, m), 7.42-7.44 (3H, m)<br>
Example 40<br>
Ethyl 5-{7-ethyl-2-methyl-4-[3-(methylsulfonyl)phenyl]pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br><br>
NMR (CDCI3,5): 1.22 (3H, t, J=8Hz), 1.33-1.57 (7H, m), 2.18 (2H, t, J=8Hz), 2.35-<br>
2.45 (2H, m), 2.56 (3H, s), 3.01 (2H, q, J=8Hz), 3.12 (3H, s), 4.08 (2H, q, J=8Hz), 5.80 (1H, d, J=5Hz), 6.51 (1H, d, J=5Hz), 7.64-7.74 (2H, m), 7.96 (1H, br s), 8.04 (lH,m) MS (ESI+): rn/z 443 (M+H)<br>
Example 41<br>
Ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethy]-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3, 8): 1.23 (3H, t, J=8Hz), 1.30-1.62 (7H, m), 2.21 (2H, t, J=8Hz), 2.35-<br>
2.45 (2H, m), 2.55 (3H, s), 3.00 (2H, q, J=8Hz), 4.10 (2H, q, J=8Hz), 5.85 (1H, d, J=5Hz), 6.53 (1H, d, J=5Hz), 7.24 (1H, dd, J=7,1Hz), 7.35 (1H, br s), 8.53 (1H, d, J=7Hz) MS (ES1+): m/z 400 (M+H)<br>
Example 42<br>
Ethyl 5-[7-ethyl-2-methyl-4-(3-nitrophenyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3,5): 1.21 (3H, t, J=8Hz), 1.34-1.59 (7H, m), 2.17 (2H, t, J=8Hz), 2.37-<br>
2.47 (2H, m), 2.57 (3H, s), 3.01 (2H, q, J=8Hz), 4.08 (2H, q, J=8Hz), 5.81 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.64-7.74 (2H, m), 8.25 (1H, br s), 8.33 (1H, m) MS (ES1+): m/z 410 (M+H)<br>
Example 43<br>
Ethyl 4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3,8): 0.98 (3H, t, J=8Hz), 2.55 (3H, s), 4.05 (2H, q, J=8Hz), 6.35 (1H,<br>
m), 6.81 (1H, m), 7.12-7.22 (2H, m), 7.41-7.50 (2H, m), 7.76 (1H, m) MS (ES1+): m/z 359 (M+H)<br>
Example 44 4-(3-Butyl-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl)benzonitrile<br>
NMR (CDCI3,8): 0.78 (3H, t, J=8Hz), 1.12-1.43 (7H,m), 2.31-2.40 (2H, m), 2.56 (3H, s), 3.00 (2H, q, J=8Hz), 5.79 (1H, d, J=5Hz), 6.50 (1H, d, J=5Hz), 7.47 (2H,<br><br>
d,J=8Hz),7.77(2H,d,J=8Hz) MS(ESl+):m/z318(M+H)<br>
Example 45<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yljpentanoate<br>
NMR (CDCI3,8): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.65 (4H, m), 2.21<br>
(2H, t, J=7Hz), 2.37-2.49 (2H, m), 2.56 (3H, s), 3.00 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.85 (1H, m), 8.53 (1H, d, J=2Hz),8.77(lH,d,J=2Hz) MS:(m/z)444,446(M+H)<br>
Example 46<br>
Ethyl 5-{4-(2-chloro-4-pyridinyl)-7-ethyl-2-[(methylthio)methyl]pyrrolo[ 1,2-b]pyridazin-<br>
3-yl}pentanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.40-1.63 (4H, m), 2.18<br>
(3H, s), 2.20 (2H, t, J=7Hz), 2.48-2.58 (2H, m), 3.02 (2H, q, J=7Hz), 3.81 (2H, s), 4.10 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 7.27 (1H, m), 7.38 (1H, s), 8.53 (1H, d, J=4Hz) MS:(m/z)446(M+H)<br>
Example 47<br>
Ethyl 6-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoate NMR (CDCI3,8): 1.15-1.29 (5H, m), 1.32-1.61 (7H, m), 2.20 (2H, t, J=8Hz), 2.33-<br>
2.43 (2H, m), 2-6 (3H, s), 3.01 (2H, q, J=8Hz), 4.10 (2H, q, J=8Hz), 5.79 (1H, d, J=5Hz), 6.51 (1H, d, J=5Hz), 7.57-7.67 (3H, m), 7.75 (1H, m) MS (ESI): m/z 404 (M+H)<br>
Example 48<br>
Ethyl 5-[4-(6-chloro-2-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.46-1.65 (4H, m), 2.22<br><br>
(2H, t, J=7Hz), 2.46-2.57 (2H, m), 2.54 (3H, s), 3.00 (2H, q, J=7Hz), 4.09 (2H, q, J=7Hz), 5.95 (lH,d,J=4Hz), 6.51 (lH,d,J=4Hz), 7.38-7.47 (2H,m), 7.80 (lH,t, J=8Hz) MS (ES1+): m/z 400<br>
sample 49<br>
hyl 5-[7-ethyl-4-(3-methoxyphenyl)-2-methylpyrrolo[ 1,2-b]pyridazin-3-yl]pentanoate NMR (CDC13,5): 1.23 (3H, I, J=7Hz), 1.36 (3H, t, J=7Hz), 1.40-1.62 (4H, m), 2.17<br>
(2H, t, J=7Hz), 2.43-2.52 (2H, m), 2.54 (3H, s), 3.00 (2H, q, J=7Hz), 3.83 (3H, s), 4.08 (2H, q, J=7Hz), 5.91 (1H, d, J=4Hz), 6.49 (1H, d, J=4Hz), 6.87-6.99 (3H, m), 7.37(lH,t,J=8Hz) MS (ESI+): m/z 395<br>
Example 50<br>
Lthyl 5-[4-(3,5-dichlorophenyl)-7-ethyl-2-methy]pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3, 8): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.39-1.52 (2H, m), 1.52-<br>
1.64 (2H, m), 2.22 (2H, t, J=7Hz), 2.38-2.48 (2H, m), 2.54 (3H, s), 3.00 (2H, q, J=7Hz), 4.10 (2H,q,J=7Hz), 5.88 (lH,d, J=4Hz), 6.51 (1H, d,J=4Hz), 7.25 (2H, m),7.45(lH,m) MS (ES1+): m/z 433<br>
Example 51<br>
Ethyl 5-[4-(5-chloro-2-thienyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDC13,5): 1.25 (3H, t, J=7Hz), 1.36 (3H,t, J=7Hz), 1.46-1.58 (2H,m), 1.60-<br>
1.74 (2H, m), 2.28 (2H, t, J=7Hz), 2.53 (3H, s), 2.56-2.66 (2H, m), 2:98 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 6.20 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 6.94 (1H, d,J=4Hz),6.98(lH,d,J=4Hz) MS(ESI+):m/z405<br>
Example 52<br>
Ethyl 5-[7-ethyl-4-(3-fluorophenyl)-2-methylpynolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3, 5): 1.23 (3H,t, J=7Hz), 139 (3H,t,J=7Hz), 1.38-1.50 (2H,m), 1.50-<br><br>
1.63 (2H, m), 2.17 (2H, t, J=7Hz), 2.39-2.48 (2H, m), 2.54 (3H, s), 3.03 (2H, q, J=7Hz), 4.09 (2H, q, J=7Hz), 5.88 (1H, d, J=4Hz), 6.50 (1H, d, J=4Hz), 7.03-7.16 (3H,m), 7.38-7.47 (lH.m) MS (ES1+): m/z 383<br>
Example 53<br>
Ethyl 5-[7-ethyl-2-methyl-4-(3-quinolinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDC13,5): 1.18 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.16<br>
(2H, t, J=7Hz), 2.44-2.56 (2H, m), 2.59 (3H, s), 3.04 (2H, q, J=7Hz), 4.03 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.62 (1H, t, J=8Hz), 7.80 (1H, t, J=8Hz), 7.90 (1H, d, J=8Hz), 8.21 (2H, m), 8.90 (1H, d, J=2Hz) MS (ESI+): m/z 416<br>
Example 54<br>
Ethyl 5-[7-ethyl-2-methyl-4-(4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3,6): 1.23 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.64 (4H, m), 2.19<br>
(2H, t, J=7Hz), 2.38-2.52 (2H, m), 2.55 (3H, s), 3.02 (2H, q, J=7Hz), 4.09 (2H, q, J=7Hz), 5.83 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.29 (2H, m), 8.72 (2H, m) MS (ESI+): m/z 366<br>
Example 55<br>
Ethyl 5-[7-ethyl-4-(3-methoxy-5-isoxazolyl)-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.55-1.82 (4H, m), 2.33<br>
(2H, t, J=7Hz), 2.55 (3H, s), 2.62-2.72 (2H, m), 2.99 (2H, q, J=7Hz), 4.08 (3H, s), 4.12 (2H, q, J=7Hz), 6.26 (1H, s), 6.34 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz)<br>
Example 56<br>
Ethyl 5-[7-ethyl-2-methyl-4-(5-methyl-3-isoxazolyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.50-1.75 (4H, m), 2.29<br>
(2H, t, J=7Hz), 2.55 (6H, s), 2.56-2.65 (2H, m), 2.99 (2H, q, J=7Hz), 4.11 (2H, q,<br><br>
J=7Hz), 6.16 (1H, d, J=4Hz), 6.22 (1H, s), 6.54 (1H, d, J=4Hz) MS (ESI+): m/z 370<br>
Example 57<br>
Ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolol 1,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDC13,5): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.36-1.63 (4H, m), 2.20<br>
(2H, t, J=7Hz), 2.48-2.63 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s), 4.09 (2H, q, J=7Hz), 4.62 (2H, s), 5.89 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 7.26 (1H, m), 7.37 (1H, s), 8.53 (1H, d, J=5Hz) MS (ES1+): m/z 430<br>
Example 58<br>
Ethyl 5-[7-ethyl-2-(methoxymethyl)-4-(3-methoxyphenyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3,8): 1.22 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.63 (4H, m), 2.16<br>
(2H, t, J=7Hz), 2.54-2.65 (2H, m), 3.04 (2H, q, J=7Hz), 3.45 (3H, s), 3.83 (3H, s), 4.08 (2H, q, J=7Hz), 4.62 (2H, s), 5.96 (1H, d, J=4Hz), 6.56 (1H, d, J=4Hz), 6.87-7.00 (3H, m), 7.38 (1H, t, J=8Hz) MS (ES1+): m/z 425<br>
Example 59<br>
Ethyl 5-[7-ethyl-2-(methoxymethyl)-4-(6-quinolinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3, 5): 1.17 (3H, t, J=7Hz), 1.43 (3H, t, J=7Hz), 1.36-1.58 (4H, m), 2.10<br>
(2H, m), 2.56-2.68 (2H, m), 3.07 (2H, q, J=7Hz), 3.48 (3H, s), 4.02 (2H, q5 J=7Hz), 4.66 (2H, s), 5.90 (1H, d, J=4Hz), 6.56 (1H, d, J=4Hz), 7.45-7.50 (1H, m), 7.72 (1H, dd, J=2 Hz, 8Hz), 7.86 (1H, d, J=2Hz), 8.16-8.24 (2H, m), 8.98 (1H, m)<br>
Example 60<br>
Ethyl 5-[7-ethyl-2-(methoxymethyl)-4-(3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br><br>
y]]pentanoate<br>
NMR (CDCI3, §): J .22 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.17<br>
(2H, t, J=7Hz), 2.52-2.64 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.10 (2H, q, J=7Hz), 4.63 (2H, s), 5.89 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.42 (1H, m), 7.71 (1H, m), 8.62 (1H, m), 8.70 (1H, m) MS (ES1+): m/z 396<br>
Example 61<br>
Ethyl 5-[4-(3-chlorophenyl)-7-elhyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.58 (4H, m), 2.17<br>
(2H, t, J=7Hz), 2.51-2.62 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s), 4.08 (2H, q, J=7Hz), 4.61 (2H, s), 5.92 (1H, d, J=4Hz), 6.56 (1H, d, J=4Hz), 7.25 (1H, m), 7.37 (lH,s), 7.42 (2H,m)<br>
Example 62<br>
Ethyl 5-[7-ethyl-2-methyl-4-(3-methylphenyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR(CDCl3,5):1.23(3H,tJ=7Hz),1.37(3H,t,J=7Hz),1.40-1.60(4H,m),2.16<br>
(2H, t, J=7Hz), 2.40 (3H, s), 2.40-2.50 (2H, m), 2.54 (3H, s), 3.03 (2H, q, J=7Hz), 4.08 (2H, q, J=7Hz), 5.90 (1H, d, J=4Hz), 6.49 (1H, d, J=4Hz), 7.10-7.15 (2H, m), 7.24 (lH,m), 7.33 (lH,m) MS:(m/z)379(M+H)<br>
Example 65<br>
Ethyl 5-[7-ethyl-2-(methoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.18<br>
(2H, t, J=7Hz), 2.42 (3H, s), 2.48-2.63 (2H, m), 3.05 (2H, q, J=7Hz), 3.46 (3H, s), 4.08 (2H, q, J=7Hz), 4.62 (2H, s), 5.90 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 7.51 (lH,s), 8.41 (lH.s), 8.53 (lH,s) MS(ESI+):m/z410<br><br>
Example 66<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-l]pentanoate NMR (CDCI3, 5): 1.24 (3H, t, J=7Hz), 1.37 (3H, 1, J=7Hz), 1.40-1.65 (4H, m), 2.21<br>
(2H, I, J=7Hz), 2.37-2.49 (2H, m), 2.56 (3H, s), 3.00 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.87 (lH,d,J=4Hz), 6.53 (!H,d, J=4Hz), 7.85 (lH,m), 8.53 (lH,d, J=2Hz),8.77(lH,d,J=2Hz) MS (ES1+): m/z 444, 446<br>
example 67<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
d]pentanoate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.63 (4H, m), 2.19<br>
(2H, t, J=7Hz), 2.50-2.66 (2H, m), 3.03 (2H, q, J=7Hz), 3.46 (3H, s), 4.10 (2H, q, J=7Hz), 4.62 (2H, s), 5.91 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 7.88 (1H, m), 8.55 (1H, d, J=2Hz), 8.77 (1H, d, J=2Hz) MS (ES1+): m/z 474, 476<br>
Example 68<br>
Ethyl 5-[4-(5,6-dichloro-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 8): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.36-1.60 (4H, m), 2.23<br>
(2H, t, J=7Hz), 2.37-2.50 (2H, m), 2.55 (3H, s), 3.02 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.81 (1H, d, J=2Hz), 8.30 (1H, d,J=2Hz) MS (ESI+): m/z 434<br>
Example 69<br>
Ethyl 4-[7-ethyl-2-(methoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
NMR (CDCI3,6): 1.37 (3H, t, J=7Hz), 1.65-1.78 (2H, m), 2.16-2.25 (2H, m), 2.42<br>
(3H, s), 2.53-2.65 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.12 (2H, q, J=7Hz),<br><br>
4.67 (2H, m), 5.91 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.53 (1H, s), 8.43 (1H, s), 8.54 (1H,s) MS (ESI+): m/z 396<br>
Example 70<br>
Ethyl 3-[7-ethyl-2-(me1hoxymelhyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
NMR (CDC13, 5): 1.25 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 2.35-2.55 (2H, m), 2.42<br>
(3H, s), 2.84-2.96 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.08 (2H, q, J=7Hz), 4.65 (2H, s), 5.91 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.51 (1H, s), 8.41 (1H, s), 8.52 (lH,s)<br>
Example 71<br>
Ethyl 4-[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
NMR (CDCI3, 5): 1.20 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.66-1.82 (2H, m), 2.16-<br>
2.28 (2H, m), 2.42 (3H, s), 2.44-2.53 (2H, m), 2.59 (3H, s), 3.02 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.51 (1H, s), 8.41 (1H, d, J=2Hz), 8.53 (1H, d, J=2Hz) MS (ESI+): m/z 366<br>
Example 72<br>
Ethyl 3-[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
NMR (CDCI3, 8): 1.24 (3H,t, J=7Hz), 1.37 (3H, t, J=7Hz), 2.30-2.43 (2H, m), 2.42<br>
(3H, s), 2.58 (3H, s), 2.76-2.86 (2H, m), 3.02 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.48 (1H, s), 8.40 (1H, d, J=2Hz), 8.53 (lH,d,J=2Hz)<br>
MS(ESl+):m/z352<br>
Example 73<br>
Ethyl 3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br><br>
yl]propanoale<br>
NMR (CDC13, 5): J .21 (3H, t, J=7Hz), 139 (2H, t, J=7Hz), 235 (2H, t, J=7Hz), 2.58<br>
(3H, s), 2.74-2.83 (2H, m), 3.01 (2H, q, J=7Hz), 4.08 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.55 (1H, d, J=4Hz), 7.87 (1H, s), 8.53 (1H, s), 8.79 (1H, s)<br>
MS: (m/z) 416 (M+),418 (M+-2), 85(bp)<br>
Example 74<br>
Ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(melhoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13, 5): 1.23 (3H, t, J=8Hz), 132-1.55 (5H, m), 2.16 (2H, t, J=8Hz), 2.46-<br>
2.57 (2H, m), 3.03 (2H, q, J=8Hz), 3.46 (3H, s), 4.09 (1H, q, J=8Hz), 4.62 (2H, s), 534 (1H, d, J=5Hz), 6.57 (1H, d, J=5Hz), 7.59-7.64 (2H, m), 7.68 (1H, br s), 7.75 (lH,m) MS (ESI+): 420 (M+H)<br>
Example 75<br>
Ethyl 5-[2-[(acetyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-<br>
3-yl]pentanoate<br>
NMR (CDC13, 5): 1.23 (3H, t, J=7Hz), 134-1.55 (7H, m), 2.11 -2.22 (5H, m), 2.47<br>
(2H,m), 3.02 (2H,q, J=7Hz), 4.09 (2H, q, J=7Hz), 5.29 (2H,s), 5.94 (lH,d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.88 (1H, m), 8.56 (1H, m), 8.79 (1H, m)<br>
Example 76<br>
To a solution of ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (1.20 g) in ethanol (12 mL) was added IN sodium hydroxide (4.62 mL) and was stirred at ambient temperature for 2 hours. The reaction mixture was acidified with IN hydrogen chloride and was partitined between ethyl acetate and water. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 100 mL) eluted with hexane-ethyl acetate= 3-1,2-1, and 1-1 to give an yellow solid (846 mg). The solid was recrystallized from hexane-ethyl acetate (5-1) to give 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid as a pale<br><br>
yellow crystals (795 mg, 71.4%).<br>
5-[4-(3-Cyanophenyl)-7-ethyl-2-melhylpyrrolo[l,2-b]pyridazin-3-yl]penlanoic acid mp: 109-110°C NMR (CDC13,6): 1.33-1.60 (7H, m), 2.42 (2H, t, J=8Hz), 2.34-2.48 (2H, m), 2.56<br>
(3H, s), 3.01 (2H, q, J=8Hz), 5.80 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.56-7.64<br>
(2H, m), 7.66 (1H, br s), 7.76 (1H, m) MS (ES1+): m/z 362 (M-H)<br>
The following compounds were obtained in substantially the same manner as that of Example 76. Example 77<br>
3-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpynolo[l,2-b]pyridazin-3-yl]propanoicacid NMR (CDC13,5): 1.36 (3H, t, J=7 H), 1.56 (2H, m), 2.03 (2H, m), 2.79 (2H, m), 3.01<br>
(2H, q, J=7Hz), 6.01 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.27 (1H, m), 7.40-7.53 (8H,m)<br>
Example 78<br>
5-{7-Ethyl-2-methyl-4-[3-(trifluoromethyl)phenyl]pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.40-1.62 (4H, m), 2.22 (2H, t, J=7Hz), 2.38-<br>
2.46 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 5.84 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.53-7.64 (3H, m), 7.72 (1H, d, J=8Hz) MS (ESI+): m/z 403 (M-H), 405 (M+H)<br>
Example 79<br>
5-[7-Ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.45-1.67 (4H, m), 2.22 (2H, t, J=7Hz), 2.42<br>
(3H, s), 2.35-2.48 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 5.83 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.53 (1H, s), 8.39 (1H, s), 8.53 (1H, s) MS (ES1+): m/z 352 (M+H)<br><br>
Example 80<br>
5-[7-Eihyl-4-(3-methoxy-5-isoxazo]y])-2-(methoxymelhy])pyrrolo[l,2-b]pyrida2in-3-IJpentanoic acid<br>
NMR (CDCI3, 5): 1.36 (3H, 1, J=7Hz), 1.58-1.83 (4H,m), 2.38 (2H, t, J=7Hz), 2.74-<br>
2.85 (2H, m), 3.03 (2H, q, J=7Hz), 3.43 (3H, s), 4.08 (3H, s), 4.62 (2H, s), 6.28 (1H, s), 6.41 (1H, d, J=4Hz), 6.67 (1H, d, J=4Hz) MS (ES1+): m/z 386 (M-H), 388 (M+H)<br>
Example 81<br>
5-{7-Ethyl-2-methyl-4-[3-(l,3-oxazol-5-yl)phenyl]pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDCI3, 5): 1.38 (3H, t, J=7Hz), 1.45-1.65 (4H, m), 2.21 (2H, t, J=7Hz), 2.43-<br>
2.53 (2H, m), 2.56 (3H, s), 3.03 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.32 (1H, d, J=8Hz), 7.39 (1H, s), 7.53 (1H, t, J=8Hz), 7.65 (1H, s), 7.73 (lH,d,J=8Hz),7.93(lH,s) MS (ES1+): m/z 402 (M-H), 404 (M+H)<br>
Example 82<br>
5-[4-(3,4-Dichlorophenyl)-7-elhyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR(CDC13,8): 1.37 (3H, t, J=7Hz), 1.42-1.65 (4H, m), 2.27 (2H, t,J=7Hz), 2.38-<br>
2.48 (2H, m), 2.54 (3H, s), 3.02 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.19 (1H, dd, J=2 Hz, 8Hz), 7.45 (1H, d, J=2Hz), 7.56 (1H, d, J=8Hz) MS (ES1+): m/z 403 (M-H), 405 (M+H)<br>
Example 83<br>
5-[4-(4-Chloro-2-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3, 5): 1.36 (3H,t, J=7Hz), 1.47-1.66 (4H,m),2.24 (2H, t, J=7Hz), 1.45-<br>
2.56 (2H, m),2.55 (3H, s), 3.00 (2H, q, J=7Hz), 5.94 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.39 (1H, dd, J=2 Hz, 7Hz), 7.53 (1H, d, J=2Hz), 8.67 (1H, d, J=7Hz) MS (ESI+): m/z 372 (M+H)<br>
Example 84<br><br>
5-[4-(5-Chloro-2-thienyl)-7-elhy]-2-(methoxymcthyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3, 5): 1.36 (3H, l, J=7Hz), 1.52-1.74 (4H, m), 2.33 (2H, 1, J=7Hz), 2.69-<br>
2.78 (2H, m), 3.01 (2H, q, J=7Hz), 3.44 (3H, s), 4.60 (2H, s), 6.25 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 6.97 (2H, m) MS (ESI+): m/z 405 (M-H), 407 (M+H)<br>
Example 85<br>
5-[7-Ethyl-4-(6-methoxy-2-pyrazinyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 8): 1.37 (3H, t, J=7Hz), 1.55-1.69 (4H, m), 2.28 (2H, m), 2.52 (2H, m),<br>
2.56 (3H, s), 3.03 (2H, q, J=7Hz), 3.97 (3H, s), 6.03 (1H, d, J=4Hz), 6.54 (1H, d, J=4Hz), 8.30 (1H, s), 8.32 (1H, s) MS (ESI+): m/z 369 (M+H)<br>
Example 86<br>
5-[4-(l-Benzofuran-2-yl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3, 8): 1.39 (3H, t, J=7Hz), 1.66-1.86 (4H, m), 2.34-2.47 (2H, m), 2.58<br>
(3H, s), 2.69-2.85 (2H, m), 3.03 (2H, q, J=7Hz), 6.47 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.16 (1H, s), 7.26-7.43 (2H, m), 7.57 (1H, d, J=8Hz), 7.68 (1H, d, J=8Hz)<br>
Example 87<br>
5-[4-(l-Benzothien-2-yl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,8): 1.37 (3H, t, J=7Hz), 1.53-1.73 (4H, m), 2.30 (2H, t, J=7Hz), 2.56<br>
(3H, s), 2.62-2.73 (2H, m), 3.02 (2H, q, J=7Hz), 6.19 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.34-7.45 (3H, m), 7.79-7.93 (2H, m)<br>
Example 88<br>
5-[7-Ethyl-2-methyl-4-(l,3-oxazol-5-yl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3,8): 1.37 (3H, 1, J=7Hz), 1.57-1.70 (2H, m), 1.70-1.88 (2H, m), 2.43<br>
(2H, t, J=7Hz), 2.56 (3H, s), 2.66-2.75 (2H, m), 3.02 (2H, q, J=7Hz), 6.41 (1H, d,<br><br>
J=4Hz), 6.60 (1H, d, J=4Hz), 7.52 (1H, s), 8.13 (1H, s) MS (ESI+): m/z 328 (M+H)<br>
Example 89 5-(7-Ethyl-2-methyl-4-phenylpyrrolo[l,2-b]pyridazin-3-yI)pentanoic acid<br>
NMR (CDC13, 8): 1.37 (3H, t, J=7Hz), 1.40-1.62 (4H, m), 2.20 (2H, t, J=7Hz), 2.43-<br>
2.52 (2H, m), 2.54 (3H, s), 3.01 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.48 (1H, d, J=4Hz), 7.33 (2H, m), 7.38-7.52 (3H, m) MS (ESI+): m/z 337 (M+H)<br>
Example 90 5-[7-Ethyl-2-methyl-4-(6-quinolinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,5): 1.39 (3H, t, J=7Hz), 1.47-1.61 (4H, m), 2.14-2.23 (2H, m), 2.44-<br>
2.55	(2H, m), 2.59 (3H, s), 3.05 (2H, q, J=7Hz), 5.86 (1H, d, J=4Hz), 6.51 (1H, d,<br>
J=4Hz), 7.49 (1H, m), 7.73 (1H, dd, J=2 Hz, 8Hz), 7.85 (1H, d, J=2Hz), 8.23 (2H,<br>
m),8.97(lH,m)<br>
MS (ESI+): m/z 386 (M-H), 388 (M+H)<br>
Example 91<br>
7-{4-[4-(Aminosulfonyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}heptanoic<br>
acid<br>
NMR (CDCI3, 5): 0.98 (2H, m), 1.17-1.48 (9H, m), 2.27 (2H, t, J=7Hz), 2.36 (2H, m),<br>
2.56	(3H, s), 3.02 (2H, q, J=7Hz), 5.06 (2H, s, br), 5.84 (1H, d, J=5Hz), 6.52 (1H,<br>
d, J=5Hz), 7.52 (2H, d, J=9Hz), 8.04 (2H, d, J=9Hz)<br>
MS (ESJ+): m/z 444 (M+H)<br>
Example 92<br>
({[4-(3-Chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-3-yl]carbonyl}amino)acetic acid<br>
NMR (CDCI3,6): 1.41 (3H, t, J=7Hz), 3.07 (2H, q, J=7Hz), 3.95 (2H, d, J=5Hz),<br>
6.02 (1H, t, br, 5Hz), 6.37 (1H, d, J=5Hz), 6.50 (1H, m), 6.75 (1H, d, J=5Hz), 7.01 (1H, d, J=7Hz), 7.37-7.45 (3H, m), 7.51 (1H, m), 7.55 (1H, m)<br><br>
Example 93<br>
5-{7-Ethyl-2-methyl-4-[3-(methylsulfonyl)phenyI]pyrrolo[l,2-b]pyriciazin-3-y]}pentanoic :id NMR (CDC13,5): 1.30-1.59 (7H, m), 2.22 (2H, t, J=8Hz), 2.33-2.49 (2H, m), 2.56<br>
(3H, s), 3.01 (2H, q, J=8Hz), 3.12 (3H, s), 5.80 (1H, d, J=5Hz), 6.50 (1H, d, J =5Hz), 7.63-7.74 (2H, m), 7.95 (1H, br s), 8.03 (1H, br d, J=8Hz) MS (ES1+): m/z 415 (M+H)<br>
Example 94<br>
5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid mp: 139-140°C<br>
NMR (CDC13,8): 1.32-1.64 (7H, m), 2.28 (2H, t, J=8Hz), 2.36-2.46 (2H, m), 2.55 (3H, s), 3.00 (2H, q, J=8Hz), 5.85 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.24 (1H, br d, J=7Hz), 7.36 (1H, br s), 8.53 (1H, d, J=7Hz) MS (ES1+): m/z 372 (M+H)<br>
Example 95<br>
5-[7-Ethyl-2-methyl-4-(2-vinyl-4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDC13,8): 1.36 (3H, t, J=8Hz), 1.40-1.62 (4H, m), 2.25 (2H, t, J=8Hz), 2.35-<br>
2.47 (2H, m), 2.56 (3H, s), 3.00 (2H, q, J=8Hz), 5.54 (1H, d, J=10Hz), 5.86 (1H, d, J=5Hz), 6.23 (1H, d, J=16Hz), 6.51 (1H, d, J=5Hz), 6.88 (1H, dd, J=16,10Hz), 7.20 (1H, dd, J=6,1Hz), 7.38 (1H, br s), 8.70 (1H, d, J=6Hz)<br>
Example 96 5-[7-Ethy]-2-methyl-4-(3-nitrophenyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br>
NMR (CDCI3,8): 1.37 (3H, t, J=8Hz), 1.41-1.59 (4H, m), 2.23 (2H, t, J=8Hz), 2.37-<br>
2.47 (2H, m), 2.57 (3H, s), 3.02 (2H, q, J=8Hz), 5.81 (1H, d, J=5Hz), 6.51 (1H, d, J=5Hz), 7.63-7.74 (2H, m), 8.25 (1H, br s), 8.32 (1H, m)<br>
Example 97<br><br>
{[7-Ethyl-4-(4-fluorophenyl)-2-isopropylpyrroIo[l,2-b]pyridazin-3-y]]rnethoxy} acetic<br><br>
acid<br>
NMR (CDCI3, 5): 1.33-1.45 (9 H, m), 3.04 (2H, q, J=8Hz), 3.43 (1H, m), 4.01 (2H,<br>
s), 4.45 (2H, s), 6.09 (1H, d, J=5Hz), 6.58 (1H, d, J=5Hz), 7.13-7.22 (2H, m), 7.40-7.49 (2H,m)<br>
Example 98<br>
5-[4-(5-Acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.43-1.63 (4H, m), 2.23 (2H, t, J=7Hz), 2.35-<br>
2.48 (2H, m), 2.57 (3H, s), 2.69 (3H, s), 3.03 (2H, q, J=7Hz), 5.80 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 8.26 (1H, m), 8.78 (1H, d, J=2Hz), 9.23 (1H, d, J=2Hz) MS: (m/z) 378 (M-H), 380 (M+H)<br>
Example 99<br>
5-{4-(2-Chloro-4-pyridinyl)-7-ethyl-2-[(methylthio)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
NMR (CDCI3, 5): 1.36 (3H, t, J=7Hz), 1.42-1.65 (4H, m), 2.18 (3H, s), 2.28 (2H, t,<br>
J=7Hz), 2.48-2.60 (2H, m), 3.02 (2H, q, J=7Hz), 3.81 (2H, s), 5.89 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 7.27 (1H, m), 7.38 (1H, s), 8.53 (1H, d, J=5Hz) MS: (m/z) 416 (M-H), 418 (M+H)<br>
Example 100<br>
5-{4-(2-Chloro-4-pyridinyl)-7-ethyl-2-[(methylsulfonyl)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.45-1.65 (4H, m), 2.29 (2H, t, J=7Hz), 2.56-<br>
2.67 (2H, m), 2.98 (2H, q, J=7Hz), 3.13 (3H, s), 4.54 (2H, s), 5.98 (1H, d, J=4Hz), 6.69 (1H, d, J=4Hz)5 7.27 (1H, m), 7.38 (1H, s), 8.56 (1H, d, J=5Hz) MS: (m/z) 448 (M-H), 450 (M+H)<br>
Example 101 5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]penlanoicacid<br>
NMR (CDCI3,5): 1.03-1.45 (4H, m), 1.36 (3H, t, J=7Hz), 1.97 (2H, t, J=7Hz), 2.36-2.48 (2H, m), 3.02 (2H, q, J=7Hz), 5.96 (1H, d, J=4Hz), 6.64 (1H, d, J=4Hz),<br><br>
7.31 (1H, d, J=5Hz), 7.39-7.53 (6H, m), 8.55 (1H, d, J=5Hz)<br>
Example 102<br>
5-[4-(6-Chloro-2-pyridinyl)-7-elhyl-2-methylpyrrolo-[l,2-b]pyridazin-3-y]]pentanoicacid NMR (CDC13,5): 1.36 (3H, t, J=7Hz), 1.56-1.73 (4H, m), 2.29 (2H, t, J=7Hz), 2.46-<br>
2.56 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 5.96 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.38-7.48 (2H, m), 7.78 (1H, t, J=8Hz) MS (ES1+): m/z 372 (M+H), MS (ESI"): m/z 370<br>
Example 103<br>
5-[7-Ethyl-4-(3-methoxyphenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.46-1.63 (4H, m), 2.22 (2H, t, J=7Hz), 2.44-<br>
2.53 (2H, m), 2.54 (3H, s), 3.01 (2H, q, J=7Hz), 3.82 (3H, s), 5.92 (1H, d, J=4Hz), 6.49 (1H, d, J=4Hz), 6.87-7.01 (3H, m), 7.37 (1H, t, J=8Hz) MS (ESI+): m/z 367, MS (ESI): m/z 365<br>
Example 104<br>
5-[4-(3,5-Dichlorophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3,8): 1.37 (3H, t, J=7Hz), 1.42-1.53 (2H, m), 1.53-1.66 (2H, m), 2.27<br>
(2H, t, J=7Hz), 2.41-2.49 (2H, m), 2.54 (3H, s), 3.01 (2H, q, J=7Hz), 5.88 (1H, d, J=4Hz), 6.52 (1H, d, J=4Hz), 7.26 (2H, m), 7.45 (1H, m) MS (ESI+): m/z 405, MS (ESI): m/z 403<br>
Example 105<br>
5-[4-(5-Chloro-2-thienyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3,8): 1.36 (3H, t, J=7Hz), 1.48-1.62 (2H, m), 1.62-1.73 (2H, m), 2.34<br>
(2H, t, J=7Hz), 2.53 (3H, s), 2.58-2.67 (2H, m), 2.99 (2H, q, J=7Hz), 6.20 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 6.94 (1H, d, J=4Hz), 6.98 (1H, d, J=4Hz) MS (ESI+): m/z 377, MS (ESI"): m/z 375<br>
Example 106 5-[7-Ethyl-4-(3-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br><br>
NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.40-1.64 (4H, m), 2.23 (2H, t, J=7Hz), 2.41-<br>
2.49 (2H, m), 2.55 (3H, s), 3.00 (2H, q, J=7Hz), 5.88 (1H, d, J=4Hz), 6.50 (1H, d, J=4Hz), 7.03-7.16 (3H, m), 7.38-7.47 (1H, m) MS (ES1+): m/z 355, MS (ESI"): m/z 353<br>
Example 107 5-[7-Ethyl-2-methyl-4-(3-quinolinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,5): 1.39 (3H, t, J=7Hz), 1.47-1.65 (4H, m), 2.20-2.30 (2H, m), 2.45-<br>
2.53 (2H, m), 2.59 (3H, s), 3.05 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.62 (1H, t, J=8Hz), 7.79 (1H, t, J=8Hz), 7.87 (1H, d, J=8Hz), 8.21 (2H, m),8.88(lH,d,J=2Hz) MS (ESI+): m/z 388, MS (ESI"): m/z 386<br>
Example 108 5-[7-Ethyl-2-methyl-4-(4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3, 8): 1.37 (3H, t, J=7Hz), 1.40-1.70 (4H, m), 2.20-2.30 (2H, m), 2.37-<br>
2.53 (2H, m), 2.56 (3H, s), 3.01 (2H, q, J=7Hz), 5.84 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.39 (2H, d, J=7Hz), 8.74 (2H, d, J=7Hz)<br>
Example 109<br>
5-[7-Ethyl-4-(3-methoxy-5-isoxazolyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 8): 1.36 (3H, t, J=7Hz), 1.57-1.84 (4H, m), 2.41 (2H, t, J=7Hz), 2.55<br>
(3H, s), 2.63-2.72 (2H, m), 3.02 (2H, q, J=7Hz), 4.08 (3H, s), 6.27 (1H, s), 6.34 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz)<br>
Example 110<br>
5-[7-Ethyl-4-(3-methoxyphenyl)-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,8): 1.06-1.33 (4H, m), 1.36 (3H, t, J=7Hz), 1.91 (2H, t, J=7Hz), 2.42-<br>
2.53 (2H, m), 3.01 (2H, q, J=7Hz), 3.83 (3H, s), 6.03 (1H, d, J=4Hz), 6.59 (1H, d, J=4Hz), 6.93-7.02 (3H, m), 7.36-7.54 (6H, m) MS (ES1+): m/z 429<br><br>
Example 111<br>
5-[7-Ethy]-2-methyl-4-(5-methy]-3-isoxazo]yl)pyrrolo[l,2-b]pyridazin-3-)'l]pentanoic<br>
acid<br>
NMR (CDCI3,5): 1.36 (3H, I, J=7Hz), 1.52-1.77 (4H, m), 2.35 (2H, t, J=7Hz), 2.55<br>
(6H, s), 2.56-2.67 (2H, m), 3.01 (2H, q, J=7Hz), 6.16 (1H, d, J=4Hz), 6.23 (1H, s), 6.54(lH,d,J=4Hz) MS (ESI+): m/z 342, MS (ESI"): m/z 340<br>
Example 112 5-[7-Ethyl-2-phenyl-4-(4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br>
NMR (CDCI3, 8): 1.11-1.33 (4H, m), 1.36 (3H, t, J=7Hz), 1.99 (2H, t, J=7Hz), 2.38-<br>
2.50 (2H, m), 3.03 (2H, q, J=7Hz), 5.94 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 7.38-7.56 (7H, m), 8.74 (2H, d, J=6Hz)<br>
Example 113 5-[7-Ethyl-2-phenyl-4-(2-pyrazinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br>
NMR (CDCI3, 5): 1.10-1.33 (4H, m), 1.36 (3H, t, J=7Hz), 1.95 (2H, t, J=7Hz), 2.45-<br>
2.57 (2H, m), 3.02 (2H, q, J=7Hz), 6.05 (1H, d, J=4Hz), 6.66 (1H, d, J=4Hz), 7.40-7.55 (5H, m), 8.67 (1H, d, J=3Hz), 8.77 (1H, s), 8.85 (1H, s) MS (ESI+): m/z 401, MS (ESI): m/z 399<br>
Example 114 5-[7-Ethyl-2-phenyl-4-(3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br>
NMR (CDCI3, 8): 1.05-1.30 (4H, m), 1.36 (3H, t, J=7Hz), 1.95 (2H, t, J=7Hz), 2.35-<br>
2.48 (2H, m), 3.02 (2H, q, J=7Hz), 5.94 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.40-7.55 (6H, m), 7.76-7.83 (1H, m), 8.65-8.72 (2H, m) MS (ESI+): m/z 400, MS (ESI"): m/z 398<br>
Example 115<br>
5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-(methoxymethy])pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br><br>
NMR (CDC)3,5): 1.37 (3H, t, J=7Hz), 1.42-1.64 (4H, m), 2.27 (2H, t, J=7Hz), 2.48-<br>
2.62 (2H, m), 3.04 (2H, q, J=7Hz), 3.45 (3H, s), 4.62 (2H, s), 5.90 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.27 (1H, m), 7.38 (1H, s), 8.53 (1H, d, J=5Hz) MS(ESI+):m/z402<br>
Example 116<br>
5-[7-Ethyl-2-(methoxymethyl)-4-(3-methoxyphenyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDC13, 5): 1.37 (3H, t, J=7Hz), 1.40-1.62 (4H, m), 2.19 (2H, t, J=7Hz), 2.55-<br>
2.66 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s),3.82 (3H, s), 4.62 (2H, s),5.96 (1H, d, J=4Hz), 6.56 (1H, d, J=4Hz), 6.87-7.00 (3H, m), 7.37 (1H, t, J=8Hz) MS (ES1+): m/z 397, MS (ESI"): m/z 395<br>
Example 117<br>
5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-(2-thienyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 6): 1.20-1.50 (4H, m), 1.38 (3H, t, J=7Hz), 2.15 (2H, t, J=7Hz), 2.55-<br>
2.68 (2H, m), 3.04 (2H, q, J=7Hz), 5.93 (1H, d, J=4Hz), 6.64 (1H, d, J=4Hz), 7.13 (1H, t, J=5Hz), 7.28 (1H, d, J=5Hz), 7.35-7.47 (3H, m), 8.54 (1H, d, J=5Hz) MS(ESI+):m/z440<br>
Example 118<br>
5-[7-Ethyl-2-(methoxymethyl)-4-(6-quinolinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 5): 1.39 (3H, t, J=7Hz), 1.45-1.60 (4H, m), 2.16 (2H, m), 2.55-2.75<br>
(2H, m), 3.07 (2H, q, J=7Hz), 3.47 (3H, s), 4.66 (2H, s), 5.89 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 7.45-7.53 (1H, m), 7.72 (1H, d, J=8Hz), 7.86 (1H, s), 8.22 (2H,m),8.94(lH,m) MS (ES1+): m/z 418, MS (ESI"): m/z 416<br>
Example 119 5-[7-Elhyl-2-(methoxymethyl)-4-(3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br><br>
acid<br>
NMR (CDCI3,5): 1.38 (3H, t, J=7Hz), 1.45-1.64 (4H, m), 2.22 (2H, t, J=7Hz), 2.48-<br>
2.68 (2H, m), 3.06 (2H, q, J=7Hz), 3.46 (3H, s), 4.63 (2H, s), 5.89 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.48 (1H, m), 7.78 (1H, m), 8.62 (1H, m), 8.69 (1H, m) MS (ESI+): m/z 368<br>
Example 120<br>
5-[4-(3-Chlorophenyl)-7-ethyl-2-(methoxymethyl)pyrro]o[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.45-1.63 (4H, m), 2.23 (2H, t, J=7Hz), 2.53-<br>
2.63 (2H, m), 3.04 (2H, q, J=7Hz), 3.45 (3H, s), 4.63 (2H, s), 5.93 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.25 (1H, m), 7.36 (1H, s), 7.42 (2H, m)<br>
Example 121<br>
5-[7-Ethyl-2-methyl-4-(3-methylphenyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,5): 1.23-1.63 (4H, m), 1.37 (3H, t, J=7Hz), 2.22 (2H, t, J=7Hz), 2.40<br>
(3H, s), 2.40-2.49 (2H, m), 2.54 (3H, s), 3.02 (2H, q, J=7Hz), 5.89 (1H, d, J=4Hz), 6.48 (1H, d, J=4Hz), 7.10-7.14 (2H, m), 7.23-7.27 (1H, m), 7.32-7.38 (1H, m) MS(ESI+):m/z351<br>
Example 124<br>
5-[7-Ethyl-2-(methoxymelhyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.44-1.65 (4H, m), 2.16-2.26 (2H, m), 2.43<br>
(3H, s), 2.47-2.69 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s), 4.63 (2H, m), 5.88 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 7.56 (1H, s), 8.42 (1H, s), 8.53 (1H, s) MS (ES1+): m/z 382,MS (ESI): m/z380<br>
Example 125<br>
5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.45-1.67 (4H, m), 2.27 (2H, l, J=7Hz), 2.38-<br>
2.52 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d,<br><br>
J=4Hz), 7.88 (1H, m), 8.53 (1H, d, J=2Hz), 8.77 (1H, d, J=2Hz) MS (ESI+):m/z 416,418<br>
Example 126<br>
5-[4-(5-Bromo-3-pyridiny])-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDC13, 8): 1.37 (3H, t, J=7Hz), 1.45-1.65 (4H, m), 2.25 (2H, t, J=7Hz), 2.49-<br>
2.68 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s), 4.63 (2H, s), 5.91 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.89 (1H, m), 8.51 (1H, s), 8.79 (1H, m) MS(ESI+):m/z446,448<br>
Example 127<br>
5-[4-(5,6-Dichloro-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.43-1.68 (4H, m), 2.29 (2H, t, J=7Hz), 2.38-<br>
2.52	(2H, m), 2.57 (3H, s), 3.02 (2H, q, J=7Hz), 5.87 (1H, d, J=4Hz), 6.53 (1H, d,<br>
J=4Hz), 7.81 (1H, d, J=2Hz), 8.31 (1H, d, J=2Hz)<br>
MS (ESI+): m/z 406, MS (ESI"): m/z 404<br>
Example 128<br>
5-[7-Ethyl-2-methyl-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.45-1.68 (4H, m), 2.23 (2H, t, J=7Hz), 2.38-<br>
2.53	(2H, m), 2.56 (3H5 s), 3.02 (2H, q, J=7Hz), 5.46 (1H, d, J=llHz), 5.86 (1H,<br>
d, J=4Hz), 5.89 (1H, d, J=17Hz), 6.52 (1H, d, J=4Hz), 6.72-6.83 (1H, dd, J=ll<br>
Hz, 17Hz), 7.77 (1H, m), 8.47 (1H, d, J=2Hz), 8.68 (1H, d, J=2Hz)<br>
MS (ES1+): m/z 364<br>
Example 129<br>
5-[7-Ethyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3, 5): 1.37 (3H, t, J=7Hz), 1.45-1.65 (4H, m), 2.22 (2H, t, J=7Hz), 2.45-<br>
2.73 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.63 (2H, m), 5.44 (1H, d,<br><br>
J=llHz), 5.87 (1H, d, J=18Hz), 5.92 (1H, d, J=4Hz), 6.57 (1H, d, J=4Hz), 6.72-6.83 (1H, dd, J=l 1 Hz, 18Hz), 7.78 (1H, s), 8.48 (1H, s), 8.68 (1H, s) MS (ES1+): m/z 394 (M+H), MS (ESI"): m/z 392<br>
Example 130<br>
5-[4-(5-Acetyl-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrro]o[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDC13,8): 1.38 (3H, t, J=7Hz), 1.44-1.60 (4H, m), 2.22 (2H, t, J=7Hz), 2.50-<br>
2.63 (2H, m), 2.69 (3H, s), 3.02 (2H, q, J=7Hz), 3.46 (3H, s), 4.64 (2H, s), 5.86 (1H, d, J=4Hz), 6.59 (1H, d, J=4Hz), 8.29 (1H, m), 8.79 (1H, d, J=2Hz), 9.23 (1H, d,J=2Hz) MS (ESI+): m/z 410, MS (ESI): m/z 408<br>
Example 131<br>
4-[7-Ethyl-2-(methoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
NMR (CDC13,5): 1.38 (3H, t, J=7Hz), 1.70-1.87 (2H, m), 2.26 (2H, t, J=7Hz), 2.45<br>
(3H, s), 2.53-2.81 (2H, m), 3.06 (2H, q, J=7Hz), 3.46 (3H, s), 4.66 (2H, m), 5.90 (1H, d, J=4Hz), 6.59 (1H, d, J=4Hz), 7.61 (1H, s), 8.43 (1H, s), 8.46 (1H, s) MS(ESl+):m/z368<br>
Example 132<br>
3-[7-Ethyl-2-(methoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
NMR (CDC13,5): 1.37 (3H, t, J=7Hz), 2.30-2.60 (2H, m), 2.42 (3H, s), 2.77-3.13<br>
(2H, m), 3.05 (2H, q, J=7Hz), 3.47 (3H, s), 4.66 (2H, s), 5.91 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 7.58 (1H, s), 8.42 (1H, s), 8.54 (1H, s) MS (ESI+): m/z 354<br>
Example 133<br>
4-[7-Ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoicacid NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.70-1.88 (2H, m), 2.22-2.32 (2H, m), 2.45<br><br>
(3H, s), 2.50-2.62 (2H, m), 2.59 (3H, s), 3.02 (2H, q, J=7Hz),'5.86 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.60 (1H, s), 8.42 (2H, m) MS (ESI+): m/z 338, MS (ESI): m/z 336<br>
Example 134<br>
3-[7-Ethy]-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoicacid NMR (CDC13, 6): 1.37 (3H, t, J=7Hz), 2.42 (3H, s), 2.40-2.53 (2H, m), 2.59 (3H, s),<br>
2.82 (2H, 1, J=7Hz), 3.03 (2H, q, J=7Hz), 5.86 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.57 (1H, s), 8.38 (1H, s), 8.52 (1H, s) MS (ESI+): m/z 324, MS (ESI"): m/z 322<br>
Example 135<br>
3-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]propanoic acid mp: 181-182°C<br>
NMR (CDC13, 5): 1.38(2H, t, J=7Hz), 2.4(2H, t, J=7Hz), 2.58(3H, s), 2.74-2.85(2H, m), 3.01(2H, q, J=7Hz), 5.89(1H, d, J=4Hz), 6.55(1H, d, J=4Hz), 7.87(1H, s), 8.54(lH,s),8.77(lH,s)<br>
MS: (m/z) 388 (M+), 390(M++2), 114(bp)<br>
Example 136<br>
5-[4-(3-Cyanophenyl)-7-ethyl-2-(methoxymethyl)pyrroIo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NNMR (CDC13,5): 1.30-1.57 (5H, m), 2.21 (2H, t, J=8Hz), 2.47-2.57 (2H, m), 3.03<br>
(2H, q, J=8Hz), 3.45 (3H, s), 4.62 (2H, s), 5.84 (1H, d, J=5Hz), 6.57 (1H, d, J=5Hz), 7.59-7.64 (2H, m), 7.68 (1H, br s), 7.75 (1H, m) MS (ESI): 392 (M+H) Example 136-2<br>
5-[4-[3-(Aminocarbonyl)phenyl]-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDCI3, 5): 1.30-1.70 (5H, overlappoed with H20), 2.20-2.50 (4H, m), 2.80-<br>
2.93 (2H, m), 3.03 (2H, q, J=8Hz), 3.46 (3H, s), 4.54 (1H, d, J=10Hz), 4.77 (1H, d, J=10Hz), 5.80 (1H, d, J=5Hz), 6.55 (1H, d, J=5Hz), 7.43-7.50 (2H, m), 7.58<br><br>
(1H, t, J=8Hz), 7.77 (1H, br s), 7.88 (1H, br s), 7.99 (1H, br d, J=8Hz) MS (ES1+): 410 (M+H)<br>
Example 137<br>
5-[4-(5-Bromo-3-pyridinyl)-7-ethy]-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]penlanoicacid NMR (CDCI3,8): 1.06-1.26 (4H, m), 1.36 (3H, t, J=7Hz), 1.94 (2H, t, J=7Hz), 2.40<br>
(2H, m), 2.99 (2H, q, J=7Hz), 5.96 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.40-7.52 (5H, m), 7.93 (1H, s), 8.59 (1H, s), 8.77 (1H, s)<br>
Example 138<br>
5-[7-Ethyl-4-(5-ethyl-3-pyridinyl)-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid NMR (CDCI3,5): 1.05-1.42 (10H, m), 1.92 (2H, m), 2.41 (2H, m), 2.75 (2H, q,<br>
J=7Hz), 3.01 (2H, q, J=7Hz), 5.93 (lH.'d, J=5Hz), 6.55 (1H, d, J=5Hz), 7.37-7.54 (5H, m), 7.62 (1H, m), 8.45 (1H, m), 8.52 (1H, m)<br>
Example 139<br>
5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-(2-thienyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3,5): 1.25-1.48 (7H, m), 2.12 (2H, t, J=7Hz), 2.62 (2H, m), 3.03 (2H, q,<br>
J=7Hz), 5.93 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.14 (1H, m), 7.37 (1H, d, J=5Hz), 7.43 (1H, d, J=5Hz), 7.92 (1H, s) 8.58 (1H, m), 8.79 (1H, m) MS(ESI+):m/z484(M+H)<br>
Example 140<br>
5-[2-[(Benzyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,5): 1.23 (3H, t, J=7Hz), 1.34-1.48 (5H, m), 2.09 (2H, m), 2.53 (2H, m),<br>
3.04 (2H, q, J=7Hz), 4.07 (2H, J=7Hz), 4.65 (2H, s), 4.72 (2H, s), 5.90 (1H, d, J=5Hz), 6.60 (1H, d, J=5Hz), 7.29-7.38 (5H, m), 7.86 (1H, s), 8.54 (1H, m), 8.77 (lH,m)<br>
Example 141<br><br>
5-(4-(5-Bromo-3-pyridiny])-2-{[(4-cyanobenzyl)oxy]methyl}-7-ethy]pyrvolo[l,2-b]pyridazin-3-yl)pentanoic acid<br>
NMR (CDCI3,8): 1.35-1.56 (7H, m), 2.18 (2H, m), 2.57 (2H, m), 3.03 (2H, q,<br>
J=7Hz), 4.69 (2H, s), 4.74 (2H, s), 5.92 (1H, d, J=5Hz), 6.62 (1H, d, J=5Hz), 7.47 (2H, d, J=8Hz), 7.64 (2H, d, J=8Hz), 7.88 (1H, s), 8.54 (1H, m), 8.79 (1H, m)<br>
Example 142<br>
5-[2-[(Benzylamino)methy]]-4-(5-bromo-3-pyridinyl)-7-ethy]pyrro]o[l32-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDC13, 8): 1.20-1.49 (7H, m), 2.17 (2H, m), 2.32 (2H, m), 3.04 (2H, q,<br>
J=7Hz), 4.29 (4H, s), 5.94 (1H, d, J=5Hz), 6.51 (1H, s, br), 6.12 (1H, d, J=5Hz), 7.27-7.36 (3H, m), 748 (2H, m), 7.84 (1H, m), 8.49 (1H, m), 8.75 (1H, m)<br>
Example 143<br>
5-[4-(5-Bromo-3-pyridinyl)-7-ethyI-2-(4-morpholinylmethyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDC13,8): 1.20-1.38 (5H, m), 1.49 (4H, m), 2.24 (2H, q, J=7Hz), 2.59 (4H,<br>
m), 3.01 (2H, q, J=7Hz), 3.70 (4H, m), 5.88 (1H, d, J=5Hz), 6.55 (1H, d5 J=5Hz), 7.90 (1H, m), 8.55 81H, m), 8.78 (1H, m)<br>
Example 144<br>
5-{4-[5-(Aminocarbonyl)-3-pyridiny]]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yI}pentanoic acid from ethyl 5-[4-(5"Cyano-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]-pyridazin-3-yl]pentanoate<br>
NMR (CDC13, 5): 1.10-1.70 (4H, m), 1.37 (3H, t, J=7Hz), 2.24-2.77 (4H, m), 2.59<br>
(3H, s), 3.02 (2H, q, J=7Hz), 5.77 (1H, d, J=4Hz), 6.52 (1H, d, J=4Hz), 7.57 (1H, br), 7.97 (1H, br), 8.07 (1H, s), 8.68 (1H, s), 9.18 (1H, s) MS(ESI+):m/z381<br>
Example 145<br>
5-[4-[5-(Aminocarbonyl)-3-pyridinyl]-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br><br>
NMR (CDCI3,5): 1.16-1.72 (4H, m), 1.37 (3H, t, J=7Hz), 2.25-2.50 (3H, m), 2.83-<br>
2.97 (1H, m), 3.04 (2H, q, J=7Hz), 3.47 (3H, s), 4.56 (1H, d, J=17Hz), 4.77 (1H, d, J=17Hz),5.81 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.52 (1H, br), 7.82 (1H,br), 8.11 (1H, m), 8.70 (1H, d, J=2Hz), 918 (1H, d, J=2Hz) MS(ESI+):m/z411<br>
Example 146<br>
To a solution of triethyl 4-phosphonocrotonate (2.13 g) in tetrahydrofuran (20 nL) was added dropwise lithium bis(trimethylsilyl)amide (l.lmol/L solution in hexanes, 15mL) at 2°C under nitrogen, and the mixture was stirred at the same temperature for 30 minutes. To the mixture was added dropwise a solution of 4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carbaldehyde (1.2 g) in tetrahydrofuran (20 mL). After being stirred for 3 hours at 2°C, the mixture was poured into saturated aqueous ammonium chloride, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent; 3% ethyl acetate in n-hexane) to give the title compound (1.06 g) as an yellow crystals.<br>
Ethyl (2E,4E)-5-[4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2,4-pentadienoate<br>
NMR (300 MHz, CDCI3,8): 1.28(3H, t, J=7Hz), 1.35(6H, d, J=7Hz), 3.30(1H,<br>
quintet, J=7Hz), 4.19(2H, quartet, J=7Hz), 5.63(1H, d, J=16Hz), 5.94QH, dd, J=16,HHz), 6.16(1H, dd, J=4.4,1.5Hz), 6.76(1H, dd, J-4.4,2.6Hz), 6.78(1H, d, J=16Hz), 7.11-7.23(3H, m), 7.33-7.40(2H, m), 7.72(1H, dd, J=2.6,1.5Hz) MS(ESI+):m/z379(M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 146. Example 147 Ethyl (2E)-3-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2-<br>
propenoate<br>
NMR (CDC13, 6): 1.25 (3H, t, J=7Hz), 1.40 (6H, d, J=7Hz), 3.38 (1H, m), 4.16 (2H,<br><br>
q, J=7Hz), 5.57 (1H, d, J=15Hz), 6.25 (1H, d, J=5Hz), 6.74 (1H, d, J=5Hz), 7.15 (1H, d, J=8.5Hz), 7.29 (1H, d, J=8.5Hz), 733 (1H, d, J=8.5Hz), 7.35 (1H, d, J=8.5Hz), 7.63 (1H, d, J=15Hz) MS(ESI'):m/z385(M-H)<br>
Example 148<br>
(2E)-3-[7-ChIoro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l&gt;b]pyridazin-3-yl]-2-<br>
propenenitrile<br>
NMR (CDC13, 5): 1.41 (6H, d, J=7Hz), 3.28 (1H, m), 4.99 (1H, d, J=15Hz), 6.24 (1H,<br>
d, J=5Hz), 6.76 (1H, d, J=15Hz), 7.17-7.27 (2H, m), 7.30-7.40 (3H&gt; m) MS (ESI"): m/z 340 (M+H)<br>
Example 149<br>
To a solution of ethyl (2E,4E)-5-[4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2,4-pentadienoate (300 mg) in tetrahydrofuran (3 mL) and acetic acid (lmL) was added dropwise N-chlorosuccinimide (106 mg). The mixture was stirred at ambient temperature for 24 hours. The resulting mixture was concentrated and partitioned between saturated aqueous sodium hydrogencarbonate and ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent; 1% ethyl acetate in n-hexane) to give the title compound (HOmg) as an oil.<br>
Ethyl (2E,4E)-5-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2,4-pentadienoate<br>
NMR (300 MHz, CDC13,8): 1.28(3H, t, J=7Hz), 1.40(6H, d, J=7Hz), 3.33(1H,<br>
quintet, J=7Hz), 4.19(2H, quartet, J=7Hz), 5.64(1 H, d, J=16Hz), 5.94(1H, dd, J=16,llHz), 6.18(1H, d, J=4.4Hz), 6.71(1H, d, J=4.4Hz), 6.79(1 H, d, J=16Hz),<br>
7.13-7.23(3H, m), 7.32-7.37(2H, m)<br>
The following compounds were obtained in substantially the same manner as that of Example 149. Example 151 Ethyl 7-chloro-4-(2-chlorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate<br><br>
NMR (300 MHz, CDCI3,8): 0.89 (3H, t, J=7.5Hz), 1.41 (6H, d, J=7.5Hz), 3.41-3.56<br>
(1H, m), 4.00 (2H, q, J=7.5Hz)5 6.16 (1H, d5 J=5Hz), 6.76 (1H, d, J=5Hz), 7.25-7.53 (4H,m) MS (ES+);m/e 377.44<br>
Example 152<br>
Ethyl 7-ch]oro-2-isopropyl-4-(2-naphthyl)pyrrolo[l,2-b]pyridazine-3-carboxy]ate<br>
NMR (300 MHz, CDCI3,8): 0.78 (3H, t, J=7.5Hz), 1.43 (6H, d, J=7.5Hz), 3.29-3.41<br>
(1H,m), 3.95 (2H, q, J=7.5Hz), 6.40 (1H, d, J=5Hz), 6.79 (1H,d, J=5Hz), 7.50-7.60 (3H, m), 7.81-8.00 (4H, m)<br>
Example 153<br>
To a solution of ethyl (2E34E)-5-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l32-b]pyridazin-3-yl]-2,4-pentadienoate(82mg) in ethanol (2 mL) was added IN sodium hydroxide solution (0.5 mL), and the mixture was stirred at ambient temperature for 12 hours. The resulting mixture was concentrated in vacuo, and the residue was dissolved in water, acidified with IN hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (eluent; 50% ethyl acetate in n-hexane) to give the title compound (14mg) as a brown amorphous solid, which was recrystallized from aqueous ethanol.<br>
(2E,4E)-5-[7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2,4-pentadienoic acid<br>
NMR (300 MHz, CDCI3, 8): 1.40 (6H, d, J=7Hz), 1.30-1.90 (lH.br), 3.34 (1H,<br>
quintet, J=7Hz), 5.64 (1H, d, J=16Hz), 5.98 (1H, dd, J=16,llHz), 6.19 (1H, d, J=4.4Hz), 6.72 (1H, d, J=4.4Hz), 6.84 (1H, d, J=16Hz), 7.14-7.37 (5H, m) MS(ES1+): m/z 383 (M-H)<br>
Example 154<br>
To a mixture of ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-(2-thienyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (130 mg) in toluene (5 mL) was added 28% sodium<br><br>
netbylate metanol solution (536 mg) and the mixture was healed under reflux for 2 hours. The solution was acidified to pH 4 with IN hydrochloric acid and extracted with chloroform. The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo. To the residue in ethanol (5 mL) was added IN sodium hydroxide solution (1 mL) and the mixture was heated at 60°Cfor 1 hour. The solution was acidified to pH 4 with IN hydrochloric acid and extracted with chloroform. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (1:1) to give 5-[7-ethyl-4-(2-methoxy-4-pyridinyl)-2-(2-thienyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid as an yellow powder (50.0 mg).<br>
5-[7-Ethyl-4-(2-methoxy-4-pyridinyl)-2-(2-thienyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDC13, 5): 130-1.48 (4H, m), 1.38 (3H, t, J=7Hz), 2.13 (2H, t, J=7Hz), 2.58-<br>
2.69 (2H, m), 3.02 (2H, q, J=7Hz), 4.02 (3H, s), 5.96 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 6.78 (1H, s), 6.90 (1H, d, J=5Hz), 7.12 (1H, m), 7.34 (1H, m), 7.42 (1H, d, J=5Hz), 8.29 (IH, d, J=5Hz)<br>
The following compounds were obtained in substantially the same manner as that of Example 354. Example 155<br>
5-[7-Ethyl-4-(2-methoxy-4-pyridinyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3, 5): 1.31-1.64 (7H, m), 2.25 (2H, t, J=8Hz), 2.43 (2H, br t, J=8Hz),<br>
2.54 (3H, s), 3.00 (2H, q, J=8Hz), 4.04 (3H, s), 5.60 (IH, br s), 5.90 (IH, d, J=5Hz), 6.51 (IH, d, J=5Hz), 6.81 (IH, br s), 6.93 (IH, br d, J=7Hz), 830 (IH, d, J=7Hz) MS(ESl+):m/z368(M+H)<br>
Example 155-2<br>
5-[7-Ethyl-2-methyl-4-(2-oxo-l,2-dihydro-4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br><br>
NMR (CDC13, 8); 1.29-1.67 (7H, m), 2.29 (2H, t, J=8Hz), 235-2.60 (5H, m), 3.00<br>
(2H, q, J=8Hz), 5.94 (1H, d, J=5Hz), 6.54 (1H, d, J=5Hz), 6.64 (1H, br d, J=7Hz), 6.84 (1H, br s), 7.70 (1H, br d, J=7Hz) MS (ESI+): m/z 354 (M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 154. Example 156<br>
5-[7-Ethyl-4-(2-methoxy-4-pyridinyl)-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDC13,5): 1.08-1.30 (4H, m), 1.36 (3H, t, J=7Hz), 1.95 (2H, t, J=7Hz), 2.48-<br>
2.53 (2H, m), 3.03 (2H, q, J=7Hz), 4.01 (3H, s), 6.02 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 6.82 (1H, s), 6.94 (1H, d, J=5Hz), 7.42-7.54 (5H, m), 8.29 (1H, d, J=5Hz) MS(ESI+):m/z430<br>
Example 157<br>
5-[7-Ethyl-2-(methoxymethyl)-4»(2-methoxy-4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,5): 1.37 (3H, t, J=7Hz), 1.40-1.64 (4H, m), 2.24 (2H, t, J=7Hz), 2.53-<br>
2.64 (2H, m), 3.03 (2H, q, J=7Hz), 3.45 (3H, s), 4.01 (3H, s), 4.61 (2H, s), 5.94 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 6.77 (1H, s), 6.89 (1H, d, J=5Hz), 8,28 (1H, d,J=5Hz) MS (ESI+): m/z398,MS (ESI): m/z 396<br>
Example 158<br>
To a solution of ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b)pyridazin-3-yl]pentanoate (120 mg) in toluene (5 mL) and leirahydrofuran (10 mL) was added sodium thiomethoxide (91.0 mg) and the mixture was heated under reflux for 4 hours. The solution was acidfied with IN hydrochloric acid and extracted with chloroform. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column<br><br>
chromatography eluting with a mixture of hexane and ethyl acetate (10:1 - 3:1) to give 5-{7-ethyl-4-[2-(methylthio)-4-pyridinyl]-2-phenylpyrroIo-[l,2-b]pyridazin-3-yl}pentanoic acid as an yellow powder (85.0 mg).<br>
5-{7-Ethyl-4-[2-(methylthio)-4-pyridinyl]-2-phenylpyrrolo[l52-b]pyrida2in-3-yl}pentanoic acid<br>
NMR(GDa3,8):1.07-117(2H,m),1.17-130(2H,m),136(3H,t,J=7Hz)&gt;1.97<br>
(2H,t, J=7Hz), 2.38-2.48 (2H, m), 2.61 (3H, s), 3.02 (2H, q, J=7Hz), 5.98 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 7.03 (1H, dd, J=l Hz, 5Hz), 7.25 (1H, m), 7.43-7.55 (5H,m),8.57(lH,d,J=5Hz) MS (ESf ): m/z 446 (M+H)<br>
Example 159<br>
A mixture of 3-[(l-amino-5-ethyl-lH-pynol-2-yl)carbonyl]benzonitrile (3.00 g), ethyl 6-benzoylhexanoate (5.07 g), and trifluoromethanesulfonic acid (376 mg) in toluene (60 mL) was refluxed for 1 hour and 20 minutes with Dean-Stark equipment. The mixture was partitioned between ethy] acetate (60 mL) and water (60 mL), and the organic layer was washed with saturated sodium bicarbonate (60 mL) and brine (60 mL), dried over magnesium sulfate, and evaporated to give a dark colored oil. Flash silica gel column chromatography eluting with acetone = 1-100 to 7-100 afforded ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo-[l,2-b]pyridazin-3-yl]pentanoate as an orange oil (4.45 g, 78.6%).<br>
Ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDC13, 5): 1.01-1.27 (7H, m), 1.36 (3H, t, J=7Hz), 1.86 (2H, t, J=7Hz), 2.40<br>
(2H, m), 3.02 (2H, q, J=7Hz), 4.02 (2H, q, J=7Hz), 5.90 (1H, d, J=5Hz), 6.61 (1H, d, J=5Hz), 7.44-7.53 (5H, s), 7.60-7.69 (2H, m), 7.74-7.79 (2H, m)<br>
The following compound was obtained in substantially the same manner as that of Example 159. Example 160 Ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-(2-thienyI)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoale<br><br>
NMR (CDCI3,5): 1.21 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.25-1.48 (4H, m), 2.07<br>
(2H, I, J=7Hz), 2.57-2.68 (2H, m), 3.04 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz),5.93 (1H, d, J=4Hz), 6.64 (1H, d, J=4Hz), 7.12 (1H, m), 7.28 (1H, dd, J=l Hz, 5Hz), 7.37 (1H, m), 7.41 (1H, s), 7.45 (1H, d, J=5Hz), 8.55 (1H, d, J=5Hz) MS: (m/z) 468 (M+H)<br>
Example 161<br>
Ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDCI3,5): 1.05-1.17 (2H, m), 1.19-1.30 (2H, m), 1.28 (3H, t, J=7Hz), 1.36<br>
(3H, t, J=7Hz), 1.91 (2H, t, J=7Hz), 2.38-2.48 (2H, m), 3.02 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.96 (1H, d, J=4Hz), 6.64 (1H, d, J=4Hz), 7.31 (1H, dd, J=2 Hz, 5Hz), 7.41-7.54 (6H, m), 856 (1H, d, J=5Hz) MS (ESI+): m/z 462 (M+H)<br>
Example 162<br>
Ethyl [4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-y]]acetate<br>
NMR (CDCI3,5): 1.08 (3H, t, J=7Hz), 137 (3H, t, J=7Hz), 3.03 (2H, q, J=7Hz), 3.36<br>
(2H, s), 3.93 (2H, q, J=7Hz), 6.09 (1H, d, J=5Hz), 6.66 (1H, d, J=5Hz), 7.33 (1H, m), 7.41-7.50 (8H,m) MS (ESI+): m/z 419 (M+H)<br>
Example 163<br>
Ethyl 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3, 5): 1.06 (3H, t, J=7Hz), 1.41 (3H, t, J=7Hz), 3.08 (2H, q, J=7Hz), 4.09<br>
(2H, q, J=7Hz), 6.34 (1H, d, J=5Hz), 6.53 (1H, m), 6.74 (1H, d, J=5Hz), 6.97 (1H, m), 7.39-7.46 (3H, m), 752 (2H, m) MS (ESI+): m/z 395 (M+H)<br>
Example 164<br>
Ethyl 4-(3-chlorophenyl)-7-ethyl-2-(2-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylate NMR (CDCI3, 8): 0.94 (3H, m), 1.41 (3H, m), 3.08 (2H, q, J=7Hz), 3.11 (2H, m),<br><br>
4.00 (2H, m), 6.36 (1H, m), 6.76 (1H, m), 7.26-7.55 (4H, m), 7.84 (1H, m), 8.15 (lH,m),8.57(lH,m) MS (ESI+): m/z 406 (M+H)<br>
Example 165<br>
Ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(l ,3-thiazol-2-yl)pynolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
NMR (CDC13,8): 1.21 (3H, t, J=7Hz), 1.33-1.50 (7H, m), 2.14 (2H, t, J=7Hz), 2.46<br>
(2H, m), 2.97 (2H, q, J=7Hz), 3.06 (2H, q, J=7Hz), 4.05 (2H, q, J=7Hz),5.88 (1H, d, J=5Hz), 6.67 (1H, d, J=5Hz), 7.43 (1H, d, J=3Hz), 7.64-7.67 (2H, m), 7.70 (1H, m), 7.78 (1H, m), 7.93 (1H, d, J=3Hz)<br>
Example 166<br>
Methyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(l-methyl-lH-pyrrol-2-yl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13,8): 1.04 (2H, m), 1.21-1.41 (5H, m), 1.99 (2H, t, J=7Hz), 2.46 (2H, m),<br>
3.02 (2H, q, J=7Hz), 3.60 (3H, s), 3.68 (3H, s), 5.89 (1H, d, J=5Hz), 6.23 (1H, m), 6.35 (1H, m), 6.62 (1H, d, J=5Hz), 6.76 (1H, m), 7.62-7.79 (4H, m)<br>
Example 167<br>
Ethyl 3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]propanoate NMR (CDCI3,8): 1.08 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 2.02 (2H, m), 2.80 (2H,<br>
m), 3.02 (2H, q, J=7Hz), 3.89 (2H, q, J=7Hz), 6.01 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.31 (1H, m), 7.41-7.54 (8H, m)<br>
Example 168<br>
Ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(l,3-oxazol-5-yl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3,8): 1.17-1.49 (10H, m), 2.08 (2H, t, J=7Hz), 2.57 (2H, m), 3.03 (2H, q,<br>
J=7Hz), 4.06 (2H, q, J=7Hz), 5.91 (1H, d, J=5Hz), 6.66 (1H, d J=5Hz), 7.55 (1H, s), 7.62-7.68 (3H, m), 7.78 (1H, m), 8.04 (1H, s)<br><br>
Example 169<br>
Ethyl 5-[7-ethyl-4-(3-methoxyphenyl)-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3,5): 1.05-1.29 (4H, m), 1.18 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.86<br>
(2H, t, J=7Hz), 2.42-2.52 (2H, m), 3.02 (2H, q, J=7Hz), 3.84 (3H, s), 4.02 (2H, q, J=7Hz), 6.02 (1H, d, J=4Hz), 6.60 (1H, d, J=4Hz), 6.95-7.02 (3H, m), 7.36-7.56 (6H,m)<br>
Example 170<br>
Ethyl 5-[7-ethyl-2-phenyl-4-(4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3,6): 1.04-1.29 (4H, m), 1.19 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.88<br>
(2H, t, J=7Hz), 2.38-2.48 (2H, m), 3.02 (2H, q, J=7Hz), 4.04 (2H, q, J=7Hz), 5.95 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.36 (2H, m), 7.42-7.54 (5H, m), 8.76 (2H, m)<br>
Example 171<br>
Ethyl 5-[7-ethyl-2-phenyl-4-(2-pyrazinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3, 5): 1.10-1.32 (4H, m), 1.18 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 1.90<br>
(2H, t, J=7Hz), 2.45-2.55 (2H, m), 3.02 (2H, q, J=7Hz), 4.02 (2H, q, J=7Hz), 6.05 (1H, d, J=4Hz), 6.66 (1H, d, J=4Hz), 7.43-7.56 (5H, m), 8.66 (1H, m), 8.77 (1H, m),8.86(lH,m)<br>
Example 172<br>
Ethyl 5-[7-ethyl-2-phenyl-4-(3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3,5): 1.04-1.30 (4H, m), 1.18 (3H51, J=7Hz), 1.37 (3H, t, J=7Hz), 1.87<br>
(2H, t, J=7Hz), 2.38-2.50 (2H, m), 3.02 (2H, q, J=7Hz), 4.01 (2H, q, J=7Hz), 5.96 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 7.42-7.55 (6H, m), 7.77 (1H, m), 8.66-8.73 (2H,m)<br>
Example 173<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.12-1.28 (7H, m), 1.36 (3H, t, J=7Hz), 1.89 (2H, t, J=7Hz); 2.43<br><br>
(2H&gt; m), 3.01 (2H, m), 4.02 (2H, q, J=7Hz), 5.97 (1H, d, J=5Hz), 6.65 (1H, d, J=5Hz), 7.43-7.55 (5H, m), 7.93 (1H, m), 8.61 (1H, m), 8.79 (1H, m)<br>
Example 174<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2
y]]pentanoale<br>
NMR (CDCI3, 6): 1.16-1.46 (JOH, m), 1.57 (2H, t, J=7Hz), 2.62 (2H7 m), 2.30 (2H,<br>
m), 3.03 (2H,q,J=7Hz),4.05 (2H,q,J=7Hz),5.93 (lH,d,J=5Hz), 6.63 (lH,d, J=5Hz), 7.36 (1H, m), 7.44 (1H, m), 7.91 (1H, m)<br>
Example 175<br>
To a solution of ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[l ,2-b]pyridazin-3-yl]pentanoate (1.00 g) in dimethylsulfoxide (20 mL) was added IN sodium hydroxide (5.31 mL) over 1.5 hours. The reaction was quenched by adding IN hydrochloric acid (6 mL) under an ice-bath. The mixture was partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was washed with water (50 x 2 mL) and brine, dried over magnesium sulfate, and evaporated. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1/3 to 1/1 afforded 5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrro]o[lJ2-b]pyridazin-3-yl]pentanoic acid as an yellow solid (668 mg).<br>
5-[4-(3-Cyanophenyl)-7-ethyL2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDC13,8): 1.03-1.25 (4H, m), 1.36 (3H, t, J=7Hz), 1.93 (2H, t, J=7Hz), 2.39<br>
(2H, m), 3.02 (2H, q, J=7Hz), 5.91(1H, d, J=5Hz)5 6.63 (1H, d, J=5Hz), 7.26-7.53 (5H, s), 156-1.69 (2H, m), 7.72-7.79 (2H5 m) MS(ESI+):m/z424(M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 175. Example 176 5-[4-(3-Cyanophenyl)-7-ethyl-2-(l,3-lhiazol-2-yl)pyrrolo[l52-b]pyridazin-3-yI]pentanoic<br>
acid<br><br>
NMR (CDC13, 5): 1.20-1.52 (7H, m), 2.19 (2H, m), 2.98 (2H, m), 3.04 (2H, q,<br>
J=7Hz), 4.05 (2H, q, J=7Hz), 538 (1H, d, J=5Hz), 6.67 (1H, d, J=5Hz), 7.43 (1H, d, J=3Hz), 7.60-7.64 (2H, m), 7.67 (1H, m), 7.76 (1H, m), 7.92 (1H, d, J=3Hz) MS (ESI+): m/z 431 (M+H)<br>
Example 177<br>
5-[4-(3-Cyanophenyl)-7-ethyl-2--yl]pentanoic acid<br>
NMR (CDC13,5): 1.12 (2H, m), 1.23-1.41 (5H, m), 2.04 (2H,1, J=7Hz), 2.48 (2H, m),<br>
3.02 (2H, q, J=7Hz), 3.68(3H, s), 5.90 (1H, d, J=5Hz), 6.22 (1H, m), 6.35 (1H, m), 6.62 (1H5 d, J=5Hz), 6.75 (1H, m), 7.57-7.789 (4H7 m) MS (ES1+): m/z 427 (M+H)<br>
Example 178<br>
5-[4-(3-CyanophenyI)-7-ethyl-2-(l,3-oxazol-5-y])pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3, 5): 1.31-1.49 (7H, m), 2.17 (2H, t, J=7Hz), 2.57 (2H, m), 3.04 (2H, q,<br>
J=7Hz), 5.42 (1H, d, J=5Hz), 6.67 (1H, d, J=5Hz), 7.56 (1H, s), 7.64 (2H, m), 7.67 (1H, s), 7.78 (1H, m), 8.07 (1H, s)<br>
Example 179<br>
5-[4-(3-Cyanophenyl)-2-(3,5-dimethyl-4-isoxazolyl)-7-ethy]pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
NMR (CDCI3, 8): 1.04-1.30 (7H, m), 1.97 (2H,1, J=7Hz), 2.26-2.35 (5H, m), 2.41<br>
(3H, s), 3.00 (2H, q, J=7Hz), 4.06 (2H, q, J=7Hz), 5.97 (1H, d, J=5Hz), 6,68 (1H, d, J=5Hz), 7.61-7.68 (2H, m), 7.73 (1H, s), 7.79 (1H, m)<br>
Example 180<br>
A solution of 3-[(l-amino-5-ethyl-lH-pyrrol-2-y])carbonyl]benzonitrile (120 mg), 1-tert-butyl 7-ethyl 2-[(3,5-dimethyl-4-isoxazolyl)carbonyl1Heptanedioate (203 rng),and toluenesulfonic acid monohydrate (3.76 mg) in toluene (1 mL) was refluxed for 1 hour. Additional p-toluenesulfonic acid monohydrate (14.5 mg) was added, and the mixture<br><br>
was refluxed for 1 hour. The mixture was stirred further for 0.5 hour after adding trifluoromethanesulfonic acid (3.76 mg). The mixture was partitioned between ethyl acetate (20 mL) and saturated sodium bicarbonate (10 mL). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated. Flash silica gel column chromatography eluting with ethyl acetate-bexane = 1/40 to 2/5 afforded ethyl 5-[4-(3-cyanophenyl)-2-(3,5-climethyl-4-isoxazolyl)-7-ethylpyrrolo-[l,2-b]pyridazin-3-yl]pentanoate as an yellow gum (75.7 mg, 19.1%).<br>
Ethyl5-[4-(3-cyanophenyl)-2-(3,5-dimethyl-4-isoxazolyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13,5): 1.04-1.30 (7H, m), 1.97 (2H, t, J=7Hz), 2.26-2.35 (5H, m), 2.41<br>
(3H, s), 3.00 (2H, q, J=7Hz), 4.06 (2H, q, J=7Hz), 5.97 (1H, d, J=5Hz), 6.68 (1H, d, J=5Hz), 7.61-7.68 (2H, m), 7.73 (1H, s), 7.79 (1H, m)<br>
Example 181<br>
To a solution of N-[2-(3-cyanobenzoyl)-5-ethyl4H-pyrrol-l-yl]-2-(methylsulfonyl)acetamide (2.70 g) in tetrahydrofuran (30 mL) was added sodium hydride (601 mg, 60% in oil) under an ice-bath. After stirring for 40 minutes, the reaction was quenched by adding IN hydrochloric acid (15 mL). The mixture was extracted with ethyl acetate (50 mL), and the extract was washed with water (50 x 2 mL) and brine (50 mL), dried over magnesium sulfate, and evaporated to give a brownish yellow solid (3.36 g). The solid was triturated in diisopropyl ether (20 mL) to give 3-[7-ethyl-3-(methyIsulfonyl)-2-oxo-l ,2-dihydropyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an yellow powder (2.31 g, 90.1%).<br>
3-[7-Ethyl-3-(methylsulfonyl)-2-oxo-l,2-dihydropyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDCI3, 8): 1.37 (3H, t, J=7Hz), 2.46-3.07 (5H, m), 6.81 (1H, d, J=5Hz), 6.70<br>
(1H, d, J=5Hz), 7.60-7.69 (3H, m), 7.83 (1H, d, J=9Hz)<br>
The following compound was obtained in substantially the same manner as that of<br>
Example 181. Example 182<br><br>
Ethyl 4-(4-cyanophenyI)-7-ethyl-2-oxo-l ,2<iihydropyrrolo></iihydropyrrolo>
NMR (CDCI3, 6): 0.78 (3H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 3.02 (2H, q, J=7Hz), 4.02<br>
(2H, q, J=7Hz), 6.15 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.42 (2H, d, J=9Hz), 7.77 (2H, d, J=9Hz),11.74 (1H, s, br) MS(ESl+):m/z336(M+H)<br>
Example 183<br>
To a solution of 3-[7-ethyl-3-(methylsulfonyl)-2-oxo-l,2-dihydropyrrolo[l,2-b]pyridazin-4-yl]benzonitrile (1.30 g) and triethylarnine (578 mg) in dichloromethane (18 mL) was added trifluoromethanesulfonic anhydride (1.61 g) under an ice-bath over 30 minutes (3 to 7°C). After stirring for 0.5 hour, the reaction was quenched by adding water (100 mL). The mixture was partitioned between ethyl acetate (200 mL) containing chloroform (200 mL) and IN hydrochloric acid (50 mL). An insoluble yellow solid was collected by filtration (0.542 g). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give a dark yellow solid (1.27 g). Both the solid was combined, and triturated in diisopropyl ether (30 mL) to give 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-2-yl trifluoromethanesulfonate as a brownish yellow powder (1.67 g, 92.6%).<br>
4-(3-Cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-2-yl trifluoromethanesulfonate<br>
NMR (CDC133 8): 1.39 (3H, t, J=7Hz), 3.02 (2H, q, J=7 Hz,), 3.22 (3H, s), 6.40 (1H,<br>
d, J=5Hz), 6.93 (1H, d, J=5Hz), 7.63 (3H, m), 7.82 (1H, m)<br>
Example 184<br>
A mixture of 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-2-yl trifluoromethanesulfonate (150 mg) and pyrrolidine (45.6 mg) in tetrahydrofuran (1 mL) was refluxed for 1.5 hours. The mixture was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (10 mL). The organic extract was washed with brine, dried over magnesium sulfate, and evaporated to give a dark colored solid. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-4 to 1 -2 afforded 3-[7-ethyl-3-(methylsulfonyl)-2-(l -pyrrolidinyl)-<br><br>
pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an yellow oil, which was crystalyzed upon standing (112 mg, 89.6%).<br>
3-[7-Ethyl-3-(rnethylsulfonyl)-2-(l-pyrrolidinyl)pynolo[l,2-b]pyridazin-4-yl]benzonitrile NMR (CDCI3, 8): 1.38 (3H, t, J=7Hz), 1.99 (4H, m), 3.99 (2H, q, J=7Hz), 3.22 (3H,<br>
s), 3.42-3.70 (4H, m), 6.28 (1H, d, J=5Hz), 6.68 (1H, d, J=5Hz), 7.57 (1H, t, J=9Hz), 7.69- 7.78 (3H,m) MS (ESI+): m/z 395 (M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 184. Example 185<br>
3-[2-(Dimethylamino)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yljbenzonitrile<br>
NMR (CDC13, 5): 1.39 (3H, t, J=7Hz), 2.97 (6H, s), 3.02 (2H, q, J=7Hz), 3.26 (3H, s),<br>
6.28 (1H, d, J=5Hz), 6.69 (1H, d, J=5Hz), 7.57 (1H, t, J=9Hz), 7.66- 7.79 (3H, m) MS (ES1+): m/z 369 (M+H)<br>
Example 186<br>
3-[7-Ethyl-2-[(2-methoxyethyl)amino]-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-<br>
yl]benzonitrile<br>
NMR (CDC13,5): 1.35 (3H, t5 J=7Hz), 2.96 (2H, q, J=7Hz), 3.07 (3H, s), 3.43 (3H, s),<br>
3.61-3.73 (4H, m), 5.96 (1H, d, J=5Hz), 6.51 (1H, d, J=5Hz), 6.75 (1H, m, br), 7.51- 7.60 (3H,m), 7.74 (lH,m) MS(ESI+):m/z399(M+H)<br>
Example 187<br>
A mixture of ethyl 2-(4-fluorobenzoyl)-3-oxo-4-phenylbutanoate (1.4 g), 1H-pyrrol-1-amine (350 mg), and p-toluenesulfonic acid monohydrate (41 mg) in ethanol (10 ml) was refluxed for 5 hours. The mixture was partioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of<br><br>
ethyl acetate and hexane (1:4) to give ethyl 2-benzyl-4-(4-iluorophenyl)pyrrolo[l,2-b]pyridazine-3-carboxylate (828 mg) as an oil.<br>
Ethyl 2-benzyl-4-(4-fluorophenyl)pyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3, 5): 0.70 (3H, t, J=7Hz), 3.71 (2H, q, J=7Hz), 4.29 (2H, s), 6.37 (1H,<br>
dd, J=l, 4Hz), 6.85 (1H, dd, J=2,4Hz), 7.10-7.30 (7H, m), 7.38-7.46 (2H, m), 7.83(lH,dd,l,2Hz)<br>
Example 188<br>
To a solution of ethyl 2-benzyl-4-(4-fluorophenyl)pyrrolo[l,2-b]pyridazine-3-carboxylate (730 mg) in tetrahydrofuran (10 ml) was added N-chlorosuccinimide (260 mg) and the mixture was stirred at 20°C for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with aqueous sodium thiosulfate, water and brine, dried over magnesium sulfate, and evaporated. The residue was purified by silica gel column chromatograpy eluting with a mixture of toluene and ethyl acetate (10:1) to give ethyl 2-benzyl-7-chloro-4-(4-fluorophenyl)pyrrolo[l,2-b]pyridazine-3-carboxylate (285 mg) as an yellow oil.<br>
Ethyl 2-benzyl-7-chloro-4-(4-fluorophenyl)pyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3,5): 0.69 (3H, t, J=7Hz), 3.70 (2H, q, J=7Hz), 437 (2H, s), 6.39 (1H, d,<br>
J=4Hz), 6.82 (1H, d, J=4Hz), 7.10-7.30 (7H, m), 7.35-7.45 (2H, m)<br>
Example 189<br>
A mixture of ethyl 3-(4-fluorobenzoyl)-4-oxopentanoate (800 mg), lH-pyrrol-1-amine (265 mg), and p-toluenesulfonic acid monohydrate (31 mg) in ethanol (5 ml) was refluxed for 5 hours. The mixture was partioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:4) to give ethyl [4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate (1.09 g) as an oil.<br>
Ethyl [4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate<br><br>
NMR (CDCI3, 5): 1.25 (3H, t, J=7Hz), 2.45 (3H, s), 3.45 (2H, s), 4.16 (2H, q, J=7Hz),<br>
6.03 (1H, dd, J=l, 4Hz), 6.72 (1H, dd, J=2, 4Hz), 7.17 (2H, dt, J=2,7Hz), 7.40 (2H, ddd, J =2, 5, 7Hz), 7.68 (1H, dd, J=l, 2Hz)<br>
Example 190<br>
To a solution of ethyl [4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridaz)ji-3-yljacetate (100 mg) in tetrahydrofuran (2 nil) was added N-chlorosuccinimide (43 mg) and the mixture was stirred at 20°C for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with aqueous ethyl acetate, water and brine, dried over magnesium sulfate, and evaporated. The residue was purified by silica gel column chromatograpy eluting with a mixture of toluene and ethyl acetate (10:1) to give ethyl [7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate (34 mg) as an yellow oil.<br>
Ethyl [7-chloro-4-(4-fluorophenyI)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate<br>
NMR (CDCI3,8): 1.25 (3H, t, J=7Hz), 2.54 (3H, s), 3.47 (2H, s), 4.16 (2HS q, J=7Hz),<br>
6.05 (1H, d, J=4Hz), 6.68 (1H, d, J=4Hz), 7.18 (2H, dt, J=2,7Hz), 7.38 
Example 191<br>
To a solution of ethyl [7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate (300 mg) in tetrahydrofuran (4 ml) was added IN sodium hydroxide (1.7 ml), followed by methanol (2 ml). After standing at 20°C overnight, the mixture was partitioned between IN hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was triturated with ether to give [7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetic acid (250 mg) as an yellow powder.<br>
[7-Chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetic acid NMR (CDCI3,8): 2.57 (3H, s), 3.54 (2H, s), 6.06 (1H, d, J=4Hz), 6.69 (1H, d,<br>
J=4Hz), 7.19 (2H, t, J=7Hz), 7.38 (2H, dd, J=5,7Hz)<br><br>
Example 192<br>
To a solution of [7-chloro-4-(4-fluorophenyl)-2-methy]pyrrolo[l,2-b]pyridazin-3-y]]acetic acid (220 mg) in tetrahydrofuran (10 rnl) was added 1,1 -carbonyldiimidazole (18 mg) and the mixture was stirred at 20°C for 1 hour, then magnesium bis(3-ethoxy-3-oxo-propanoate) (109 mg) was added. After the mixture was stirred overnight at 20°C, magnesium bis(3-ethoxy-3-oxo-propanoate) (109 mg) was added. After stirring for 3 hours, the mixture was partitioned between IN hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give the product (237 mg) as an oil, which was triturated with ethyl acetate and washed with isopropyl ether to give ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-3-oxobutanoate (212 mg) as an yellow powder.<br>
Ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-3-oxobutanoate<br>
mp 116-118°C<br>
NMR (CDC13, 5): 1.25 (3H, t, J=7Hz), 2.46 (3H, s), 3.40 (2H, s), 3.75 (2H, s), 4.16<br>
(2H, q, J=7Hz), 6.04 (1H, d, J=4Hz), 6.68 (1H, d, J=4Hz), 7.20 (2H, t, J=7Hz), 7.28(2H,dd,J=5,7Hz)<br>
Example 193<br>
To a solution of ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-3-oxo-butanoate (160 mg) in methanol (5 ml) was added sodium borohydride (23.4 mg) at 0°C and the mixture was stirred at the same temperature for 1 hour. The mixture was partitioned between IN hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was purified by preparative thin-layer chromatograpy eluting with a mixture of ethyl acetate and hexane (1:3) and triturated with ethyl acetate to give ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yI]-3-hydroxybutanoate (95 mg) as an yellow powder.<br>
Ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrroIo[l,2-b]pyridazin-3-yl]-3-<br><br>
hydroxybutanoate<br>
NMR (CDCI3, 5): 1.23 (3H, t, J=7Hz), 2.18-2.38 (2H, m), 2.67 (3H, s), 2.70-2.85<br>
(2H, m), 4.03 (1H, m), 4.09 (2H, q, J=7Hz), 5.96 (1H, d, J=4Hz), 6.65 (1H, d, J=4Hz), 7.19 (2H, t, J=7Hz), 7.30-7.45 (2H, m)<br>
Example 194<br>
To a solution of ethyl 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-3-hydroxybutanoate (52 mg) in tetrahydrofuran (1 ml) was added IN sodium hydroxide (0.27 ml), followed by methanol (1 ml). After standing at 20°C overnight, the mixture was partitioned between IN hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated to give 4-[7-chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-3-hydroxybutanoic acid (45 mg) as an yellow oil.<br>
4-[7-Chloro-4-(4-fluorophenyl)-2-methylpyrrolo[l32-b]pyridazin-3-yl]-3-hydroxybutanoic acid<br>
NMR (CDCI3,8): 2.125-2.45 (2H, m), 2.66 (3H, s), 2.70-2.88 (2H, m), 4.02 (1H, m),<br>
5.97 (1H, d, J=4Hz), 6.65 (1H, d, J=4Hz), 7.20 (2H, t, J=7Hz), 7.30-7.45 (2H, m)<br>
Example 195<br>
A mixture of ethyl 7-(4-fluorobenzoyl)-8-oxononanoate (300 mg)7 (l-amino-5-ethyl-lH-pyrrol-2-yl)(4-fluorophenyl)methanone (216 mg), and p-toluenesulfonic acid monohydrate (35.4 mg) in ethanol (6 ml) was refluxed for 5 hours. The mixture was partioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:4) to give ethyl 6-[7-ethyl-2,4-bis(4-fluorophenyl)pyrrolo[l,2-b]pyridazin-3-yl1Hexanoate (83 mg) and ethyl 6-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoate (40 mg) as an oil.<br>
Ethyl 6-[7-ethyl-2,4-bis(4-fluorophenyl)pyrrolo[l,2-b]pyridazin-3-yl1Hexanoate<br>
NMR (CDC13, 8): 0.85-1.00 (2H, m), 1.00-1.10 (2H, m), 1.16-1.30 (2H, m), 1.21 (3H,<br><br>
t, J=7Hz), 136 (3H, t, J=7Hz), 2.00 (2H, t, J=7Hz), 2.40 (2H, t, J=7Hz), 3.01 (2H, q, J=7Hz), 4.06 (2H, q, J=7Hz), 5.97 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.12-7.24 (4H, m), 7.38 (2H, dd, J=5,9Hz), 7.50 (2H, dd, J=5,9Hz)<br>
Ethyl 6-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoate NMR (CDC13,5): 1.15-1.30 (2H, m), 1.23 (3H, t, J=7Hz), 1.35-1.45 (2H, m), 1.37<br>
(3H, t, J=7Hz), 1.45-1.55 (2H, m), 2.18 (2H, t, J=7Hz), 2.40 (2H, t, J=7Hz), 2.54 (3H, s), 3.01 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.85 (1H, d, J=4Hz), 6.49 (1H, d, J=4Hz), 7.16 (2H, t, J=9Hz), 7.32 (2H, dd, J=5, 9Hz)<br>
Example 196<br>
A mixture of (l-amino-5-ethyl-lH-pyrrol-2-yl)(4-fluorophenyl)methanone (500 mg), ethyl 8-acetyl-9-oxodecanoate (678 mg), and p-toluenesulfonic acid monohydrate (82 mg) in ethanol (5 ml) was refluxed for 2 hours. The mixture was partioned between ethyl acetate and IN hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with toluene to give ethyl 6-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-eb]pyridazin-3-yl1Hexanoate (130 mg) as an oil and [5-ethyl-l-({(lE)-l-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]ethylidene}amino)-lH-pyrrol-2-yl](4-fluorophenyl)-methanone (70 mg) as an yellow crystal.<br>
[5-Ethyl-l-({(lE)-l-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]ethylidene}amino)-lH-pyrrol-2-yl](4-fluorophenyl)methanone<br>
NMR (CDCI3,5): 1.13 (3H, t, J=7Hz), 1.39 (3H, t, J=7Hz), 1.80-2.00 (2H, m), 1.91<br>
(3H, s), 2.86 (3H, s), 3.06 (2H, q, J=7Hz), 5.97 (1H, d, J=4Hz), 6.11 (1H, d, J=4Hz), 6.62 (2H, t, J=4Hz), 7.11 (4H, t, J=9Hz), 7.48 (2H, dd, J=5, 9Hz) , 7.82 (2H,dd,J=5,9Hz)<br>
Ethyl 6-[7-ethyl-4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoate NMR (CDCI3, 5): 1.15-1.30 (2H, m), 1.23 (3H, t, J=7Hz), 1.35-1.45 (2H, m), 1.37<br>
(3H, t, J=7Hz), 1.45-1.55 (2H, m), 2.18 (2H, t, J=7Hz), 2.40 (2H, t, J=7Hz), 2.54<br><br>
(3H, s), 3.01 (2H, q, J=7Hz), 4.10 (2H, q, J=7Hz), 5.85 (1H, d, J=4Hz), 6.49 (1H, d, J=4Hz), 7.16 (2H, t, J=9Hz), 7.32 (2H, dd, J=5, 9Hz)<br>
Example 197<br>
A mixture of ethyl 7-(4-cyanobenzoyl)-8-oxononanoate (2.2 g), 2-elhyl-lH-pyrrol-1-amine (809 mg), and p-toluenesulfonic acid monohydrate (64 mg) in toluene (40 ml) was refluxed for 20 minutes. The mixture was partioned between ethyl acetate and IN hydrochloric acid. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and hexane (1:5) to give the product, which was triturated with hexane to give ethyl 6-[4-(4-cyanophenyl)-7-ethyl-2-methyIpyrrolo-[l,2-b]pyridazin-3-yl1Hexanoate (2.21 g) as an yellow crystals.<br>
Ethyl 6-[4-(4-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoate NMR (CDC13,5): 1.15-1.25 (2H,m), 1.25 (3H, t, J=7Hz), 130-1.45 (2H,rn), 1.38<br>
(3H, t, J=7Hz), 1.45-1.65 (2H, m), 2.19 (2H, t, J=7Hz), 2.38 (2H, t, J=7Hz), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 4r12 (2H, q, J=7Hz), 5.80 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.48 (2H, t, J=9Hz), 7.78 (2H, d, J=9Hz)<br>
Example 198<br>
To a solution of ethyl 6-[4-(4-cyanophenyl)-7-ethyl-2-methylpyrroIo[l,2-b]pyridazin-3-yl1Hexanoate (1.5 g) in tetrahydrofuran (15 ml) was added 2N potassium hydroxide (7.4 ml), followed by methanol (7.4 ml). After stirring at 50°C for 2 hours and 60°C for 3 hours, the mixture was partitioned between IN hydrochloric acid and ethyl acetate. The precipitates were filtered and washed with ethyl acetate. The organic layer and the washings were combined, washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was triturated with ethyl acetate and the precipitates were filtered. The filtrate was purified by silica gel column chromatograpy eluting with a mixture of ethyl acetate and hexane (1:1) and triturated with isopropyl ether to give 6-[4-(4-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl1Hexanoic acid (650 mg) as an yellow crystals. The two precipitates were combined and recrystallized from ethyl acetate to give 6-{4-[4-(aminocarbonyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}hexanoic acid (550 mg, 37.6%) as an yellow crystals.<br><br>
6-[4-(4-Cyanopheny])-7-ethyl-2-meihylpyrrolo[l72-b]pyridazin-3-y]1Hexanoicacid NMR(CDC13,§): 1.15-1.30 (2H,m), 1.35-1.45 (2H,m), 1.38 (3H,t,J=7Hz), 1.45-<br>
1.60 (2H, m), 2.26 (2H, t, J=7Hz), 2.38 (2H, t, J=7Hz), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 5.80 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.48 (2H, t, J=9Hz), 7.79 (2H, d,J=9Hz)<br>
6-{4-[4-(Aminocarbonyl)phenyl]-7-ethyl-2-meth-acid<br>
NMR (CDC13,8): 1.1-1.20 (2H, m), 1.29 (3H, t, J=7Hz), 130-1.45 (4H, m), 2.10 (2H,<br>
t, J=7Hz), 2.37 (2H, t, J=7Hz), 251 (3H, s), 2.92 (2H, q, J=7Hz), 5.73 (1H, d, J=4Hz), 6.51 (1H, d, J=4Hz), 7.45 (2H, t, J=9Hz), 7.47 (1H, s), 7.80 (2H, d, J=9Hz),8.09(lH,s)<br>
Example 199<br>
To a solution of 3-[(l-amino-5-ethyl-lH-pyrrol-2-yI)carbonyl]benzonitrile (200 mg) in toluene (6 mL) was added 2,4-pentanedione (837 mg) and p-toluenesulfonic acid monohydrate (32 mg) at ambient temperature. The reaction mixture was refluxed for 1 hour. The residue was purified by flash silica gel chromatography (silica gel, 80 mL) eluted with hexane-ethyl acetate = 10-1 to give 3-(3-acetyl-7-ethyI-2-methyIpyrrolo[l,2-b]pyridazin-4-yl)benzonitriIe (63 mg, 24.8%) as an yellow solid.<br>
3-(3-Acetyl-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl)benzonitrile<br>
NMR (CDCI3,5): 1.39 (3H, t, J=8Hz), 1.95 (3H&gt; s), 2.50 (3H, s), 3.04 (2H, q, J=8Hz),<br>
6.27 (1H, d, J=5Hz), 6.69 (1H, d, J=5Hz), 7.59-7.72 (2H, m), 7.76-7.84 (2H, m) MS (ES1+): m/z 304 (M+H)<br>
Example 200<br>
To a solution of ethyl (2E)-3-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2-propenoate (50 mg) in toluene was added dropwise 15 M diisobutylalminum hydride (0.277 mL) in toluene (24 mL) in a dryice-acetone bath. After addition, the mixture was stirred for 2 hours (-10°C). The reaction<br><br>
mixture was quenched with sodium, potassium-tartarate and was filtered through Celite. The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 40 mL) eluted with hexane-ethyl acetate = 10-1,5-1, and 3-1 to give (2E)-3-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2-propen-l-ol as an yellow solid (30 mg).<br>
(2E)-3-t7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2-propen-l-ol<br>
NMR(CDC13,5): 1.38 (6H,d, J=7Hz), 3.31 (lH,m), 4.05-4.11 (2H,m),5.48 (lH,dt,<br>
J=15, 6Hz), 6.11 (1H, d, J=5Hz), 6.45 (1H, d, J=15Hz), 6.68 (1H, d, J=5Hz), 7.08-7.18 (2H, m), 7.29-7.40 (2H, m) MS(ESI"):m/z345(M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 200. Example 201 [4-(4-Fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]methanol<br>
NMR (CDC13,5): 1.45 (1H, t, J=5Hz), 2.65 (3H, s), 4.47 (2H, d, J=5Hz), 6.13 (1H,<br>
m), 6.73 (1H, m), 7.14-7.28 (2H, m), 7.43-7.51 (2H, m), 7.70 (1H, m) MS (ESI+): m/z 257 (M+H)<br>
Example 202 [7-Ethyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[lJ2-b]pyridazin-3-yl]methanol<br>
NMR (CDCI3,5): 1.31-1.46 (10 H, m), 3.04 (2H, q, J=8Hz), 346 (1H, m), 4.49 (2H,<br>
d, J=5Hz), 6.05 (1H, d, J=5Hz), 6.56 (1H, d, J=5Hz), 7.12-7.22 (2H, m), 7.41-7.50 (2H, m) MS(ESI+):m/z313(M+H)<br>
Example 203<br>
2-{[7-Ethyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l52»b]pyridazin-3-yl]methoxy}ethanol NMR (CDCJ3, 8): 1.30-145 (9 H, m), 3.04 (2H, q, J=8Hz), 3.35 (1H, m), 3.46 (2H, t,<br><br>
J=6Hz), 3.69 (2H, br t, J=8Hz), 4.30 (2H, s), 6.07 (1H, d, J=5Hz), 6.55 (1H, d, J=5Hz), 7.11-7.22 (2H, m), 7.41-7.51 (2H5 m) MS(ESl+):m/z357(M+H)<br>
Example 204<br>
To a solution of (2E)-3-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-2-propen-l-ol (30 mg) in N,N-dimethylformamide (1 mL) was added 60% sodium hydride in oil (3.8 mg) in an ice-water bath under nitrogen atmosphere. After 20 minutes, to the mixture was added methyl iodide (18.5 mg) at the temperature. After 15 minutes, the reaction mixture was stirred at ambient temperature for 5 hours. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water three times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (hexane-ethyl acetate = 10-1) to give 7-chloro-4-(4-fluorophenyl)-2-isopropyl-3-[(lE)-3-methoxy-l-propenyl]pyrrolo[l,2-b]pyridazine as a brown oil (3.5 mg, 10.2 %).<br>
7-Chloro-4-(4-fluorophenyl)-2-isopropyl-3-[(lE)-3-methoxy-l-propenyl]pyrrolo[l,2-b]pyridazine<br>
NMR (CDC13, 8): 1.38 (3H, t, J=7Hz), 3.31 (1H, m), 4.05-4.11 (2H, m), 5.48 (1H, dt,<br>
J=15, 6Hz), 6.11 (1H, d, J=5Hz), 6.45 (1H, d, J=15Hz), 6.68 (1H, d, J=5Hz), 7.08-7.18 (2H, m), 7.29-7.40 (2H, m) MS(ESr):m/z345(M+H)<br>
Example 205<br>
To dimethylsulfoxide (0.5 mL) was added 60% sodium hydride in oil (27 mg) and was heated at 60°C for 40 minutes. To this mixture was added (3-carboxypropyl)(triphenyl)phosphonium bromide (124 mg) at ambient temperature and was stirred for 40 minutes. 7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carbaldehyde (40 mg) was added therein at ambient temperature. After 4 hours, the reaction mixture was acidified with IN hydrogen chloride and was partitioned between ethyl acetate and water. The organic layer was washed with water three times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (hexane-ethyl acetate = 1-1) to give (4E)-5-[7-chloro-4-(4-<br><br>
fluorophenyl)»2-isopropylpyrro]o[l,2-b]pyridazin-3-yl]-4-pentenoic acid as an yellow oil (21mg,E:Z=16:l,563%).<br>
(4E)-5-[7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l32-b]pyridazin-3-yl]-4-pentenoic acid<br>
NMR (CDCI3, 5): 1.40 (6H, d, J=7Hz), 2.20-2.37 (4H, m), 3.25 (1H, m), 5.30 (0.94H,<br>
dt, J=15,7Hz), 5.01 (0.06H, m), 6.09 (1H, d, J=5Hz), 6.24 (0.94H, d, J=15Hz), 6.84 (0.06H, d, J=10Hz), 6.67 (0.94H, d, J=5Hz), 6.70 (0.06H, d, J=5Hz), 7.07-7.17 (2H, m), 7.26-7.35 (2H, m). MS (ESI'): m/z 385 (M-H)<br>
Example 206<br>
To a solution of 7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carbaldehyde (40 mg) was added IN sodium hydroxide (193 mg) and acetone (0.425 mL) at ambient temperature. After 8 hours, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (hexane-ethyl acetate = 5-1) to give (3E)-4-[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrroIo[l,2-b]-pyridazin-3-yl]3-buten-2-one as an yellow solid (33 mg).<br>
(3E)-4-[7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]-3-buten-2-one<br>
NMR (CDCI3, 5): 1.40 (6H, d, J=7Hz), 2.13 (3H, s), 3.38 (1H, m), 5.89(1H, d,<br>
J=15Hz), 6.23 (1H, d, J=5Hz), 6.75 (1H, d, J=5Hz), 7.13-7.23 (2H, m), 7.30-739 (2H,m),7.49(lH,d,J=15Hz)<br>
Example 207<br>
A solution of ethyl 4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate (100 mg) in tetrahydrofuran (1 mL) was purged with nitrogen gas under a dryice-acetone bath. To the mixture was added 2,2-azobisisobutyronitrile (0.5 mg) was<br>
added to the mixture. After 5 minutes, was added l,3-dibromo-5,5-dimethy]-2,4-imidazolidinedione (43.8 mg). The resulting mixture was stirred for 3 hours (-78 to -<br><br>
30°C). Water (5 mL) was added, and the mixture was extracted with ethyl acetate. The organic extract was washed with brine, dried over anhydrous magnesium sulfate, and evaporated to give an yellow gum. Flash silica gel column chromatography eluting with toluene-hexane = 1-5 to 2-3 afforded ethyl 7-bromo-4-(4-fIuorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate product as an yellow gum (90.0 mg, 72.5%).<br>
Ethyl 7-bromo-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate NMR (CDC13,8): 0.98 (3H, t, J=7Hz), 1.40 (6H, d, J=7Hz), 3.31 (1H, septet, J=7Hz),<br>
4.05 (2H, q, J=7Hz), 639 (1H, d, J=5Hz), 6.87 (1H, d, J=5Hz), 7.16 (2H, t, J=9Hz), 7.45 (2H, dd, J=4 and 9Hz) MS(ESI+):m/z405(M+H)<br>
Example 208<br>
A suspension of sodium hydride (74.4 mg) in dimethylsulfoxide (1.4 mL) was stirred for 1 hour at 60°C. The mixture was added to a solution of methyl triphenylphosphonium bromide (1.11 g) in dimethylsulfoxide (1.0 mL) at room temperature. After stirring for 0.5 hour, the mixture was added ethyl 4-(4-fluorophenyl)-7-formyl-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxy]ate (500 mg). After stirring for 15 hours, the mixture was partitioned between ethyl acetate (20 mL) and water (5 mL). The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and evaporated to give an orange gum. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-7 to 3-1 afforded ethyl 4-(4-fluorophenyl)-2-isopropy]-7-vinylpyrrolo[l,2-b]pyridazine-3-carboxylate an yellow gum, which was solidified upon standing (361 mg, 72.6%).<br>
Ethyl 4-(4-fluorophenyl)-2-isopropyl-7-vinylpyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3, 8): 0.97 (3H, t, J=7Hz), 1.38 (6H, d, J=7Hz), 3.32 (1H, septet, J=7Hz),<br>
4.03 (2H, q, J=7Hz), 5.35 (1H, dd, J=2 and 12Hz), 6.11 (1H, dd, J=2 and 18Hz), 6.34 (1H, d, J=5Hz), 6.99 (1H, d, J=5Hz), 7.16 (1H, t, J=9Hz), 7.25 (1H, dd, J=12 and 18Hz), 7.45 (2H, d, J=4 and 9Hz)<br><br>
Example 209<br>
To a solution of ethyl 7-{4-[4-({[(benzyloxy)carbonyl]-amino}sulfonyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2--b]pyridazin-3-yl}heptanoate (169 mg) in ethanol (2 xnL) was added 10% palladium on activated carbon (1.6 mg), and the mixture was stirred under hydrogen pressure (3 kg/cm2) for 2 hours. The resulting mixture was filtered through celite, and the filtrate was concentrated to give an yellow gum. Preparative silica gel thin layer chromatography eluting with ethyl acetate-hexane = 1-1 afforded ethyl 7-{4-[4-(aminosulfonyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}heptanoate as an yellow gum (76.8 mg, 58.4%).<br>
Ethyl 7-{4»[4-(aminosulfonyl)phenyl]-7-ethyl-2-methylpyrrolo[l52-b]pyridazin-3-yl}heptanoate<br>
NMR (CDC13, 5): 1.07-1.25 (7H, m), 1.30-1.46 (7H, m), 2.18 (2H, t, J=7Hz), 2.36<br>
(2H, m), 2.55 (3H, s), 3.00 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.21 (2H, s), 5.82 (1H, d, J=5Hz), 6.50 (1H, d, J=5Hz), 7.52 (2H, d, J=9Hz), 8.05 (2H, d, J=9Hz) MS (ESI+): m/z 472 (M+H)<br>
Example 210<br>
To a solution of ethyl 4-(4-cyanophenyl)-2-(2-ethoxy-2-oxoethyl)-7-ethylpyrrolo[l,2-b]pyridazine-3-carboxylate (77.9 mg) in ethanol (0.5 mL)-tetrahydrofuran (0.5 mL) was added IN potassium hydroxide. The resulting solution was stirred for 2.5 hours at room temperature. The mixture was stirred for futher 1 hour after adding IN potassium hydroxide (0.04 mL). The reaction was quenched by adding IN hydrochloric acid (0.23 mL). The volatile was evaporated off, and the resulting residue was partitioned between ethyl acetate (10 mL) and IN hydrochloric acid (6 mL). The organic layer was washed with brine, dried, and evaporated to give [4-(4-cyanophenyl)-3-(ethoxycarbonyl)-7-ethylpyrrolo[l,2-b]pyridazin-2-yl]acetic acid as an yellow solid (67.7 mg,93.4%).<br>
[4_(4-Cyanophenyl)-3-(ethoxycarbonyl)-7-ethylpyrrolo[l,2-b]pyridazin-2-yl]acetic acid NMR (CDC13,5): 0.84 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 3.05 (2H, q, J=7Hz), 3.93<br>
(2H, q, J=7Hz), 4.18 (3H, s), 6.27 (1H, d, J=5Hz), 6.74 (1H, d, J=5Hz), 7.52 (2H,<br><br>
d, J=9Hz), 7.76 (2H, d, J=9Hz)<br>
MS(ESl+):m/z378(M-fH)<br>
Example 211<br>
To a solution of ethyl 2-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazine-3-carboxylate (35.0 mg) in tetrahydrofuran (1 mL) was added 60% sodium hydride (4.50 mg) under an ice-bath. The resulting mixture was stirred for 1 hour. The reaction was quenched by adding IN HC1 (4 mL). The mixture was extracted with ethyl acetate (10 mL), and the organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated. Preparative silica gel thin layer chromatography eluting with ethyl chloroform-methanol = 10-1 afforded 4-(7-ethyl-l33-dioxo-l-jS--tetrahydropyridolS--ejpyrrolotl--b]-pyridazin-10-yl)benzonitrile as an yellow solid (3.86 mg, 12.6%).<br>
4-(7-ethyl-13-dioxo-l,253,4-tetrahydropyrido[3,4-e]pyrrolo[l,2-b]pyridazin-10-yl)benzonitrile<br>
NMR (CDC13,5): 1.40 (3H, t, J=7Hz), 3,08 (2H, q, J=7Hz), 4.16 (3H, s), 6.38 (1H, d,<br>
J=5Hz), 6.85 (1H, d, J=5Hz), 7.46 (2H, d, J=9Hz), 7.78 (2H, d, J=9Hz), 7.92 (1H, s,br)<br>
Example 212<br>
To methanol (1 mL) was added 60% sodium hydride (6.51 mg) at room temperature. Then,4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-2-yl trifluoromethanesulfonate (70.0 mg) was added to the mixture. The resulting mixture was stirred for 2 hours at room temperature and 1 hour at 50°C. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated. Preparative silica gel thin layer chromatography eluting with ethyl acetate-hexane = 1-1 afforded 3-[7-ethyl-2-methoxy-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an yellow solid (1.92 mg, 3.7%).<br>
3-[7-Ethyl-2-methoxy-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]ben2onitrile NMR (CDCI3,5): 1.38 (3H, t, J=7Hz), 3.01 (2H, q, J=7Hz,), 3.24 (3H, s), 4.18 (3H,<br><br>
s), 6.12 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.53-7.64 (3H, m), 7.76 (1H, m)<br>
Example 213<br>
To a solution of ethyl 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylate (92.6 mg) in telrahydrofuran (1 mL) and ethanol (0.5 mL) was added IN sodium hydroxide (0.349 mL). The resulting mixture was stirred for 3 hours at room temperature. The resulting mixture was stirred further for 40 minutes after adding IN sodium hydroxide (0.1 mL). The mixture was stirred further for 1.5 hours after adding IN sodium hydroxide (0.1 mL). The reaction was quenched by adiding IN hydrochloric acid (1 mL), and the mixture was partitioned between ethyl acetate (20 mL) and water (10 mL). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give a red oil. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-1 afforded 3-(6-ethyl-l,l-dioxido-3-oxo-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]-<br>
pyridazin-9-yl)benzonitrile as a red foam (52.4 mg, 64.0%). 3-(6-Ethyl-l,l-dioxido-3-oxo-253-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-yl)benzonitrile<br>
NMR (CDC13,5): 1.45 (3H, t, J=7Hz), 3.21, (3H, s), 4.28 (2H, s), 6.91 (1H, d,<br>
J=5Hz), 7.26 (1H, d, J=5Hz), 7.75 (1H, t, J=9Hz), 7.91 (1H, d, J=9Hz), 8.08-8.16 (2H, m) MS(ESI+):m/z352(M+H)<br>
Example 214<br>
To a solution of 3-(6-ethyl-l,l-dioxido-3-oxo-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-yl)benzonitriIe (60.0 mg) in tetrahydrofuran (0.2 mL) was added 1 M solution of borane-tetrahydrofuran complex in tetrahydrofuran (0.487 mL) under an ice-bath. After stirring for 1 hour, the reaction was quenched by adding IN hydrochloric acid (1 mL). The mixture was partitioned between ethyl acetate (20 mL) and water (10 mL), and the organic layer was washed with brine, dried, and evaporated to give 3-(6-ethyl-3-hydroxy-l,l-dioxido-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-<br>
9-yl)-<br>
benzonitrile as an yellow foam (576 mg, 99.8%).<br><br>
3-(6-Ethyl-3-hydroxy4,l-dioxido-2,3-dihydropyrrolo[l,2-b]thieno[23-e]pyridazin-9-yl)benzonitrile<br>
NMR (CDCI3, 5): 1.45 (3H, I, J=7Hz), 3.21, (3H, s), 4.28 (2H, s), 6.91 (1H, d,<br>
J=5Hz), 7.26 (1H, d, J=5Hz), 7.75 (IH, t, J=9Hz), 7.91 (1H, d, J=9Hz), 8.08-8.16 (2H, m)<br>
Example 215<br>
To a solution of 3-(6-ethyl-3-hydroxy-l ,l-dioxido-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-yl)benzonitrile (54.0 mg) in tetrahydrofuran (1 mL) was added 60% sodium hydride (6.69 mg) under an ice-bath. After stirring for 0.5 hour, methyl iodide (25.9 mg) was added, and the mixture was stirred for 3 hours 20 minutes at room temperature. The mixture was stirred for another 6 hours after adding mehtyl iodide (25.9 mg). The mixture was further stirred for 1 hour after adding 60% sodium hydride (3.0 mg) and methyl iodide (25.9 mg). The mixture was partitioned between ethyl acetate and IN hydrochloric acid, and the organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give an yellow oil. Preparative silica gel thin layer chromatography eluting with ethyl acetate-hexane = 1-2 afforded 3-(6-ethyl-l,l-dioxidopyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-yl)benzonitrile (5.9 mg, 10.5%, an yellow solid) and3-(6-ethyl-3-methoxy-l,l-dioxido-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-yl)benzonitrile (16.8 mg, 30.0%, an orange gum).<br>
3-(6-Ethyl-l,l-dioxidopyiTolo[lJ2-b]thieno[2,3-e]pyridazin-9-yl)benzonitrile<br>
NMR (CDC13,5): 1.40 (3H, t, J=7Hz), 3.07 (2H, q, J=7Hz), 6.68 (IH, d, J=5Hz),<br>
6.82 (IH, d, J=5Hz), 7.02 (IH, d, J=7Hz), 7.37 (IH, d, J=7Hz), 7.72 (IH, t, J=9Hz), 7.87 (IH, d, J=9Hz), 8.11-8.16 (2H, m)<br>
3-(6-Ethyl-3-methoxy-l,l-dioxido-2,3-dihydropyrrolo[l,2-b]thieno[2,3-e]pyridazin-9-<br>
yl)benzonitrile<br>
NMR (CDCI3,6): 1.42 (3H, t, J=7Hz), 3.12 (2H, q, J=7Hz), 3.67 (3H, s), 3.73 (2H,<br>
m), 5.02 (IH, m), 6.74 (IH, d, J=5Hz), 6.97 (IH, d, J=5Hz), 7.70 (IH, t, J=9Hz), 7.85 (IH, d, J=9Hz), 8.04-8.13 (2H, m) MS(ESI+):m/z368(M+H)<br><br>
Example 216<br>
A mixture of 3-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]benzonitrile (1.00 g), ethyl 3-(methylsulfonyl)-2-oxopropanoate (1.34 g), and p-toluenesulfonic acid monohydrate (79.5 mg) in toluene (20 mL) was refluxed for 1 hour with Dean-Stark condenser, The volatile was removed in vacuo. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-10 to 9-15 afforded the intermediate imine (1.38 g, 67.7%) as an orange foam. The foam was dissolved in N-methylmorpholine (10 mL), and the solution was stirred for 1 hour at 130°C. The mixture was partitioned between ethyl acetate (50 mL) and water (30 mL). The organic layer was washed with water (30 x 2 mL) and brine, dried over magnesium sulfate, and evaporated to give a dark orange solid. The solid was triturated in diisopropyl ether (10 mL) to give 2-(trimethylsilyl)ethyl 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylate as an yellow powder (1.11 g, 67.7%).<br>
2-(Trimethylsilyl)ethyl4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylate<br>
NMR (CDC13,8): 0.12 (9H, s), 1.22 (2H5 m), 1.39 (3H, t, J=7Hz), 3.09 (2H, q,<br>
J=7Hz), 3.23 (3H, s), 4.53 (2H, m), 6.30 (1H, d, J=5Hz), 6.89 (1H, d, J=5Hz), 7.50-7.67 (3H, m), 7.82 (1H, m) MS (ES1+): m/z 470 (M+H)<br>
The following compound was obtained in substantially the same manner as that of Example 216. Example 217<br>
Ethyl 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylate<br>
NMR (CDCI3,8): 1.39 (3H, t, J=7Hz), 1.47 (3H, t, J=7Hz), 3.10 (2H, q, J=7Hz), 3.21,<br>
(3H, s), 4.51 (2H, q, J=7Hz), 6.30 (1H, d, J=5Hz), 6.90 (1H, d, J=5Hz), 7.61-7.67 (3H,m),7.72(lH,m)<br>
Example 218<br>
A solution of 2-(trimethylsilyI)ethyl 4-(3-cyanophenyl)-7-ethyl-3-<br><br>
(methyIsuIfonyI)pyrrolo[l,2-b]pyridazine-2-carboxylate (1.09 ) in trifluoroacetic acid (5 mL) was stirred for 1.5 hours under an ice-bath. The reaction was quenched by adding water (20 mL). An yellow crystal was formed upon the addition, which was collected by filtration. The crystal was washed with water (5 mL) and hexane (3 mL) to give 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylic acid as an yellow crystal (756 mg, 88.2%).<br>
4-(3-Cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxylicacid NMR (CDC13,5): 1.41 (2H, m), 3.10 (2H, q, J=7Hz), 3.30 (3H, s), 6.36 (1H, d,<br>
J=5Hz), 6.94 (1H, d, J=5Hz), 7.53-7.67 (3H, m), 7.82 (1H, m) MS (ESI+): m/z 370 (M+H)<br>
Example 219<br>
A mixture of 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyI)pyrrolo[l ,2-b]pyridazine-2-carboxylic acid (40.0 mg), diemthylamine hydrochloride (12.4 mg), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (25.2 mg), and 1-hydroxybenzotriazole (21.9 mg) in N,N-dimethylformamide (1 mL) was stirred for 3 hours at room temperature. The mixture was partitioned between ehtyl acetate (20 mL) and IN hydrochloric acid (10 mL). The organic layer was washed with water (10 x 3 mL), saturated sodium bicarbonate(10 mL), and brine, dried over magnesium sulfate, and evaporated to give 4-(3-cyanophenyl)-7-ethyl-N,N-dimethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxamide as an yellow solid (43.4 mg, 101%).<br>
4-(3-Cyanophenyl)-7-ethyl-N,N-dimethy]-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazine-2-carboxamide<br>
NMR (CDCI3,5): 1.38 (2H, m), 3.07 (2H, q, J=7Hz), 3.12 (3H, s), 3.18 (3H, s), 3.27<br>
(3H, s), 6.27 (1H, d, J=5Hz), 6.85 (1H, d, J=5Hz), 7.57-7.67 (3H, m), 7.81 (1H,<br>
m) MS(ESI+):m/z397(M+H)<br>
Example 220<br>
A mixture of ethyl 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrroIo[l ,2-b]pyridazine-3-carboxylate (450 mg) and 85% potassium hydroxide (3.01 g) in a mixture<br><br>
of ethanol (3 mL) and water (2 mL) was refluxed for 2.5 hours. The reaction mixture was cooled under an ice-bath, and quenched by adding concentrated hydrochloric (5 mL). The mixture was partitioned between ethyl acetate (20 mL) and water (10 mL), and the organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give an yellow solid (388 mg). The solid was triturated in hexane to give 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carboxylic acid as an yellow powder (361 mg, 86.4%).<br>
4-(3-Chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carboxylicacid NMR (CDC13, 5): 1.41 (3H, l, J=7Hz), 3.08 (2H3 q, J=7Hz), 6.37 (1H, d, J=5Hz),<br>
6.55 (1H, m), 6.76 (1H, d, J=5Hz), 7.02 (1H, d, J=3Hz), 7.40-7.55 (5H, m) MS(ESI+):m/z367(M+H)<br>
Example 221<br>
To a solution of 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carboxylic acid (358 mg,) and N,N-dimethylformamide (1.39 mg) in dichloromethane (3 mL) was added oxalyl chloride (157 mg) at room temperature. After stirring for 30 minutes, the volatile was removed in vacuo, and the residue was azeotroped with toluene three times to afford 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carbonyl chloride as an yellow gum (396 mg, 106%).<br>
4-(3-Chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carbonyl chloride NMR (CDCI3,5): 1.42 (3H, t, J=7Hz), 3.10 (2H, q, J=7Hz), 6.45 (1H, d, J=5Hz),<br>
6.59 (1H, m), 6.82 (1H, d, J=5Hz), 7.06 (1H, d, J=7Hz), 7.38-7.55 (4H, m), 7.63 (lH,m)<br>
Example 222<br>
To a solution of methyl aminoacetate hydrochloride (26.1 mg) and triethylamine (42.0 mg) in dichloromethane (0.5 mL) was added a solution of 4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazine-3-carbonyl chloride (40.0 mg) in dichloromethane (0.5 mL) under an ice-bath. The mixture was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (10 mL), and the organic layer was washed with brine (10 mL), dried over magnesium sulfate, and evaporated to give methyl ({[4-(3-<br><br>
chlorophenyl)-7-ethyl-2-(3-furyl)pyrrolo[l,2-b]pyridazin-3-yl]carbony]}am]no)acetale as an yellow gum (50.6 mg, 111%).<br>
Methyl ({[4-(3-chlorophenyl)-7-elhyl-2-(3-furyl)pyrrolo[l,2-b]pyridazin-3-yl]carbonyl}amino)acetate<br>
NMR (CDCI3,8): 1.41 (3H, t, J=7Hz), 3.10 (2H, q, J=7Hz), 3.69 (3H, s), 3.95 (2H, d,<br>
J=5Hz), 6.01 (1H, t, br, 5Hz), 6.35 (1H, d, J=5Hz), 6.51 (1H, m), 6.75 (1H, d, J=5Hz), 7.01 (1H, d, J=7Hz), 7.37-7.48 (3H, m), 7.53 (1H, m), 758 (1H, m) MS(ESI+):m/z438(M+H)<br>
The following compound was obtained in substantially the same manner as that of Example 222. Example 223<br>
4-(3-Chlorophenyl)-7-ethyl-2»(2-furyl)-N,N-bis(2-hydroxyethyl)pyrrolo[l,2-b]pyridazine-3-carboxamide<br>
NMR (CDCI3,6): 1.42 (3H, t, J=7Hz), 2.35-2.72 (4H, m), 3.08 (2H, d, J=5Hz), 3.20-<br>
3.63 (4H, m), 3.82 (2H, m), 6.40 (1H, t, br, 5Hz), 6.54 (1H, m), 6.75 (1H, d, J=5Hz), 7.04 (1H, d, J=3Hz), 7.40-7.48 (2H, m), 7.53-7.60 (2H, m), 7.71 (1H, m) MS(ES1+):m/z454(M+H)<br>
Example 224<br>
To a solution of 3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]propanoic acid (100 mg) in dioxane (0.5 mL) was added triethylamine (25.2 mg) followed by a solution of pivaloyl chloride (30.1 mg) in dioxane (0.5 mL). A white precipitate was formed. After stirring for 40 minutes at room temperature, the precipitate was removed by filtration, and washed with dioxane (2 mL). To the combined washing was added a solution of 2-aminoethanesulfonic acid (38.6 mg) in IN sodium hydroxide (0.247 mL). The resulting mixture was stirred for 1 hour at room temperature. The mixture was partitioned between ethyl acetate (15 mL) and water (5 mL). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated. Preparative silica gel thin layer chromatography eluting with chloroform-melhanol = 5-1 afforded 2-({3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo-[l,2-b]pyridazin-3-yl]propanoyl}amino)ethanesulfonic acid as an yellow solid (104 mg,<br><br>
82.0%).<br>
2-({3-[4-(3-Chloropheny])-7-elhy]-2-pheny]pyrrolo[l,2-b]pyridazin-3-y]]propanoyl}amino)ethanesulfonic acid<br>
NMR (CDC13,5): 1.27 (5H, m), 2.59 (4H, m), 2.90-3.14 (4H, m), 5.96 (1H, m), 6.06<br>
(1H, in), 7.06-7.40 (9H,m)<br>
Example 225<br>
A solution of 3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l ,2-b]pyridazin-3-yl]propanoic acid (100 mg), (2R53R,4S-S,6R)-2-amino-3--bis[(2,2-dimethylpropanoyl)-<br>
oxy]-6-{[(232-dimethylpropanoyl)oxy]methyl}tetrahydro-2H-pyran-4-ylpivalate (255 mg), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.494 mmol), and 1-hydroxybenzotriazole (66.7 mg) in N,N-dimethylformamide (1 mL) was stirred for 1 hour at room temperature. The mixture was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (10 mL). The organic layer was washed with water (10 x 3 mL), saturated Sodium bicarbonate (10 mL), and brine, dried over magnesium sulfate, and evaporated to give an yellow foam (339 mg). Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-10 to 2-5 afforded (2R,3R,4S-S,6R)-2-({3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]propanoyl}amino)-3,5-bis[(2,2-dimethylpropanoyl)oxy]-6-{[(2,2-dimethylpropanoyl)-oxy]methy]}tetrahydro-2H-pyran-4-yl pivalate an yellow foam (240 mg, 108%).<br>
(2R,3R,4S,5S,6R)-2-({3-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]propanoyl}amino)-3,5-bis[(2,2-dimethy]propanoyl)oxy]-6-{[(2,2-dimethylpropanoyl)oxy]methyl}tetrahydro-2H-pyran-4-yl pivalate<br>
NMR (CDC13, 8): 0.97-1.26 (36H, m), 1.35 (3H, t, J=7Hz), 1.83 (2H, m), 2.81 (2H,<br>
m), 3.01 (2H, q, J=7Hz), 3.87-4.16 (3H, m), 4.90-5.27 (3H, m), 5.36-5.51 (2H, m), 6.01 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.29 (1H, m), 7.40-7.59 (8H, m)<br>
Example 226<br>
To a solution of ethyl [4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]acetate (114 mg) in tetrahydrofuran (2 mL) was added 1 M<br><br>
diisobutylaluminum hydride in toluene (0.816 mL) under an ice-bath. After stirring for 1 hour at room temperature, additional 1 M diisobutylaluminum hydride (0.41 mL) was added. The reaction was quenched by adding IN hydrochloric acid (1 mL) after 1 hour. The mixture was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (10 mL), and filtered through celite. The organic layer was washed with water (10 mL) and brine, dried over magnesium sulfate, and evaporated to give an yellow gum. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1-20 to 2-50 afforded 2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethanol as an yellow oil, which was crystalyzed upon standing (107 mg, 104%).<br>
2-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethanol<br>
NMR (CDC13,5): 1.37 (3H, t, J=7Hz), 2.77 (2H, t, J=7Hz), 3.01 (2H, q, J=7Hz), 3.26<br>
(2H, m), 3.26 (2H, m), 6.00 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.34 (1H, m), 7.41-7.55 (8H,m)<br>
Example 227<br>
To a mixture of 2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l;2-b]pyridazin-3-yl]ethanoI (105 mg), 2,3,4,6-tetra-O-acetyl-beta-D-galactosyl bromide (299 mg), silver carbonate (154 mg) in toluene (2 mL) was added silver triflate (3.58 mg) under an ice bath. After 40 minutes, 2,3,4,6-tetra-O-acetyl-beta-D-galactosyl bromide (114 mg), silver carbonate (229 mg) was added, and the mixture was stirred for 50 minutes. The mixtrure was further stirred for 50 minutes after adding 2,3,4,6-tetra-O-acetyl-beta-D-galactosyl bromide (114 mg), silver carbonate (154 mg). The mixture was filtered through celite, and the filtrate was paritiotned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give an yellow gum. Hash silica gel column chromatography eluting with ethyl acetate-hexane = 1-10 to 7/10 afforded (2R,3R,4S-S,6R)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-{2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}tetrahydro-2H-pyran-3-yl acetate as an yellow gum (115 mg, 58.4%).<br>
(2R,3R,4S,5S,6R)-4,5-bis(Acetyloxy)-6-[(acetyloxy)methyl]-2-{2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}tetrahydro-2H-pyran-3-yl acetate<br><br>
NMR (CDCI3, 5): J .35 (3H, t, J=7Hz), 1.70 (3H, m), 1.94 (3H, s), 2.04 (3H, s), 2.11<br>
(3H, s), 2.78 (2H, m), 3.01 (2H, q, J=7Hz), 3.10 (1H, m), 3.46 (1H, m), 3.62 (1H, t, J=6Hz), 3.79 (1H, d, J=8Hz), 3.98 (2H, m), 4.83 (1H, dd, J=3 and 10Hz), 4.97 (1H, dd, J=8 and 10Hz), 5.28 (1H, d, J=3Hz), 6.02 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.31 (1H, m), 7.41-7.56 (8H, m)<br>
Example 228<br>
To a solution of (2R,3R,4S,5S,6R)-4--bis(acetyloxy)-6-[(acetyloxy)methyl]-2-{2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}tetrahydro-2H-pyran-3-yl acetate (113 mg) in methanol (2 mL) was added sodium methoxide (0.86 mg) at room temperature. After stirring for 2 hours, the solvent was evaporated off, and the mixture was partitioned between ethyl acetate (20 mL) and water (10 mL). The organic layer was washed with brine, dried over magnesium sulfate, and evaporated to give an yellow foam (77.3 mg). The foam was triturated in hexane to give (2R,3R,4S-R,6R)-2-{2-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol as an yellow powder (48.3 mg,89.7%).<br>
(2R,3R,4S-R,6R)-2-{2-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol<br>
NMR (CDCI3,8): 1.36 (3H, t, J=7Hz), 1.92 (1H, m), 2.06 (1H, m), 2.56 (1H, s, br),<br>
2.76-2.92 (3H, m), 3.02 (2H, q, J=7Hz), 3.24 (2H, m), 3.38-3.50 (3H, m), 3.63-3.84 (3H, m), 2.41 (1H, s, br), 6.01 (1H, d, J=5Hz), 6.63 (1H, d, J=5Hz), 7.32 (1H, m), 7.41-7.57 (8H,m)<br>
The following compounds were obtained in substantially the same manner as that of Example 228. Example 229<br>
3-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]propanamide<br>
NMR (CDCI3,5): 1.38 (3H, t, J=7Hz), 1.97 (2H, m), 2.83 (2H, m), 3.01 (2H, q,<br><br>
J=7Hz), 3.31-3.52 (3H, m), 3.61-3.76 (2H, m), 3.88 (1H, m), 4.63 (1H, d, J=9Hz), 6.01 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.34 (1H, m), 7.42-7.59 (8H, m)<br>
Example 230<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(hydroxyrnethyl)pyrrolo[l,2-b]pyrida2in-3-yl]pentanoate from ethyl 5-[2-[(acetyloxy)methyl]-4-(5-brorno-3-pyridinyl)-7-ethylpyrrolo[ 1,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13,5): 1.24 (3H, t, J=7Hz), 1.34-1.50 (5H, m), 1.54 (2H, m), 2.19 (2H, t,<br>
J=7Hz), 2.37 (2H, m), 3.02 (2H, q, J=7Hz), 3.71 (1H, t, J=5Hz), 4.10 (2H, q, J=7Hz), 4.86 (2H, d, J=5Hz), 5.97 (1H, d, J=5Hz), 6.60 (1H, d, J=5Hz), 7.88 (1H, m), 8.55 (1H, m), 8.79 (lH,m)<br>
Example 231<br>
To a solution of 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid (50 mg) in N,N-dimethylfoimamide (1 mL) was added 1,1 -carbonyldiimidazole (33.6 mg) at ambient temperature. After 1 hour stirring, to the mixture was added methanesulfonamide (19.7 mg) and l,8-diazabicyclo[5.4.0]undec-7-ene (31.6 mg). The mixture was heated at 50°C for 2 hours. The reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was acidified with IN hydrogen chloride and was extracted with ethyl acetate. The organic layer was washed with water 3 times and brine, dried over magnesium sulfate, and evaporated in vacuo to give an yellow solid. The residue was crystallized from IPE to give yellow solid (45 mg). The solid was recrystallized from ethanol to give N-{5-[4-(3-cyanophenyl)-7-ethyI-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoyl}methanesulfonamide (25 mg,) as an yellow solid.<br>
N-{5-[4-(3-Cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoyl}methanesulfonamide<br>
NMR (CDCI3,5): 1.33-1.61 (7H,m),2.21 (2H,t, J=8Hz), 2.40 (2H,t, J=8Hz), 2.55<br>
(3H, s), 3.00 (2H, q, J=8Hz), 3.29 (3H, s), 5.80 (1H, d, J=5Hz), 6.52 (1H, d, J=5Hz), 7.58-7.67 (3H, m), 7.76 (1H, m), 7.86 (1H, br s) MS(ESI+):m/z439(M+H)<br><br>
Example 232<br>
To a solution of ethyl 5-[4-(3-cyanopheny])-7-ethyI-2-melhyJpyrroIo[l,2-bJpyridazin-3-yl]pentanoate (45 mg) in tetrahydrofuran (1 mL) was added lithium borohydride (5 mg) in an ice-water bath. Then the reaction mixture was stirred at ambient temperature. After 2 hours, another lithium borohydride (5 mg) was added therein and was stirred overnight. The reaction mixture was partitioned between ethyj acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, and was evaporated in vacuo. The residue was purified by p-TLC (hexane-elhyl acetate = 1-1) to give 3-[7-ethyl-3-(6-hydroxyhexyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile (26 mg, 64.5%) as an yellow oil and 6-{4-[3-(aminomethyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}-l-hexanol (13 mg, 31.9%) as a yello solid.<br>
3-[7-Ethyl-3-(6-hydroxyhexyl)-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
NMR (CDC13,8): 1.15-1.53 (11H, m), 2.32-2.41 (2H, m), 2.56 (3H, s), 3.01 (2H, q,<br>
J=8Hz), 3.58 (2H, br t, J=8Hz), 5.58 (1H, br t, J=8Hz), 5.79 (1H, d, J=5Hz), 6.51 (lH3d,J=5Hz), 7,57-7.63 (2H,m),7.65 (1H, brs), 7.75 (lH,m) MS(ESI+):m/z362(M+H)<br>
6-{4-[3-(Aminomethyl)phenyl]-7-ethyl-2-methylpyrrolo[l32-b]pyridazin-3-yl}-l-hexanol NMR (CDC13,8): 1.03-1.43 (11H, m), 2.41 (2H, t, J=8Hz), 2.55 (3H, s), 3.01 (2H, q,<br>
J=8Hz), 3.39-3.61 (2H, m), 3.88-4.04 (2H, m), 4.25 (2H, br s), 5.31 (1H, d, J=5Hz), 6.49 (1H, d, J=5Hz), 7.28-7.40 (3H, m), 7.51 (1H, t, J=8Hz) MS(ESI+):m/z366(M+H)<br>
Ex-mEil233<br>
To a suspension of 6.{4-[4-(ammocarbonyl)phenyl]-7-elhyl-2-rae,hylpyrroIo[l,2-<br>
Mpyndazin-3-yl1Hexanoic acid (590 mg) in wa.e, (3 mL) was added IN sodium bydroxide (li -P a. ambien, temperafure. Ate 5 hours, .he mixure became dear sLion The soiu.ion was ffl.ered ,h,ough membrane finer, washed w„h wa,er (0.4 mL  and was freezedned for 15 hours ,o give 6-,4-[4-(ami„ocarbonyl)pheny1]-7-e,hyl-2-acid sodium sa&gt;, (6,2 mg, 98,%) as a pa,e<br>
yellow powder.<br><br>
6-{4-[4-(Aminocarbonyl)phenyl]-7<br>
acid sodium salt<br>
NMR (DMSO-d6,5): 1.10-1.15 (2H, m), 1.20-1.40 (7H, m), 1.74 (2H, t, J=8Hz), 2.25-2.38 (2H, m), 2.50 (3H, s), 2.91 (2H, q, J=8Hz), 5.72 (1H, d, J=5Hz), 6.50 (1H, d, J=5Hz), 7.39-7.46 (3H, m), 7.97 (2H, d, J=8Hz), 8.26 (1H, br s)<br>
Example 234<br>
A solution of 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid (100 mg), triethylamime (29.4 mg), and diphenylphosphoryl azide (79.9 mg) in tert-butanol (2 mL) was heated at 80°C for 8 hours. The cooled reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (hexane-ethyl acetate = 3-1) to give tert-butyl 4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butylcarbamate (28 mg, 23.4%) as an yellow oil.<br>
tert-Butyl4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butylcarbamate<br>
NMR(CDC13,5): 1.27-1.47 (14H,m), 2.34-2.45 (2H,m),2.55 (3H,s), 2.91-3.02<br>
(4H, m), 4.39 (1H, br s), 5.79 (1H, d, J=5Hz), 6.51 (1H, d5 J=5Hz), 7.56-7.67 (3H, m),7.75(lH,m) MS(ESI+):m/z433(M+H)<br>
Example 235<br>
To tert-butyl 4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l ,2-b]pyridazin-3-yl]butylcarbamate (25 mg) was added 4N hydrogen chloride in ethyl acetate (1 mL) at ambient temperature. After 1 hour, the mixture was evaporated in vacuo. The residue was triturated with isopropyl ether to give 3-[3-(4-aminobutyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile hydrochloride as dark green amorphous (18 mg).<br>
3-[3-(4-Aminobutyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile hydrochloride<br><br>
NMR (CDCI3, 8): 1.27-1.47 (14H, m), 2.34-2.45 (2H, m), 2.55 (3H, s), 2.91-3.02<br>
(4H, m), 4.39 (1H, br s), 5.79 (1H, d, J=5Hz), 6.51 (1H, d, J=5Hz), 7.56-7.67 (3H, m),7.75(lH,m) MS(ESI+):m/z333(M+H)<br>
Example 236<br>
To lithium chloride (16.5 mg) was added a solution of ethyl 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-<br>
methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (65 mg) and tributyl(vinyl)stannane (56.7 mg) in dioxane (1 mL) and tetrakis(triphenylphosphine)palladium(0) (1.9 mg). The mixture was refluxed. After 4 hours, tributyl(vinyl)stannane (50 mg) and tetrakis(triphenylphosphine)palladium(0) (1.9 mg) was added. After refluxed overnight, the reaction mixture was quenched with potassium fluoride (1.8 mmol) in H2O. The mixture was filtered through Celite and was washed with ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 50 mL) eluted with hexane-ethyl acetate = 5-1 and 3-1 to give ethyl 5-[7-ethyl-2-methyl-4-(2-vinyl-4-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (18 mg, 28.3%) as an yellow oil.<br>
Ethyl 5-[7-ethyl-2-methyl-4-(2-vinyl-4-pyridinyI)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDCI3, 5): 1.15-1.70 (10H, m), 2.18 (2H, t, J=8Hz), 2.36-2.46 (2H, m), 2.55<br>
(3H, s), 3.00 (2H, q, J=8Hz), 4.08 (2H, q, J=8Hz), 5.54 (1H, d, J=10Hz), 5.86 (1H, d, J=5Hz), 6.25 (1H, d, J=16Hz), 6.51 (1H, d, J=5Hz), 6.87 (1H, dd, J=16,10Hz), 7.16 (1H, dd, J=6,1Hz), 7.33 (1H, br s), 8.70 (1H, d, J=6Hz) MS (ESI+): m/z 392 (M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 236. Example 237<br>
Ethyl 5-{4-[5-(l-ethoxyvinyl)-3-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br><br>
NMR (CDCI3, 6): J .23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.42 (3H, t, J=7Hz),<br>
1.40-1.60 (4H, m), 2.20 (2H, t, J=7Hz), 2.38-2.52 (2H, m), 2.56 (3H, s), 3.03 (2H, q, J=7Hz), 3.96 (2H, q, J=7Hz), 4.09 (2H, q, J=7Hz), 4.34 (1H, d, J=2Hz), 4.76 (1H, d, J=2Hz), 5.87 (1H, d, J=4Hz), 6.52 (1H, d, J=4Hz), 7.89 (1H, m), 8.53 (1H, d,J=2Hz),8.93(lH,d,J=2Hz) MS:(m/z)436(M+H)<br>
Example 238<br>
Ethyl 5-[7-ethyl-2-methyl-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR (CDC13, 8): 1.22 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.65 (4H, m), 2.18<br>
(2H, t, J=7Hz), 2.40-2.53 (2H, m), 2.56 (3H, s), 3.02 (2H, q, J=7Hz), 4.08 (2H, q, J=7Hz), 5.43 (1H, d, J=llHz), 5.88 (1H, d, J=4Hz), 5.89 (1H, d, J=18Hz), 6.52 (1H, d, J=4Hz), 6.71-6.83 (1H, dd, J=ll Hz, 18Hz), 7.73 (1H, m), 8.47 (1H, d, J=2Hz), 8.68 (1H, d, J=2Hz)<br>
Example 239<br>
Ethyl 5-[7-ethyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3, 5): 1.22 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.17<br>
(2H, t, J=7Hz), 2.52-2.65 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.08 (2H, q, J=7Hz), 4.63 (2H, s), 5.43 (1H, d, J=llHz), 5.88 (1H, d, J=18Hz), 5.91 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 6.71-6.83 (1H, dd, J=ll Hz, 18Hz), 7.75 (1H, m), 8.49 (1H, d, J=2Hz), 8.71 (1H, d, J=2Hz)<br>
Example 240<br>
Ethyl 5-[4-[5-(l-ethoxyvinyl)-3-pyridinyl]-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3, 5): 1.22 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.42 (3H, t, J=7Hz),<br>
1.40-1.63 (4H, m), 2.18 (2H, t, J=7Hz), 2.51-2.63 (2H, m), 3.03 (2H, q, J=7Hz), 3.47 (3H, s), 3.93 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 4.35 (1H, d, J=3Hz), 4.63 (2H, s), 4.77 (1H, d, J=3Hz), 5.92 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.92 (1H, m), 8.53 (1H, d, J=2Hz), 8.93 (1H, d, J=2Hz)<br><br>
MS(ESl+):m/z466<br>
Example 241<br>
Ethyl 5-[7-ethyl-2-phenyl-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]penlanoate NMR (CDCI3, 5): 1.15-1.31 (7H, m), 1.37 (3H, t, J=7Hz), 1.87 (2H, t, J=7Hz), 2.43<br>
(2H, m), 3.01 (2H, q, J=7Hz), 3.98 (2H, q, J=7Hz), 5.45 (1H, d, J=l 1Hz), 5.88 (lH,d,J=18Hz), 5.98 (lH,d,J=5Hz), 6.62 (lH,d,J=5Hz), 6.78 (lH,dd,J=ll and 18Hz), 7.44-7.55 (5H, m), 7.81 (1H, m), 8.55 (1H, m), 8.72 (1H, m)<br>
Example 242<br>
A solution of 5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l ,2-b]pyridazin-3-yl]pentanoic acid (50 mg) in dioxane (1.5 mL) in a sealed tube was added 50% dimethylamine in water (1.5 mL). The mixture was heated at 175°C overnight. The cooled reaction mixture was concentrated in vacuo. The residue was dissolved in water (1 mL) and the pH was adjusted to 7-8. The mixture was extracted with chloroform three times. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 50 mL) eluted with chloroform-ethyl acetate = 1-1 and chloroform-methanol = 20-1 to give yellow oil (43 mg). The oil was crystallized from isopropyl ether to give 5-{4-[2-(dimethylamino)-4-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid as an yellow solid (27 mg, 52.8%).<br>
5-{4-[2-(Dimethylamino)-4-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
NMR (CDCI3,5): 1.36 (3H, t, J=8Hz), 1.40-1.65 (4H, m), 2.25 (2H, t, J=8Hz), 1.86-<br>
1.96 (2H, m), 2.55 (3H, s), 3.00 (2H, q, J=8Hz), 4.08 (2H, q, J=8Hz), 5.54 (1H, d, J=10Hz), 5.86 (1H, d, J=5Hz), 6.25 (1H, d, J=16Hz), 6.51 (1H, d, J=5Hz), 6.87 (1H, dd, J=16,10Hz), 7.16 (1H, dd, J=651Hz), 7.33 (1H, br s), 8.70 (1H, d, J=6Hz)<br>
Example 243<br>
To a suspension of 7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carbaldehyde (40 mg) in ethanol (1 mL) was added 2-aminoelhanol (11.8<br><br>
mg), sodium cyanoborohydride (12.1 mg), and acetic acid (1 drop) in an ice-water bath. After 10 minutes, the mixture was stirred at ambient temperature. After 2 hours, sodium cyanoborohydride (11.8 mg) was added and the reaction mixture was acidified to pH4 with acetic acid (5 drops). After stirring overnight, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium bicarbonate, water, and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (chloroform-methanol = 10-1) to give 2-({[7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]methyl}amino)ethanol as pale yellow oil (21 mg).<br>
2-({[7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]methyl}amino)ethanol<br>
NMR (CDC13, 8): 1.43 (6H, d, J=7Hz), 2.65 (2H, t, J=7Hz), 342 (1H, m), 3.53 (2H, t,<br>
J=7Hz), 3.59 (2H, s), 6.01 (1H, d, J=5Hz), 6.77 (1H, d, J=5Hz), 7.14-7.24 (2H, m), 7.35-7.44 (2H,m) MS (ESI+): m/z 362 (M+H)<br>
Example 244<br>
To a solution of [4-(4-fluorophenyl)-2-methylpyrrolo-[l,2-b]pyridazin-3-yI]methanol (505 mg) and triethylamine (997 mg) in dichloromethane (4 mL) and dimethyl sulfoxide (2 mL) was added sulfur trioxide pyridine complex (941 mg) in an ice-water bath under nitrogen. After 30 minutes, the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated to about 1/3 volume. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water three times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 30 mL) eluted with hexane-chloroform = 3-1 and 2-1 to give 4-(4-fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazine-3-carbaldehyde as an yelow solid (340 mg, 67.9%).<br>
4-(4-Fluorophenyl)-2-methylpyrrolo[l,2-b]pyridazine-3-carbaldehyde<br>
NMR (CDCI3,6): 2.77 (3H, s), 6.50 (1H, m), 6.86 (1H, m), 7.20-7.30 (2H, m), 7.44-<br>
7.54 (2H, m), 8.89 (1H, br s), 9.79 (1H, s)<br><br>
Example 245<br>
A mixture of ethyl 4-(4-fluoropbenyl)-2-isopropyl-7-viny]pyrrolo[l,2-b]pyridazine-3-carboxylate (8.9 g) and 10% palladium on carbon (900 mg) in ethanol (180 mL) was stirred under hydrogen atomosphere (3.5 atm) at ambient temperature. After 10 hours, the mixture was stood overnight. To the mixture was added 10% palladium on carbon (900 mg) and was stirred under hydrogen atomosphere (3.5 atm) at ambient temperature. After 12 hours, the mixture was stood overnight. To the mixture was added 10% palladium on carbon (900 mg) and was stirred under hydrogen atomosphere (3.5 atm) at ambient temperature for 8 hours. The mixture was filtered through Celite. The filtrate was concentrated in vacuo to give ethyl 7-ethyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate as an yellow oil (9.0 g, 100.5%).<br>
Ethyl 7-ethyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate NMR (CDC13,8): 0.96 (3H, t, J=8Hz), 1.38 (3H, t, J=8Hz), 3.05 (2H, q, J=8Hz), 4.01<br>
(2H, q, J=8Hz), 6.27 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.10-7.19 (2H, m), 7.41-7.49 (2H,m) MS(ESI+):m/z362(M+H)<br>
The following compounds were obtained in substantially the same manner as that<br>
of Example 245.<br>
Example 246 5-[7-Elhyl-4-(5-ethyl-3-pyridinyl)-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid<br>
from5-[7-ethyl-2-methyl-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
NMR (CDCI3,5): 1.30 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.45-1.65 (4H5 m), 2.22<br>
(2H, m), 2.35-2.50 (2H, m), 2.56 (3H, s), 2.75 (2H, q, J=7Hz), 3.00 (2H, q, J=7Hz), 5.84 (1H, d, J=4Hz), 6.52 (1H, d, J=4Hz), 7.57 (1H, s), 8.42 (1H, d, J=2Hz),8.53(lH,d,J=2Hz) MS (ES1+): m/z 366 (M+H), MS (ESI'): m/z 364<br>
Rxample 247 547-Ethyl-4-(5-ethyl-3-pyridinyl)-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br><br>
yl]pentanoic acid<br>
NMR(CDC13,8): 130 (3H,t,J=7Hz),l.37 (3H,t,J=7Hz), 1.45-1.64 (4H,m),2.17<br>
(2H, m), 2.45-2.67 (2H, m), 2.73 (2H, q, J=7Hz), 3.04 (2H, q, J=7Hz), 3.45 (3H, s), 4.62 (2H, m), 5.89 (1H, d, J=4Hz), 6.58 (1H, d, J=4Hz), 7.59 (1H, s), 8.44 (1H, s),854(lH,s) MS (ESI+): m/z 396<br>
Example 248<br>
Ethyl 5-[7-ethyl-4-(5-ethyl-3-pyridinyl)-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate NMR(CDC13,5): 1.04-1.23 (7H,m), 132 (3H, t, J=7Hz), 137 (3H,t,J=7Hz), 1.86<br>
(2H,1, J=7Hz), 2.42 (2H, m), 2.74 (2H, q, J=7Hz), 3.01 (2H, q, J=7Hz), 3.99 (2H, q, J=7Hz), 5.97 (1H, d, J=5Hz), 6.62 (1H, d, J=5Hz), 7.45-7.53 (5H, m), 7.60 (1H, m), 8.50 (1H, m), 8.56 (1H, m)<br>
Example 249<br>
To a solution of 3-(7-ethyl-2-neopentylpyrrolo[l,2-b]pyridazin-4-yl)benzamide (35 mg) in ethanol (1 mL) was added water (0.2 mL) and potassium hydroxide (68.9 mg) at ambient temperature. The reaction mixture was heated at 60°C. After 2 hours, potassium hydroxide (100 mg) was added. After 5 hours, potassium hydroxide (100 mg) was added. After 12 hours, the mixture was acidified with IN hydrogen chloride. The precipitate was filtered, washed with water and ethyl acetate to give 3-(7-ethyl-2-neopentylpyrrolo-[l,2-b]pyridazin-4-yl)benzoic acid as an yellow solid (19 mg, 54.1%).<br>
3-(7-Ethyl-2-neopentylpyrrolo[l ,2-b]pyridazin-4-yl)benzoic acid<br>
NMR (CDC13,5): 1.05 (9H, s), 1.39 (3H, t, J=8Hz), 2.69 (2H, s), 3.04 (2H, q, J=8Hz),<br>
6.42 (1H, s), 6.54 (1H, d, J=5Hz), 6.65 (1H, d, J=5Hz), 7.62 (1H, t, J=8Hz), 7.97 (1H, d, J=8Hz), 8.21 (1H, d, J=8Hz), 8.46 (1H, br s) MS(ESI+):m/z337(M+H)<br>
The following compound was obtained in substantially the same manner as that of Example 249.<br><br>
Example 250 3-[7-Ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-y]]ben2oic acid<br>
NMR (CDCI3, 5): J .44 (3H, t, J=8Hz), 3.11 (2H, q, J=8Hz), 6.56 (1H, m), 6.61 (1H,<br>
d,J=5Hz), 6.72 (lH,d,J=5Hz), 7.03 (lH,brs), 7.07 (lH,d,J=5Hz), 7.55-7.69 (2H, m), 8.03 (1H, br d, J=8Hz), 8.23 (1H, br d, J=8Hz), 8.52 (1H, br s)<br>
Example 251<br>
A solution of ethyl 5-{4-[5-(l-ethoxyvinyl)-3-pyridinyl]-7-ethyI-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoate (190 mg) in methanol (5 mL) and IN hydrochloric acid (5 mL) was stirred at ambient temperature for 2 hours. The solution was diluted with brine and extracted with chloroform. The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (10:1 - 2:1) to give ethyl 5-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate as an yellow oil (160 mg).<br>
Ethyl 5-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3,5): 1.24 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.19<br>
(2H, t, J=7Hz), 2.36-2.47 (2H, m), 2.57 (3H, s), 2.70 (3H, s), 3.02 (2H, q, J=7Hz), 4.08 (2H, q, J=7Hz), 5.81 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 8.23 (1H, m), 8.78 (1H, d, J=2Hz), 9.23 (1H, d, J=2Hz) MS:(m/z)408(M+H)<br>
The following compound was obtained in substantially the same manner as that of Example 251. Example 252<br>
Ethyl 5-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDCI3, 5): 1.24 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 1.40-1.59 (4H, m), 2.17<br>
(2H, t, J=7Hz), 2.50-2.63 (2H, m), 2.70 (3H, s), 3.03 (2H, q, J=7Hz), 3.46 (3H, s), 4.12 (2H, q, J=7Hz), 4.63 (2H, s), 5.86 (1H, d, J=4Hz), 6.59 (1H, d, J=4Hz), 8.26<br><br>
(lH,m), 8.79 (lH,d,J=2Hz), 9.24 (lH,d,J=2Hz) MS(ESI+):m/z438<br>
Example 253<br>
To a solution of ethyl 5-{4-(2-chloro-4-pyridinyl)-7-ethyl-2-[(methylthio)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate (139 mg) in tetrahydrofuran (4 rnL) and water (1 mL) was added oxone (287 mg) and the mixture was stirred at ambient temperature for 4 hours. The solution was diluted with water and extracted with ethyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate solution, sodium thiosulfate solution and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (10:1 -1:1) to give ethyl 5-{4-(2-chloro-4-pyridinyl)-7-ethyl-2-[(methylsulfonyl)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate as an yellow oil (124 mg).<br>
Ethyl5-{4-(2-chloro-4-pyridinyl)-7-ethyl-2-[(methylsulfonyl)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br>
NMR (CDC13, 5): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.63 (4H, m), 2.21<br>
(2H, t, J=7Hz), 2.57-2.68 (2H, m), 3.02 (2H, q, J=7Hz), 3.12 (3H, s), 4.10 (2H, q, J=7Hz), 4.53 (2H, s), 5.98 (1H, d, J=4Hz), 6.68 (1H, d, J=4Hz), 7.27 (1H, m), 7.38 (1H, s), 8.56 (1H, d, J=5Hz)<br>
Example 254<br>
A mixture of ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (167 mg) and copper(I) cyanide (37 mg) in l-methyl-2-pyrrolidinone (3 mL) was stirred at 170°C for 4 hours.  The mixture was partitioned between ethyl acetate and water.   The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo.  The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (20:1 - 5:1) to give ethyl 5-[4-(5-cyano-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate as an yellow oil (88 mg). Ethyl 5-[4-(5-cyano-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br><br>
NMR (CDCI3,8): 1.24 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.62 (4H, m), 2.2]<br>
(2H, t, J=7Hz), 2.35-2.47 (2H, m), 2.57 (3H, s), 3.02 (2H, q, J=7Hz), 4.12 (2H, q, J=7Hz), 5.79 (1H, d, J=4Hz), 6.54 (1H, d, J=4Hz), 7.98 (1H, m), 8.80 (1H, d, J=2Hz),8.97(lH,d,J=2Hz) MS(ESI+):m/z391.<br>
The following compounds were obtained in substantially the same manner as that of Example 254. Example 255<br>
5-[4-(5-Cyano-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,8): 1.37 (3H, t, J=7Hz), 1.40-1.67 (4H, m), 2.28 (2H, m), 2.37-2.47<br>
(2H, m), 2.57 (3H, s), 3.01 (2H, q, J=7Hz), 5.80 (1H, d, J=4Hz), 6.55 (1H, d, J=4Hz), 8.01 (1H, s), 8.81 (1H, br), 8.98 (1H, br)<br>
Example 256<br>
Ethyl 5-[4-(5-cyano-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
NMR (CDCI3,8): 1.23 (3H, t, J=7Hz), 1.37 (3H, t, J=7Hz), 1.40-1.60 (4H, m), 2.19<br>
(2H, t, J=7Hz), 2.49-2.60 (2H, m), 3.04 (2H, q, J=7Hz), 3.46 (3H, s), 4.12 (2H, q, J=7Hz), 4.63 (2H, s), 5.84 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 8.02 (1H, m), 8.83 (1H, d, J=2Hz), 8.98 (1H, d, J=2Hz)<br>
Example 257<br>
5-[4-(5-Cyano-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
NMR (CDCI3,8): 1.38 (3H, t, J=7Hz), 1.40-1.65 (4H, m), 2.27 (2H, t, J=7Hz), 2.48-<br>
2.64 (2H, m), 3.03 (2H, q, J=7Hz), 3.46 (3H, s), 4.64 (2H, s), 5.84 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 8.03 (1H, s), 8.82 (1H, s), 8.97 (1H, s)<br>
Example 258<br>
5-[4-(5-Cyano-3-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid NMR (CDCI3,8): 1.06-1.24 (4H, m), 1.36 (3H, t, J=7Hz), 1.94 (2H, t, J=7Hz), 2.38<br><br>
(2H, m), 2.99 (2H, q, J=7Hz), 5.88 (1H, d, J=5Hz), 6.64 (1H, d, J=5Hz), 7.44-7.52 (5H, in), 8.06 (1H, s), 8.87 (1H, s), 8.98 (1H, s) MS(ESI+):m/z425(M+H)<br>
Example 259<br>
To a suspension of lithium aluminum hydride (98.8 mg) in tetrahydrofuran (10 mL) was added ethyl 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (600 mg) in tetrahydrofuran (10 mL) under ice-water cooling and the mixture was stirred at 0°C for 2 hours. The reaction was quenched with saturated potassium sodium tartrate solution and the insolubles were filtereed off and washed with ethyl acetate. The filtrates were washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (10:1 - 2:1) to give 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-l-pentanol as an yellow oil (478 mg).<br>
5-[4-(3-ChlorophenyI)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-l-pentanol<br>
NMR (CDC13,5): 0.90-1.22 (6H, m), 1.27 (1H, t, J=7Hz), 1.36 (3H, t, J=7Hz), 2.37-<br>
2.47 (2H, m), 3.02 (2H, q, J=7Hz), 3.29-3.41 (2H, m), 5.97 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.32 (1H, m), 7.40-7.55 (8H, m)<br>
Example 260<br>
To a solution of 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-l-pentanol (63.0 mg) and triethylamine (22.8 mg) in dichloromethane (3 mL) was added methanesulfonyl chloride (18.9 mg) under ice-water cooling and the mixture was stirred at 0°C for 1 hour. The solution was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was added to sodium cyanide (14.7 mg) in dimethylformamide (2 mL) and the mixture was stirred at 60°C for 5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (20:1 - 5:1) to give 6-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[ 1,2-b]<br><br>
pyridazin-3-yl1Hexanenitrile as an yellow oil (58.5 mg).<br>
6-[4-(3-chlorophenyl)-7-ethyl-2-pheny]pyrrolo[l,2-b]pyridazin-3-yl1Hexaneni(rile NMR (CDCI3, 5): 1.00-1.15 (4H&gt; m), 1.17-1.28 (2H, m), 1.36 (3H, t, J=7Hz), 1.98<br>
(2H, t, J=7Hz), 2.38-2.47 (2H, m), 3.03 (2H, q, J=7Hz), 5.99 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.32 (1H, m), 7.38-7.56 (8H, m) MS(ESI+):m/z428<br>
Example 261<br>
A mixture of 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l ,2-b]pyridazin-3-yl]-l-pentanoI (65 mg), trimethyloxonium tetrafluoroborate (27.5 mg) and 2,6-di-t-butyl-4-methylpyridine (47.8 mg) in 1,2-dichloroethane (3 mL) was stirred at ambient temperature for 4 hours. The solution was washed with water, IN hydrochloric acid, water, saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (20:1 - 5:1) to give 4-(3-chlorophenyl)-7-ethyl-3-(5-methoxypentyl)-2-phenylpyrrolo[l,2-b]pyridazine as an yellow oil (60 mg).<br>
4-(3-chlorophenyl)-7-ethyl-3-(5-methoxypentyl)-2-phenylpyrrolo[l,2-b]pyridazine NMR (CDCI3,8): 00.90-132 (6H, m), 1.36 (3H, t, J=7Hz), 2.37-2.47 (2H, m), 3.03<br>
(2H, q, J=7Hz), 3.08 (2H, t, J=7Hz), 3.31 (3H, s), 5.97 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.27-7.33 (1H, m), 7.38-7.53 (8H, m) MS (ES1+): m/z 433<br>
Example 262<br>
To a solution of 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-l-pentanol (55 mg) and triethylamine (19.9 mg) in dichloromethane (3 mL) was added methanesulfonyl chloride (16.5 mg) under ice-water cooling and the mixture was stirred at 0°C for 1 hour. The solution was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. To the residue in 1,2-dichloroethane (3 mL) was added 2 M dimethylamine in tetrahydrofuran (3 mL) and the mixture was stirred at 60°C for 120 hours. The solution was diluted with chloroform, washed with brine, dried over<br><br>
magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture ofhexane and ethyl acetate (20:1 - 5:1) to give 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[],2-b]pyridazin-3-yl]-N,N-dimethyl-1-pentanamine as an yellow oil (38 mg).<br>
N-{5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentyl}-N,N-dimethylamine<br>
NMR (CDC13,5): 0.86-0.97 (2H, m), 1.02-1.15 (4H, m), 1.36 (3H, t, J=7Hz), 1.97-<br>
2.04 (2H, m), 2.11 (6H, s), 2.37-2.47 (2H, m), 3.02 (2H, q, J=7Hz), 5.97 (1H, d, J=4Hz), 6.61 (1H, d3 J=4Hz), 7.31 (1H, m), 7.39-7.54 (8H, m) MS(ESI+):m/z446<br>
Example 263<br>
To a stirred solution of 5-[4-(3-cyanophenyl)-7-elhyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid (60 mg) in dichloromethane (2 ml) was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (35.3 mg) and 2-animopyridine (20 mg) and the reaction mixture was stirred for 10 minutes. 4-Dimethylaminopyridine (2 mg) was added and the reaction mixture was stirred at room temperature for 15 hours. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel eluting with a mixture of ethyl acetate and n-hexane (1:2) to give5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pentanamide(55.7mg) as an yellow amoiphous.<br>
5-[4
NMR (CDCI3,5): 1.12 (2H, quintet, J=7Hz), 1.30 (2H, quintet, J=7Hz), 1.36 (3H, t, J=7Hz), 1.95 (2H, t, J=7Hz), 243 (2H, q, J=7Hz), 3.02 (2H, q, J=7Hz), 5.90 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.00-7.05 (1H, m), 7.43-7.54 (5H, m), 7.59-7.77 (6H5 m), 8.11 (1H, d, J=7.5Hz), 8.24 (1H, d, J=4Hz) MS:(m/z)499(M+),45(bp)<br><br>
The following compounds were obtained in substantially the same manner as that )f Example 263. Example 264<br>
5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pentanamide<br>
NMR (CDCI3,8): 1.15 (2H, quintet, J=7Hz), 1.24(2H, quintet, J=7Hz), 1.36(3H, t,<br>
J=7Hz), 1.91(2H, t, J=7Hz), 2.45(2H, t, J=7Hz), 3.00(2H, q, J=7Hz), 5.97(1H, d, J=5Hz), 6.60(1H, d, J=4Hz), 7.00(1H, t, J=7Hz), 7.30(1H, s), 7.38-7.53(7H, m), 7.65-7.73(2H, m), 8.11(1H, d, J=7Hz), 8.25(1H, d, J=5Hz)<br>
MS: (m/z) 509 (M++H), 74 (bp)<br>
Example 265<br>
N-{5-[4-(3-Chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoyl}methanesulfonamide<br>
NMR (CDCI3,6): 1.08 (2H, quintet, J=7Hz), 1.23 (2H, quintet, J=7Hz), 1.36 (3H, t,<br>
J=7Hz), 1.85 (2H, t, J=7Hz), 2.44 (2H, t, J=7Hz), 3.02 (2H, q, J=7Hz), 3.21 (3H, s), 5.99 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.30-7.33 (1H, m), 7.43-7.55 (8H, m)<br>
Example 266<br>
5-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-(2-pyridinyl)pent anamide<br>
NMR (CDCI3,5): 1.12 (2H, quintet, J=7Hz), 1.27 (2H, quintet, J=7Hz), 1.36 (3H, t,<br>
J=7Hz), 1.97 (2H, t, J=7Hz), 2.45 (2H, t, J=7Hz), 3.01 (2H, q, J=7Hz), 5.95 (1H, d, J=5Hz), 6.63 (1H, d, J=4Hz), 7.01 (1H, t, J=7Hz), 7.31 (1H, d, J=7Hz), 7.41-7.53 (6H, m), 7.68 (1H, ddd, J=7,7,lHz), 7.77 (1H, s), 8.12 (1H, d, J=7.5Hz), 8.24 (1H, d, J=5Hz), 8.53 (1H, d, J=6Hz) MS: (m/z) 510 (M++H), 80 (bp)<br>
Example 267 N-{5-[4-(5-Bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br><br>
yl]pentanoyI}melhanesulfonamide<br>
mp: 124-125°C<br>
NMR (CDC13, 5): 1.37 (3H, t, J=7Hz), 1.43-1.49 (2H, m), 1.55-1.65 (2H, m), 2.23 (2H, t, J=7Hz), 2.34-2.48 (2H, m), 2.55 (3H, s), 3.01 (2H, q, J=7Hz), 3.28 (3H, s), 5.87 (1H, d, J=4Hz), 6.53 (1H, d, J=4Hz), 7.09 (1H, s), 7.40 (1H, s), 8.53 (1H, s), 8.77 (lH,s)<br>
MS: (m/z) 493(M+), 491 (M+-2), 137 (bp)<br>
Example 268<br>
To a solution of ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (100.0 mg) and (bromomethyl)benzene (111 mg) in N,N-dimethylformamide (1 mL) was added 60% sodium hydride (17.4 mg) under an ice-bath. After stirring for 2.5 hour, the reaction was quenched by adding IN hydrochloric acid (1 mL), and the mixture was partitioend between ethyl acetate (10 mL) and water (5 mL). The organic layer was washed with IN hydrochloric acid (5 mL), water (5 mL, three times), and brine, dried over magnesium sulfate, and evaporated. Flash silica gel column chromatography eluting with ethyl acetate-hexane = 1/40 to 20/40 afforded ethyl 5-[2-[(benzyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate as an yellow gum (47.7 mg, 39.9%).<br>
Ethyl 5-[2-[(benzyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13,5): 1.23 (3H, t, J=7Hz), 1.34-1.48 (5H, m), 2.09 (2H, m), 2.53 (2H, m),<br>
3.04 (2H, q, J=7Hz), 4.07 (2H, J=7Hz), 4.65 (2H, s), 4.72 (2H, s), 5.90 (1H, d, J=5Hz), 6.60 (1H, d, J=5Hz), 7.29-7.38 (5H, m), 7.86 (1H, s), 8.54 (1H, m), 8.77 (lH,m)<br>
The following compound was obtained in substantially the same manner as that of Example 268. Example 269<br>
Ethyl 5-(4-(5-bromo-3-pyridinyl)-2-{[(4-cyanobenzyl)oxy]methyl}-7-ethylpyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br><br>
NMR (CDCI3, 5): 1.23 (3H, J=7Hz), ] .35-1.55 (7H, m), 2.12 (2H,1, J=7Hz), 2.57<br>
(2H, m), 3.02 (2H, q, J=7Hz), 4.07 (2H, q, J=7Hz), 4.49 (2H, s), 4.76 (2H, s), 5.93 (1H, d, J=7Hz), 6.62 (1H, d, J=7Hz), 7.48 (2H, d, J=8Hz), 7.65 (2H, d, J=8Hz), 7.86 (1H, m), 8.54 (1H, m), 8.78 (1H, m)<br>
Example 270<br>
To a solution of ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-;hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (200 mg) and triethylamine [65.9 mg) in dichloromethane (2 mL) was added methanesulfonyl chloride (54.7 nig) under an ice-bath. After stirring for 1 hour, the reaction was quenched by adding IN hydrochloric acid (1 mL). The mixrure was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (5 mL). The organic layer was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, and evaporated to give ethyl 5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(methylsulfonyl)oxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate as an yellow gum (247 mg).<br>
Ethyl 5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(methylsulfonyl)oxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br>
NMR (CDCI3, 5): 1.22 (3H, t, J=7Hz), 1.344.65 (7H, m), 2.20 (2H, t, J=7Hz), 2.55<br>
(2H, m), 3.02 (2H, q, J=7Hz), 3.15 (3H, s), 4.07 (2H, q, J=7Hz), 5.42 (2H, s), 5.99 (1H, d, J=5Hz), 6.68 (1H, d, J=5Hz), 7.87 (1H, m), 8.54 (1H, m), 8.81 (1H, m)<br>
Example 271<br>
A mixture of ethyl 5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(methylsulfonyl)oxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate (50.0 mg), benzyl amine (29.8 mg) in dichloromathane (1 mL) was stirred for 20 hour at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried, and evaporated. Preparative thin layer chromatography eluting with ethyl acetate-hexane = 1:2 afforded ethyl 5-[2-[(benzylamino)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3' yl]pentanoate as an yellow gum (19.1 mg).<br><br>
Ethyl 5-[2-[(benzylamino)methyl]-4-(5-bromo-3-pyridinyl)-7-ethy]pyrrolo[l32-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13, 5): 1.23 (3H, t, J=7Hz), 1.30-1 .50 (7H, m), 2.13 (2H, t, J=7Hz), 2.42<br>
(2H, m), 3.03 (2H, q, J=7Hz), 3.96 (4H, m), 4.09 (2H, q, J=7Hz), 5.89 (1H, d, J=5Hz), 6.57 (1H, d, J=5Hz), 7,23-7.42 (5H, m), 7.86 (1H, m), 8.53 (1H, m), 8.77 (lH,m)<br>
The following compound was obtained in substantially the same manner as that of Example 271. Example 272<br>
Ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(4-morpholinylmethyl)pyrrolo[ 1,2-b]pyridazin-3-yl]pentanoate<br>
NMR (CDC13,5): 1.23 (3H, t, J=7Hz), 1.31-1.56 (7H, m), 2.19 (2H, t, J=7Hz), 2.45-<br>
2.65 (6H, m), 3.02 (2H, q, J=7Hz), 3.60-3.75 (6H, m), 4.09 (2H, q, J-7Hz), 5.88 (1H, d, J=5Hz), 6.57 (1H, d, J=5Hz), 7.89 (1H, m), 8.55 (1H, m), 8.78 (1H, m)<br>
Example 273<br>
To a solution of (7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl)methanol (40 mg) in N,N-dimethylformarnide (1 mL) was added 40% sodium hydride in oil (5.5 mg) in an ice-water bath. After 20 minutes, to the mixture was added 2-bromoethyl acetate (31 mg) at the temperature. After 15 minutes, the reaction mixture was stirred at ambient temperature for 5 hours. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water three times' and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by p-TLC (hexane-ethyl acetate = 10-1) to give [7-chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-yl]methyl acetate as a pale yellow solid (42 mg).<br>
[7-Chloro-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazin-3-y]]methyl acetate NMR (CDCI3,5): 1.41 (6H, d, J=8Hz), 2.06 (3H, s), 3.21 (1H, m), 4.92 (2H, s), 6.14<br>
(1H, d, J=5Hz), 6.72 (1H, d, J=5Hz), 7.13-7.24 (2H, m), 7.34-7.43 (2H, m) MS(ES1+):m/z361(M+H)<br><br>
The following compound was obtained in substantially the same manner as that of Preparation 20. Example 274<br>
Ethyl {[7-ethyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l ,2-b]pyridazin-3-yl]methoxy}acetate<br>
NMR (CDCI3,5): 1.25 (3H, t, J=8Hz), 130-1.45 (9 H, m), 3.04 (2H, q, J=8Hz), 3.51<br>
(lH,m), 3.97 (2H,s),4J5(2H,q,J=8Hz), 4.40 (2H,s), 6.06 (lH,d,J=5Hz), 6.56 (1H, d, J=5Hz), 7.11-7.22 (2H, m), 7.41-7.51 (2H, m) MS(ESI+):m/z399(M+H)<br>
The following compound was obtained in substantially the same manner as that of Preparation 276. Example 275<br>
Ethyl 2-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazine-3-carboxylate<br>
NMR (CDCI3,5): 0.84 (3H, t, J=7Hz), 1.38 (3H, t, J=7Hz), 3.06 (2H, q, J=7Hz), 3.96<br>
(2H, q, J=7Hz), 4.02 (3H, s), 5.41 (1H, s, br), 6.09 (1H, s, br), 6.28 (1H, d, J=5Hz), 6.75 (1H, d, J=5Hz), 7.53 (2H, d, J=9Hz), 7.77 (2H, d, J=9Hz) MS (ES1+): m/z 753 (2M + H)<br>
Example 276<br>
A mixture of 4-(3-cyanophenyl)-7-ethyl-3-(methylsulfonyl)pyrrolo[l ,2-b]pyridazine-2-carboxylic acid (40.0 mg), pyrrolidine (10.8 mg), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (31.1 mg), and 1-hydroxybenzotriazole (21.9 mg) in N5N-dimethylformamide (1 mL) was stirred for 6 hour at room temperature. The mixture was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (10 mL). The organic layer was washed with water (10 mL) three times, saturated sodium bicarbonate (10 mL), and brine, dried, and evaporated to give 3-[7-ethyl-3-(methylsulfonyl)-2-(l-pyrrolidinylcarbonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an yellow solid (35.6 mg).<br>
3-[7-Ethyl-3-(methylsulfonyl)-2-(l-pyrrolidiny]carbonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br><br>
NMR (CDCI3, 8): 1.38 (2H, m), 1.99 (4H, m), 3.07 (2H, q, J=7Hz), 3.23 (3H, s), 3.59<br>
(2H, t, J=7Hz), 3.68 (2H, t, J=7Hz), 6.27 (1H, d, J=5Hz), 6.83 (1H, d, J =5Hz), 7.57-7.66 (3H, m), 7.79 (1H, m) MS(ES1+):m/z423(M+H)<br>
Example 277<br>
To a solution of 3-[7-ethy]-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-y]]benzoic acid (40 mg) in N,N-dimethylformamide (4 rnL) was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30 mg), 1-hydroxybenzotriazole (24 mg), and 2-aminoethanol (15 mg) at ambient temperature. After stirring overnight, the reaction mixture was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with water 3 times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel column chromatography (silica gel, 40 mL) eluted with chloroform-methanol = 50-1 and 20-1 to give an yellow solid (42 mg). The solid was triturated with isopropyl ether to give 3-[7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-yl]-N-(2-hydroxyethyI)benzamide as an yellow solid (35 mg).<br>
3-[7-Ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-4-yl]-N-(2-hydroxyethyl)benzamide<br>
NMR (CDCI3, 5): 1.43 (3H, t, J=8Hz), 239-2.49 (2H, m), 3.10 (2H, q, J=8Hz), 3.60-<br>
3.74 (2H, m), 3.80-3.94 (2H, m), 6.53-6.86 (4H, m), 7.00 (1H, s), 6.61 (1H, d, J=5Hz), 6.72 (1H, d, J=5Hz), 7.03 (1H, br s), 7.07 (1H, d, J=5Hz), 7.55-7.65 (2H, m), 7.86-7.97 (2H, m), 8.17 (1H, br s) MS (ESI+): m/z 376 (M+H)<br>
The following compounds were obtained in substantially the same manner as that of Example 283. Example 278<br>
5-[4-(3-Cyanophenyl)-7-ethyI-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-methylpentanamide mp: 60°C<br>
NMR (CDC13, 6): 1.02-1.12 (2H5 m), 1.17-1.25 (2H, m), 1.36 (3H, t, J=7Hz), 1.73 (2H, t, J=7Hz), 2.40( 2H, t, J=7Hz), 2.71 (3H, d, J=7Hz), 3.03 (2H, q, J=7Hz),<br><br>
5.09 (1H, broad s), 5.90 (1H, d, J=4Hz), 6.63 1H, d, J=4Hz), 7.45-7.55 (5H, m), 7.60-7.78 (4H,m)<br>
MS: (m/z) 437 (M++H), 115 (bp)<br>
Example 279<br>
4-(3-Chlorophenyl)-7-ethyl-3-[5-(4-morpholinyl)-5-oxopentyl]-2-phenylpyrrolo[l,2-b]pyridazine mp: 55-58°C<br>
NMR (CDC13,8): 1.05-1.14 (2H, m), 1.17-1.23 (2H, m), 1.35 (3H, t, J=7Hz), 1.84 (2H, t, J=7Hz), 2.45 (2H, t, J=7Hz), 3.02 (2H, q, J=7Hz), 3.24 (2H, t, J=6Hz), 3.50 (2H, I, J=6Hz), 3.55-3.62 (4H, m), 5.99 (1H, d, J=4Hz), 6.62 (1H, d, J=4Hz), 7.30-7.35 (1H, m), 7.40-7.55 (8H, m)<br>
MS: (m/z) 502 (M++H), 115 (bp)<br>
Example 280<br>
5-[4-(3-ChIorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-methylpentanamide mp: 70-72°C<br>
NMR (CDC13, 5): 1.06 (2H, quintet, J=7Hz), 1.22 (2H, quintet, J=7Hz), 1.36 (3H, t, J=7Hz), 1.72 (2H, t, J=7Hz), 2.43 (2H, t, J=7Hz), 2.70 (3H, d, J=7Hz), 3.03 (2H, q, J=7Hz), 5.08 (1H, broad s), 5.99 (1H, d, J=4Hz), 6.61 (1H, d, J=4Hz), 7.29-7.33 (1H, m), 7.41-7.55 (8H, m)<br>
MS: (m/z) 446 (M++H), 115 (bp)<br>
Example 281<br>
5-[4-(2-Chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]-N-<br>
methylpentanamide<br>
NMR (CDC13,8): 1.07 (2H, quintet, J=7Hz), 1.23 (2H, quintet, J=7Hz), 1.36(3H, t,<br>
J=7Hz), 1.74 (2H, t, J=7Hz), 2.41 (2H, t, J=7Hz), 2.71 (3H, d, J=7Hz), 3.02 (2H, q, J=7Hz), 5.10 (1H,broad s), 5.95 (1H, d, J=4Hz), 6.64 (1H, d, J=4Hz), 7.31 (1H, d, J=7Hz), 7.42 (1H, s), 7.46-7.52 (1H, m), 7.41-7.55 (1H, d, J=7Hz)<br>
MS: (m/z) 447 (M++H), 115 (bp)<br><br>
Example 282<br>
3-{7-Ethyl-3-[5-(4-moipholinyl)-5-oxopenlyl]-2-phenylpyrrolo[l,2-b]pyridazin-4-yljbenzonitrile from 5-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[l ,2-b]pyridazin-3-yljpentanoic acid mp: 66-69°C<br>
NMR (CDC13, 5): 1.04-1.12 (2H, m), 1.17-1.23 (2H, m), 1.36 (3H, t, J=7Hz), 1.84 (2H, t, J=7Hz), 2.42 (2H, I, J=7Hz), 3.03 (2H, q, J=7Hz), 3.23 (2H, t, J=6Hz), 3.50 (2H, t, J=6Hz), 3.55-3.63 (4H, m), 5.90 (1H, d, J=4Hz), 6.63 (1H, d, J=4Hz), 7.43-7.55 (5H, m), 7.60-7.78 (4H, m)<br>
MS: (m/z) 493 (M++H),126 (bp)<br>
Example 283<br>
To a solution of 5-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid (50 mg) in N,N-dimethylformamide (1 mL) was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (35 mg) and 1-hydroxybenzotriazole (28 mg) at ambient temperature. After 30 minutes, lo the mixture was added morpholine (24 mg). After 5 hours, the reaction mixture was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with water three times and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by flash silica gel column chromatography (silica gel, 40 mL) eluted with hexane-ethyl acetate = 3-1,2-1,1-1,1-3, and 0-1 to give 3-{7-ethyl-2-methyl-3-[5-(4-morpholinyl)-5-oxopentyl]pyrrolo[l52-b]pyridazin-4-yl}benzonitrile as an yellow gum (53 mg).<br>
3-{7-Ethyl-2-methyl-3-[5-(4-moipholinyl)-5-oxopentyl]pyrrolo[l,2-b]pyridazin-4-yl}benzonitrile<br>
NMR (CDC13,5): 1.15-1.61 (7H, m), 2.18 (2H, t, J=8Hz), 2.41 (2H, t, J=8Hz)&gt; 2.56<br>
(3H, s), 3.00 (2H, q, J=8Hz), 3.82 (2H, t, J=5Hz), 3.51-3.68 (6H, m), 5.78 (1H, d, J=5Hz), 6.50 (1H, d, J=5Hz), 7.56-7.67 (3H, m), 7.74 (1H, m) MS(ES1+):m/z431(M+H)<br>
The following compound was obtained in substantially the same manner as that of<br><br>
Example 283.<br>
Example 284<br>
5-4-(3-Cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyrida2in-3-yl]pentanamide<br>
NMR (CDCI3, 5): 1.31-1.61 (7H, m), 2.11 (2H, t, J=8Hz), 2.40 (2H, 1, J=8Hz), 2.56<br>
(3H, s), 3.00 (2H, q, J=8Hz), 5.36 (2H, br s), 5.79 (1H, d, J=5Hz), 6.50 (1H, d, J=5Hz), 7.56-7.67 (3H, m), 7.75 (1H, m) MS (ESI+): m/z 361 (M+H)<br>
Preparation 178<br>
To a suspension of 60% sodium hydride (8.79 g) in tetrahydrofuran (500 mL) was addded cyclohexanol (10 g) and the mixture was stirred at 0 "C for 0.5 hour. To the mixture was added bromoacetic acid (13.9 g) under ice-water cooling and the mixture was heated under reflux for 2 hours. After adding water to the mixture and organic solvent was evaporated in vacuo. The aqueous solution was diluted with water, washed with ether, acidified with 1 N hydrochloric acid, and extracted with ether. The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo to give (cyclohexyloxy)acetic acid as colorless oil (13.3 g).<br>
(cyclohexyloxy)acetic acid<br>
1H NMR (CDCI3) 6 1.18-1.47 (5H,m), 1.52-1.63 (1H, m), 1.72-1.85 (2H, m), 1.90-2.03 (2H, m), 3.36-3.47 (1H, m), 4.13 (2H, s).<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 178. Preparation 179 isopropoxyacetic acid<br>
1H NMR (CDCI3) 5 1.24 (6H, d, J= 7 Hz), 3.68-3.82 (1H, m), 4.11 (2H, s).<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 129 and Preparation 130. Preparation 180 tert-butyl 4-(benzyIoxy)-3-oxobutanoate<br>
H NMR (CDCI3) 6 1.44 (9H, s), 3.45 (2H, s), 4.14 (2H, s), 4.60 (2H, s), 7.28-7.40<br><br>
(5H,m).<br>
Preparation 181<br>
tert-butyl 4-(cyclohexyloxy)-3-oxobutanoate<br>
H NMR(CDCb) 5 1.18-1.43 (5H,m), 1.47 (9H, s), 1.53-1.63 (lH,m), 1.69-1.85 (2H,m), 1.87-1.97 (2H,m), 3.24-3.38 (lH,m), 3.46 (2H,s), 4.11 (2H,s).<br>
Preparation 182<br>
tert-butyl 4-isopropoxy-3-oxobulanoate<br>
1H NMR (CDC13) 6 1.20 (6H, d, J= 7 Hz), 1.47 (9H, s),3.45 (2H, s), 3.60-3.70 (1H, m),4.08(2H,s).<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 159. Preparation 183 1-tert-butyl 4-ethyl 2-acetylsuccinate<br>
1H NMR (CDCI3) 5 1.25 (3H, t, J= 7 Hz), 1.47 (9H, s), 235 (3H, s), 3.08 (2H, m), 3.93 (1H, m), 4.12 (2H, q, J= 7 Hz).<br>
Preparation 184<br>
1-tert-butyl 7-ethyl 2-[(benzyloxy)acetyl1Heptanedioate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.30-1.50 (2H, m), 1.40 (9H, s), 1.56-1.72<br>
(2H, m), 1.75-1.95 (2H, m), 2.28 (2H,1, J= 7 Hz), 3.52 (1H, t, J= 7 Hz), 4.11 (2H,<br>
q, J= 7 Hz), 4.16 (2H, s), 4.59 (2H, s), 7.27-7.40 (5H, m).<br>
Preparation 185<br>
1-tert-butyl 5-ethyI 2-[(benzyloxy)acetyl]pentanedioate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.41 (9H, s), 2.10-2.23 (2H, m), 2.36 (2H, t, J= 7 Hz), 3.66 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.18 (2H, s), 4.60 (2H, s), 726-7.38 (5H,m).<br>
Preparation 186<br>
1-tert-butyl 7-ethyl 2-[(cyclohexyloxy)acetyl1Heptanedioate<br><br>
1H NMR (CDCh) 6 1.25 (3H, t, J= 7 Hz), 1.44 (9H, s), 1.15-1.92 (16H,m), 2.29 (2H, t, J= 7 Hz), 3.24-3.38 (1H, m), 3.56 (1H, t, J= 7 Hz), 4.12 (4H, m),<br>
Preparation 187<br>
1-tert-butyl 7-ethyl 2-(isopropoxyacetyl)heptanedioate<br>
1H NMR (CDC13) 6 1.20 (6H,d, J= 7 Hz), 1.25 (3H, t, J= 7 Hz), 1.25-1.45 (2H,m), 1.45(9H,s),1.60-1.72(2H5m),1.75-1.95(2H,m),2.29(2H,t,J=7Hz),3.54 (1H, t, J= 7 Hz), 3.60-3.68 (1H, m), 4.11 (2H, s), 4.12 (2H, q, J= 7 Hz).<br>
MS(ESl+):m/z345.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 20. Preparation 188 1-tert-butyl 5-ethyl 2-[(cyclohexyloxy)acetyl]pentanedioate<br>
H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.45 (9H,s), 1.18-1.62 (6H,m), 1.66-1.78 (2H, m), 1.84-1.98 (2H, m), 2.10-2.23 (2H, m), 2.38 (2H, t, J= 7 Hz), 3.25-3.38 (1H, m), 3.69 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.15 (2H, s). MS(ESI+):m/z357.<br>
Preparation 189<br>
To a suspension of 60% sodium hydride (527 mg) in dimethylformamide (20 mL) was added 3,5-pyridinedicarboxylic acid (2.00 g) under ice-water cooling and the mixture was stirred at 0 °C for 1 hour. To the mixture was added (bromomethyl)benzene (2.05 g) and the mixture was stirred at 60 C for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was triturated with ethyl acetate to give 5-[(benzyloxy)carbonyl]nicotinic acid as a pale yellow powder (722 mg). 5-[(benzyloxy)carbonyl]nicotinic acid<br>
1H NMR (DMSO-d6) 6 5.42 (2H, s), 7.34-7.54 (5H, m), 8.63 (1H, m), 9.23-9.34 (2H,<br>
m).<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 24.<br><br>
Preparation 190<br>
l-tert-butyl 4-ethy] 2-acetyl-2-[(5-methyl-3-pyridinyl)carbonyl]succinate<br>
1H NMR (CDC1.0 o 1.23 (3H, t, J= 7 Hz), 1.40 (9H, s), 2.38 (3H, s), 2.45 (3H, s),<br>
3.20 (2H, m), 4.13 (2H, q, J= 7 Hz), 7.88 (1H, s), 8.57 (1H, s), 8.74 (1H, s). MS(ESI+):m/z363.<br>
Preparation 191<br>
ethyl 2-[(5-methyl-3-pyridinyl)carbonyl]-3-oxobutanoate<br>
1H NMR (CDC13) 6 0.96 (3H, t, J= 7 Hz), 2.15 (3H, s), 2.45 (3H, s), 4.03 (2H, q, J= 7 Hz), 4.12 (1H, t, J= 7 Hz), 7.89 (1H, s), 8.54 (1H, s), 8.72 (1H, s).<br>
MS (ES1+): m/z 250.<br>
Preparation 192<br>
l-tert-butyl 6-ethyl 2-acetyl-2-[(5-bromo-3-pyridinyl)carbonyl1Hexanedioate<br>
1H NMR (CDCI3) 5 1.25 (3H, t, J= 7 Hz), 1.36 (9H, s), 1.60-1.73(2H, m), 2.23-2.35<br>
(2H, m), 2.38 (2H, t, J= 7 Hz), 2.48 (3H, s), 4.12 (2H, q, J= 7 Hz), 8.20 (1H, m),<br>
8.78 (lH,m), 8.81 (lH,m).<br>
Preparation 193<br>
l-tert-butyl 5-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(methoxyacetyl)pentanedioate 1H NMR (CDCI3) 6 1-25 (3H, t, J= 7 Hz), 1.39 (9H, s), 2.40-2.47 (2H, m), 2.55-2.67 (2H, m), 3.36 (3H, s), 4.12 (2H, q, J= 7 Hz), 4.27 (1H, d, J= 17 Hz), 4.40 (1H, d, J= 17 Hz), 8.21 (1H, m), 8.79 (1H, d, J= 2 Hz), 8.82 (1H, d, J= 2 Hz). MS (ESI+): m/z 472 474.<br>
Preparation 194<br>
l-tert-butyl 7-ethyl 2-acetyl-2-({5-[(benzyloxy)carbonylj-3-<br>
pyridinyl}carbonyl)heptanedioate<br>
1H NMR (CDCI3) 5 1.23 (3H, t, J= 7 Hz), 1.20-1.40 (2H, m), 1.32 (9H, s), 1.65-1.76 (2H, m), 2.19-2.26 (2H, m), 2.32 (2H, t, J= 7 Hz), 2.44 (3H, s), 4.12 (2H, q, J= 7 Hz), 5.41 (2H, s), 7.35-7.48 (5H, m), 8.62 (1H, m), 9.07 (1H, d, J= 2 Hz), 9.33 (lH,d,J=2Hz). MS (ES1+): m/z 526.<br><br>
Preparation 195<br>
1-tert-bulyl 7-ethyl 2-[(benzyloxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl1Heptanedioate<br>
1H NMR (CDCI3) 6 1.23 (3H, t, J= 7 Hz), 1.20-1.46 (2H, m), 1.32 (9H, s), 1.60-1.74 (2H, m), 2.10-2.36 (4H, m), 2.35 (3H, s), 4.10 (2H, q, J= 7 Hz), 4.38 (1H, d, J= 18 Hz), 4.53 (1H, d, J= 18 Hz), 4.54 (2H, m), 7.27-7.40 (5H, m), 7.79 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.72 (1H, d, J= 2 Hz). MS(ES1+):m/z512.<br>
Preparation 196<br>
1-tert-butyl 5-ethyl 2-[(benzyloxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl]pentanedioate<br>
1H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.34 (9H, s), 2.35 (3H, s), 2.40-2.72 (4H, m), 4.12 (2H, q, J= 7 Hz), 4.38 (1H, d, J= 17 Hz), 4.50 (1H, d, J= 17 Hz), 4.53 (2H, m), 7.25-7.38 (5H, m), 7.81 (1H, s), 8.54 (1H, s), 8.73 (1H, s). MS (ESI+): m/z 484.<br>
Preparation 197<br>
1-tert-butyl 7-ethyl 2-[(cyclohexyloxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl1Heptanedioate<br>
1H NMR (CDCI3) 5 1.25 (3H, t, J= 7 Hz), 1.16-1.55 (10H, m), 1.37 (9H, s), 1.60-1.76 (2H, m), 1.78-1.90 (2H, m), 2.15-2.28 (2H, m), 2.31 (2H, t, J= 7 Hz), 2.39 (3H, s), 3.17-3.29 (1H, m), 4.12 (2H, q, J= 7 Hz), 4.34 (1H, d, J= 18 Hz), 4.44 (1H, d, J= 18 Hz), 7.86 (1H, s), 8.56 (1H, s), 8.76 (1H, s). MS (ES1+): m/z 504.<br>
Preparation 198<br>
1-tert-butyl 7-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-<br>
[(cyclohexyloxy)acetyl1Heptanedioate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J= 7 Hz), 1.39 (9H, s), 1.16-1.88 (14H, m), 2.15-2.40 (4H, m), 3.16-3.28 (1H, m), 4.10 (2H, q, J= 7 Hz), 4.28 (1H, d, J= 18 Hz), 4.38 (1H, d,J= 18 Hz), 8.20 (1H, m), 8.78 (1H, d, J= 2 Hz), 8.84 (1H, d, J= 2 Hz).<br><br>
MS (ESI+): m/z 568 570.<br>
Preparation 199<br>
1-tert-butyl 5-ethyl 2-[(cyc]ohexyloxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbony]]pentanedioate<br>
!H NMR (CDC13) 6 1 -24 (3H, t, J= 7 Hz), 1.15-1.38 (4H, m), 1.39 (9H, s), 1.45-1.75 (4H, m), 1.76-1.93 (2H, m), 2.39 (3H, s), 2.45-2.75 (4H, m), 3.17-3.30 (1H, m), 4.12 (2H, q, J= 7 Hz), 4.32 (1H, d, J= 17 Hz), 4.41 (1H, d, J= 17 Hz), 7.88 (1H, s), 8.55 (lH,s), 8.77 (lH,s).<br>
MS (ESI+): m/z 476.<br>
Preparation 200<br>
1-tert-butyl 5-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-<br>
[(cyclohexyloxy)acetyl]pentanedioate<br>
1H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.15-1.35 (4H, m), 1.40 (9H, s), 1.40-1.65 (2H, m), 1.65-1.75 (2H, m), 1.75-1.92 (2H, m), 2.35-2.85 (4H, m), 3.16-3.32 (1H, m), 4.12 (2H, q, J= 7 Hz), 4.28 (1H, d, J= 17 Hz), 4.35 (1H, d, J= 17 Hz), 8.22 (1H, t, J= 2 Hz), 8.78 (1H, d, J= 2 Hz), 8.87 (1H, d, J= 2 Hz). MS (ES1+): m/z 540 542.<br>
Preparation 201<br>
1-tert-butyl 7-ethyl 2-(isopropoxyacetyl)-2-[(5-methyl-3-<br>
pyridinyl)carbonyl1Heptanedioate<br>
1H NMR (CDCI3) 6 1.12 (6H, d, J= 7 Hz), 1.23 (3H, t, J= 7 Hz), 1.30-1.55 (2H, m), 1.37 (9H, s), 1.63-1.77 (2H, m), 2.19-2.28 (2H, m), 2.28 (2H, t, J= 7 Hz), 2.39 (3H, s), 3.53-3.64 (1H, m), 4.10 (2H, q, J= 7 Hz), 4.31 (1H, d, J= 18 Hz), 4.42 (1H, d, J= 18 Hz), 7.86 (1H, s), 8.55 (1H, s), 8.74 (1H, s).<br>
MS (ESI+): m/z 464.<br>
Preparation 202<br>
1-tert-butyl 7-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(isopropoxyacetyl)heptanedioate 1H NMR (CDCI3) 5 1.10 (6H, d, J= 7 Hz), 1.24 (3H, t, J= 7 Hz), 1.39 (9H, s), 1.18-1.48 (2H, m), 1.64-1.77 (2H, m), 2.18-2.37 (4H, m), 3.52-3.64 (1H, m), 4.12 (2H,<br><br>
q, J= 7 Hz), 4.25 (1H, d, J= 17 Hz), 4.36 (1H, d, J= 17 Hz), 8.19 (1H, t, J= 2 Hz), 8.77 (1H, d, J= 2 Hz), 8.83 (1H, d, J= 2 Hz). MS (ESI+): m/z 528 530.<br>
Reparation 203<br>
l-tcrt-butyl 7-ethyl 2-[(acetyloxy)acelyl]-2-[(5-methyl-3-<br>
:&gt;yridinyl)carbonyl1Heptanedioale<br>
1H NMR (CDC13) 6 1.24 (3H, t, J= 7 Hz), 1.33 (9H, s), 1.20-1.42 (2H, m), 1.63-1.74 (2H, m), 2.14 (3H, s), 2.27-2.38 (4H, m), 2.40 (3H, s), 4.10 (2H, q, J= 7 Hz), 5.08 (1H, d, J= 18 Hz), 5.36 (1H, d, J= 18 Hz), 7.84 (1H, s), 8.56 (1H, s), 8.75 (1H, s). MS (ES1+): m/z 464.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 78. Preparation 204 ethyl 3-[(5-methyl-3-pyridinyl)carbonyl]-4-oxopentanoate<br>
1H NMR (CDCI3) 6 1.23 (3H, t, J= 7 Hz), 2.21 (3H, s), 2.44 (3H, s), 3.03 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.96 (1H, t, J= 7 Hz), 8.08 (1H, s), 8.66 (1H, s), 9.03 (lH,s). MS (ES1+): m/z 264.<br>
Preparation 205<br>
ethyl 5-[(5-bromo-3-pyridinyl)carbonyl]-6-oxoheptanoate<br>
1H NMR (CDCI3) 5 1.25 (3H, t, J= 7 Hz), 1.60-1.78 (2H,m), 1.98-2.12 (2H, m), 2.20<br>
(3H, s), 2.36 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.39 (1H, t, J= 7 Hz), 8.38<br>
(1H, m), 8.87 (1H, d, J= 2 Hz), 9.08 (1H, d, J= 2 Hz).<br>
Preparation 206<br>
ethyl 4-[(5-bromo-3-pyridinyl)carbonyl]-6-methoxy-5-oxohexanoate<br>
1H NMR (CDCI3) 5 1.25 (3H, t, J= 7 Hz), 2.04-2.16 (1H, m), 2.20-2.34 (1H, m), 2.40-2.48 (2H, m), 3.22 (3H, s), 3.93 (1H, d, J= 17 Hz), 4.00 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.85 (1H, m), 8.47 (1H, m), 8.88 (1H, s), 9.16 (1H, s). MS(ESI+):m/z372 374.<br><br>
Preparation 207<br>
benzyl 5-(2-acetyl-7-ethoxy-7-oxoheplanoyl)nicotinate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J= 7 Hz), 1.30-1.43 (2H, m), 1.65-1.75 (2H, m), 1.93-2.15 (2H, m), 2.19 (3H, s), 2.29 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.44 (1H, t, J= 7 Hz), 5.43 (2H, s), 7.35-7.50 (5H, m), 8.81 (1H, m), 9.28 (1H, d, J= 2 Hz),9.39(lH,d,J=2Hz). MS (ESI+): m/z 426.<br>
Preparation 208<br>
ethyl 8-(benzyloxy)-6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
1H NMR (CDCI3) 6 1.22 (3H, t, J= 7 Hz), 1.30-1.43 (2H, m), 1.60-1.69 (2H, m), 1.73-1.86 (1H, m), 1.95-2.08 (1H, m), 2.25 (2H, t, J= 7 Hz), 2.34 (3H, s), 4.05 (2H, s), 4.07 (2H, q, J= 7 Hz), 4.35-4.45 (2H, m), 4.69 (1H, t, J= 7 Hz), 7.09 (2H, m), 7.17-7.25 (3H, m), 7.93 (1H, s), 8.58 (1H, d, J= 2 Hz), 8.94 (1H, d, J= 2 Hz). MS (ESI+): m/z 412.<br>
Preparation 209<br>
ethyl 6-(benzyloxy)-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDCI3) 5 1.23 (3H, t, J= 7 Hz), 2.07-2.35 (2H, m), 2.34 (3H, s), 2.38-2.48 (2H, m), 4.05 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.34 (1H, d, J= 17 Hz), 4.41 (1H, d, J= 17 Hz), 4.90 (1H, m), 7.03 (2H, m), 7.15-7.25 (3H, m), 8.00 (1H, s), 8.57 (1H, s),9.02(lH,s). MS (ESI+): m/z 384.<br>
Preparation 210<br>
ethyl 8-(cyclohexyloxy)-6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
1H NMR (CDCI3) 5 0.91-1.70 (12H, m), 1.23 (3H, t, J= 7 Hz), 1.70-1.85 (2H, m), 1.96-2.04 (2H, m), 2.27 (2H, t, J= 7 Hz), 2.43 (3H, s), 3.14-3.28 (1H, m), 4.00 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.76 (1H, t, J= 7 Hz), 8.04 (1H, s), 8.62 (1H, s), 9.00 (1H, s). MS (ES1+): m/z 404.<br><br>
Preparation 211<br>
ethyl 6-[(5-bromo-3-pyridinyl)carbony]]-8-(cyclohexyloxy)-7-oxooctanoate<br>
1H NMR (CDC13) 6 0.95-1.87 (14H, m), 1.23 (3H, t, J= 7 Hz), 1 .96-2.07 (2H, m), 2.28 (2H, t, J= 7 Hz), 3.16-3.27 (1H, m), 3.96-4.07 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.72 (1H, t, J= 7 Hz), 8.38 (1H, m), 8.87 (1H, d, J= 2 Hz), 9.08 (1H, d, J= 2 Hz). MS (ES1+): m/z 468 470.<br>
Preparation 212<br>
ethyl 6-(cyclohexyloxy)-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDC13) 6 0.88-1.25 (5H, m), 1.24 (3H, t, J= 7 Hz), 1.40-1.83 (5H, m), 2.04-2.14 (1H, m), 2.18-2.34 (1H, m), 2.42 (2H, m), 2.44 (3H, s), 3.13-3.27 (1H, m), 4.00 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.93 (1H, m), 8.13 (1H, s), 8.63 (1H, d, J= 2Hz),9.07(lH,d,J=2Hz). MS (ESI+): m/z 376.<br>
Preparation 213<br>
ethyl 4-[(5-bromo-3-pyridinyl)carbonyl]-6-(cyclohexyloxy)-5-oxohexanoate<br>
1H NMR (CDCI3) 8 0.88-1.85 (10H, m), 1.25 (3H, t, J= 7 Hz), 2.02-2.14 (1H, m), 2.18-2.34 (1H, m), 2.40-2.50 (2H, m), 3.15-3.27 (1H, m), 3.97 (1H, d, J= 17 Hz),<br>
4.02	(1H, d, J= 17 Hz), 4.13 (2H, q, J= 7 Hz), 4.87-4.95 (1H, m), 8.48 (1H, t, J= 2<br>
Hz), 8.88 (1H, d, J= 2 Hz), 9.19 (1H, d, J= 2 Hz).<br>
MS (ES1+): m/z 440 442.<br>
Preparation 214<br>
ethyl 8-isopropoxy-6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
:H NMR (CDCI3) 6 0.86 (3H, d, J= 7 Hz), 1.02 (3H, d, J= 7 Hz), 1.23 (3H, t, J= 7 Hz), 1.30-1.48 (2H, m), 1.60-1.72 (2H, m), 1.72-1.88 (1H, m), 1.95-2.07 (1H, m), 2.27 (2H, t, J= 7 Hz), 2.43 (3H, s), 3.44-3.54 (1H, m), 3.95 (1H, d, J= 18 Hz),<br>
4.03	(1H, d, J= 18 Hz), 4.08 (2H, q, J= 7 Hz), 4.73 (1H, t, J= 7 Hz), 8.06 (1H, s),<br>
8.63 (lH,s), 9.02 (lH,s).<br>
MS (ES1+): m/z 364.<br>
Preparation 215<br><br>
ethyl 6-[(5-bromo-3-pyridiny])carbonyl]-8-isopropoxy-7-oxooctanoate<br>
1H NMR (CDCI3) 5 0.88 (3H, d, J= 7 Hz), 1.03 (3H, t, J= 7 Hz), 1.23 (3H, t, J= 7 Hz), 1.20-1.46 (2H, m), 1.58-1.72 (2H, m), 1.73-1.87 (1H, m), 1.95-2.07 (1H, m),2.27 (2H, 1, J= 7 Hz), 3.46-3.58 (1H, m), 3.94 (1H, d, J= 17 Hz), 4.03 (1H, d, J= 17 Hz), 4.10 (2H, q, J= 7 Hz), 4.68 (1H, t, J= 7 Hz), 8.40 (1H, t, J= 2 Hz), 8.86 (1H, d, J= 2 Hz), 9.08 (1H, d, J= 2 Hz). MS(ESl+):m/z428 430.<br>
Preparation 216<br>
ethyl 8-(acetyloxy)-6-[(5-methyl-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
1H NMR (CDCI3) 8 1.24 (3H, t, J= 7 Hz), 1.37-1.47 (2H, m), 1.60-1.77 (2H, m), 2.01 (3H, s), 1.97-2.08 (2H, m), 2.29 (2H, t, J= 7 Hz), 2.44 (3H, s), 4.10 (2H, q, J= 7 Hz), 4.52 (1H, t, J= 7 Hz), 4.68 (1H, d, J= 18 Hz), 4.76 (1H, d, J= 18 Hz), 8.04 (1H, s), 8.66 (1H, s), 8.98 (1H, s). MS(ESI+):m/z364.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 21. Example 285<br>
ethyl [7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]acetate 1H NMR (CDCI3) 6 1.24 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.40 (3H, s), 2.50 (3H, s), 3.02 (2H, q, J= 7 Hz), 3.44 (2H, s), 4.14 (2H, q, J= 7 Hz), 5.98 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.55 (1H, s), 8.45 (1H, s), 8.54 (1H, s). MS (ES1+): m/z 338.<br>
Example 286<br>
ethyl 7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylate 1H NMR (CDCh) 6 0.96 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.41 (3H, s), 2.61 (3H, s), 3.04 (2H, q, J= 7 Hz), 4.05 (2H, q, J= 7 Hz), 6.30 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.58 (1H, s), 8.48 (1H, d, J= 2 Hz), 8.51 (1H, d, J= 2 Hz). MS (ES1+): m/z 324.<br>
Example 287<br><br>
ethyl 4-[4-(5-bromo-3-pyrJdinyl)-7-ethyl-2-methylpyno]o[l,2-b]pyridazin-3-yl]butanoate !H NMR (CDCI.0 6 1.21 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.67-1.78 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.42-2.54 (2H, m), 2.59 (3H, s), 3.01 (2H, q, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 5.87 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ES1+): m/z 430 432.<br>
Example 288<br>
ethyl 3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpropanoate<br>
1H NMR (CDCI3) 5 1.20 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.42 (2H, t, J= 7 Hz), 2.85-2.97 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.46 (3H, s), 4.08 (2H, q, J= 7 Hz), 4.65 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.54 (1H, d, J=2Hz),8.78(lH,d,J=2Hz). MS (ES1+): m/z 446 448.<br>
Example 289<br>
ethyl 4-[2-[(acetyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yljbutanoate<br>
-U NMR (CDCI3) 6 1.20 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.60-1.75 (2H, m),<br>
2.17	(3H, s), 2.10-2.28 (2H, m), 2.45-2.60 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.05<br>
(2H, q, J= 7 Hz), 5.32 (2H, s), 5.95 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.88<br>
(1H, m), 8.55 (1H, m), 8.78 (1H, m).<br>
MS (ES1+): m/z 488 490.<br>
Example 290<br>
benzyl 5-[3-(5-ethoxy-5-oxopentyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-<br>
yl]nicotinate<br>
1H NMR (CDCb) 6 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.33-1.60 (4H, m),<br>
2.18	(2H, t, J= 7 Hz), 2.35-2.47 (2H, m), 2.56 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.10<br>
(2H, q, J= 7 Hz), 5.42 (2H, s), 5.82 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.36-<br>
7.47 (5H, m), 8.33 (1H, m), 8.77 (1H, d, J= 2 Hz), 9.33 (1H, d, J= 2 Hz).<br>
MS (ES1+): m/z 500.<br><br>
Example 293<br>
ethyl 5-[2-[(benzyloxy)methyl]-7-elhyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridaziiv<br>
3-yl]pentanoate<br>
!H NMR (CDCI3) 5 1.22 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.20-1.50 (4H, m), 2.06 (2H, t, J= 7 Hz), 2.42 (3H, s), 2.47-2.63 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.0s (2H, q, J= 7 Hz), 4.64 (2H, s), 4.73 (2H, s), 5.90 (1H, d, J= 4 Hz), 6.58 (1H, d, J 4 Hz), 7.27-7.39 (5H, m), 751 (1H, s), 8.41 (1H, d, J= 2 Hz), 8.53 (1H, d, J= 2 Hz).<br>
Example 292<br>
ethyl 3-[2-[(benzyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyiidazJD<br>
3-yl]propanoate<br>
1H NMR (CDCI3) 6 1.16 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.36 (2H, t, J= 7 IV,. 2.42 (3H, s), 2.80-3.00 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.03 (2H, q, J= 7 Hz), i (-(2H, s), 4.75 (2H, s), 5.92 (1H, d, J= 2 Hz), 6.59 (1H, d, J= 2 Hz), 7.26-7.38 (ML m), 7.48 (1H, s), 8.40 (1H, d, J= 2 Hz), 8.53 (1H, d, J= 2 Hz). MS (ES1+): m/z 458.<br>
Example 293<br>
ethyl 5-[2-[(cyclohexyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 5 1.20-1.60 (10H, m), 1.25 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 I b 1 1.70-1.83 (2H, m), 1.96-2.07 (2H, m), 2.15 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.5.<br>
2.68	(2H, m), 3.04 (2H, q, J= 7 Hz), 3.42-3.53 (1H, m), 4.08 (2H, q, J= 7 11/)<br>
4.68	(2H, s), 5.88 (1H, d, J= 4 Hz), 6.55 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.42 
Example 294<br>
ethyl 5-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexyloxy)methyl]-7-ethylpyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1HNMR (CDCI3) 6 1.22-1.62 (10H, m), 1.23 (3H, I, J= 7 Hz), 1.37 (3H, t, J =    11/). 1.73-1.86 (2H,m), 1.98-2.07 (2H,m),2.18 (2H,1, J= 7 Hz),2.53-2.70 (211 mi.<br><br>
3.03 (2H, q, J= 7 Hz), 3.42-3.56 (1H, m), 4.12 (2H, q, J= 7 Hz), 4.69 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.77 (lH,dJ=2Hz).<br>
Example 295<br>
:thyl 3-[2-[(cyclohexyloxy)methyi]-7-ethyl-4-(5-methyl-3-pyridiny])pyrrolo[l,2-<br>
)]pyridazin-3-yl]propanoate<br>
1H NMR (CDC13) 6 1.19 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.16-1.45 (4H, m), 1.52-1.65 (2H, m), 1.73-1.83 (2H, m), 1.98-2.07 (2H, m), 2.35-2.47 (2H, m), 2.42 (3H, s), 2.84-2.98 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.45-3.56 (1H, m), 4.06 (2H, q, J= 7 Hz), 4.71 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.50 (1H, s), 8.42 (lH,s), 8.53 (lH,s).<br>
MS (ES1+): m/z 450.<br>
Example 296<br>
ethyl 3-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexyloxy)methyl]-7-ethylpyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoate<br>
1H NMR (CDCI3) 5 1.20 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.15-1.60 (6H, m), 1.73-1.85 (2H, m), 1.97-2.08 (2H, m), 2.45 (2H, t, J= 7 Hz), 2.83-2.97 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.42-3.56 (1H, m), 4.08 (2H, q, J= 7 Hz), 4.71 (2H, s), 5.90 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.86 (1H, t, J= 2 Hz), 8.53 (1H, d, J= 2 Hz),8.77(lH,d,J=2Hz). MS(ESl+):m/z514 516.<br>
Example 297<br>
ethyl 5-[7-ethyl-2-(isopropoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]pentanoate<br>
1H NMR (CDCI3) 6 1.23 (3H, t, J= 7 Hz), 1.26 (6H, d, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.38-1.62 (4H, m), 2.17 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.53-2.68 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.76-3.88 (1H, m), 4.08 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS(ESI+):m/z438.<br><br>
Example 298<br>
ethyl 5-[4-(5-bromo-3-pyndinyl)-7-ethyl-2-(isopropoxymethyl)pyirolo[l,2-b]pyridazin-3-<br>
y]]pentanoate<br>
H NMR (CDCI3) 0 1.23 (3H, i, J= 7 Hz), 1.25 (6H, d, J= 7 Hz), 1.37 (3H, t, .1= 7 Hz), 1.37-1.64 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.54-2.72 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.75-3.87 (1H, m), 4.09 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS (ESI+): m/z 502 504.<br>
Example 299<br>
ethyl 5-[2-[(acetyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]pentanoate<br>
H NMR (CDCb) 6 1.23 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.30-1.58 (4H, m), 2.13 (2H, t, J= 7 Hz), 2.18 (3H, s), 2.44 (3H, s), 2.40-2.55 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 5.29 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS (ESI+): m/z 438.<br>
The following compound(s) was(were) obtained in substantially the same manner<br>
as that of Example 236.<br>
Example 300<br>
ethyl 4-{4-[5-(l-ethoxyvinyl)-3-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yljbutanoate<br>
TH NMR (CDCI3) 5 1.24 (3H, t, J= 7 Hz), 1.38 (3H51, J= 7 Hz), 1.41 (3H, t, J= 7 Hz), 1.68-1.80 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.44-2.54 (2H, m), 2.59 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.95 (2H, q, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.36 (1H, d, J= 3 Hz), 4.77 (1H, d, J= 3 Hz), 5.88 (1H,d, J= 4 Hz), 6.52 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.53 (1H, d, J= 2 Hz), 8.93 (1H, d, J= 2 Hz). MS (ESI+): m/z 422.<br>
Example 301<br>
ethyl 3-[4-[5-(l -ethoxyvinyl)-3-pyridinyl]-7-ethyl-2-(methoxymethyl)pyrrolo[l ,2-<br>
b]pyridazin-3-yl]propanoate<br><br>
1H NMR (CDCI3) 6 1.19 (3H, t, J= 7 Hz), 1.26 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.42 (2H, t, J= 7 Hz), 2.84-2.97 (2H, m), 3.07 (2H, q, J= 7 Hz), 3.47 (3H, s), 3.97 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.36 (1H, d, J= 3 Hz), 4.66 (2H, s), 4.77 (1H, d, J= 3 Hz), 5.95 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.95 (1H, d, J= 2 Hz).<br>
MS(ESl+):m/z438.<br>
Example 302<br>
ethyl 3-[7-elhyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDCI3) 6 1.18 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.40 (2H, t, J= 7 Hz), 2.84-2.98 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.47 (3H, s), 4.04 (2H, q, J= 7 Hz), 4.65 (2H, s), 5.46 (1H, d, J= 11 Hz), 5.87 (1H, d, J= 18 Hz), 5.94 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 6.72-6.83 (1H, dd, J= 11 Hz, 18 Hz), 7.74 (1H, m), 8.49 (1H, d, J= 2 Hz), 8.72 (1H, d, J= 2 Hz). MS(ESI+):m/z394.<br>
Example 303<br>
methyl 4-[7-ethyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.65-1.78 (2H, m), 2.23 (2H, t, J= 7 Hz), 2.54-2.70 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.47 (3H, s), 3.58 (3H, s), 4.67 (2H, s), 5.46 (1H, d, J= 11 Hz), 5.88 (1H, d, J= 18 Hz), 5.93 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 6.73-6.83 (1H, dd, J= 11 Hz, 18 Hz), 7.77 (1H, m), 8.51 (1H, d, J= 2 Hz),8.71(lH,d,J=2Hz). MS (ESI+): m/z 394.<br>
Example 304<br>
methyl 4-[4-[5-(l-ethoxyvinyl)-3-pyridinyl]-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]butanoate<br>
1H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.67-1.82 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.53-2.67 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.47 (3H, s), 3.58 (3H, s), 3.95 (2H, q, J= 7 Hz), 4.34 (1H, d, J= 2 Hz), 4.67 (2H, s), 4.77 (1H, d, J=<br><br>
2 Hz), 5.93 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.54 (1H, d, J= 2Hz),8.95(lH,d,J=2Hz). MS (ES1+): m/z 438.<br>
xample 305<br>
Ihyl 3-{4-[5-(l-eth°xyvinyl)-3-pyridinyl]-7-ethyI-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
l}propanoate<br>
1H NMR (CDC13) 6 1.19 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.44 (3H, t, J= 7 Hz), 2.33-2.43 (2H, m), 2.58 (3H, s), 2.76-2.87 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.96 (2H, q, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 4.36 (1H, d', J= 2 Hz), 4.77 (1H, d, J= 2 Hz), 5.91 (1H, d, J= 4 Hz), 6.54 (1H, d, J= 4-Hz), 7.91 (1H, m), 8.53 (1H, d, J= 2 Hz),8.96(lH,d,J=2Hz). MS (ES1+): m/z 408.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 251. Example 306<br>
ethyl 4-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butanoate 5H NMR (CDCI3) 6 1.19 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.66-1.82 (2H, m), 2.21 (2H, t, J= 7 Hz), 2.41-2.51 (2H, m), 2.60 (3H, s), 2.69 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.03 (2H, q, J= 7 Hz), 5.83 (1H, d, i= 4 Hz), 6.53 (1H, d, J= 4 Hz), 8.25 (1H, m), 8.79 (1H, d, J= 2 Hz), 9.25 (1H, d, J= 2 Hz). MS (ES1+): m/z 394.<br>
Example 307<br>
ethyl 3-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpropanoate<br>
1H NMR (CDCI3) 6 1.18 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.41 (2H, t, J= 7 Hz), 2.70 (3H, s), 2.83-2.96 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.47 (3H, s), 4.03 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 8.26 (1H, m), 8.79 (1H, d, J= 2 Hz), 9.25 (1H, d, J= 2 Hz).<br>
Example 308<br><br>
methyl 4-[4-(5-acetyl-3-pyncliny])-7-elhy]-2-(methoxymethyl)pyrro]o[l,2-b]pyridazin-3-y]]butanoate<br>
1H NMR (CDC13) 6 1 .38 (3H, t, J= 7 Hz), 1.64-1.80 (2H, m), 2.20 (2H, t, J= 7 Hz), 2.53-2.65 (2H, m), 2.70 (3H, s), 3.05 (2H, q, J= 7 Hz), 3.47 (3H, s), 3.57 (3H, s), 4.67 (2H, s), 5.87 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 8.27 (1H, s), 8.81 (1H, d, J= 2 Hz), 9.26 (1H, d, J= 2 Hz).<br>
MS (ESI+): m/z 410.<br>
Example 309<br>
ethyl 3-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDC13) 8 1.19 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.33-2.42 (2H, m), 2.59 (3H, s), 2.69 (3H, s), 2.75-2.83 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.05 (2H, q, J= 7 Hz), 5.83 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 8.25 (1H, m), 8.78 (1H, d, J= 2 Hz), 9.26 (1H, d, J= 2 Hz). MS (ESI+): m/z 380.<br>
Example 310<br>
A mixture of benzyl 5-[3-(5-ethoxy-5-oxopentyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]nicotinate (330 mg) and 10% palladium on carbon (33 mg) in methanol (10 mL) was stirred under 4 atm hydrogen atmosphere at ambient temperature for 2 hours. The catalysts were filterred off and washed with chloroform. The filtrates were evaporated in vacuo to give 5-[3-(5-ethoxy-5-oxopentyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]nicotinic acid as yellow oil (272 mg).<br>
5-[3-(5-ethoxy-5-oxopentyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]nicotinic acid 1H NMR (CDCb) o 1.21 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.35-1.63 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.38-2.49 (2H, m), 2.57 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.11 (2H, q, J= 7 Hz), 5.85 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 8.40 (1H, m), 8.83 (1H, d, J= 2 Hz), 9.37 (1H, d, J= 2 Hz). MS (ESI"): m/z 408, MS (ES1+): m/z410.<br>
Example 311<br><br>
To a solution of 5-[3-(5-ethoxy-5-oxopentyl)-7-elhyl-2-methylpyrrolo[l,2-b]pyridazin-4-yl]nicotinic acid (235 mg) and triethylarnine (87.1 mg) in t-butanol (10 TIL) was added diphenylphosphoryl azide (237 mg) and the mixture was heated under reflux for 2 hours. After evaporation of solvent, the residue was partitioned between sthyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and ethyl acetate (20:1 - 2:1) to give ethyl 5-(4-{5-[(tert-butoxycarbonyl)amino]-3-pyridinyl}-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl)pentanoate as yellow oil (190 mg). ethyl 5-(4-{5-[(tert-butoxycarbonyl)amino]-3-pyridinyl}-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br>
1H NMR (CDC13) 8 1 -24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.42-1.67 (4H, m), 1.52 (9H, s), 2.19-2.28 (2H, m), 2.38-2.50 (2H, m), 2.55 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 5.92 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 6.93 (1H, br), 7.87 (1H, s), 8.30 (1H, d, J= 2 Hz), 8.70 (1H, d, J= 2 Hz). MS(ESI+):m/z481.<br>
Example 312<br>
A solution of ethyl 5-(4-{5-[(tert-butoxycarbonyl)amino]-3-pyridinyl}-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl)pentanoate (190 mg) in 2 N hydrogen chloride ethyl acetate solution (4 mL) was stirred at ambient temperature for 2 hours. After evaporation of solvent, the residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of chloroform and methanol (100:1 -20:1) to give ethyl 5-[4-(5-amino-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate as yellow oil (140 mg).<br>
ethyl 5-[4-(5-amino-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCI3) 5 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.40-1.65 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.45 (2H, t, J= 7 Hz), 2.54 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.97(2H,br),4.12(2H,q,J=7Hz),5.94(lH,d,J=4Hz),6.53(lH,d,J=4Hz),<br><br>
7.02 (1H, m), 8.02 (1H, d, J= 2 Hz), 8.17 (1H, d, J= 2 Hz).<br>
MS (ESI+): m/z 381 (M+H).<br>
Example 313<br>
To a solution of ethyl 5-[4-(5-amino-3-pyridinyl)-7-ethy]-2-methy]pyrroIo[l,2-b]pyridazin-3-yl]pentanoate (55 mg), 37% formaldehyde solution (277 mg) and sodium cyanoborohydride (27.3 mg) in acetnitrile (1 mL) and methanol (1 mL) was added acetic acid (2 drops) and the mixture was stirred at ambient temperature for 2 hours. The solution was diluted with saturated sodium bicarbonate solution and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative silica gel column chromatography eluting with a mixture of chloroform and methanol (20:1) to give ethyl 5-{4-[5-(dimethylamino)-3-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoate as yellow oil (36.5 mg).<br>
ethyl 5-{4-[5-(dimethylamino)-3-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br>
H NMR (CDC13) 6 1.23 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.40-1.63 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.40-2.53 (2H, m), 2.55 (3H, s), 3.02 (6H, s), 3.03 (2H, q, J= 7 Hz), 4.09 (2H, q, J= 7 Hz), 5.93 (1H, d, J= 4 Hz), 6.50 (1H, d, J= 4 Hz), 6.96 (1H, m), 7.95 (1H, d, J= 2 Hz), 8.20 (1H, d, J= 2 Hz). MS(ESI+):m/z409.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 245. Example 314<br>
3-[7-ethyl-4-(5-ethyl-3-pyridinyl)-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCI3) 6 1.29 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.45-2.58 (2H, m),<br>
2.73 (2H, q, J= 7 Hz), 2.82-3.02 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.47 (3H, s), 4.67<br>
(2H, s), 5.91 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.58 (1H, m), 8.43 (1H, d,<br>
J=2Hz),8.53(lH,d,J=2Hz). MS (ESI): m/z 366,MS (ESI+): m/z 368.<br><br>
Example 315<br>
4-[7-ethyl-4-(5-ethyl-3-pyridinyl)-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (CDCI3) 6 1.31 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.69-1.85 (2H, m), 2.20-2.31 (2H, m), 2.52-2.75 (2H, m), 2.77 (2H, q, J= 7 Hz), 3.06 (2H, q, J= 7 Hz), 3.46 (3H, s), 4.60-4.80 (2H, m), 5.91 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.61 (lH,s), 8.44-8.53 (2H,m).<br>
MS (ESI+): m/z 382.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 228. Example 316<br>
methyl 4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yljbutanoate<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.65-1.79 (2H, m), 2.25 (2H, t, J= 7 Hz), 2.39-2.53 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.61 (3H, s), 4.90 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.79 (1H, d, J= 2 Hz). MS (ESI+): m/z 432 434 .<br>
Example 317<br>
ethyl 5-[7-ethyl-2-(hydroxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
1H NMR (CDCI3) 6 1.23 (3H, t, J= 7 Hz), 1.38 (3H,t, J= 7 Hz), 1.35-1.60 (4H,m), 2.17 (2H, t, J= 7 Hz), 2.35-2.45 (2H, m), 2.43 (3H, s), 3.04 (2H, q, J= 7 Hz), 3.83 (1H, t, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.85 (2H, d, J= 7 Hz), 5.96 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.50 (1H, s), 8.42 (1H, s), 8.54 (1H, s). MS (ESI+): m/z 396.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 268. Example 318<br><br>
methyl 4-[4-(5-bromo-3-pyridiny])-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoate<br>
1H NMR (CDCb) 6 1.37 (3H, t, J= 7 Hz), 1.65-1.79 (2H, m), 2.24 (2H, t, J= 7 Hz), 2.52-2.70 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.46 (3H, s), 3.60 (3H, s), 4.76 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.79(lH,d,J=2Hz). MS(ES1+):m/z446 448.<br>
Example 319<br>
ethyl 5-[2-[(2-tert-butoxy-2-oxoethoxy)methyl]-7-ethyl-4-(5-methyl-3-<br>
pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.30-1.60 (4H, m), 1.47 (9H, s), 2.17 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.58-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.08 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.81 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.43 (1H, s), 8.53 (1H, s). MS(ESI+):m/z510.<br>
Example 320<br>
ethyl 5-[2-[(cyclopropylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 6 0.20-0.32 (2H, m), 0.53-0.63 (2H, m), 1.07-1.20 (1H, m), 1.22 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.40-1.60 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.53-2.68 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.41 (2H, d, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.70 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.43 (1H, s), 8.53 (1H, s). MS(ESl+):m/z450.<br>
Example 321<br>
ethyl 5-[2-[(cyclohexylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridiny])pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 6 0.88-1.05 (2H,m), 1.16-1.35 (4H, m), 1.25 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.38-1.59 (4H, m), 1.60-1.87 (5H, m), 2.16 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.54-2.67 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.35 (2H, d, J= 7 Hz), 4.10 (2H,<br><br>
q, J= 7 Hz), 4.64 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.43 (1H, d, J= 2 Hz), 853 (1H, d, J= 2 Hz). MS(ESl+):m/z492.<br>
Example 322<br>
ethyl 5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(3-pyridinylniethoxy)methy]]pyrrolo[ 1,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDC13) 6 1.22 (3H, t, J= 7 Hz), 1.39 (3H, t, J= 7 Hz), 1.35-1.54 (4H, m), 2.12 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.50-2.63 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.66 (2H, s), 4.76 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.28 (1H, m), 7.52 (1H, s), 7.72 (1H, d, J= 8 Hz), 8.42 (1H, d, J= 2 Hz), 8.54 (2H, m), 8.62 (lH,d, J= 2 Hz).<br>
MS (ES1+): m/z 487.<br>
Example 323<br>
ethyl 5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(2-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDC13) 8 1.21 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.36-1.54 (4H, m), 2.12 (2H, t, J= 7 Hz), 2.42 (3H, s), 2.56-2.68 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.77 (2H, s),4.85 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.22 (1H, m), 7.43-7.54 (2H, m), 7.66-7.74 (1H, m), 8.42 (1H, d, J= 2 Hz), 8.54 (1H, d, J= 2 Hz), 8.57 (1H, d, J= 5 Hz). MS (ESI+): m/z 487.<br>
Example 324<br>
ethyl 5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(4-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCI3) 8 1.22 (3H, t, J= 7 Hz), 1.39 (3H, t, J= 7 Hz), 1.38-1.57 (4H,m), 2.12 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.52-2.68 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.66 (2H, s), 4.77 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 2 Hz), 7.28 (2H, d, J= 7 Hz), 7.52 (1H, s), 8.42 (1H, d, J= 2 Hz), 8.53 (1H, d, J= 2 Hz),8.58(2H,d,J=7Hz). MS(ESl+):m/z487.<br><br>
Example 325<br>
ethyl 5-{7-ethyl-4-(5-melhyl-3-pyridinyl)-2-[(2-pyrazinylmethoxy)melhyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCI3) 5 1 -22 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.38-1.57 (4H, m), 2.13 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.52-2.68 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.07 (2H, q, J= 7 Hz), 4.82 (2H, s), 4.88 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.43 (1H, d, J= 2 Hz), 8.48-8.57 (3H, m), 8.75 (1H, m).<br>
MS (ESI+): m/z 488.<br>
Example 326<br>
ethyl 5-[4-(3-cyanophenyl)-2-(ethoxymethyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCI3) 8 1.18-1.29 (6H, m), 1.34-1.53 (7H, m), 2.14 (2H, t, J = 7 Hz),<br>
2.52 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.53 (2H, q, J = 7 Hz), 4.07 (2H, q, J = 7 Hz), 4.66 (1H, s), 5.73 (U, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.60 (2H, m), 7.67 (1H, s), 7.75 (1H, m)<br>
Example 327<br>
ethyl 5-[2-[(benzyloxy)methyl]-4-(3-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCI3) 6 1.22 (3H, t, J = 7 Hz), 1.30-1.46 (7H, m), 2.06 (2H, t, J = 7 Hz),<br>
2.51	(2H, m), 3.02 (2H, q, J = 7 Hz), 4.07 (2H, q, J = 7 Hz), 4.64 (3H, s), 4.72<br>
(3H, s), 5.83 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.25-7.38 (5H, m), 7.57<br>
(2H, d, J = 9 Hz), 7.65 (1H, s), 7.74 (1H, m).<br>
Example 328<br>
methyl 4-({[4-(3-cyanophenyl)-3-(5-ethoxy-5-oxopentyl)-7-ethylpyrrolo[l,2-b]pyridazin-<br>
2-yl]methoxy}methyl)benzoate<br>
1H NMR (CDCI3) 6 1.22 (3H, t, J = 7 Hz), 1.32-1.49 (7H, m), 2.01 (2H, t, J = 7 Hz),<br>
2.52	(2H, m), 3.02 (2H, t, J = 7 Hz), 3.92 (3H, s), 4.07 (2H, t, J = 7 Hz), 4.69 (2H,<br>
s), 4.75 (2H, s), 6.84 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.43 (2H, d, J = 9<br>
Hz), 7.60 (2H, m), 7.65 (1H, s), 7.75 (1H, m), 8.02 (2H, d, J = 9 Hz).<br><br>
Example 329<br>
A solution of ethyl 5-[2-[(2-tert-buloxy-2-oxoethoxy)methyl]-7-ethyl-4-(5-methy]-3-pyridiny])pyrro]o[l,2-b]pyridazin-3-y]]pentanoate (60 mg) in tifluoroacetic acid (2 mL) was stirred at ambient temperature for 2 hours, and evaporated in vacuo to give<br>
{[3-(5-elhoxy-5-oxopenty])-7-ethyl-4-(5-methy]-3-pyridinyl)pyrrolo[l,2-b]pyridazin-2-yI]methoxy}acetic acid as brown oil (55 mg).<br>
{[3-(5-ethoxy-5-oxopenty])-7-ethyI-4-(5-methyl-3-pyridinyl)pyrro]o[l,2-b]pyridazin-2-yl]methoxy}acetic acid<br>
1H NMR (CDC13) 6 1.25 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.35-1.60 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.50-2.58 (2H, m), 2.67 (3H, s), 3.03 (2H, q, j= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.30 (2H, s), 4.87 (2H, s), 5.86 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 8.15 (1H, s), 8.69 (1H, s), 8.85 (1H, s). MS (ESI): m/z 452, MS (ESI+): m/z 454.<br>
Example 330<br>
To a solution of {[3-(5-ethoxy-5-oxopentyl)-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-2-yl]methoxy}acetic acid (55 mg), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (34.9 mg) and 1-hydroxybenotriazole (24.6 mg) in dimethylformamide (2 mL) was added morpholine (12.7 mg) and the mixture was stirred at ambient temperature for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of ethyl acetate and methanol (50:1 - 20:1) to give ethyl 5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{ [2-(4-morpholinyl)-2-oxoethoxy]methyl}pyrrolo[ 1,2-b]pyridazin-3-yl)pentanoate as yellow oil (50 mg).<br>
ethyl 5-(7-ethyl-4-(5-methyl'3-pyridinyl)-2-{[2-(4-morpholinyl)-2-oxoethoxy]methyl}pyrrolo[l ,2-b]pyridazin-3-yl)pentanoate<br>
1HNMR(CDCl3)6l.22(3H,t,J=7Hz),1.37(3H,t,J=7Hz), 1.40-1.63 (4H,m), 2.15 (2H, t, J= 7 Hz), 2,43 (3H, s), 2.54-2.68 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.48-<br><br>
3.57 (2H, m), 3.63-3.78 (6H, m), 4.08 (2H, q, J= 7 Hz), 4.30 (2H, s), 4.78 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.43 (1H, d, J= 2 Hz), 8.54(lH,d,J=2Hz). MS(ESI+):m/z523.<br>
The following compound(s) was(were) obtained in substantially the same manner<br>
as that of Example 330. '<br>
Example 331<br>
ethyl 5-[7-ethyl-2-{[2-(methylamino)-2-oxoethoxy]methyl}-4-(5-methyl-3-<br>
pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDC13) 6 1.23 (3H, t, J= 7 Hz), 1.38 (3H,t, J= 7 Hz), 1.38-1.62 (4H,m), 2.18 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.48-2.62 (2H, m), 2.88 (3H, d, J= 7 Hz), 3.03 (2H, q, J= 7 Hz), 4.11 (2H, q, J= 7 Hz), 4.13 (2H, s), 4.77 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 6.79 (1H, br), 7.53 (1H, s), 8.44 (1H, s), 8.56 (1H, s). MS(ESI+):m/z467.<br>
The following compound(s) was(were) obtained in substantially the same manner<br>
as that of Example 271.<br>
Example 332<br>
ethyl 5-[2-[(benzylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[ 1,2-<br>
b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 6 1.22 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.30-1.50 (2H, m), 1.60-1.85 (2H, m), 2.12 (2H, t, J= 7 Hz), 2.30-2.45 (2H, m), 2.42 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.96 (2H, s), 3.98 (2H, s), 4.08 (2H, q, J= 7 Hz), 5.87 (1H, d, J= 4 Hz), 6.54 (1H, d, J= 4 Hz), 7.27-7.43 (5H, m), 7.48 (1H, s), 8.38 (1H, d, J= 2 Hz),8.53(lH,d,J=2Hz). MS(ESl+):m/z485.<br>
•Example 333<br>
A mixture of ethyl 5-[7-ethyl-2-(hydroxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (100 mg), lH-isoindole-l,3(2H) dione (44.6 mg) diisopropyl azodicarboxylate (76.7 mg) and triphenylphosphine (99.5 mg) in tetrahydrofuran (2 mL) was stirred at ambient temperature for 1 hour. After evaporation<br><br>
of solvent, the residue was purified by silica gel column chromatography eluling with a mixture of hexane and ethyl acetate (20:1 - 1:1) to give ethyl 5-[2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolofl,2-bJpyridazin-3-yl]pentanoate as yellow oil (107 mg).<br>
ethyl 5-[2-[(13-dioxo-13-dihydro-2H-isoindol-2-yl)methyl]-7-ethyl-4-5-methyl-3-pyridinyI)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDC13) 6 0.89 (3H,t, J= 7 Hz), 1.26 (3H, t, J= 7 Hz), 1.20-1.40 (2H, m), 1.53-1.75 (2H, m), 2.24 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.47 (2H, q, J= 7 Hz), 2.50-2.64 (2H, m), 4.12 (2H, q, J=; 7 Hz), 5.10 (2H, s), 5.85 (1H, d, J= 4 Hz), 6.43 (1H, d, J= 4 Hz), 7.51 (1H, s), 7.78 (2H, m), 7.96 (2H, m), 8.43 (1H, s), 8.55 (1H, s). MS(ESI+):m/z525.<br>
Example 334<br>
A mixture of ethyl 5-[2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (107 mg) and hydrazine monohydrate (51.1 mg) in ethanol (2 mL) was heated under reflux for 2 hours. After evaporation of solvent, the residue was partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give ethyl 5-[2-(aminomethyl)-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate as yellow oil (67.6 mg).<br>
ethyl 5-[2-(aminomethyl)-7-ethyl-4-(5-methyl-3-pyridiny])pyrrolo[ 1,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCI3) 6 1.23 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.38-1.62 (4H, m), 2.14 (2H&gt; t, J= 7 Hz), 2.42 (3H, s), 2.38-2.56 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.06 (2H, s), 4.08 (2H, q, J= 7 Hz), 5.90 (1H, d, J= 4 Hz), 6.55 (1H, d, J= 4 Hz), 7.51 (lH,s), 8.41 (lH,s), 8.53 (lH,s). MS(ESl+):m/z395.<br>
Example 335<br>
A mixture of ethyl 5-[2-(aminomethyl)-7-ethyl-4-(5-methyl-3-<br><br>
pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoale (67.6 mg) and acetic anhydride (19.2 mg) in dichloromethane (3 mL) was stirred at ambient temperature for 1 hour. The solution was diluted with chloroform, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative silica gel column chromatography eluting with a mixture of chloroform and methanol (20:1) to give ethyl 5-[2-[(acetylamino)melhyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate as yellow oil (70 mg).<br>
ethyl 5-[2"[(acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1HNMR(CDCl3)6l.22(3H5t,J=7Hz),1.40(3H,t,J=7Hz),1.40-1.63(4H,m)5 2.12 (2H, m), 2.15 (3H, s), 2.43 (3H, s), 2.40-2.53 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.66 (2H, m), 5.94 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 6.85 (1H, br), 7.50 (1H, s), 8.40 (1H, d, J= 2 Hz), 8.54 (1H, d, J= 2 Hz). MS(ESI+):m/z437.<br>
Example 336<br>
To a solution of ethyl 5-[2-(aminomethyl)-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yI]pentanoate (80 mg) and pyridine (1 mL) in dichloromethane (2 mL) was added methanesulfonyl chloride (34.8 mg) under ice-water cooling and the mixture was stirred at ambient temperature for 1 hour. The solution was diluted with chloroform, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative silica gel column chromatography eluting with a mixture of chloroform and methanol (20:1) to give ethyl 5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[(methylsulfonyl)amino]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate as yellow oil (62.8 mg)<br>
ethyl 5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[(methylsulfonyl)amino]methyl}pyrrolo[l,2-<br>
b]pyridazin-3-yl)pentanoate<br>
1H NMR (CDC13) 6 1.23 (3H, t, J= 7 Hz), 1.39 (3H, t, J= 7 Hz), 1.40-1.62 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.38-2.51 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.06 (3H, s), 4.08 (2H, q, J= 7 Hz), 4.58 (2H, s), 5.63 (1H, br), 5.97 (1H, d, J= 4 Hz),<br><br>
6.61 (1H, d, J= 4 Hz), 7.50 (1H, s), 8.41 (1H, d, J= 2 Hz), 8.54 (1H, d, J= 2 Hz).<br>
MS(ESl+):m/z473.<br>
Example 337<br>
A mixture of ethyl 5-[2-(aminomethyl)-7-etbyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (75 mg), benzoic acid (27.9 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (54.7 mg) and 1-hydroxybenotriazole (38.5 mg) in dimethylformamide (2 mL) was stirred at ambient temperature for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative silica gel column chromatography eluting with a mixture of chloroform and methanol (20:1) to give ethyl 5-[2-[(benzoylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate as yellow oil (60 mg).<br>
ethyl 5-[2-[(benzoylamino)methyl]-7-ethyl-4-(5»methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDC13) 5 1.23 (3H, t, J= 7 Hz), 1.42 (3H, t, J= 7 Hz), 1.42-1.65 (4H, m),<br>
2.17	(2H, t, J= 7 Hz), 2.44 (3H, s), 2.44-2.58 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.08<br>
(2H, q, J= 7 Hz), 4.86 (2H, m), 5.96 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.46-<br>
7.59 (4H, m), 7.78 (1H, br), 7.91-7.97 (2H, m), 8.44 (1H, d, J= 2 Hz), 8.56 (1H, d,<br>
J= 2 Hz).<br>
MS (ES1+): m/z 499.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 337. Example 338<br>
ethyl5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[(2-pyrazinylcarbonyl)amino]methyl}pyrrolofl,2-b]pyridazin-3-yl)pentanoate<br>
1H NMR (CDCI3) 5 1.23 (3H,t, J= 7 Hz), 1.41 (3H, t, J= 7 Hz), 1.42-1.64 (4H,m),<br>
2.18	(2H, t, J= 7 Hz), 2.44 (3H, s), 2.47-2.59 (2H, m)&gt; 3.08 (2H, q, J= 7 Hz), 4.09<br>
(2H, q, J= 7 Hz), 4.89 (2H, d, J= 7 Hz), 5.96 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4<br>
Hz), 7.53 (1H, s), 8.43 (1H, d, J= 2 Hz), 8.55 (1H, d, J= 2 Hz), 8.62 (1H, m), 8.79<br><br>
(1H, m), 9.15 (1H, br), 9.46 (1H, m). MS(ESI+):m/z501.<br>
Example 339<br>
To a solution of ethyl 5-[2-(aminomethyl)-7-etbyl-4-(5-methyl-3-pyridinyl)pyrrolo[l ,2-b]pyridazin-3-yl]pentanoate (80 mg) and pyridine (1 mL) in dichloromethane (2 mL) was added methyl chloridocarbonate (34.8 mg) under ice-water cooling and the mixture was stirred at ambient temperature for 2 hours. After evaporation of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by preparative silica gel column chromatography eluting with a mixture of chloroform and methanol (20:1) to give ethyl 5-[7-ethyl-2-{[(methoxycarbonyl)amino]methyl}-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate as yellow oil (70 mg).<br>
ethyl 5-[7-ethyl-2-{[(methoxycarbonyl)amino]methyl}-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1HNMR (CDC13) 6 1.23 (3H, t, J= 7 Hz), 1.39 (3H, t, J= 7 Hz), 1.40-1.63 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.40-2.55 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.07 (3H, s), 4.12 (2H, q, J= 7 Hz), 4.57 (2H,m), 5.72 (1H, br), 5.97 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.51 (1H, s), 8.41 (1H, s), 8.56 (1H, s).<br>
Example 340<br>
To a solution of ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (70.0 mg) and triethyl amine (18.5 mg) in dichloromethane (1 mL) was added methanesulfonyl chloride (20.9 mg) under an ice bath. After stirring for 1 hour, to the mixture was added 1-methylpiperazine (27.0 mg). The mixture was stirred for 0.5 hour under an ice bath and overnight at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated. Preparative silicagel thin layer chromatography (chloroform-methanol = 20-1) afforded ethyl 5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-methyl-l-piperazinyl)methyl]pyrroIo[l,2-b]pyridazin-3-yljpentanoate as an yellow gum (52.4 mg, 63.5%).<br><br>
ethyl 5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-rnethy]-l-piperazinyl)methyI]pyrro]o[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDC13): 1.23 (3H, t, J = 7 Hz), 1.33-1.60 (7 H, m), 2.16 (2H, t, J = 7 Hz), 2.29 (3H, s), 2.34-2.65 (6H, m), 3.00 (2H, q, J = 7 Hz), 3.54 (2H, s), 4.08 (2H, q, J = 7 Hz), 5.86 (1H, d, J = 5 Hz), 6.55 (1H, d, J = 5 Hz9,7.87 (1H, m), 8.54 (1H, m),8.77(lH,m).<br>
Example 341<br>
To a solution of ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate (300 mg, 0.652 mmol) and tetrabromomethane (432 mg, 1.30 mmol) in tetrahydrofuran (3 mL) was added triphenylphosphine (308 mg, 1.17 mmol) over 40 minutes. The mixture was concentrated, and the residue was chromatographed on a flash silica gel column chromatography (ethyl acetate-hexane = 1-8 to 1-5) to afford ethyl 5-[2-(bromomethyl)-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate as an yellow gum (229 mg, 50.4%).<br>
ethyl 5-[2-(bromomethyl)-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDC13) 5 1.23 (3H,t, J = 7 Hz), 1.37 (3H, t, J = 7 Hz), 1.41-1.50 (4H,m), 2.19 (2H, t, J = 7 Hz), 2.58 (2H, m), 3.01 (2H, q, J = 7 Hz), 4.08 (2H, q, J = 7 Hz), 4.66 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.88 (1H, m), 8.55 (lH,m),8.79(lH,m).<br>
Example 342<br>
A mixture of ethyl 5-[2-(bromomethyl)-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (70.0 mg) and potassium cyanide (13.1 mg) in N,N-dimethylformamide (1 mL) was stirred for 28 hours at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water (two times), brine, dried over magnesium sulfate, and evaporated to give ethyl 5-[4-(5-bromo-3-pyridinyl)-2-(cyanomethyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yljpentanoate as an yellow gum (28.8 mg, 45.9%).<br><br>
ethyl 5-[4-(5-bromo-3-pyridiny])-2-(cyanomethyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-y]]pentanoate<br>
1H NMR (CDCI3) 6 1.24 (3H,t, J = 7 Hz), 1.46-1.65 (7H,m),2.22 (2H,t, J = 7 Hz), 2.48 (2H, m), 3.04 (2H, q, J = 7 Hz), 3.98 (2H, s), 4.10 (2H, q, J = 7 Hz), 5.98 (1H, d, J = 5 Hz), 6.65 (1H, d, J = 5 Hz), 7.88 (1H, m), 8.55 (1H, m), 8.81 (1H, m).<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 76. Example 343 [7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]aceticacid<br>
1H NMR (CDCI3) 6 1.36 (3H, t, J= 7 Hz), 2.45 (3H, s), 2.56 (3H, s), 3.02 (2H, q, J= 7 Hz), 3.28 (1H, d, J= 17 Hz), 3.53 (1H, d, J= 17 Hz), 5.91 (1H, d, J= 4 Hz), 6.52 (1H, d, J= 4 Hz), 7.71 (1H, s), 8.47 (1H, s), 8.59 (1H, s). MS (ESI'): m/z 308, MS (ESI+): m/z 310.<br>
Example 344<br>
4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butanoic acid 1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.65-1.85 (2H, m), 2.31 (2H, t, J= 7 Hz), 2.45-2.63 (2H, m), 2.59 (3H, s), 3.03 (2H, q, J= 7 Hz), 5.88 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.90 (1H, s), 8.53 (1H, s), 8.75 (1H, s). MS (ESI"): m/z 400 402, MS (ES1+): m/z 402 404.<br>
Example 345 4-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butanoicacid<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.68-1.82 (2H, m), 2.26 (2H, t, J= 7 Hz), 2.45-2.58 (2H, m), 2.60 (3H, s), 2.70 (3H, s), 3.03 (2H, q, J= 7 Hz), 5.83 (1H, d, J= 4 Hz), 6.54 (1H, d, J= 4 Hz), 8.28 (1H, m), 8.77 (1H, d, J= 2 Hz), 9.19 (1H, d, J= 2 Hz).<br>
Example 346 3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br><br>
y]]propanoic acid<br>
1H NMR (CDCI3) 8 1.37 (3H, t, J= 7 Hz), 2.49 (2H, t, J= 7 Hz), 2.80-3.00 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.46 (3H, s), 4.66 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.88 (1H, s), 8.55 (1H, s), 8.77 (1H, s). MS (ESI"): m/z 416 418, MS (ESI+): m/z 418 420.<br>
Example 347<br>
3-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCI3) 8 1.38 (3H, t, J= 7 Hz), 2.48 (2H, t, J= 7 Hz), 2.68 (3H, s), 2.85-2.97 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.47 (3H, s), 4.67 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 8.27 (1H, m), 8.78 (1H, d, J= 2 Hz), 9.23 (1H, d, J= 2 Hz).<br>
MS (ESI"): m/z 380, MS (ESI+): m/z 382.<br>
Example 348<br>
3-[7-ethyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCb) 8 1.38 (3H, t, J= 7 Hz), 2.46-2.58 (2H, m), 2.83-3.03 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.47 (3H, s), 4.68 (2H, s), 5.46 (1H, d, J= 11 Hz), 5.88 (1H, d, J= 18 Hz), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 6.68-6.82 (1H, dd, J= 11 Hz, 18 Hz), 7.78 (1H, m), 8.47 (1H, d, J= 2 Hz), 8.68 (1H, d, J= 2 Hz). MS (ESI"): m/z 364, MS (ESI+): m/z 366.<br>
Example 349<br>
4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrro]o[l,2-b]pyridazin-3-yljbutanoic acid<br>
1H NMR (CDCI3) 8 1.37 (3H, t, J= 7 Hz), 1.68-1.82 (2H, m), 2.29 (2H, t, J= 7 Hz), 2.55-2.75 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.45 (3H, s), 4.64 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.61 (1H,d,J= 4 Hz), 7.91 (1H,m), 8.56 (1H,d, J= 2 Hz), 8.77 (1H,d, J=2Hz). MS (ESI'): m/z 430 432, MS (ESI+): m/z 432 434.<br><br>
Example 350<br>
4-[7-ethyl-2-(methoxymethyl)-4-(5-vinyl-3-pyridinyl)pyrro]o[l,2-b]pyridazin-3-yljbutanoic acid<br>
1H NMR (CDC13) 6 1.38 (3H, t, J= 7 Hz), 1.72-1.87 (2H, m), 2.26 (2H, t, J= 7 Hz), 2.53-2.80 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.46 (3H, s), 4.68 (2H, m), 5.47 (1H, d, J= 11 Hz), 5.88 (1H, d, J= 18 Hz), 5.93 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 6.72-6.83 (1H, dd, J= 11 Hz, 18 Hz), 7.81 (1H, m), 8.50 (1H, d, J= 2 Hz), 8.63 (lH,d,J=2Hz).<br>
MS (ESI): m/z 378, MS (ESI+): m/z 380.<br>
Example 351<br>
4-[4-(5-acetyl-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
2H NMR (CDC13) 6 1.38 (3H, t, J= 7 Hz), 1.66-1.83 (2H, m), 2.26 (2H, t, J= 7 Hz), 2.55-2.70 (2H, m), 2.70 (3H, s), 3.05 (2H, q, J= 7 Hz), 3.46 (3H, s), 4.67 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz),8.29 (1H, m), 8.80 (1H, d, J= 2 Hz), 9.22(lH,d,J=2Hz). MS (ESI): m/z 394 , MS (ESI+): m/z 396.<br>
Example 352<br>
5-[4-(5-amino-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid :H NMR (CDCI3) 5 1.34 (3H, t, J= 7 Hz), 1.44-1.65 (4H,m), 2.16-2.32 (2H,m), 2.34-2.46 (2H, m), 2.53 (3H, s), 3.02 (2H, q, J= 7 Hz), 5.06 (2H, br), 5.86 (1H, d, J= 4 Hz), 5.98 (1H, d, J= 4 Hz), 7.45 (1H, s), 7.84 (1H, s), 8.58 (1H, s). MS (ESI"): m/z 351, MS (ES1+): m/z 353.<br>
Example 353<br>
5-{4-[5-(dimethylamino)-3-pyridinyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCI3) 5 1.37 (3H, t, J= 7 Hz), 1.40-1.70 (4H, m), 2.23 (2H, m), 2.36-2.50 (2H, m), 2.56 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.06 (6H, s), 5.88 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.13 (1H, s), 7.90 (1H, s), 8.14 (1H, m). MS (ES1+): m/z 381.<br><br>
Example 354<br>
3-[4-(5-acetyl-3-pyridinyl)-7-ethy]-2-methy]pyrrolo[l,2-b]pyridazin-3-yl]propanoicacid 1H NMR (CDCI3) 5 1.37 (3H, t, J= 7 Hz), 2.40-2.53 (2H, m), 2.60 (3H, s), 2.68 (3H, s), 2.83 (2H, t, J= 7 Hz), 3.03 (2H, q, J= 7 Hz), 5.83 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 8.27 (1H, m), 8.78 (1H, d, J= 2 Hz), 9.22 (1H, d, J= 2 Hz). MS (ESI): m/z 350, MS (ESI+): m/z 352.<br>
Example 355<br>
5-[2-[(benzyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
!H NMR (CDCb) 8 1.37 (3H, t, J= 7 Hz), 1.35-1.55 (4H, m), 2.05-2.20 (2H, m), 2.42 (3H, s), 2.40-2.70 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.63 (2H, s), 4.74 (2H, m), 5.88 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.27-7.42 (5H, m), 7.53 (1H, s), 8.40 (1H, s),8.53(lH,s). MS(ESI+):m/z458.<br>
Example 356<br>
3-[2-[(benzyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCI3) 5 1.38 (3H, t, J= 7 Hz), 2.40 (3H, s), 2.40-2.54 (2H, m), 2.80-3.08 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.65 (2H, s), 4.77 (2H, m), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.26-7.42 (5H, m), 7.54 (1H, s), 8.39 (1H, d, J= 2 Hz), 8.48 (lH,d,J=2Hz). MS (ESI"): m/z 428, MS (ESI+): m/z 430.<br>
Example 357 5-[2-[(cyclohexyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]penlanoic acid<br>
1H NMR (CDCI3) 5 1.20-1.45 (6H, m), 1.36 (3H, t, J= 7 Hz), 1.45-1.63 (4H, m), 1.70-1.83 (2H, m), 1.95-2.08 (2H, m), 2.14-2.28 (2H, m), 2.42 (3H, s), 2.46-2.60 (1H, m), 2.60-2.75 (1H, m), 3.03 (2H, q, J= 7 Hz), 3.42-3.54 (1H, m), 4.72 (2H, m), 5.87 (1H, d, J= 4 Hz), 6.54 (1H, d, J= 4 Hz), 7.55 (1H, s), 8.41 (1H, s), 8.53<br><br>
(lH,s). MS (ESI"): m/z 448, MS (ESI4): m/z 450.<br>
Example 358<br>
5-{4-(5-bromo-3-pyriclinyl)-2-[(cyclohexy]oxy)methyl]-7-ethylpyrro]o[l,2-b]pyridazin-3-yljpentanoicacid<br>
1H NMR (CDC13) 8 1.18-1.60 (10H, m), 1.36 (3H, t, J= 7 Hz), 1.70-1.80 (2H, m), 1.95-2.05 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.50-2.70 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.42-3.53 (1H, m), 4.68 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.88 (1H, s), 8.54 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz).<br>
MS(ESI+):m/z514 516.<br>
Example 359<br>
3-[2-[(cyclohexyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCI3) 6 1.20-1.45 (5H, m), 1.37 (3H, t, J= 7 Hz), 1.50-1.60 (1H, m),<br>
1.72-1.84 (2H, m), 1.96-2.08 (2H, m), 2.42 (3H, s), 2.48-2.62 (2H, m), 2.80-3.10 . (2H, m), 3.03 (2H, q, J= 7 Hz), 3.44-3.66 (1H, m), 4.73 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.55 (1H, s), 8.40 (1H, s), 8.51 (1H, s).<br>
MS (ESI+): m/z 422.<br>
Example 360<br>
3-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexyloxy)methyl]-7-ethylpyrrolo[l,2-b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDCI3) 6 1.18-1.47 (5H, m), 1.37 (3H, t, J= 7 Hz), 1.52-1.63 (1H, m), 1.72-1.85 (2H, m), 1.97-2.07 (2H, m), 2.48-2.62 (2H, m), 2.80-3.10 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.44-3.57 (1H, m), 4.73 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.88 (1H, t, J= 2 Hz), 8.55 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ESI"): m/z 484 486, MS (ESI+): m/z 486 488.<br>
Example 361<br>
5-[7-ethyl-2-(isopropoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br><br>
1H NMR (CDCI3) 6 1.25 (6H, d, J= 7 Hz), 1.37 (3H, 1, J= 7 Hz), 1.44-1.63 (4H, m), 2.15-2.27 (2H, m), 2.43 (3H, s), 2.47-2.60 (1H, m), 2.60-2.73 (1H, m), 3.03 (2H, q, J= 7 Hz), 3.75-3.87 (1H, m), 4.67 (2H, s), 5.87 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.55 (1H, s), 8.41 (1H, s), 8.53 (1H, s).<br>
MS (ESI"): m/z 408, MS (ESI+): m/z 410.<br>
Example 362<br>
5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(isopropoxymethyl)pyrrolo[l,2-b]pyridazin-3-y]]pentanoic kcid<br>
1H NMR (CDCb) 6 1.25 (6H, d, J= 7 Hz), 1.36 (3H, t, J= 7 Hz), 1.45-1.65 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.50-2.60 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.75-3.85 (1H, m), 4.66 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ESI+): m/z 474 476.<br>
Example 363<br>
5-[7-ethyl-2-(hydroxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
1HNMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.40-1.65 (4H, m), 2.22 (2H, t, J= 7 Hz), 2.33-2.45 (2H, m), 2.43 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.87 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.56 (1H, s), 8.43 (1H, s), 8.54 (1H, s). MS (ESI): m/z 366, MS (ES1+): m/z 368.<br>
Example 364<br>
5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[2-(4-morpholinyl)-2-<br>
oxoelhoxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoicacid<br>
1H NMR (CDCI3) 5 1.37 (3H, t, J= 7 Hz), 1.40-1.63 (4H, m), 2.22 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.50-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.51 (2H, m), 3.57-3.75 (6H, m),4.32 (2H, s), 4.70-4.86 (2H, m), 5.90 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS (ESI"): m/z 493, MS (ESI+): m/z 495.<br>
Example 365<br><br>
5-[7-ethyl-2-{[2-(methylamino)-2-oxoethoxy]methyl}-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-y]]pentanoic acid<br>
1H NMR (CDCI3) 6 1.37 (3H, t, J= 7 Hz), 1.40-1.65 (4H, m), 2.22 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.45-2.64 (2H5 m), 2.87 (3H, m), 3.03 (2H, q, J= 7 Hz), 4.13 (2H, s), 4.74 (2H, m), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 6.83 (1H, br), 7.57 (lH,s), 8.42 (lH,s), 8.53 (lH,s). MS (ESI"): m/z 437, MS (ES1+): m/z 439.<br>
Example 366<br>
5-[2-[(cyclopropylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-3]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCI3) 6 0.23-0.33 (2H, m), 0.55-0.64 (2H, m), 1.07-1.22 (1H, m), 1.36 (3H, t, J= 7 Hz), 1.45-1.68 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.50-2.75 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.40 (2H, d, J= 7 Hz), 4.70 (2H, m), 5.87 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.57 (1H, s), 8.40 (1H, s), 8.54 (1H, s). MS (ESI+): m/z 422.<br>
Example 367<br>
5-[2-[(cyclohexylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCI3) 5 0.87-1.04 (2H, m), 1.10-1.82 (13H, m), 1.37 (3H, t, J= 7 Hz), 2.18 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.47-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.33 (2H, d, J= 7 Hz), 4.63 (2H, m), 5.87 (1H, d, J= 4 Hz), 6.56 (1H, d, J= 4 Hz), 7.56 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS (ESI"): m/z 462, MS (ESI+): m/z 464.<br>
Example 368<br>
5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(3-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.35-1.57 (4H, m), 2.13 (2H, t, J= 7 Hz), 2.42 (3H, s), 2.47-2.66 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.77 (2H, m), 5.90 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.28-7.36 (1H, m), 7.53 (1H, s), 7.73 (1H, d, J= 8 Hz), 8.41 (1H, d, J= 2 Hz), 8.53 (2H, m), 8.63 (1H, s).<br><br>
MS (ESI"): m/z 457, MS (ES1+): m/z 459.<br>
Example 369<br>
5-{7-elhyl-4-(5-methyl-3-pyridiny])-2-[(2-pyridiny]methoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDC13) 6 1.37 (3H, t, J= 7 Hz), 1.45-1.65 (4H, m), 2.23 (2H, t, J= 7 Hz),<br>
2.41	(3H, s), 2.48-2.74 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.80 (2H, s), 4.82 (2H, m),<br>
5.88 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.26 (1H, m), 7.47-7.53 (2H, m),<br>
7.69-7.77 (1H, m), 8.42 (1H, d, J= 2 Hz), 8.50 (1H, d, J= 2 Hz), 8.58 (1H, d, J= 7<br>
Hz).<br>
MS (ESI): m/z 457, MS (ESI+): m/z 459.<br>
Example 370<br>
5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(4-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.40-1.62 (4H, m), 2.16 (2H, t, J= 7 Hz), 2.43 (3H, s), 2.48-2.71 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.79 (2H, m), 5.91 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.32 (2H, d, J= 7 Hz), 7.54 (1H, s),<br>
8.42	(1H, d, J= 2 Hz), 8.54 (1H, d, J= 2 Hz), 8.55 (2H, d, J= 7 Hz).<br>
MS (ESI): m/z 457, MS (ESI+): m/z 459.<br>
Example 371<br>
5-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(2-pyrazinylmethoxy)methyl]pyrroIo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCI3) 6 1.37 (3H, t, J= 7 Hz), 1.45-1.62 (4H, m), 2.18 (2H, t, J= 7 Hz),<br>
2.43	(3H, s), 2.48-2.73 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.83 (2H, s), 4.88 (2H, m),<br>
5.90 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.54 (1H, s), 8.42 (1H, s), 8.48-8.56<br>
(3H,m),8.76(lH,s).<br>
MS (ES1+): m/z 458, MS (ESI+): m/z 460.<br>
Example 372<br>
5-[2-[(benzylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br><br>
1H NMR (DMSO-d6) 6 1.33 (3H, t, J= 7 Hz), 1.28-3.48 (4H, m), 2.03-2.13 (2H, m), 2.30-2.45 (2H, m), 2.40 (3H, s), 3.06 (2H, q, J= 7 Hz), 4.37 (2H, s), 4.46 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.68 (1H, d, J= 4 Hz), 7.40-7.52 (3H, m), 7.56-7.67 (3H, m), 8.36 (1H, d, J= 2 Hz), 8.57 (1H, d, J= 2 Hz).<br>
MS (ESI+): m/z 457.<br>
Example 373<br>
5-[2-[(acetylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridiny])pyrro]o[l,2-b]pyiidazin-3-yljpentanoic acid<br>
1H NMR (CDC13) 6 1.40 (3H, t, J= 7 Hz), 1.40-1.64 (4H, m), 2.16 (3H, s), 2.23 (2H, t, J= 7 Hz), 2.35-2.50 (2H, m), 2.43 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.63-4.72 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 6.88-6.97 (1H, br), 7.53 (1H, s), 8.41 (lH,s), 8.53 (lH,s). MS (ESI"): m/z 407, MS (ESI+): m/z 409.<br>
Example 374<br>
5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[(methylsulfonyl)amino]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.46-1.66 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.39-2.53 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.05 (3H, s), 4.57 (2H, s), 5.72 (1H, br), 5.96 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.54 (1H, s), 8.41 (1H, d, J= 2 Hz), 8.55 (1H, d, J= 2 Hz). MS (ESI"): m/z 443, MS (ESI+): m/z 445.<br>
Example 375 5-[2-[(benzoylamino)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpentanoic acid<br>
1H NMR (CDCI3) 6 1.42 (3H, t, J= 7 Hz), 1.50-1.68 (4H, m), 2.25 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.40-2.60 (2H, m), 3.07 (2H, q, J= 7 Hz), 4.89 (2H, m), 5.95 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.46-7.60 (4H, m), 7.83 (1H, br), 7.93 (2H, d, J= 8 Hz), 8.44 (1H, d, J= 2 Hz), 8.56 (1H, d, J= 2 Hz).<br>
MS (ESI"): m/z 469, MS (ESI+): m/z 471.<br><br>
Example 376<br>
5-(7-ethyl-4-(5-melhyl-3-pyridiny])-2-{[(2-pyraz-b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (CDCI3) 5 1.41 (3H, I, J= 7 Hz), 1.51-1.72 (4H, m), 2.24 (2H, t, J= 7 Hz), 2.44 (3H, s), 2.45-2.58 (2H, m), 3.10 (2H, q, J= 7 Hz), 4.90 (2H, m), 5.94 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.55 (1H, s), 8.43 (1H, s), 8.53 (1H, s), 8.62 (1H, m), 8.79 (1H, d, J= 2 Hz), 9.20 (1H, br), 9.45 (1H, d, J= 2 Hz). MS (ES1+): m/z 471, MS (ESI+): m/z 473.<br>
Example 377<br>
5-[7-ethyl-2-{[(methoxycarbonyl)amino]methyl}-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCI3) 6 1.38 (3H, t, J= 7 Hz), 1.45-1.65 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.40-2.53 (2H, m), 2.44 (3H, s), 3.02 (2H, q, J= 7 Hz), 3.05 (3H, s), 4.58 (2H, s), 5.69 (1H, br), 5.96 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.41 (1H, d, J= 2 Hz), 8.54 (1H, d, J= 2 Hz).<br>
Example 378<br>
To a solution of ethyl 7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylate (682 mg) in ethanol (20 mL) was added potassium hydroxide (5 g) solution (10 mL) and the mixture was heated under reflux for 1 hour. The solution was acidified with 1 N hydrochloric acid to pH 3-4 and diluted with brine, and extracted with chloroform twice. The organic layer was separated, dried over magnesium sulfate, and evaporated in vacuo. The crude produt was triturated with ethyl acetate to give 7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylic acid as a yellow powder (590 mg)<br>
7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylicacid 1H NMR (CDCI3) 6 1.39 (3H, t, J= 7 Hz), 2.44 (3H, s), 2.69 (3H, s), 3.05 (2H, q, J= 7 Hz), 6.29 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.97 (1H, s), 8.41 (1H, s), 8.58 (lH,s). MS (ESO: m/z 294 , MS (ES1+): m/z 296.<br><br>
The following compound(s) was(were) obtained in substantially the same manner<br>
as that of Example 175.<br>
Example 379<br>
5-[4-(3-cyanophenyl)-2-(ethoxymethyl)-7-ethylpyrrolo[lJ2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
1HNMR(CDCl3)61.25(3H3t3J = 7Hz),134-1.53(7H,m)&gt;2.2()(2H,tJJ = 7Hz), 2.53 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.62 (2H, q, J = 7 Hz), 4.66 (2H, s), 5.33 (1H, d, J = 5 Hz), 6,57 (1H, d, J = 5 Hz), 7.60 (2H, m), 7.66 (1H, s), 7.74 (1H, m)<br>
Example 380<br>
5-[2-[(benzyloxy)methyl]-4-(3-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDC13) 6 1.30-1.46 (7H, m), 2.11 (2H, t, J = 7 Hz), 2.50 (2H, rn), 3.02 (2H, q, J = 7 Hz), 4.64 (3H, s), 4.71 (3H, s), 5.83 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.25-7.34 (5H, m), 7.57 (2H, d, J = 9 Hz), 7.65 (1H, s), 7.74 (1H, m). MS (ESI+): m/z 468 (M + H)<br>
Example 381<br>
4-({[3-(4-carboxybutyl)-4-(3-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazin-2-yl]methoxy}methyl)benzoic acid<br>
1H-NMR (CDC13) 6 1.05-1.43 (7H, m), 1.92 (2H, m), 2.31 (2H, m), 3.04 (2H, m), 4.65 (2H, s), 4.72 (2H, s), 5.82 (1H, m), 6.58 (1H, m), 7.46-7.77 (6H, m), 8.09 (2H,d,J = 8Hz). MS(ESI+):m/z510(M-H) Example 381-2<br>
4-({[4-[3-(carbamoyl)phenyl]-3-(4-carboxybutyl)-7-ethylpyrrolo[l,2-b]pyridazin-2-yl]methoxy}methyl)benzoic acid<br>
1H-NMR (CDCI3) 8 1.20-1.45 (7H, m), 2.03 (2H, m), 2.52 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.69 (2H, s), 4.73 (2H, s), 5.36 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.39-7.60 (4H, m), 7.77 (1H, s), 7.93 (1H, d, J = 8 Hz), 7.98 (2H, d,J = 8 Hz). MS(ESI+):m/z528(M-H)<br>
The following compound(s) was(were) obtained in substantially the same manner<br><br>
as that of Example 77. Example 382<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-m-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCb) 6 1.34 (3H, t, J = 7 Hz),1.38-1.59 (4H, m), 2.22 (2H, m), 2.43-2.60 (5H, m), 2.83-3.04 (8H, m), 3.74 (3H, s),5.88 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.87 (1H, m), 8.54 (1H, m), 8.76 (1H, m).<br>
Example 383<br>
5-[4-(5-bromo-3-pyridinyl)-2-(cyanomethyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yljpentanoic acid<br>
1H NMR (CDCb) 5 1.35-1.60 (7H, m), 2.27 (2H, m), 2.46 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.98 (2H, s), 3.97 (1H, d, J = 5 Hz), 6.65 (1H, d, J = 5 Hz), 7.90 (1H, m), 8.54 (lH,s,br), 8.79 (lH,s,br).<br>
Example 384<br>
5-[4-(5-brorno-3-pyridinyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCb) 5 1.35-1.60 (7H, m), 2.22 (2H, t, J = 7 Hz), 2.38 (2H, m), 3.02 (2H,<br>
q, J = 7 Hz), 4.86 (2H, s), 5.95 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.88 (1H,<br>
m), 8.54 (1H, s, br), 8.79 (1H, s, br).<br>
Example 385<br>
To a solution of 7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxylic acid (70 mg), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (68.2 mg) and 1-hydroxybenotriazole (48 mg) in dimethylformamide (2 mL) was added 2-aminoethanoI (17.4 mg) and the mixture was stirred at ambient temperature for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of chloroform and methanol (50:1 - 10:1). The crude product was triturated with isopropylether to give 7-ethyl-N-(2-hydroxyethyl)-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-<br><br>
3-carboxamide as a yellow powder (47 mg).<br>
7-ethyl-N-(2-hydroxyethyl)-2-methyl-4-(5-melhyl-3-pyridinyl)pyrrolo[l32-b] 3-carboxamide<br>
1H NMR (CDCb) 6 1.38 (3H, t, J= 7 Hz), 2.39 (3H, s), 2.57 (3H, s), 3.02 (2H, q, J= 7 Hz), 3.33 (2H, m), 3.45 (2H, m), 6.03 (1H, br), 6.31 (1H, d, J= 4 Hz), 6.66 (1H, d, J= 4 Hz), 7.71 (1H, s), 8.47 (1H, s), 8.58 (1H, s).<br>
MS (ESI): m/z 337, MS (ESI+): m/z 339.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 385. Example 386<br>
N-butyl-7-ethyl-2-methyl-4-(5"methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carboxamide<br>
1H NMR (CDCI3) 8 0.80 (3H, t, J= 7 Hz), 0.96-1.08 (2H, m), 1.08-1.25 (2H, m), 1.38 (3H, t, J= 7 Hz), 2.40 (3H, s), 2.56 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.16 (2H, m), 5.36 (1H, br), 6.31 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.69 (1H, s), 8.53 (1H, s),8.62(lH,s).<br>
MS(ESl+):m/z351.<br>
Example 387<br>
ethyl 3-({[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]carbonyl}amino)propanoate<br>
1HNMR (CDCI3) 5 1.24 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.21 (2H, t, J= 7 Hz), 2.40 (3H, s), 2.55 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.43 (2H, q, J= 7 Hz), 4.04 (2H, q, J= 7 Hz), 6.08 (1H, br), 6.30 (1H, d, J= 4 Hz), 6.65 (1H, d, J= 4 Hz), 7.67 (1H,  • s), 8.50 (1H, d, J= 1 Hz), 8.60 (1H, d, J= 1 Hz). MS(ESl+):m/z395.<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Preparation 176.<br>
Example 388 4-(5-bromo-3-pyridinyl)-7-ethyl-2-methyl-3-[3-(4-morpholinyl)-3-oxopropyl]pyrrolo[l,2-<br><br>
b]pyridazine<br>
1H NMR(CDC13) 5:1H NMR(CDC13) 6:1.37(3H, t, J=7Hz), 2.41(2H, t, J=7Hz),<br>
2.60(3H, s), 2.72-2.82(2H, m), 3.01(2H, q, J=7Hz), 3.19(2H, t, J=5Hz), 3.55(4H, t, J=5Hz), 3.63(2H, t, J=5Hz), 5.89(1H, d, J=4Hz), 6.55(1H, d, J=4Hz), 7.87(1H, t, J=lHz), 8.54(1H, d, J=lHz), 8.77(1H, d, J=lHz)<br>
MS(m/z) 457(M+), 459(M++2), 115(bp)<br>
mp. 178-180°C<br>
Example 389<br>
3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-N-<br>
tnethylpropanamide<br>
1H NMR(CDC13) 6:1H NMR(CDC13) 5:1.38(3H, t, J=7Hz), 2.20(2H, t, J=7Hz), 2.60(3H, s), 2.75(3H, d, J=6Hz), 2.78-2.89(2H, m), 3.01(2H, q, J=7Hz), 5.21-5.27(1H, m), 5.88(1H, d, J=4Hz), 6.54(1H, d, J=4Hz), 7.86(1H, t, J=lHz), 8.53(1H, d, J=lHz), 8.78(1H, d, J=lHz) MS(m/z) 401(M++1),403(M++1), 115(bp) mp. 172-174-<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 263. Example 390<br>
N-{3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-y]]propanoyl}methanesulfonamide<br>
1H NMR(CDC13) 6:1.36(3H, t, J=7Hz), 2.33-2.45(2H, m), 2.58(3H, s), 2.84-2.95(2H, m), 3.01(2H, q, J=7Hz), 3.26(3H,s), 5.89(1H, d, J=4Hz), 6.56(1H, d, J=4Hz), 7.90(1H, s), 8.50(1H, s), 8.77(1H, s)<br>
MS(m/z) 465(M+, bp), 467(M+-2, bp)<br>
mp. 196.5-197.5r<br>
The following compound(s) was(were) obtained in substantially the same manner as that of Example 224. Example 391<br><br>
2-[{3-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrit&gt;lo[l,2-b]pyridazin-3-yl]propanoyl}(methyl)amino]ethanesulfonic acid<br>
1H NMR (CDCJ3) 6 1.32 (3H, t, J = 7 Hz), 1.90 2H, m), 2.26 (3H, s), 2.57-2.2.78 (4H, m), 2.98 (2H, q, J = 7 Hz), 3.31 (2H, m), 6.00 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 7.20-7.52 (5H,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of<br>
Preparation 20.<br>
Preparation 217<br>
1-tert-butyl 7-ethyl 2-(isobutoxyacetyl)heptanedioate<br>
1H NMR (300 MHz, CDC13) 6 0.95 (6H, d, J = 7 Hz), 1.27 (3H, t, J = 7 Hz), 1.31-1.41 (2H, m), 1.46 (9H, s), 1.66 (2H, tt, J = 7,7 Hz), 1.75-1.98 (3H, m), 2.31 (2H, t, J = 8 Hz), 3.26 (2H, d, J = 7 Hz), 3.56 (1H, t, J = 7 Hz), 4.06-4.17 (4H, m).<br>
Preparation 218<br>
1-tert-butyl 6-ethyl 2-(isobutoxyacetyl)hexanedioate<br>
1H NMR (300 MHz, CDC13) 5 0.93 (6H, d, J = 7 Hz), 1.25 (3H, t, J = 7 Hz), 1.45 (9H, s), 1.59-1.69 (2H, m), 1.80-1.95 (3H, m), 2.32 (2H, t, J = 7 Hz), 2.25 (2H, d, J = 7 Hz), 3.57 (1H, t, J = 7 Hz), 4.10 (2H, s), 4.12 (2H, q, J = 7 Hz).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 24. Preparation 219 1 -tert-butyl 6-ethyl 2-acetyl-2-(2-chloroisonicotinoyl)hexanedioate<br>
1H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.34 (9H, s), 1.60-1.73 (2H, m), 2.22-2.32 (2H, m), 2.39 (2H, t, J= 7 Hz), 2.49 (3H, s), 4.12 (2H, q, J= 7 Hz), 7.43 (1H, d, J= 5 Hz), 7.57 (1H, s), 8.50 (1H, d, J= 5 Hz). MS (ESI+): m/z 412.<br>
Preparation 220<br>
1 -tert-butyl 5-ethyl 2-acetyl-2-(2-chloroisonicotinoyl)pentanedioate<br>
1H NMR (CDCI3) 6 1.37 (3H, t, J= 7 Hz), 1.72-1.84 (2H, m), 2.33 (2H, t, J= 7 Hz), 2.47-2.57 (2H, m), 2.58 (3H, s), 3.03 (2H, q, J= 7 Hz), 5.88 (1H, d, J= 4 Hz), 6.53<br><br>
(1H, d, J= 4 Hz), 7.27 (1H, m), 7.38 (1H, s), 8.53 (1H, d, J= 5 Hz). MS (ESI"): m/z 356, MS (ES1+): m/z 358.<br>
Preparation 221<br>
1 -tert-buty) 7-ethyl 2-(2-chloroisonicotinoyl)-2-(phenylacetyl)heptanedioate<br>
1H NMR (CDC13) 5 1.24 (3H, t, J= 7 Hz), 1.35 (9H, s), 1.63-1.76 (2H, m), 2.22-2.37 (4H, m), 3.93 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.29 (1H, d, J= 17 Hz), 7.22 (2H, d, J= 8 Hz), 7.26-7.36 (4H, m), 7.50 (1H, s), 8.42 (1H, d, J= 5 Hz). MS (ESI+): m/z 502.<br>
Preparation 222<br>
tert-buty] 2-[2-(2-methoxy-2-oxoethoxy)ethyl]-2-[(5-methyl-3-pyridinyl)carbonyl]-3-<br>
oxobutanoate<br>
1H NMR (CDCI3) 6 1.33 (9H, s), 2.39 (3H, s), 2.47 (3H, s), 2.62 (2H, t, J= 7 Hz), 3.66 (2H, m), 3.70 (3H, s), 3.90 (2H, s), 7.87 (1H, s), 8.56 (1H, s), 8.75 (1H, s).<br>
MS (ESI+): m/z 394.<br>
Preparation 223<br>
1-tert-butyl 4-ethyl 2-acetyl-2-[(5-bromo-3-pyridinyl)carbonyl]succinate<br>
1H NMR (CDCI3) 6 1.27 (3H, t, J= 7 Hz), 1.41 (9H, s), 2.45 (3H, s), 3.22 (2H, m), 4.12 (2H, q, J= 7 Hz), 8.22 (1H, m), 8.80 (1H, m), 8.82 (1H, m).<br>
MS (ES1+): m/z 428 430.<br>
Preparation 224<br>
1-tert-butyl 5-ethyl 2-[(acetyloxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl]pentanedioate<br>
1H NMR (CDC13) 6 1.23 (3H, t, J= 7 Hz), 1.35 (9H, s), 2.14 (3H, s), 2.40 (3H, s), 2.40-2.48 (2H, m), 2.62-2.70 (2H, m), 4.12 (2H, q, J= 7 Hz), 5.12 (1H, d, J= 18 Hz), 5.34 (1H, d, J= 18 Hz), 7.85 (1H, s), 8.58 (1H, s), 8.78 (1H, s). MS (ESI+): m/z 436.<br>
Preparation 225<br>
1-tert-butyl 6-ethyl 2-[(acetyloxy)acetyl]-2-[(5-methyl-3-pyridiny])carbonyl1Hexanedioate<br><br>
1H NMR (CDC13) 5 1.24 (3H, t, J= 7 Hz), 1.34 (9H, s), 1.60-1.75 (2H, m), 2.14 (3H, s), 2.26-2.39 (4H, m), 2.40 (3H, s), 4.12 (2H, q, J= 7 Hz), 5.13 (1H, d, J= 18 Hz), 5.40 (1H, d, J= 18 Hz), 7.86 (1H, s), 8.57 (1H, s), 8.78 (1H, s).<br>
MS (ESI+): m/z 450.<br>
'reparation 226<br>
-tert-butyl 7-elhyl 2-[(acetyloxy)acetyl]-2-(3-cyanobenzoyl)heptanedioate<br>
- NMR (CDC13) 6 1.24 (3H, t, J= 7 Hz), 1.32 (9H, s), 1.26-1.46 (2H, m), 1.66-1.77 (2H, m), 2.14 (3H, s), 2.26-2.38 (4H, m), 4.12 (2H, q, J= 7 Hz), 5.06 (1H, d, J= 18 Hz), 5.42 (1H, d, J= 18 Hz), 7.57 (1H, t, J= 8 Hz), 7.81 (1H, d, J= 8 Hz), 7.92 (lH,d,J=8Hz),8.09(lH,s).<br>
Preparation 227<br>
1-tert-butyl 6-ethyl 2-[(acetyloxy)acetyl]-2-[(5-bromo-3-pyridinyl)carbonyl1Hexanedioate 1H NMR (CDCI3) 0 1.25 (3H, t, J= 7 Hz), 1.36 (9H, s), 1.60-1.74 (2H, m), 1.85-1.96 (2H, m), 2.14 (3H, s), 2.28-2.42 (2H, m), 4.12 (2H, q, J= 7 Hz), 5.12 (1H, d, J= 17 Hz), 5.42 (1H, d, J= 17 Hz), 8.23 (1H, m), 8.81 (1H, m), 8.83 (1H, m).<br>
Preparation 228<br>
1-tert-butyl 5-ethyl 2-[(acetyloxy)acetyl]-2-[(5-bromo-3-pyridinyl)carbonyl]pentanedioate 1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.37 (9H, s), 2.14 (3H, s), 2.41-2.51 (2H, m), 2.66 (2H, t, J= 7 Hz), 4.13 (2H, q, J= 7 Hz), 5.11 (1H, d, J= 18 Hz), 5.33 (1H, d, J= 18 Hz), 8.22 (1H, m), 8.82 (2H, m). MS (ES1+): m/z 500 502.<br>
Preparation 229<br>
1-tert-butyl 5-ethyl 2-[(cyclohexylmethoxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl]pentanedioate<br>
1H NMR (CDC13) 5 0.80-0.98 (2H, m), 1.00-1.32 (3H,m), 1.23 (3H, t, J= 7 Hz), 1.38 (9H, s), 1.46-1.62 (6H, m), 2.39 (3H, s), 2.40-2.72 (4H, m), 3.19 (2H, d, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.31 (1H, d, J= 17 Hz), 4.39 (1H, d, J= 17 Hz), 7.88 (1H, s), 8.56 (lH,s), 8.77 (lH,s). MS(ESl+):m/z490.<br><br>
Preparation 230<br>
1-tert-buty] 5-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-<br>
[(cyclohexylmethoxy)acetyl]pentanedioate<br>
1H NMR (CDC13) 5 0.78-0.98 (2H, m), 1.10-1.33 (3H, m), 1.25 (3H,1, J= 7 Hz), 1.40 (9H, s), 1.38-1.83 (6H, m), 2.35-2.75 (4H, m), 3.22 (2H, d, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.25 (1H, d, J= 17 Hz), 4.37 (1H, d, J= 17 Hz), 8.22 (1H, s), 8.78 (1H, s),8.86(lH,s). MS(ESl+):m/z554 556.<br>
Preparation 231<br>
1-tert-butyl 6-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-<br>
[(cyclohexylmethoxy)acetyl1Hexanedioate<br>
1H NMR (CDCI3) 6 0.80-0.97 (2H, m), 1.12-1.35 (3H, m), 1.25 (3H, t, J= 7 Hz), 1.39 (9H, s), 1.46-1.80 (10H, m), 2.22-2.45 (2H,m), 3.20 (2H, d, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.30 (1H, d, J= 17 Hz), 4.38 (1H, d, J= 17 Hz), 8.22 (1H, s), 8.78 (1H, s),8.85(lH,s).<br>
MS(ESl+):m/z568 570.<br>
Preparation 232<br>
1-tert-butyl 6-ethyl 2-[(cyclopropylmethoxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl1Hexanedioate<br>
1H NMR (CDCI3) 6 0.16-0.28 (2H, m), 0.48-0.59 (2H, m), 0.98-1.12 (1H, m), 1.24 (3H, t, J= 7 Hz), 1.37 (9H, s), 1.55-1.80 (4H, m), 2.18-2.40 (2H, m), 2.39 (3H, s), 3.31 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.38 (1H, d, J= 17 Hz), 4.53 (1H, d, J= 17 Hz), 7.88 (1H, s), 8.55 (1H, d, J= 2 Hz), 8.75 (1H, d, J= 2 Hz). MS(ESl+):m/z462.<br>
Preparation 233<br>
1-tert-butyl 5-ethyl 2-[(cyclopropy]methoxy)acetyl]-2-[(5-methyl-3-<br>
pyridinyl)carbonyl]pentanedioate<br>
1H NMR (CDCI3) 6 0.15-0.23 (2H, m), 0.48-0.56 (2H, m), 0.95-1.10 (1H, m), 1.24 (3H, t, J= 7 Hz), 1.39 (9H, s), 2.39 (3H, s), 2.40-2.68 (4H, m), 3.28 (2H, m), 4.12<br><br>
(2H, q, J= 7 Hz), 4.36 (1H, d, J= 17 Hz), 4.48 (1H, d, J= 17 Hz), 7.88 (1H, s), 8.55 (1H, s), 8.75 (lH,s). MS(ESl+):m/z448.<br>
Preparation 234<br>
1-tert-butyl 5-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-[(2-<br>
methoxyethoxy)acetyl]pentanedioate<br>
1H NMR (CDC13) 5 1.26 (3H, t, J= 7 Hz), 1.46 (9H, s), 2.15-2.25 (2H, m), 2.42-2.72 (2H, m), 3.38 (3H, s), 3.48-3.72 (4H, m), 4.12 (2H, q, J= 7 Hz), 4.43 (1H, d, J= 17 Hz), 4.58 (1H, d, J= 17 Hz), 8.22 (1H, s), 8.78 (1H, s), 8.82 (1H, s). MS(ES1+):m/z516 518.<br>
Preparation 235<br>
tert-butyl 2-[(5-bromo-3-pyridinyl)carbonyl]-3-oxobutanoate<br>
1H NMR (CDCI3) 6 1.22,1.30 (9H, s), 2.22,2.45 (3H, s), 7.96, 8.13 (1H, s), 8.66, 8.76-8.80 (2H,m).<br>
Preparation 236<br>
1-tert-butyl 6-ethyl 2-[(acetyloxy)acetyl]-2-[(5-chloro-3-pyridinyl)carbonyl1Hexanedioate 1H NMR (300 MHz, CDCI3) 5 1.25 (3H, t, J = 7 Hz), 1.36 (9H, s), 1.63-1.71 (2H, m), 2.14 (3H, s), 2.27-2.40 (4H, m), 4.13 (2H, q, J = 7 Hz), 5.11 (1H, d, J = 18 Hz), 5.38 (1H, d, J = 18 Hz), 8.07 (1H, dd, J = 2 Hz), 8.71 (1H, d, J = 2 Hz), 8.80 (1H, d,J = 2Hz).<br>
Preparation 237<br>
1-tert-butyl 7-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-<br>
[(cyclopropylmethoxy)acetyl1Heptanedioate<br>
1H NMR (300 MHz, CDC13) 8 0.15-0.20 (2H, m), 0.49-0.58 (2H, m), 0.95-1.04 (1H, m), 1.24 (3H, t, J = 7 Hz), 1.38 (9H, s), 1.68 (2H, tt, J = 7,7 Hz), 2.14-2.33 (4H, m), 3.26-3.29 (2H, m), 4.07-4.19 (4H, m), 4.31 (1H, d, J = 17 Hz), 4.45 (1H, d, J = 17 Hz), 8.05 (1H, dd, J = 2 Hz), 8.68 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz).<br>
Preparation 238<br><br>
1-lert-butyl 6-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-<br>
[(cyclopropy]methoxy)acetyl1Hexanedioate<br>
!H NMR (300 MHz, CDC13) 6 0.14-0.21 (2H, m), 0.49-0.55 (2H, m), 0.92-1.04 (1H, m), 1.25 (3H, t, J = 7 Hz), 1.39 (9H, s), 1.62-1.74 (2H, m), 1.82-1.90 (2H, m), 2.21-2.33 (2H, m), 3.27-3.31 (2H, m), 4.12 (2H, q, J = 7 Hz), 4.34 (1H, d, J = 18 Hz), 4.46 (1H, d, J = 18 Hz), 8.07 (1H, dd, J = 2,2 Hz), 8.68 (1H, d, J = 2 Hz), 8.80(lH,d,J = 2Hz).<br>
Preparation 239<br>
1-tert-butyl 7-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(isobutoxyacetyl)heptanedioate 1H NMR (300 MHz, CDCI3) 6 0.85 (6H, d, J = 7 Hz), 1.24 (3H, t, J = 7 Hz), 1.38 (9H, s), 1.67 (2H, t, J = 7 Hz), 1.75-1.93 (3H, m), 2.24-2.33 (4H, m), 3.17 (2H, d, J = 7 Hz), 4.11 (2H, q, J = 7 Hz), 4.28 (1H, d, J = 17 Hz), 4.38 (1H, d, J = 17 Hz), 8.20 (1H, dd, J = 2, 2 Hz), 8.79 (1H, d, J = 2 Hz), 8.84 (1H, d, J = 2 Hz).<br>
Preparation 240<br>
1-tert-butyl 5-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-(isobutoxyacetyl)pentanedioate 1H NMR (300 MHz, CDCI3) 6 0.84 (6H, d, J = 7 Hz), 1.24 (3H, t, J = 7 Hz), 1.39 (9H, s), 1.80 (1H, qt, J = 7 Hz), 2.34-2.71 (4H, m), 3.17 (2H, d, J = 7 Hz), 4.12 (2H, q, J = 7 Hz), 4.28 (1H, d, J = 18 Hz), 4.36 (1H, d, J = 18 Hz), 8.07 (1H, s), 8.69 (1H, s),8.83(lH,s).<br>
Preparation 241<br>
1-tert-butyl 5-ethyl 2-[(acetyloxy)acetyl]-2-(3-chlorobenzoyl)pentanedioate<br>
1H NMR (300 MHz, CDCI3) 8 1.24 (3H, t, J = 7 Hz), 1.34 (9H, s), 2.14 (3H, s), 2.35-2.44 (2H, m), 2.60-2.68 (2H, m), 4.11 (2H, q, J = 7 Hz), 5.11 (1H, d, J = 18 Hz), 5.35 (1H, d, J = 18 Hz), 7.38 (1H, dd, J = 8, 8 Hz), 7.53 (1H, d, J = 8 Hz), 7.60 (lH,d,J = 8Hz),7.79(lH,s).<br>
Preparation 242<br>
1-tert-butyl 6-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(isobutoxyacetyl)hexanedioate 1H NMR (300 MHz, CDCI3) 5 0.85 (6H, d, J = 7 Hz), 1.25 (3H, t, J = 7 Hz), 1.39 (9H, s), 1.59-1.72 (2H, m), 1.80 (1H, qt, J = 7, 7Hz), 2.19-2.39 (4H, m), 3.18 (2H, d, J<br><br>
= 7 Hz), 4.12 (2H, q, J = 7 Hz), 4.31 (1H, d, J = 17 Hz), 4.40 (1H, d, J = 17 Hz), 8.22 (1H, dd, J = 2,2 Hz), 8.79 (1H, d, J = 2 Hz), 8.85 (1H, d, J = 2 Hz).<br>
Preparation 243<br>
tert-butyl 3-(5-bromo-3-pyridinyl)-2-[(5-bromo-3-pyridinyl)carbonyl]-3-oxopropanoate<br>
1H NMR (CDC13) 6 1.05 (9H, s), 7.86 (2H, s), 8.46 (2H, s), 8.61 (2H, s).<br>
MS (ESI): m/z 481483 485.<br>
Preparation 244<br>
1-tert-butyl 6-ethyl 2-[(acetyloxy)acetyl]-2-(3-chlorobenzoyl)hexanedioate<br>
1H NMR (CDC13) 6 1.24 (3H, t, J = 8 Hz), 1.33 (9H, s), 1.56-1.72 (2H, m), 2.15 (3H, s), 2.20-2.41 (4H, m), 4.11 (2H, q, J = 8 Hz), 5.13 (1H, d, J = 18 Hz), 5.40 (1H, d, J = 18 Hz), 7.38 (1H, t, J = 8 Hz), 7.52 (1H, br d, J = 8 Hz), 7.60 (1H, br d, J = 8 Hz),7.79(lH,brs).<br>
Preparation 245<br>
1-tert-butyl 7-ethyl 2-(methoxyacetyl)-2-[(5-methoxy-3-pyridinyl)carbonyl1Heptanedioate 1HNMR (CDCI3) 5 1.23 (3H, t, J = 8 Hz), 1.27-1.43 (11H, m), 1.60-1.74 (2H, m), 2.15-2.34 (4H, m), 3.37 (3H, s), 3.90 (3H, s), 4.10 (2H, q, J = 8 Hz), 4.35 (1H, d, J = 18 Hz), 4.48 (1H, d, J = 18 Hz), 7.58 (1H, m), 8.43 (1H, d, J = 3 Hz), 8.50 (lH,d,J = lHz). MS (ESI4): m/z 452 (M + H).<br>
Preparation 246<br>
1-tert-butyl 7-ethyl 2-acetyl-2-[(5-methoxy-3-pyridinyl)carbonyl1Heptanedioate<br>
1H NMR (CDCI3) 5 1.24 (3H, t, J = 8 Hz), 1.27-1.40 (11H, m), 1.60-1.74 (2H, m), 2.15-2.34 (4H, m), 2.44 (3H, s), 3.89 (3H, s), 4.10 (2H, q, J = 8 Hz), 7.61 (1H, m), 8.43 (1H, d, J = 3 Hz), 8.49 (1H, d, J = 1 Hz). MS (ESI+): m/z 422 (M + H).<br>
Preparation 247<br>
1-tert-butyl 5-ethyI 2-(methoxyacetyl)-2-[(5-rnethoxy-3-pyridinyl)carbonyl]pentanedioate 1H NMR (CDCI3) 6 1.24 (3H, t, J = 8 Hz), 1.38 (9H, s), 2.36-2.48 (2H, m), 2.53-2.67<br><br>
(2H, m), 3.37 (3H, s), 3.90 (3H, s), 4.11 (2H, q, J = 8 Hz), 4.33 (1H, d, J = 18 Hz), 4.45 (1H, d, J = 18 Hz), 7.59 (1H, m), 8.43 (1H, d, J = 3 Hz), 8.51 (1H, d, J = 1 Hz). MS (ESI+): m/z 446 (M + + Na).<br>
Preparation 248<br>
1 -tert-butyl 6-ethyl 2-(methoxyacetyl)-2-[(5-methoxy-3-pyridinyl)carbonyl1Hexanedioate 1H NMR (CDC13) 6 1.24 (3H, t, J = 8 Hz), 1.37 (9H, s), 1.52-1.75 (2H, m), 2.18-2.39 (4H, m), 3.38 (3H, s), 3.90 (3H, s), 4.11 (2H, q, J = 8 Hz), 4.37 (1H, d, J = 18 Hz), 4.51 (1H, d, J = 18 Hz), 7.60 (1H, m), 8.43 (1H, d, J = 3 Hz), 8.50 (1H, d, J = 1 Hz). MS (ESI+): m/z 438 (M + H).<br>
Preparation 249<br>
1-tert-butyl 7-ethyl 2-(methoxyacetyl)-2-(5-pyrimidinylcarbonyl)heptanedioate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J = 8 Hz), 1.30-1.44 (llH,m), 1.62-1.75 (2H,m), 2.16-2.35 (4H, m), 3.35 (3H, s), 4.11 (2H, q, J = 8 Hz), 4.20 (1H, d, J = 18 Hz), 4.33 (1H, d, J = 18 Hz), 9.01 (2H, s), 9.31 (1H, s). MS (ESI+): m/z 423 (M + H).<br>
Preparation 250<br>
1-tert-butyl 6-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-(rnethoxyacetyl)hexanedioate 1H NMR (CDCI3) 6 1.26 (3H, t, J = 8 Hz), 1.39 (9H, s), 1.57-1.74 (2H, m), 1.78 (2H, br t, J = 8 Hz), 2.23-2.41 (2H, m), 3.38 (3H, s), 4.14 (2H, q, J = 8 Hz), 4.33 (1H, d, J = 18 Hz), 4.45 (1H, d, J = 18 Hz), 8.07 (1H, m), 8.71 (1H, br s), 8.80 (1H, br s). MS(ES1+):m/z442(M + H).<br>
Preparation 251<br>
1 -tert-butyl 5-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-(methoxyacetyl)pentanedioate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J = 8 Hz), 1.39 (9H, s), 2.37-2.48 (2H, m), 2.53-2.65 (2H, m), 3.36 (3H, s), 4.13 (2H, q, J = 8 Hz), 4.26 (1H, d, J = 18 Hz), 4.40 (1H, d, J = 18 Hz), 8.06 (1H, br s), 8.70 (1H, br s), 8.80 (1H, br s).<br>
MS(ESI+):m/z428(M + H).<br><br>
Preparation 252<br>
1-tert-butyl 7-ethyl 2-[(5-chloro-3-pyridinyl)carbonyl]-2-(methoxyacety])heptaneclioate 1H NMR (CDCI3) 5 1.24 (3H, t, J = 8 Hz), 1.31-1.48 (11H, m), 1.55-1.75 (2H, m), 2.15-2.35 (4H, m), 3.36 (3H, s), 4.10 (2H, q, J = 8 Hz), 4.27 (1H, d, J = 18 Hz), 4.43 (1H, d, J = 18 Hz), 8.03 (1H, t, J = 2 Hz), 8.69 (1H, d, J = 2 Hz), 8.77 (1H, d, J = 2 Hz). MS (ESI+): m/z 456 (M + H).<br>
Preparation 253<br>
methyl 4-(acetyloxy)-2-[(5-bromo-3-pyridinyl)carbonyl]-3-oxobutanoate<br>
1HNMR (CDCI3) 6 2.21 (3H, s), 3.58 (3H, br s), 4.87 (1H, br s), 5.19 (2H, br s), 7.98 (1H, br s), 8.58 (1H, br s), 8.79 (1H, br s).<br>
MS (ES1+): m/z 358,360 (M + H).<br>
Preparation 254<br>
tert-butyl 2-(2-{2-[2-(acetyloxy)ethoxy]ethoxy}ethyl)-2-[(5-methyl-3-<br>
pyridinyl)carbonyl]-3-oxobutanoate<br>
1H-NMR (CDCI3) 6 1.32 (9H, s), 2.07 (3H, s), 2.38 (3H, s), 2.45 (3H, s), 2.57 (2H, t,<br>
J = 7 Hz), 3.43 (4H, m), 3.57 (4H, m), 4.16 (2H, m), 7.84 (1H, m), 8.53 (1H, m),<br>
8.75 (lH,m).<br>
Preparation 255<br>
1-tert-butyl 6-ethyl 2-[(5-bromo-3-pyridinyl)carbonyl]-2-(methoxyacetyl)hexanedioate H NMR (CDCI3) 6 1.26 (3H, t, J= 7 Hz), 1.39 (9H, s), 1.55-1.75 (2H, m), 2.23-2.45 (4H, m), 3.38 (3H, s), 4.12 (2H, q, J= 7 Hz), 4.34 (1H, d, J= 18 Hz), 4.47 (1H, d, J= 18 Hz), 8.22 (1H, m), 8.81 (1H, d, J= 2 Hz), 8.83 (1H, d, J= 2 Hz). MS (ES1+): m/z 486 488.<br>
Preparation 256<br>
ethyl 2-(2-chloroisonicotinoyl)-3-oxobutanoate<br>
1H NMR (CDCI3) 5 0.91-1.00 (3H, m), 2.24 (1.2H, s), 2.48 (1.8H, s), 4.02 (1.2H, q, J = 8 Hz), 4.10 (0.8H, q J = 8 Hz), 7.24 (0.6H, m), 7.39 (0.6H, s), 7.45 (0.4H, m),<br><br>
7.54 (lH,s), 8.49 (lH,m). MS (ES1+): m/z 298 (M + H).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 78. Preparation 257 ethyl 5-(2-chloroisonicotinoyl)-6-oxoheptanoate<br>
1H NMR (CDC1-0 5 1.25 (3H, t, J= 7 Hz), 1.60-1.73 (2H, m), 1.98-2.10 (2H, m), 2.20 (3H, s), 2.35 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.37 (1H, t, J= 7 Hz), 7.67 (1H, d, J= 5 Hz), 7.77 (1H, s), 8.59 (1H, d, J= 5 Hz).<br>
MS (ESI+): m/z 312 .<br>
Preparation 258<br>
ethyl 4-(2-chloroisonicotinoyl)-5-oxohexanoate<br>
1H NMR (CDC13) 5 1.26 (3H, t, J= 7 Hz), 2.21 (3H, s), 2.22-2.35 (2H, m), 2.36-2.47 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.57 (1H, t, J= 7 Hz), 7.76 (1H, dd, J= 2 Hz, 5 Hz), 7.83 (1H, d, J= 2 Hz), 8.61 (1H, d, J= 5 Hz).<br>
MS (ES1+): m/z 298.<br>
Preparation 259<br>
ethyl 6-(2-chloroisonicotinoyl)-7-oxo-8-phenyloctanoate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J= 7 Hz), 1.20-1.38 (2H, m), 1.60-1.72 (2H, m), 1.95-2.06 (2H, m), 2.28 (2H, t, J= 7 Hz), 3.71 (1H, d, J= 17 Hz), 3.80 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.41 (1H, t, J= 7 Hz), 7.10 (2H, m), 7.20-7.33 (4H, m), 7.39 (1H, s), 8.42 (1H, d, J= 5 Hz).<br>
Preparation 260<br>
methyl ({3-[(5-methyl-3-pyridinyl)carbonyl]-4-oxopentyl}oxy)acetate<br>
1H NMR (CDCI3) o 2.23 (3H, s), 2.23-2.40 (2H,m), 2.44 (3H, s), 3.58 (2H, m), 3.71 (3H, s), 4.02 (2H, s), 4.89 (1H, t, J= 7 Hz), 8.12 (1H, s), 8.64 (1H, s), 9.07 (1H, s).<br>
MS (ESI+): m/z 294.<br>
Preparation 261<br><br>
methyl (4-oxo-4-phenylbutoxy)acetate<br>
1H NMR (CDCI3) 6 2.04-2.16 (2H, m), 3.15 (2H, t, J= 7 Hz), 3.64 (2H, t, J= 7 Hz),<br>
3.73 (3H, s), 4.09 (2H, s), 7.46 (2H, t, J= 8 Hz), 7.56 (1H, t, J= 8 Hz), 7.99 (2H, cl,<br>
J= 8 Hz). MS(ES1+):m/z237.<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 78. Preparation 262 ethyl 3-[(5-bromo-3-pyridinyl)carbonyl]-4-oxopentanoate<br>
1H NMR (CDCI3) 8 1.24 (3H, t, J= 7 Hz), 2.22 (3H, s), 2.97-3.17 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.91 (1H, m), 8.41 (1H, m), 8.88 (1H, m), 9.12 (1H, m).<br>
MS (ESI+): m/z 328 330.<br>
Preparation 263<br>
ethyl 6-(acetyloxy)-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.98 (3H, s), 2.23-2.34 (2H, m), 2.40-2.50 (2H, m), 2.45 (3H, s), 4.12 (2H, q, J= 7 Hz), 4.69 (2H, m), 4.82 (1H, t, J= 7 Hz), 8.14 (1H, s), 8.67 (1H, s), 9.07 (1H, s). MS(ESI+):m/z336.<br>
Preparation 264<br>
ethyl 7-(acetyloxy)-5-[(5-methyl-3-pyridinyl)carbonyl]-6-oxoheptanoate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.60-1.80 (2H, m), 2.02 (3H, s), 1.97-2.13 (2H, m), 2.35 (2H, t, J= 7 Hz), 2.45 (3H, s), 4.12 (2H, q, J= 7 Hz), 4.56 (1H, t, J= 7 Hz), 4.69 (1H, d, J= 17 Hz), 4.78 (1H, d, J= 17 Hz), 8.06 (1H, s), 8.66 (1H, s), 9.00 (lH,s).<br>
MS (ESI+): m/z 350.<br>
Preparation 265<br>
ethyl 8-(acetyloxy)-6-(3-cyanobenzoyl)-7-oxooctanoate<br>
1H NMR (CDCI3) 0 1 -24 (3H, t, J= 7 Hz), 1.35-1.50 (2H, m), 1.60-1.78 (2H, m), 2.04 (3H, s), 2.00-2.12 (2H, m), 2.29 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.49 (1H,<br><br>
I, J= 7 Hz), 4.68 (1H, d, J= 17 Hz), 4.75 (1H, d, J= 17 Hz), 7.66 (1H, t, J= 8 Hz), 7.88 (1H, d, J= 8 Hz), 8.16 (1H, d, J= 8 Hz), 8.26 (1H, s). MS (ESP): m/z 372.<br>
Preparation 266<br>
ethyl 7-(acetyloxy)-5-[(5-bromo-3-pyridinyl)carbonyl]-6-oxoheptanoate<br>
1H NMR (CDC13) 5 1.25 (3H, t, J= 7 Hz), 1.60-1.82 (2H, m), 2.04 (3H, s), 2.03-2.15 (2H, m), 2.35 (2H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.51 (1H, t, J= 7 Hz), 4.70 (1H, d, J= 17 Hz), 4.75 (1H, d, J= 17 Hz), 8.39 (1H, m), 8.88 (1H, s), 9.07 (1H, s). MS (ESI): m/z 414 416, MS (ESI+): m/z 414 416.<br>
Preparation 267<br>
ethyl 6-(acetyloxy)-4-[(5-bromo-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDCI3) 6-1.26 (3H, t, J= 7 Hz), 2.00 (3H, s), 2.22-2.36 (2H, m), 2.43-2.53 (2H, m), 4.13 (2H, q, J= 7 Hz), 4.70 (2H, m), 4.80 (1H, t, J= 7 Hz), 8.48 (1H, s), 8.90 (lH,s), 9.19 (lH.s). MS (ESI+): m/z 400 402.<br>
Preparation 268<br>
ethyl 6-(cyclohexylmethoxy)-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate 1H NMR (CDCI3) 6 0.60-0.82 (2H, m), 0.93-1.10 (3H, m), 1.12-1.65 (6H, m), 1.25 (3H, t, J= 7 Hz), 2.07-2.17 (1H, m), 2.22-2.35 (1H, m), 2.42 (2H, m), 2.44 (3H, s), 3.05-3.23 (2H, m), 3.96 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.92 (1H, m), 8.16 (1H, s), 8.66 (lH,s), 9.08 (lH,s). MS (ESI+): m/z 390.<br>
Preparation 269<br>
ethyl 4-[(5-bromo-3-pyridinyl)carbonyl]-6-(cyclohexylmethoxy)-5-oxohexanoate<br>
1H NMR (CDCI3) 6 0.63-0.84 (2H, m), 0.93-1.88 (3H, m), 1.25 (3H, t, J= 7 Hz), 1.35-1.90 (6H, m), 2.02-2.14 (1H, m), 2.20-2.36 (1H, m), 2.44 (2H, t, J= 7 Hz), 3.04-3.20 (2H, m), 3.95 (2H, s), 4.13 (2H, q, J= 7 Hz), 4.85-4.93 (1H, m), 8.50 (1H, m), 8.88 (1H, d, J= 2 Hz), 9.20 (1H, d, J= 2 Hz).<br>
MS(ESl+):m/z454 456.<br><br>
Preparation 270<br>
ethyl 5-[(5-bromo-3-pyridinyl)carbonyl]-7-(cyclohexylmethoxy)-6-oxoheptanoate<br>
1H NMR (300 MHz, CDCI3) 6 0.75-0.86 (2H, m), 0.95-1.15 (3H, m), 1.24 (3H, t, J= 7 Hz), 1.40-1.90 (10H, m), 2.36 (2H, t, J= 7 Hz), 3.12 (2H, q, J= 7 Hz), 3.97 (2H, s), 4.12 (2H, q, J= 7 Hz), 4.71 (1H, t, J= 7 Hz), 8.41 (1H, s), 8.88 (1H, s), 9.12 (lH,s). MS(ES1+):m/z468 470.<br>
Preparation 271<br>
ethyl 7-(cyclopropylmethoxy)-5-[(5-methyl-3-pyridinyl)carbonyl]-6-oxoheptanoate 1H NMR (CDC13) 6 -0.08-0.00 (1H, m), 0.00-0.15 (1H, m), 0.28-0.49 (2H, m), 0.72-0.87 (1H, m), 1.23 (3H, t, J= 7 Hz), 1.58-2.13 (4H, m), 2.32 (2H, t, J= 7 Hz), 2.44 (3H, s), 3.10-3.26 (2H, m), 4.02 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.77 (1H, t, J= 7 Hz), 8.07 (1H, s), 8.63 (1H, s), 9.03 (1H, s). MS (ESI+): m/z 362.<br>
Preparation 272<br>
ethyl 6-(cyclopropylmethoxy)-4-[(5-methyl-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDCI3) 6 -0.08-0.00 (1H, m), 0.00-0.13 (1H, m), 0.23-0.47 (2H, m), 0.68-0.84 (1H, m), 1.24 (3H, t, J= 7 Hz), 2.03-2.17 (1H, m), 2.22-2.36 (1H, m), 2.40 (2H, m), 2.44 (3H, s), 3.12 (2H, m), 3.98 (1H, d, J= 17 Hz), 4.06 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.93 (1H, m), 8.12 (1H, s), 8.65 (1H, s), 9.08 (1H, s).<br>
MS (ESI+): m/z 348.<br>
Preparation 273<br>
ethyl 4-[(5-bromo-3-pyridinyl)carbonyl]-6-(2-methoxyethoxy)-5-oxohexanoate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.90-2.37 (2H, m), 2.43 (2H, t, J= 7 Hz), 3.18 (3H, s), 3.16-3.73 (4H, m), 4.06 (2H, q, J= 7 Hz), 4.10-4.24 (2H, m), 4.86-4.93 (1H, m), 8.51 (1H, m), 8.87 (1H, d, J= 2 Hz), 9.20 (1H, d, J= 2 Hz).<br>
MS (EST): m/z 414 416, MS (ESI+): m/z 416 418.<br>
Preparation 274<br><br>
l-(5-bromo-3-pyridinyl)-l,3-butanedione<br>
1H NMR (CDCI3) 6 2.25 (3H, s), 6.18 (1H, s), 8.31 (1H, s), 8.78 (1H, s), 8.96 (1H, s). MS(ESI+):m/z242 244.<br>
Preparation 275<br>
ethyl 7-(acetyloxy)-5-[(5-chloro-3-pyridinyl)carbonyl]-6-oxoheptanoate<br>
1H NMR (300 MHz, CDC13) 6 1.25 (3H, t, J = 7 Hz), 1.60-1.70 (4H, m), 2.04 (3H, s), 2.35 (2H, t, J = 6 Hz), 4.12 (2H, q, J = 7 Hz), 4.52 (1H, t, J = 7 Hz), 4.69 (1H, d, J = 18 Hz), 4.78 (1H, d, J = 18 Hz), 8.24 (1H, s), 8.78 (1H, s), 9.05 (1H, s).<br>
Preparation 276<br>
ethyl 6-[(5-chloro-3-pyridinyl)carbonyl]-8-(cyclopropylmethoxy)-7-oxooctanoate<br>
1H NMR (300 MHz, CDCI3) 5 -0.09-0.11 (2H, m), 0.25-0.35 (1H, m), 0.37-0.46 (1H, m), 0.70-0.79 (1H, m), 1.24 (3H, t, J = 7 Hz), 1.29-1.41 (2H, m), 1.64 (2H, t, J = 7 Hz), 1.72-1.84 (1H, m), 1.96-2.08 (1H, m), 2.28 (2H, t, J = 7 Hz), 3.12 (1H, dd, J = 10,7 Hz), 3.21 (1H, dd, J = 10,7 Hz), 3.97 (1H, d, J = 12 Hz), 4.05 (1H, d, J = 12 Hz), 4.11 (2H, q, J = 7 Hz), 4.70 (1H, t, J = 7 Hz), 8.26 (1H, dd, J = 2, 2 Hz), 8.77 (1H, dd, J = 2 Hz), 9.09 (1H, dd, J = 2 Hz).<br>
Preparation 277<br>
ethyl 5-[(5-chloro-3-pyridinyl)carbonyl]-7-(cyclopropylmethoxy)-6-oxoheptanoate<br>
1H NMR (300 MHz, CDCI3) 8 -0.07-0.09 (2H, m), 0.24-0.46 (2H, m), 0.68-0.79 (1H, m), 1.23 (3H, t, J = 7 Hz), 1.47-1.84 (3H, m), 1.98-2.10 (1H, m), 2.33 (2H, t, J = 7 Hz), 3.12 (1H, dd, J = 10,7 Hz), 3.21 (1H, dd, J = 10,7 Hz), 3.97 (1H, d, J = 17 Hz), 4.06 (1H, d, J = 17 Hz), 4.10 (2H, q, J = 7 Hz), 4.73 (1H, t, J = 6 Hz), 8.27 (1H, dd, J = 2,2 Hz), 8.77 (1H, d, J = 2 Hz), 9.10 (1H, d, J = 2 Hz).<br>
Preparation 278<br>
ethyl 6-[(5-bromo-3-pyridinyl)carbonyl]-8-isobutoxy-7-oxooctanoate<br>
1H NMR (300 MHz, CDCI3) 6 0.72 (3H, d, J = 7 Hz), 0.77 (3H, d, J = 7 Hz), 1.24 (3H, t, J = 7 Hz), 1.30-1.42 (2H, m), 1.54-1.70 (3H, m), 1.75-1.87 (1H, m), 1.95-2.08 (1H, m), 2.28 (2H, t, J = 8 Hz), 3.10 (1H, dd, J = 9,7 Hz), 3.14 (1H, dd, J = 9,7 Hz), 3.98 (2H, s), 4.11 (2H, q, J = 7 Hz), 4.70 (1H, t, J = 6 Hz), 8.39 (1H, dd,<br><br>
J = 2 Hz), 8.87 (1H, d, J = 2 Hz), 9.08 (1H, d, J = 2 Hz).<br>
Preparation 279<br>
ethy] 4-[(5-chloro-3-pyridiny])carbonyl]-6-isobutoxy-5-oxohexanoale<br>
1H NMR (300 MHz, CDC13) 6 0.68 (3H, d, J = 7 Hz), 0.72 (3H, d, J = 7 Hz), 1.25 (3H, t, J = 7 Hz), 1.52 (1H, qt, J = 7, 7 Hz), 2.02-2.13 (1H, m), 2.20-2.32 (1H, m), 2.44 (2H, t, J = 7 Hz), 3.07 (1H, dd, J = 9,7 Hz), 3.12 (1H, dd, J = 9, 7 Hz), 3.98 (2H, s), 4.14 (2H, q, J = 7 Hz), 4.90 (1H, d, J = 9 Hz), 4.92 (1H, d, J = 9 Hz), 8.34 (1H, dd, J = 2 Hz), 8.78 (1H, d, J = 2 Hz), 9.15 (1H, d, J = 2 Hz).<br>
Preparation 280<br>
ethyl 6-(acetyloxy)-4-(3-chlorobenzoyl)-5-oxohexanoate<br>
1H NMR (300 MHz, CDC13) 6 1.26 (3H, t, J = 7 Hz), 1.95 (3H, s), 2.20-2.29 (2H, m), 2.41-2.47 (2H, m), 4.15 (2H, q, J = 7 Hz), 4.64 (1H, d, J = 17 Hz), 4.71 (1H, d, J = 17 Hz), 4.78 (1H, t, J = 6 Hz), 7.48 (1H, dd, J = 8, 8 Hz), 7.60 (1H, d, J = 8 Hz), 7.96 (1H, d, J = 8 Hz), 8.04 (1H, s).<br>
Preparation 281<br>
ethyl 5-[(5-bromo-3-pyridinyl)carbonyl]-7-isobutoxy-6-oxoheptanoate<br>
1H NMR (300 MHz, CDCI3) 6 0.72 (3H, d, J = 7 Hz), 0.77 (3H, d, J = 7 Hz), 1.23 (3H, t, J = 7 Hz), 1.61-1.73 (3H, m), 1.77-1.88 (1H, m), 1.98-2.10 (1H, m), 2.33 (2H, t, J = 7 Hz), 3.10 (1H, dd, J = 9,7 Hz), 3.15 (1H, dd, J = 9, 7 Hz), 3.99 (2H, s), 4.11 (2H, q, J = 7 Hz), 4.73 (1H, t, J = 7 Hz), 8.40 (1H, dd, J = 2,2 Hz), 8.87 (1H, d, J = 2 Hz), 9.10 (1H, d, J = 2 Hz).<br>
Preparation 282<br>
1,3-bis(5-bromo-3-pyridinyl)-l ,3-propanedione<br>
1H NMR (DMSO-d6) 5 7.60 (1H, s), 8.78 (2H, s), 8.88 (2H, s), 9.30 (2H, s).<br>
Preparation 283<br>
ethyl 7-(acetyloxy)-5-(3-chlorobenzoyl)-6-oxoheptanoate<br>
1H NMR (CDCI3) 0 1.24 (3H, t, J = 8 Hz), 1.57-1.75 (2H,m), 1.90-2.12 (5H,m), 2.34 (2H, t, J = 8 Hz), 4.11 (2H, q, J = 8 Hz), 4.52 (1H, t, J = 8 Hz), 4.71 (2H, q, J<br><br>
= 8 Hz), 4.65 (1H,d,J = 16 Hz), 4.75 (1H, d, J = 16 Hz), 7.43 (1 H, t, J = 8 Hz), 7.60 (1H, br d, J = 8 Hz), 7.84 (1H, br d, J = 8 Hz), 7.96 (1H, br s).<br>
Preparation 284<br>
ethyl 8-methoxy-6-[(5-mcthoxy-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
1H NMR (CDCb) 6 1.23 (3H, t, J = 8 Hz), 1.27-1.43 (2H, m), 1.55-1.70 (2H, in), 1.84 (1H, m), 2.00 (1H,m), 2.27 (2H, d, J = 8 Hz), 3.26 (3H, s), 3.92 (3H, s), 3.98 (2H, d, J = 5 Hz), 4.10 (2H, q, J = 8 Hz), 4.67 (1H, t, J = 8 Hz), 7.71 (1H, m), 8.50 (1H, d, J = 3 Hz), 8.78 (1H, br s). MS(ESl+):m/z352(M + H).<br>
Preparation 285<br>
ethyl 6-[(5-methoxy-3-pyridinyl)carbonyl]-7-oxooctanoate<br>
1H NMR (CDC13) 5 1.24 (3H, t, J = 8 Hz), 1.27-1.41 (2H, m), 1.60-1.73 (2H, m), 1.90-2.14 (2H, m), 2.18 (3H, s), 2.24-2.84 (2H, m), 3.26 (3H, s), 3.92 (3H, s), 4.10 (2H, q, J = 8 Hz), 4.40 (1H, t, J = 8 Hz), 7.71 (1H, m), 8.51 (1H, d, J = 3 Hz), 8.78(lH,brs).<br>
Preparation 286<br>
ethyl 6-methoxy-4-[(5-methoxy-3-pyridinyl)carbonyl]-5-oxohexanoate<br>
1H NMR (CDC13) o 1.24 (3H, t, J = 8 Hz), 2.10 (1H, m), 2.25 (1H, m), 2.38-2.47 (2H, m), 3.24 (3H, s), 3.94 (3H, s), 3.95 (1H, d, J = 16 Hz), 4.00 (1H, d, J = 16 Hz), 4.12 (2H, q, J = 8 Hz), 4.38 (1H, m), 7.83 (1H, m), 8.52 (1H, d, J = 3 Hz), 8.87 (lH,d,J = lHz). MS (ESI+): m/z 346 (M+ + Na).<br>
Preparation 287<br>
ethyl 7-methoxy-5-[(5-melhoxy-3-pyridinyl)carbonyl]-6-oxoheptanoale<br>
1H NMR (CDCI3) 5 1.23 (3H, t, J = 8 Hz), 1.54-1.74 (2H, m), 1.84 (1H, m), 2.02 (1H, m), 2.32 (2H, d, J = 8 Hz), 3.26 (3H, s), 3.92 (3H, s), 3.99 (2H, d, J = 5 Hz), 4.10 (2H, q, J = 8 Hz), 4.70 (1H, t, J = 8 Hz), 7.71 (1H, m), 8.51 (1H, d, J = 3 Hz), 8.79(lH,brs).<br>
MS (ESI+): m/z 338 (M + H).<br><br>
Preparation 288<br>
ethyl 8-melhoxy-7-oxo-6-(5-pyrimidinylcarbonyl)octanoate<br>
1H NMR (CDCl3) 0 1.23 (3H, t, J = 8 Hz), 1.25-1.45 (2H, m), 1.55-1.70 (2H, m),<br>
1.81	(1H, m), 2.03 (1H, m), 2.28 (2H, t, J = 8 Hz), 3.24 (3H, s), 3.92 (1H, d, J =<br>
18 Hz), 4.01 (1H, d, J = 18 Hz), 4.10 (2H, q, J = 8 Hz), 9.26 (2H, s), 9.40 (1H, s).<br>
MS (ES1+): m/z 323 (M + H).<br>
Preparation 289<br>
ethyl 5-[(5-chloro-3-pyridinyl)carbonyl]-7-methoxy-6-oxoheptanoate<br>
1H NMR (CDCI3) 6 1.24 (3H, t, J = 8 Hz), 1.52-1.74 (2H, m), 1.83 (1H, m), 2.02 (1H, m), 2.34-2.40 (2H, m), 3.25 (3H, s), 3.92 (1H, d, J = 16 Hz), 4.01 (1H, d, J = 16 Hz), 4.11 (2H, q, J = 8 Hz), 4.68 (1H, t, J = 8 Hz), 8.23 (1H, br s), 8.78 (1H, br s), 9.05(lH,brs). MS (ESI+): m/z 342 (M + H).<br>
Preparation 290<br>
ethyl 4-[(5-chloro-3-pyridinyl)carbony]]-6-methoxy-5-oxohexanoate<br>
!H NMR (CDCb) 6 1.25 (3H, t, J = 8 Hz), 2.09 (1H, m), 2.25 (1H, m), 2.38-2.49 (2H, m), 3.22 (3H, s), 3.91 (1H, d, J = 18 Hz), 4.00 (1H, d, J = 18 Hz), 4.14 (2H, q, J = 8 Hz), 4.85 (1H, m), 8.33 (1H, br s), 8.78 (1H, br s), 9.14 (1H, br s). MS (ES1+): m/z 328 (M+ H).<br>
Preparation 291<br>
ethyl 6-[(5-chloro-3-pyridinyl)carbonyl]-8-methoxy-7-oxooctanoate<br>
1H NMR (CDCI3) 6 1.23 (3H,t, J = 8 Hz), 1.27-1.43 (2H,m), 1.50-1.71 (2H, m),<br>
1.82	(1H,m), 2.00 (1H, m), 2.27 (2H, d, J = 8 Hz), 3.25 (3H, s), 3.92 (1H, d, J =<br>
16 Hz), 4.02 (1H, d, J = 16 Hz), 4.10 (2H, q,J = 8 Hz), 4.63 (1H, t, J = 8 Hz),<br>
8.23 (1H, br s), 8.78 (1H, br s), 9.03 (1H, br s).<br>
MS (ES1+): m/z 356 (M + H).<br>
Preparation 292 2-[2-({3-[(5-methyl-3-pyridinyl)carbonyl]-4-oxopentyl}oxy)ethoxy]elhyl acetate<br><br>
trifluoroacctale<br>
1H-NMR (CDCI3) 5 2.06 (3H, s), 2.28 (3H, s), 2.33 (2H, m), 2.65 (3H, s), 3.47-3.67 (8H, m), 4.17 (2H, m), 4.71 (1H, t, J = 7 Hz), 8.66 (1H, m), 8.88 (1H, m), 9.31 (lH,m).<br>
reparation 293<br>
hyl 5-[(5-bromo-3-pyridinyl)carbonyl]-7-rnethoxy-6-oxoheptanoale 1H NMR (CDCI3) 5 1.23 (3H, t, J= 7 Hz), 1.56-1.73 (2H, m), 1.77-1.92 (1H, m), 1.96-2.10 (1H, m), 2.32 (2H, t, J= 7 Hz), 3.25 (3H, s), 3.92 (1H, d, J= 17 Hz), 4.02 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.67 (1H, t, J= 7 Hz), 8.39 (1H, m), 8.87 (1H, d, J= 2 Hz), 9.09 (1H, d, J= 2 Hz). MS(ESI+):m/z386 388.<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 129 and 130. Preparation 294 tert-butyl 3-oxo-4-phenylbutanoate<br>
1H NMR (CDCI3) 6 1.46 (9H, s), 3.37 (2H, s), 3.82 (2H, s), 7.21 (2H, d, J= 8 Hz), 7.25-7.37 (3H,m).<br>
Preparation 295<br>
tert-butyl 3-oxo-3-phenylpropanoate<br>
1H NMR (CDC13) 5 1.43 (9H, s), 3.81 (2H, s), 7.40-7.52 (2H, m), 7.56-7.63 (1H, m), 7.94(2H,d,J=8Hz).<br>
Preparation 296<br>
tert-butyl 4-(cyclohexylmethoxy)-3-oxobutanoate<br>
1H NMR (CDCI3) 6 0.89-1.07 (2H,m), 1.13-1.40 (3H,m), 1.47 (9H, s), 1.60-1.83 (6H, m), 3.28 (2H, d, J= 7 Hz), 3.45 (2H, s), 4.06 (2H, s).<br>
Preparation 297<br>
tert-butyl 4-(cyclopropylmethoxy)-3-oxobutanoate<br>
1H NMR (CDCI3) 5 0.20-0.28 (2H, m), 0.55-0.64 (2H, m), 1.03-1.17 (1H, m), 1.47<br><br>
(9H, s), 3.36 (2H, d, J= 7 Hz), 3.45 (2H, s), 4.15 (2H, s).<br>
Preparation 298<br>
lert-bulyl 4-(2-methoxyethoxy)-3-oxobutanoate<br>
1H NMR (CDC13) 5 1.47 (9H, s), 3.38 (3H, s), 3.44 (2H, s), 3.57 (2H, m), 3.70 (2H, m),4.20(2H,s).<br>
Preparation 299<br>
lert-butyl 4-isobutoxy-3-oxobutanoate<br>
!H NMR (300 MHz, CDCI3) 8 0.93 (6H, d, J = 7 Hz), 145 (9H, s), 1.91 (1H, qt, J = 7, 7 Hz), 3.26 (2H, d, J = 7 Hz), 3.45 (2H, s), 4.07 (2H, s).<br>
Preparation 300<br>
tert-butyl 3-(3-methyl-2-thienyl)-3-oxopropanoate<br>
!H-NMR (CDCI3) 6 1.47 (9H, s),2.57 (3H, s), 3.79 (2H, s), 6.96 (1H, d, J = 5 Hz), 7.44(lH,d,J=5Hz).<br>
Preparation 301<br>
tert-butyl 3-(5-methyl-3-isoxazolyl)-3-oxopropanoate<br>
1H-NMR (CDCI3) 6 1.475-1.57 (9H, m), 2.49 (3H, m), 3.95 (2H, s), 6.40 (1H, s).<br>
The following cornpound(s) was(were) obtained in a similar manner to that of Preparation 132. Preparation 302 ethyl (2E)-5-(3-cyanobenzoyl)-6-oxo-2-heptenoate<br>
5H-NMR (CDCI3) 5 1.28 (3H, t, J = 7 Hz), 2.20 (3H, s), 2.88 (2H, m), 4.16 (2H, q, J = 7 Hz), 4.54 (1H, t, J = 7 Hz), 5.88 (1H, d, J = 16 Hz), 6.82 (1H, dt, J = 7 and 16 Hz), 7.65 (1H, t, J = 8Hz), 7.89 (1H, d, J = 8 Hz), 8.20 (1H, d, J = 8 Hz), 8.27 (1H,<br>
s). MS (ES1+): m/z 300.14 (M + H)<br>
Preparation 303<br>
1-tert-butyl 7-ethyl 2-[(3-methyl-2-thienyl)carbonyl1Heptanedioate<br><br>
1H-NMR (CDCb) 6 1.25 (3H,t J = 7 Hz), 1.35-1.51 (UH,m), 1.65 (2H, m), 1.96 (2H,m),230(2H,t,J = 7Hz),258(3H,s),3.94(lH,l,J = 7Hz),4.12(2H,q,J<br>
= 7 Hz),6.97 (1H, d, J = 5 Hz), 7.44 (1H, d, J = 5 Hz).<br>
Reparation 304<br>
-tert-butyl 7-elhyl 2-[(5-methyl-3-isoxazolyl)carbonyl1Heptanedioate<br>
1H-NMR (CDC13) 5 11.24 (3H, t, J = 7 Hz), 1.39 (9H,s), 1.67 (2H, m), 1.98 (2H,m), 2.49 (3H, s), 4.10 (2H, q, J = 7 Hz), 4.26 (1H, t, J = 7 Hz), 6.37 (1H, s).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 152. Preparation 305 methyl 7-oxo-7-(2-thienyl)heptanoate<br>
1H-NMR (CDCb) 6 1.41 (2H, m), 1.63-1.82 (4H, m), 2.33 (2H, t, J = 7 Hz), 2.91 (2H, t, J = 7 Hz), 3.67 (3H, s), 1.73 (1H, m), 7.62 (1H, m), 7.70 (1H, m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 153. Preparation 306 5-methoxynicotinoyl chloride hydrochloride<br>
Preparation 307<br>
5-pyrimidinecarbonyl chloride hydrochloride<br>
Preparation 308<br>
5-chloronicotinoyl chloride hydrochloride<br>
Preparation 309<br>
methyl 2-bromo-4-(chlorocarbonyl)benzoate<br>
The following compound(s) was(were) obtained in a similar manner to that of Praparation 159. Preparation 310<br><br>
1-terl-butyl 7-ethyl 2-(phenylacelyl)heptanedioate<br>
1H NMR (CDCb) 6 1.24 (3H, t, J= 7 Hz), 1.18-1.50 (2H, m), 1.46 (9H, s), 1 .50-1.75 (2H, m), 1.75-1.88 (2H, m), 2.24 (2H, 1, J= 7 Hz), 3.47 (1H, t, J= 7 Hz), 3.81 (2H, s), 4.10 (2H, q, J= 7 Hz), 7.20 (2H, d, J= 8 Hz), 7.25-7.37 (3H, m).<br>
Preparation 311<br>
tert-butyl 2-[2-(2-methoxy-2-oxoethoxy)ethyl]-3-oxobutanoate<br>
1H NMR (CDCI3) 6 1.46 (9H, s), 2.04-2.23 (2H, m), 2.29 (3H, s), 3.54 (2H, t, J= 7 Hz), 3.69 (1H, t, J= 7 Hz), 3.74 (3H, s), 4.04 (2H, s).<br>
Preparation 312<br>
tert-butyl 2-benzoyl-4-(2-methoxy-2-oxoethoxy)butanoate<br>
1H NMR (CDCI3) 5 1-34 (9H, s), 2.26-2.40 (2H, m), 3.55-3.67 (2H, m), 3.70 (3H, s),<br>
4.04 (2H, s), 4.57 (1H, t, J= 7 Hz), 7.47 (2H, t, J= 8 Hz), 7.56 (1H, m), 8.01 (2H,<br>
d,J=8Hz).<br>
Preparation 313<br>
1-tert-butyl 6-ethyl 2-[(acetyloxy)acetyl1Hexanedioate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.48 (9H, s), 1.60-1.73 (2H, m), 1.82-1.95<br>
(2H, m), 2.17 (3H, s), 2.32 (2H, t, 3= 7 Hz), 3.43 (1H, t, J= 7 Hz), 4.12 (2H, q, J=<br>
7 Hz), 4.72 (1H, d, J= 17 Hz), 4.83 (1H, d, J= 17 Hz).<br>
Preparation 314<br>
1-tert-butyl 5-ethyl 2-[(cyclohexylmethoxy)acetyl]pentanedioate<br>
1H NMR (CDCI3) 6 0.85-1.06 (2H, m), 1.13-1.34 (3H, m), 1.26 (3H, t, J= 7 Hz), 1.45 (9H, s), 1.60-1.85 (6H, m), 2.08-2.23 (2H, m), 2.36 (2H, t, J= 7 Hz), 3.27 (2H, d, J= 7 Hz), 3.67 (1H, t, J= 7 Hz), 4.10 (2H, s), 4.12 (2H, q, J= 7 Hz).<br>
Preparation 315<br>
1-tert-butyl 6-ethyl 2-[(cyclohexylmethoxy)acelyl1Hexanedioate<br>
1H NMR (CDCI3) 6 0.88-1.06 (2H, m), 1.12-1.34 (3H, m), 1.25 (3H, t, J= 7 Hz), 1.45<br>
(9H, s), 1.54-1.94 (10H, m), 2.32 (2H, t, J= 7 Hz), 3.27 (2H, d, J= 7 Hz), 3.56 (1H,<br>
t, J= 7 Hz), 4.09 (2H, s), 4.11 (2H, q, J= 7 Hz).<br><br>
MS(ESl+):m/z385.<br>
Reparation 316<br>
1 -terl-butyl 6-ethyl 2-[(cyclopropylmethoxy)acetyl1Hexanedioate<br>
1H NMR (CDCI3) 5 0.22-0.33 (2H, m), 0.54-0.64 (2H, m), 1.04-1.18 (1H, m), 1.25 (3H, t, J= 7 Hz), 1.45 (9H, s), 1.60-1.73 (2H, m), 1.83-1.95 (2H, m), 2.33 (2H, t, J= 7 Hz), 3.33 (2H, d, J= 7 Hz), 3.53 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.18 (2H,m). MS(ESI+):m/z343.<br>
Preparation 317<br>
1 -tert-butyl 5-elhyl 2-[(cyclopropylmethoxy)acetyl]pentanedioate<br>
1H NMR (CDCI3) 5 0.20-0.35 (2H, m), 0.56-0.64 (2H, m), 1.04-1.16 (1H, m), 1.26 (3H, t, J= 7 Hz), 1.45 (9H, s), 2.12-2.24 (2H, m), 2.38 (2H, t, J= 7 Hz), 3.36 (2H, m), 3.65 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.19 (2H, s).<br>
Preparation 318<br>
1-tert-butyl 5-ethyl 2-[(2-methoxyethoxy)acetyl]pentanedioate<br>
1H NMR (CDCI3) 6 1.25 (3H, t, J= 7 Hz), 1.46 (9H, s), 2.10-2.23 (2H, m), 2.38 (2H, t, J= 7 Hz), 3.37 (3H, s), 3.60 (2H, m), 3.62 (1H, t, J= 7 Hz), 3.70 (2H, m), 4.12 (2H, q, J= 7 Hz), 4.23 (1H, d, J= 17 Hz), 4.30 (1H, d, J= 17 Hz). MS(ESl+):m/z333.<br>
Preparation 319<br>
1-tert-butyl 5-ethyl 2-(isobutoxyacetyl)pentanedioate<br>
1H NMR (300 MHz, CDCI3) 5 0.93 (6H, d, J = 7 Hz), 1.26 (3H, t, J = 7 Hz), 1.45 (9H, s), 1.91 (1H, qt, J = 7,7 Hz), 2.13 (2H, m), 2.37 (2H, t, J = 7 Hz), 3.25 (2H, d, J = 7 Hz), 3.67 (1H, t, J = 7 Hz), 4.12 (2H, s), 4.13 (2H, q, J = 7 Hz).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 164. Preparation 320 methyl 2-bromo-4-[(5-ethyl-lH-pyrrol-2-yl)carbonyl]benzoate<br><br>
1H-NMR (CDC13) 5 1 32 (3H, i, J = 7 Hz), 2.72 (2H, q, J = 7 Hz), 3.97 (3H, s), 6,10 (1H,m),6.77(lH,m),7.81(lH,d,J = 8Hz),7.85(1H,d,J = 8Hz),8.110H,s),<br>
9.32QH,s,br).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 165. Preparation 321 tert-butyl 2-(2-{2-[2-(acetyloxy)ethoxy]ethoxy}ethyl)-3-oxobutanoate<br>
1H-NMR (CDC13) 6 1.46 (9H, s), 2.00-2.17 (5H, m), 2.25 (3H, s), 3.45-3.70 (10H, m), 4.22 (2H,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 178. Preparation 322 isobutoxyacetic acid<br>
1H NMR (300 MHz, CDCfe) 6 0.94 (6H, ds J = 7 Hz), 1.93 (1H, qt, J = 7,7 Hz), 3.34 (2H,d,J = 7Hz),4.12(2H,s).<br>
Preparation 323<br>
To a suspension of 60% NaH (2.66 g) in DMF (20 mL) was added methyl hydroxyacetate (5.00 g) under ice-water cooling, and the mixture was stirred at 0 "C for 0.5 hour. To this was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (12.8 g) under ice-water cooling, and the mixture was stirred at ambient temperature for 2 hours. The mixture was partitioned between AcOEt and water. The organic layer was separated, washed with water and brine, dried over MgSC&gt;4, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and AcOEt (10:1 - 3:1) to give methyl [2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]acetate pale yellow oil (4.45 g).<br>
methyl [2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]acetate<br>
1H NMR (CDCI3) 5 1.48-1.95 (6H, m), 3.46-3.57 (2H, m), 3.64-3.75 (2H, m), 3.76 (3H, s), 3.82-3.97 (2H, m), 4.20 (2H, s), 4.66 (1H, m).<br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Preparation 324<br>
A mixture of methyl [2-(tetr1Hydro-2H-pyran-2-yloxy)ethoxy]acetate (1.07 g) and pyridinium p-toluenesulfonate (24.6 mg) in MeOH (10 mL) was heated under reflux for 2 hours. After evaporation of solvent, the residue was purified by silica gel column chromatography eluting with a mixture of hexane and AcOEt (10:1 -1:3) to give methyl (2-hydroxyethoxy)acetate as colorless oil (555 mg).<br>
methyl (2-hydroxyethoxy)acetate<br>
1H NMR (CDC13) 5 3.69 (2H, m), 3.76 (2H, m), 3.78 (3H, s), 4.16 (2H, s).<br>
Preparation 325<br>
To solution of methyl (2-hydroxyethoxy)acetate (540 mg), imidazole (411 mg) and triphenylphosphine (1.37 g) in ether (2 mL) and CH3CN (1 mL) was added iodine (1.43 g) under ice-water cooling and the mixture was stirred at 0  for 2 hours. After<br>
insolubles were filterred off, the filtrates were diluted with AcOEt, washed with aq NaoSO3 solution and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and AcOEt (20:1 - 5:1) to give methyl (2-iodoethoxy)acetate as colorless oil (898 mg).<br>
methyl (2-iodoethoxy)acetate<br>
]H NMR (CDCl3) 6 3.30 (2H, t, J= 7 Hz), 3.77 (3H, s), 3.84 (2H, t, J= 7 Hz), 4.17 (2H,s).<br>
Preparation 326<br>
To a suspension of 60% N1H (1.02 g) in THF (50 mL) was added tert-butyl 4-(acetyloxy)-3-oxobutanoate (5.00 g) under ice-water cooling and the mixture was stirred at 0 °C for 0.5 hour. To this added ethyl 3-iodopropanoate (5.54 g) and the mixture was stirred at 50 C for 8 hours. The mixture was partitioned between AcOEt and water. The organic layer was separated, washed with brine, dried over MgS04, and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and AcOEt (20:1 - 3:1) to give 1-tert-butyl 5-ethyl 2-[(acetyloxy)acetyl]pentanedioale as yellow oil (4.27 g).<br><br>
1-tert-butyl 5-ethyl 2-[(acetyloxy)acetyl]pentanedioate<br>
1H NMR (CDCl3) 5 1.26 (3H, t, J= 7 Hz), 1.46 (9H, s), 2.14-2.24 (2H, m), 2.17 (3H, s), 2.36 (2H, U J= 7 Hz), 3.60 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.73 (1H, d, J= 18 Hz), 4.83 (1H, d, J= 18 Hz).<br>
Preparation 327<br>
To a solution of benzyl 4-thiomorpholinecarboxylate (4.8 g) in methanol (30 mL) and H2O (20 mL) was added oxone (16.2 g) under ice water cooling and the mixture was stirred at ambient temperature for 2 hours. The solution was evaporated in vacuo and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined organic layer was washed with water and brine, dried over MgS04 and evaporated in vacuo. The residue was purified by silica gel column chromatography eluting with a mixture of hexane and EtOAc to give benzyl 4-thiomorpholinecarboxylate 1,1-dioxide as a colorless solid (3.8 g).<br>
benzyl 4-thiomorpholinecarboxylate l?l-dioxide<br>
1H NMR (300 MHz, CDC13) 5 3.02 (4H, br s), 4.01 (4H, t, J = 5 Hz), 5.16 (2H, s), 7.33-7.40 (1H,m).<br>
Preparation 328<br>
To a solution of thiomorpholine (2 g) in IN NaOH (11.6 mL) was added benzyl chloridocarbonate (1.66 mL) under ice water cooling and the mixture was stirred at ambient temperature for 2 hours. The solution was neutrolized with IN HC1 and extracted with EtOAc twice. The combined organic layer was washed with water and brine, dried over MgS04 and evaporated in vacuo. The residue was purified by silica gel column chromatography to give benzyl 4-thiomorpholinecarboxylate as a colorless solid (4.8 g).<br>
benzyl 4-thiomorpholinecarboxylate<br>
1H NMR (300 MHz, CDC13) 6 2.59 (4H, br s), 3.77 (4H, t, J = 5 Hz), 5.14 (2H, s), 7.30-7.41 (1H,m).<br>
Preparation 329<br><br>
To a solution of benzyl 4-thiomorpholinecarboxylate 1,1 -dioxide (3.8 g) in methanol (32 mL) and 1,4-dioxane (8 mL) was added Palladium, 10 wt. % on activated carbon (380 mg) at ambient temperature. The mixture was stirred at ambient temperature for 4 hours under H2 (3.4 atom). The mixture was filtered and evaporated in vacuo to give thiomorpholine 1,1-dioxide as a colorless solid (2.22 g).<br>
thiomorpholine 1,1-dioxide<br>
1H NMR (300 MHz, CDC13) 5 3.03 (4H, t, J = 5 Hz), 3.33 (4H, t, J = 5 Hz).<br>
MS(m/z)136(M+H).<br>
Preparation 330<br>
To a suspension of [(5-chloro-4-mercapto~6-methyl-3-pyridinyl)oxy]acetic acid (10 g) in dichloromelhane (100 mL) was added Et3N (14 mL) in ice-MeOH bath. To this was added trifluoromethanesulfonic anhydride (143 mL) dropwise below lO'C over 30 min. After 2 hours the mixture was partitioned between CHCl3 and water. The aqueous layer was extracted with CHCl3 twice. The combined organic layer was dried over MgSO4 and evaporated in vacuo to give brown oil. The residue was purified by silica gel column chromatography (silica gel, 100 mL) eluted with hexane-EtOAc = 15-1 and 10-1 to give 5-chloro-3-pyridinyl trifluoromethanesulfonate (15.8 g) as a pale brown oil.<br>
5-chloro-3-pyridinyl trifluoromethanesulfonate<br>
1H NMR (300 MHz, CDC13) 8 7.69 (1H, dd, J = 4,4 Hz), 8.52 (1H, d, J = 4 Hz), 8.65 (lH,d,J=4Hz).<br>
Preparation 331<br>
To ethanol (66 mL) and DMF (66 mL) was added Et3N (29.4 mL), 1,3-propanediylbis(diphenylphosphine) (3.48 g) and palladium acetate (1.9 g) in ice-water bath. To this was added 5-chloro-3-pyridinyl trifluoromethanesulfonate (22.1 g) at the temperature. The mixture was stirred at 50˚C for 4 hours under CO (1 atom). The mixture was partitioned betwwen ElOAc and water. The aqueous layer was extracted with EtOAc. The combined organic layer was washed with water three times, dried over MgSO4 and evaporated in vacuo. The residue was purified by silica gel column chromatography (silica gel, 200 mL) eluted with hexane-EtOAc = 15-1 and 10-1 to give ethyl 5-<br><br>
chloronicolinale (10.5 g) as a pale brown oil.<br>
ethyl 5-chloronicotinate<br>
1HNMR(300MHz5CDCl3)5l.42(3H,t,J = 7Hz),4.43(2H,q3J = 7Hz),8.28(lH, dd, J = 3,3 Hz), 8.74 (1H, d, J = 3 Hz), 9.09 (1H, d, J = 3 Hz).<br>
Preparation 332<br>
To 5-chloronicotinate (10.5 g) was added IN NaOH (84.9 mL) at ambient temperature. The mixture was heated at 60°C for 1 hour. The reaction mixture was adjusted to pH 4-5 with HC1. The precipitate was filtered to give 5-chloronicotinic acid (6.9 g) a colorless solid.<br>
1H NMR (300 MHz, DMSO-d6) 6 8.30 (1H, dd, J = 3 Hz), 8.88 (1H, d, J = 3 Hz), 9.01 (1H, d, J = 3 Hz), 13.8 (1H, br s).<br>
5-chloronicotinic acid<br>
1H NMR (300 MHz, DMSO-d6) 5 8.30 (1H, dd, J = 3,3 Hz), 8.88 (1H, d, J = 3 Hz), 9.01 (1H, d, J = 3 Hz), 13.8 (1H, br s).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 332. Preparation 333 5-methoxynicotinic acid<br>
1H NMR (DMSO-d6) 8 3.87 (3H, s), 7.73 (1H, m), 8.48 (1H, d, J = 3 Hz), 8.65 (1H, d, J = 1 Hz).<br>
MS(ESl+):m/zl54(M + H).<br>
Preparation 334 5-pyrimidinecarboxylic acid<br>
1H NMR (DMSO-d6) 6 9.20 (2H, s), 9.37 (1H, s).<br>
MS (ESI+): m/z 148 (M+ + Na).<br>
Preparation 335<br>
To a solution of diisopropylamine (5.41 g) in THF (30 mL) was added 1.5 M n-<br><br>
butyllithium hexane solution (35 mL) under dryice acetone cooling and the mixture was stirred at -78 °C for 10 minutes. To this was added lert-butyl acetate (5.87 g) under dryice acetone cooling and the mixture was stirred at -78 ˚C for 10 minutes and added dropwise to a solution of 5-bromonicotinic acid (3.00 g) and N, N-carbonyldiimidazole (2.65 g) in THF (30 mL) under dryice acetone cooling. The mixture was stirred at -78 °C for 0.5 hour. The mixture was partitioned between ethyl acetate and aq NH4CI solution. The organic layer was separated, washed with aq N1HC03 solution and brine, dried over MgS04, and evaporated in vacuo. The residue was triturated with isopropyl ether to give tert-butyl 3-(5-bromo-3-pyridinyl)-3-oxopropanoate as a colorless powder (3.71 g).<br>
tert-butyl 3-(5-bromo-3-pyridinyl)-3-oxopropanoate<br>
Enol form:1H NMR (CDCl3) 6 1.54 (9H, s), 5.62 (1H, s), 8.19 (1H, m), 8.72 (1H, d,<br>
J= 2 Hz), 8.86 (1H, d, J= 2 Hz). Keto form:1H NMR (CDCl3) 8 1.44 (9H, s), 3.90 (2H, s), 8.37 (1H, m), 8.86 (1H, d,<br>
J= 2 Hz), 9.03 (1H, d, J= 2 Hz). MS (ESf): m/z 300 302.<br>
Preparation 336<br>
To a suspension of N1H in DMF (50 mL) which was washed with hexane 3 times was added methyl 5-hydroxynicotinate (10.2 g) portionwise below lO'C in an ice-water<br>
bath under nitrogen atmosphere. After 30 min, methyl iodide (4.56 mL) was added dropwise therein. The precipitate appeared and the mixture was hard to be stirred. DMF (30 mL) was added. After 20 min, the mixture was stirred at ambient temperature for 3 h. The reaction mixture was quenched with MeOH and was concentrated in vacuo. To the residue was added CHCl3, sat. N1HCO3, and brine. The organic layer was separated and the aqueous layer was extracted with CHCl3.  The combined organic layer was dried over MgSCU and was evaporated in vacuo. The residue was purified by flash silica gel chromatography (silica gel, 200 mL) eluted with hexane-AcOEt - 5-1 and 3-1 to give methyl 5-methoxynicotinate (3.47 g) as a pale brown solid .<br>
methyl 5-methoxynicotinate<br>
1H NMR (CDCl3) 6 3.91 (3H, s), 3.96 (3H, s), 7.76 (1H, m), 8.47 (1H, d, J = 3 Hz),<br><br>
8.83	(1H, d, J = 1 Hz).<br>
MS(ESl+):m/zl68(M + H).<br>
Preparation 337<br>
To a solution of methyl 2-bromo-4-[(5-ethyl-lH-pyrrol»2-yl)carbonyl]benzoate (330 mg) in N,N-dimethylformamide (5 mL) was added 60% sodium hydride in oil (58.4 mg) in an ice-bath over 5 miutes. After stirring for 1 hour,<br>
(aminooxy)(diphenyl)phosphine oxide (340 mg) was added portionwise over 40 minutes. The resulting mixture was stirred for 1 hour in the bath. The reaction was quenched by adding water (10 mL). The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water (two times) and brine, dried over magnesium sulfate, and evaporated. The residue was dissolved in ethyl acetatec-hexane (1-5), and to the solution was added silicagel. The mixture was filtered, and the filtrate was evaporated to give methyl 4-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]-2-bromobenzoate as an orange solid (310 mg).<br>
methyl 4-[(l-amino-5-ethyl-lH-pyrrol-2-yl)carbonyl]-2-bromobenzoate<br>
1H-NMR (CDCl3) 6 1.29 (3H, t, J = 7 Hz), 2,76 (2H, q, J = 7 Hz), 3.97 (3H, s), 5.73 (2H, s, br), 5.93 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 7.73 (1H, d, J = 8 Hz),<br>
7.84	(lH, d, J = 8 Hz), 8.02 (1H, s).<br>
Preparation 338<br>
To a solution of dimethyl 2-bromoterephthalate (1.04 g) in methanol (10 mL) was added 1 N sodium hydroxide (5.71 mL) at room temperature. After stirring for 1.5 hour, the reaction was quenched by adding 1 N hydrochloric acid (7 mL). White crystals were formed. Water (10 mL) was added to aid crystalyzation. The crystals were collected by filtration, washed with water, and dried in the air. 3-Bromo-4-(methoxycarbonyl)benzoic acid was obtained as white crystals (532 mg).<br>
3-bromo-4-(methoxycarbonyI)benzoicacid<br>
'H-NMR (DMSO-d6) 5 3.89 (3H, s), 7.87 (1H, d, J ˚ 8 Hz), 8.01 (1H, d, J = 8 Hz), 8.17 (lH,s).<br><br>
Preparation 339<br>
A mixture of 2-[2-(2-ch]oroethoxy)ethoxy]ethyl acetate (6.23 g) and sodium iodide (22.2 g) in acetone (60 mL) was refluxed for 4 hours. The mixture was further refluxed for 4 hours after adding sodium iodide (J 1.0 g). The solvent was evaporated off, and the residue was partitioend between EtOAc (50 mL) and water (50 mL). The aqueous layer was washed with 10% sodium thiosulfate and brine, dried over MgSO4, and evaporated to give 2-[2-(2-iodoethoxy)ethoxy]ethyl acetate as a pale yellow oil (9.74<br>
g)-<br>
2-[2-(2-iodoethoxy)ethoxy]ethyl acetate<br>
'H-NMR (CDC13) 6 2.09 (3H, s), 3.27 (2H, t, J = 7 Hz), 3.65-3.78 (8H, m), 4.24 (2H, m).<br>
Preparation 340<br>
A solution of 1-tert-butyl 7-ethyl 2-[(5-metbyl-3~ isoxazolyl)carbonyl1Heptanedioate (126 mg) in trifluoroacetic acid (1 mL) was stirred for 1.5 hour at room temperature. The volatile was evaporated off, and azeotroped with toluene to give 7-ethoxy-2-[(5-methyl-3-isoxazolyl)carbonyl]-7-oxoheptanoic acid as a pale orange oil (106 mg).<br>
7-ethoxy-2-[(5-methyl-3-isoxazolyl)carbonyl]-7-oxoheptanoic acid<br>
'H-NMR (CDCl3) 6 1.24 (3H, t, J = 7 Hz), 1.41 (2H, m), 1.65 (2H, m), 2.02 (2H, m), 2.30 (2H, m), 2.50 (3H, s), 2.55 (1H, s, br), 4.10 (2H, q, J = 7 Hz), 4.47 (1H, t, J = 7Hz),6.40(lH,s). MS (ESI+): m/z 296.22 (M-H) and 593.52 (2M-H)<br>
Preparation 341<br>
To a suspension of dimethyl sulfone (5.43 g) in tetr1Hydrofuran (10 mL) was addded 1.59 M n-butyl lithium (36.3 mL) in a dryice-acetone bath under a nitrogen atmosphere. After stirring for 0.5 hour, a solution of methyl methoxyacetate (2.00 g) in tetr1Hydrofuran (5 mL) was added. The resulting mixture was stirred for 2 hours in the bath and allowed to warm to room temperature over 2 hours. The mixture was partitioned between EtOAc and 4 N hydrochloric acid. The reaction was quenched by<br><br>
adding 4 N hydrochloric acid in EtOAc (15 mL). The mixture was partitioned between EtOAc (100 mL) and brine (100 mL). The aqueous layer was washed with EtOAc (100 mL, five times). The organic layer was combined, and the combined extracts were dried over MgS04, and evaporated. Flash silicagel column chromatography (EtOAc-hexane = 50-200 to 300-100) afforded 2-(methylsulfonyl)-l~methoxyethanone as a colorless oil (2.24 g).<br>
l-methoxy-3-(methylsulfonyl)acetone<br>
1H-NMR (CDC13) 6 2.99 (3H, s), 3.08 (2H, s), 3.47 (3H, s), 4.19 (2H, s).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 1. Example 392<br>
ethyl 4-[3-bromo-4-(methoxycarbonyl)phenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazine-3-carboxylate<br>
1H-NMR (CDCl3) 6 0.98 (3H, t, J = 7 Hz), 1.38 (3H, t, J = 7 Hz), 2.61 (3H, s), 3.04 (2H, q, J = 7 Hz), 3.98 (3H, s), 4.05 (2H, q, J = 7 Hz), 6.29 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 7 Hz), 7.44 (1H, d, J = 8 Hz), 7.76 (1H, s), 7.89 (1H, d, J = 8 Hz).<br>
Example 393<br>
3-[7-ethyI-2-(methoxymethyl)-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-<br>
yl]benzonitrile<br>
1H-NMR (CDCl3) 6 1.38 (3H, t, J = 7 Hz), 2.98 (2H, q, J = 7 Hz), 3.18 (3H, s), 3.45 (3H, s), 4.59 (2H, s), 6.25 (1H, d, J = 5 Hz), 6.71 (1H, d, J = 5 Hz), 7.65 (1H, t, J = 8 Hz), 7.78 (1H, d, J = 8 Hz), 7.94 (1H, d, J = 8 Hz), 7.99 (1H, s). MS(ESI+):m/z370(M + H)<br>
The following compound(s) was(were) obtained in a similar manner to that of<br>
Example 16.<br>
Example 394 5-{4-[3-(aminocarbonyl)phenyl]-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl}pentanoic<br>
acid<br>
1H-NMRCCDCL2) 6 1.02 (4H,m), 1.28 (3H,t, J = 7 Hz), 1.70 (2H,m), 2.37 (2H,m),<br><br>
2.92 (2H, q, J = 7 Hz), 5.87 (1H, d, J = 5 Hz), 6.66 (1H, d, J = 5 Hz), 7.46-7.67 (1H,m), 7.96-8.08 (3H,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 21. Example 395<br>
ethyl 4-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butanoate 1H NMR (CDC13) 8 1.21 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.65-1.78 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.40-2.52 (2H, m), 2.58 (3H, s), 3.03 (2H, q, J= 7 Hz), 4.05 (2H, q, J= 7 Hz), 5.86 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.25 (1H, d, J= 5 Hz), 7.36 (1H, s), 8.53 (1H, d, J= 5 Hz). MS (ESI+): m/z 386 .<br>
Example 396<br>
ethyl 3-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l ,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDCl3) 5 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.30-2.39 (2H, m), 2.57 (3H, s), 2.74-2.83 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 5.88 (1H, d, J= 4 Hz), 6.55 (1H, d, J= 4 Hz), 7.24 (1H, d, J= 5 Hz), 7.35 (1H, s), 8.53 (lH,d,J=1Hz). MS (ESI+): m/z 372.<br>
Example 397<br>
ethyl 5-[2-benzyl-4-(2-chloro-4-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCl3) 6 1.23 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 1.30-1.50 (4H, m), 2.10 (2H, t, J= 7 Hz), 2.23-2.35 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.09 (2H, q, J= 7 Hz), 4.21 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.14-7.32 (7H, m), 8.50(lH,d,J=1Hz).<br>
Example 398<br>
methyl {2-[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]ethoxy}acetate<br><br>
1H NMR (CDCl3) 5 137 (3H, t, J= 7 Hz), 2.42 (3H, s), 2.61 (3H, s), 2.78-2.88 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.46-3.57 (2H, m), 3.71 (3H, s), 3.95 (2H, s), 5.87 (1H, d, J= 4 Hz), 6.52 (1H,d,J= 4 Hz), 7.54 (1H, s), 8.43 (1H, d, J= 2 Hz), 8.53 (JH, d, J=2Hz).<br>
MS (ES1+): m/z 368.<br>
Example 399<br>
ithyl [4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]acetate1H NMR (CDCl3) 6 1.26 (3H, t, J= 7 Hz), 1.38 (3H, t, J= 7 Hz), 2.51 (3H, s), 3.03 (2H, q, J= 7 Hz), 3.43 (2H, s), 4.12 (2H, q, J= 7 Hz), 5.99 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.94 (1H, m), 8.58 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS(ESl+):m/z402 404.<br>
Example 400<br>
ethyl 3-[2-[(acetyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]propanoate<br>
1H NMR (CDCl3) 5 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.16 (3H, s), 2.32-2.42 (2H, m), 2.44 (3H, s), 2.77-2.90 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 5.31 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.42 (1H, d, J=2 Hz), 8.55 (1H, d, J= 2 Hz). MS (ESI+): m/z 410.<br>
Example 401<br>
ethyl 4-[2-[(acetyloxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]butanoate<br>
1H NMR (CDC13) 5 1.25 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.64-1.78 (2H, m), 2.10-2.23 (2H, m), 2.17 (3H, s), 2.43 (3H, s), 2.43-2.58 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 5.33 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.43 (1H, s), 8.55 (1H, s). MS (ES1+): m/z 424.<br>
Example 402<br>
ethyl 5-[2-[(acetyloxy)methyl]-4-(3-cyanophenyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br><br>
yljpentanoate<br>
1HNMR (CDC13) 6 1.24 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.40-1.60 (4H, m),<br>
2.16	(2H, t, J= 7 Hz), 2.17 (3H, s), 2.40-2.52 (2H,m), 3.03 (2H, q, J= 7 Hz), 4.12<br>
(2H, q, J= 7 Hz), 5.29 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.60-<br>
7.68 (3H,m), 7.75-7.83 (lH,m).<br>
MS(ESl+):m/z448.<br>
Example 403<br>
ethyl 4-[2-[(acetyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[ 1,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCl3) 6 1.22 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.65-1.82 (2H, m),<br>
2.17	(3H, s), 2.21 (2H, t, J= 7 Hz), 2.45-2.63 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.05<br>
(2H, q, J= 7 Hz), 5.33 (2H, s), 5.95 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.90<br>
(1H, m), 8.57 (1H, d, J= 2 Hz), 8.80 (1H, d, J= 2 Hz).<br>
MS (ESI+): m/z 488 490.<br>
Example 404<br>
ethyl 3-[2-[(acetyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDC13) 8 1.23 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.16 (3H, s), 2.36 (2H, t, J= 7 Hz), 2.77-2.95 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 5.31 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.64 (1H, d, J= 4 Hz), 7.88 (1H, s), 8.56 (1H, m),8.80(lH,m). MS(ESl+):m/z474 476.<br>
Example 405<br>
ethyl 3-[2-[(cyclohexylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]propanoate<br>
1H NMR (CDCl3) 8 0.88-1.06 (2H, m), 1.19 (3H, t, J= 7 Hz), 1.15-1.36 (3H, m), 1.37 (3H, t, J= 7 Hz), 1.58-1.85 (6H, m), 2.42 (2H, m), 2.43 (3H, s), 2.83-2.97 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.38 (2H, d, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.42 (1H, d, J= 2 Hz), 8.54(lH,d,J=2Hz).<br><br>
Example 406 hyl 3-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexylmelhoxy)melhyJ]-7-ethy]pyrrolo[ 1,2-|pyiidazin-3-yl}propanoate1H NMR (CDCb) 6 0.85-1.06 (2H, m), 1.20 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), J .1 6-1.46 (3H, m), 1.55-1.84 (6H, m), 2.43 (2H, t, J= 7 Hz), 2.82-3.00 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.37 (2H,d, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78(lH,d,J=2Hz).<br>
MS (ES1+): m/z 528 530.<br>
Example 407<br>
;thyl 4-{4-(5-bromo-3-pyridinyl)-2-[(cyciohexylmethoxy)methy]]-7-ethylpyrrolo[l,2-<br>
3]pyridazin-3-yl}butanoate<br>
1H NMR (CDC13) 6 0.87-1.06 (2H, m), 1.21 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.16-1.46 (3H, m), 1.50-1.85 (8H, m), 2.23 (2H, t, J= 7 Hz), 2.55-2.75 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.38 (2H, d, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.67 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.89 (1H,m), 8.56 (1H, d, J= 2 Hz), 8.79(lH,d,J=2Hz). MS(ESI+):m/z542 544.<br>
Example 408<br>
ethyl 4-[2-[(cyclopropylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]butanoate<br>
1H NMR (CDC13) 6 0.22-0.32 (2H, m), 0.53-0.65 (2H, m), 1.10-1.20 (1H, m), 1.19 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 1.65-1.80 (2H, m), 2.14-2.30 (2H, m), 2.43 (3H, s), 2.57-2.74 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.43 (2H, d, J= 7 Hz), 4.03 (2H, q, J= 7 Hz), 4.74 (2H, s), 5.90 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.43 (lH,s), 8.54 (lH,s). MS (ES1+): m/z 436.<br>
Example 409<br><br>
clhy] 3-[2-[(cyclopropylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyriclinyl)pyrro]ol],2-b]pyridazin-3-yl]propanoate<br>
1H NMR (CDCb) 5 0.22-0.32 (2H, m), 0.54-0.63 (2H, m), J .10-1.20 (1H, m), 1.21 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.40-2.50 (2H, m), 2.43 (3H, s), 2.86-2.98 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.42 (2H, d, J= 7 Hz), 4.06 (2H, q, J= 7 Hz), 4.71 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.42 (1H, s), 8.54 (1H, s). MS (ESI+): m/z 422.<br>
Example 410<br>
ethyl 3-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-methoxyethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoate<br>
1H NMR (CDC13) 6 1.20 (3H, t, J= 7 Hz), 1.37 (3H, t, J= 7 Hz), 2.44 (2H, t, J= 7 Hz), 2.82-2.98 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.38 (3H, s), 3.58 (2H, m), 3.76 (2H, m), 4.05 (2H, q, J= 7 Hz), 4.76 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.54 (1H, s), 8.79 (1H, s). MS (ESI+): m/z 490 492.<br>
Example 411 4-(5-bromo-3-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazine<br>
1H NMR (CDC13) 5 1.39 (3H, t, J= 7 Hz), 2.54 (3H, s), 3.04 (2H, q, J= 7 Hz), 6.39 (1H, s), 6.51 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 8.17 (1H, m), 8.76 (1H, d, J=2Hz),8.86(lH,d,J=2Hz). MS(ESI+):m/z316 318.<br>
Example 412<br>
ethyl 4-[2-[(acetyloxy)methyl]-4-(5-chloro-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (300 MHz, CDCl3) 5 1.20 (3H, t, J = 7 Hz), 1.37 (3H, t, J = 7 Hz), 1.70 (2H, tt, J = 7,7 Hz), 2.17 (3H, s), 2.20 (2H, t, J = 7 Hz), 2.45-2.54 (2H, m), 3.02 (2H, q, J = 7 Hz), 4.04 (2H, q, J = 7 Hz), 5.33 (2H, s), 5.94 (1H, d, J = 4 Hz), 6.63 (1H, d, J = 4 Hz), 7.74 (1H, dd, J = 2,2 Hz), 8.53 (1H, d, J = 2 Hz), 8.70 (1H, d, J = 2 Hz).<br><br>
Example 413<br>
ethyl 5-{4~(5-ch]oro-3-pyridiny])-2-[(cyclopropylmethoxy)methyl]-7-ethy]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (300 MHz, CDC13) 6 0.23-0.26 (2H, m), 0.54-0.59 (2H, m), 1.07-1.16 (1H, m), 1.23 (3H, t, J = 7 Hz), 1.37 (3H, t, J = 7 Hz), 1.41-1.56 (4H, m), 2.17 (2H, t, J = 7 Hz), 2.53-2.64 (2H, m), 3.03 (2H, q, J =7 Hz), 3.41 (2H, d, J = 7 Hz), 4.09 (2H, q, J = 7 Hz), 4.70 (2H, s), 5.90 (1H,d, .1 = 5 Hz), 6.58 (1H, d, J = 5 Hz), 7.72 (lH,s),8.51 (1H,S),8.68(1H,S).<br>
Example 414<br>
ethyl 4-{4-(5-chloro-3-pyridinyl)-2-[(cyclopropylmethoxy)methyl]-7-ethylpyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (300 MHz, CDCl3) 6 0.24 (2H, dt, J = 7,7 Hz), 0.56 (2H, dt, J = 7, 7 Hz), l.07-1.15 (lH,m), 1.20 (3H,t, J = 7 Hz), 1.37 (3H,t, J = 7 Hz), 1.72 (2H, tt, J = 7, 7 Hz), 2.21 (2H, t, J = 7 Hz), 2.55-2.66 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.43 (2H, d, J = 7 Hz), 4.04 (2H, q, J = 7 Hz), 4.73 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.74 (1H, dd, J = 2, 2 Hz), 8.52 (1H, d, J = 2 Hz), 8.68 (1H, d, J = 2 Hz).<br>
Example 415<br>
ethyl 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(isobutoxymethyl)pynolo[l,2-b]pyridazin-3-<br>
yljpentanoate<br>
1H NMR (300 MHz, CDCb) 6 0.92 (6 H, d, J = 7 Hz), 1.26 (3H, t, J = 7 Hz), 1.34 (3H, t, J = 7 Hz), 1.38-1.56 (4H, m), 1.92 (1H, qt, J = 7, 7 Hz), 2.15 (2H, 1, J = 7 Hz), 2.51-2.63 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.33 (2H, d, J = 7 Hz), 4.09 (2H, q, J = 7 Hz), 4.65 (2H, s), 5.90 (1H, d, J = 7 Hz), 6.59 (1H, d, J = 7 Hz), 7.88 (1H, dd, J = 2,2 Hz), 8.55 (1H, d, J = 2 Hz), 8.77 (1H, d, J = 2 Hz).<br>
Example 416<br>
ethyl 3-[4-(5-chloro-3-pyridinyI)-7-ethyl-2-(isobutoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (300 MHz, CDCl3) 5 0.92 (6H, d, J = 7 Hz), 1.19 (3H, t, J = 7 Hz), 1.37 (3H,<br><br>
I, J = 7 Hz), 1.91 (1H, ql, J = 7,7 Hz), 2.41 (2H, t, J = 8 Hz), 2.84-2.94 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.35 (2H, d, J = 7 H), 4.05 (2H, q, J = 7 Hz), 4.68 (2H, s), 5.92 (1H, d, J = 4 Hz), 6.61 (1H, d, J =4 Hz), 7.72 (1H, dd, J = 2,2 Hz), 8.51 (1H, d, J = 2 Hz), 8.69 (1H, d, J = 2 Hz).<br>
Example 417<br>
hyl 3-[2-[(acelyloxy)methyl]-4-(3-chlorophenyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-l]propanoate<br>
1H NMR (300 MHz, CDC13) 6 1.19 (3H, t, J = 7 Hz), 1.36 (3H, t, J = 7 Hz), 2.15 (3H, s), 2.33 (2H, t, J = 8 Hz), 2.82 (2H, t, J = 8 Hz), 3.02 (2H, q, J = 7 Hz), 4.06 (2H, q, J = 7 Hz), 5.31 (2H, s), 5.97 (1H, d, J = 4 Hz), 6.61 (1H, d, J = 4 Hz), 7.23-7.26 (1H, m), 7.37 (1H, s), 7.44-7.46 (2H, m).<br>
Example 418<br>
:thyl 4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(isobutoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
/ljbutanoate<br>
1H NMR (300 MHz, CDC13) 6 0.92 (6H, d, J = 7 Hz), 1.20 (3H, t, J = 7 Hz), 1.37 (3H, t, J = 7 Hz), 1.71 (2H, tt, J = 8, 8 Hz), 1.91 (1H, qt, J = 7, 7 Hz), 2.20 (2H, t, J = 8 Hz), 2.56-2.66 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.34 (2H, d, J = 7 Hz), 4.05 (2H, q, J = 7 Hz), 4.69 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.89 (1H, s), 8.56 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz).<br>
Example 419 2,4-bis(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazine<br>
1H NMR (CDCl3) 6 1.45 (3H, t, J= 7 Hz), 3.14 (2H, q, J= 7 Hz), 6.66 (1H, d, J= 4<br>
Hz), 6.86 (1H, d, J= 4 Hz), 6.91 (1H, s), 8.23 (1H, m), 8.48 (1H, m), 8.77 (1H, m),<br>
8.83 (1H, m), 8.94 (1H, d, J= 2 Hz), 9.18 (1H, d, J= 2 Hz).<br>
Example 420<br>
ethyl 4-[2-[(acetyloxy)methyl]-4-(3-chlorophenyl)-7-elhylpyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCl3) 6 1.19 (3H, t, J = 8 Hz), 1.34 (3H, t, J = 8 Hz), 1.63-1.76 (2H, m), 2.10-2.22 (1H, m), 2.45-2.55 (2H, m), 3.01 (2H, q, J = 8 Hz), 4.04 (2H, q, J = 8<br><br>
Hz), 5.32 (2H, s), 5.95 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.21-7.29 (1H, overlappled with CDC1,), 7.36 (1H, br s), 7.38-7.46 (2H, m). MS (ESI+): m/z 443 (M + H).<br>
Example 421<br>
elhyl 5-[7-ethyl-2-(methoxymethy])-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoate<br>
1H NMR (CDC13) 6 1.23 (3H, t, J = 8 Hz), 1.33-1.60 (7H, m), 1.55-1.70 (2H, m), 2.17 (2H, t, J = 8 Hz), 2.46-2.64 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.46 (3H, s), 3.90 (3H, s), 4.09 (2H, q, J = 8 Hz), 4.62 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.23 (1H, m), 8.22 (1H, d, J = 1 Hz), 8.40 (1H, d, J = 3 Hz).<br>
MS(ESI+):m/z426(M + H).<br>
Example 422<br>
ethyl 5-[7-ethyl-4-(5-methoxy-3-pyridinyl)-2-methylpyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCl3) 5 1.23 (3H, t, J = 8 Hz), 1.33-1.62 (7H, m), 2.18 (2H, t, J = 8 Hz), 2.38-2.49 (2H, m), 2.56 (3H, s), 3.01 (2H, q, J = 8 Hz), 3.90 (3H, s), 4.08 (2H, q, J = 8 Hz), 5.89 (1H, d, J = 5 Hz), 6.51 (1H, d, J = 5 Hz), 7.21 (1H, m), 8.21 (1H, d, J = 1 Hz), 8.40 (1H, d, J = 3 Hz). MS(ESI+):m/z396(M + H).<br>
Example 423<br>
ethyl 3-[7-ethyl-2-(methoxymethyl)-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyndazin-3-<br>
yl]propanoate<br>
1H NMR (CDCb) 5 1.20 (3H, t, J = 8 Hz), 1.38 (3H, t, J = 8 Hz), 2.40 (2H, t, J = 8 Hz), 2.81-2.96 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (3H, s), 3.90 (3H, s), 4.05 (2H, q, J = 8 Hz), 4.65 (2H, s), 5.96 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.21 (1H, m), 8.23 (1H, br s), 8.40 (1H, d, J = 3 Hz). MS (ES1+): m/z 398 (M + H).<br>
Example 424<br>
ethyl 4-[7-ethyl-2-(methoxymethyl)-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br><br>
yl]butanoafe<br>
1H NMR (CDCl3) 6 1 -20 (1H, 1, J = 8 Hz), J .38 (1H, t, J = 8 Hz), 1.64-1.79 (2H, m), 2.14-2.24 (2H, m), 2.53-2.66 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 3.90 (1H, s), 4.04 (2H, q, J = 8 Hz), 4.67 (2H, br s), 5.94 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.23 (1H, m), 8.22 (1H, d, J = 1 Hz), 8.40 (1H, d, J = 3 Hz). MS(ESl+):m/z412(M+H).<br>
;ample 425<br>
Nyl 5-[7-ethyl-2-(methoxymethyl)-4-(5-pyrimidinyl)pyrrolo[l,2-b]pyridazin-3-<br>
Ipentanoate<br>
1H NMR (CDCl3) 6 1.23 (1H, t, J = 8 Hz), 1.30-1.62 (7H, m), 2.19 (2H, t, J = 8 Hz), 2.46-2.60 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 3.90 (1H, s), 4.09 (2H, q, J = 8 Hz), 4.63 (2H, s), 5.90 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 8.80 (2H, s), 9.34 (lH,s).<br>
MS (ESI+): m/z 397 (M + H).<br>
ixample 426<br>
thyl4-[4-(5-chloio-3-pyridinyl)-7-elhyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
l]butanoate<br>
1H NMR (CDCl3) 6 1.21 (1H, t, J = 8 Hz), 1.37 (1H, t, J = 8 Hz), 1.62-1.76 (2H, m), 2.21 (2H, t, J = 8 Hz), 2.49-2.67 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.46 (1H, s), 4.06 (2H, q, J = 8 Hz), 4.67 (2H, br s), 5.92 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 7.74 (1H, m), 8.53 (1H, d, J = 1 Hz), 8.69 (1H, d, J = 2 Hz). MS(ESl+):m/z414(M-H).<br>
Example 427<br>
ethyl 3-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(melhoxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoale<br>
1H NMR (CDCl3) 6 1 -20 (1H, t, J = 8 Hz), 1.38 (1H, t, J = 8 Hz), 2.40 (2H, t, J = 8 Hz), 2.82-2.94 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 4.06 (2H, q, J = 8 Hz), 4.65 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 5 Hz), 7.73 (1H, br s), 8.51 (lH.br s), 8.70 (lH.br s). MS(ESl+):m/z402(M+H).<br><br>
Example 428<br>
ethyl 5-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(methoxymelhyl)pyrrolo[l,2-b]pyricl'izin-3-]pentanoate<br>
1H NMR (CDCL3) 6 1.23 (1H, t, J = 8 Hz), 1.34-1.60 (7H, m), 2.19 (2H, t, J = 8 Hz), 2.47-2.64 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.46 (1H, s), 4.10 (2H, q, J = 8 Hz), 4.62 (2H, s), 5.90 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.73 (1H, m), 8.51 (lH,brs),8.68(lH,brs).<br>
MS (ESI+): m/z 426 (M + H).<br>
Example 429<br>
nethyl 2-[(acetyloxy)methyl]-4-(5-bromo-3-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazine-<br>
8-carboxylate<br>
up 122-123 deg.<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J = 8 Hz), 2.12 (1H, s), 3.06 (2H, t, J = 8 Hz), 3.61 (1H, s), 5.43 (2H, s), 6.37 (1H, d, J = 5 Hz), 6.78 (1H, d, J = 5 Hz), 7.93 (1H, t, J = 1 Hz), 8.57 (1H, d, J = 1 Hz), 8.78 (1H, d, J = 1 Hz). MS (ES1+): m/z 432,434 (M + H).<br>
Example 430<br>
2-(2-{2-[7-ethyl-2-methyl-4-(5-melhyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]ethoxy}ethoxy)ethyl acetate<br>
1H-NMR (CDCl3) 5 1.37 (1H, t ,J = 7 Hz), 2.05 (1H, s), 2.42 (1H, s), 2.59 (1H, s), 2.75 (2H, m), 3.00 (2H, q, J = 7 Hz), 3.39-3.48 (4H, m), 3.54 (2H, m), 3.63 (2H, m), 4.16 (2H, m), 5.86 (1H, d, J = 5 Hz), 6.52 (1H, d, J = 5 Hz), 7.50 (1H, m), 8.43 (lH,m), 8.52 (lH,m).<br>
Example 431<br>
ethyl (2E)-4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-2-<br>
butenoate<br>
1H-NMR (CDCl3) 6 1.27 (1H, t, J = 7 Hz), 1.36 (1H, t, J = 7 Hz), 2.49 (1H, s), 3.02 (2H, q, J = 7 Hz), 3.30 (2H, m), 4.16 (2H, q, J = 7 Hz), 5.58 (1H, d, J = 16 Hz), 5.90 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 6.97 (1H, dt, J = 7 and 16 Hz), 7.58<br><br>
(2H, m), 7.65 (1H, s), 7.75 (1H, m).<br>
Example 432<br>
ethyl 4-[4-(5-bromo-3-pyridinyi)-7-elhyl-2-(methoxymethy])pyrrolo[l,2-b]pyridazin-3-<br>
yljbutanoate<br>
1H NMR (300 MHz, CDC13) 6 1.23 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.65-1.78 (2H, m), 2.23 (2H, t, J= 7 Hz), 2.54-2.72 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.46 (1H, s), 4.06 (2H, q, J= 7 Hz), 4.66 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ES1+): m/z 460 462.<br>
Example 433<br>
ethyl 4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazine-3-carboxylate1H NMR (CDCl3) 6 0.99 (1H, t, J = 8 Hz), 1.38 (1H, t, J = 8 Hz), 2.63 (1H, s), 3.05 (2H, q, J = 8 Hz), 4.07 (2H, q, J = 8 Hz), 6.27 (1H, d, J = 5 Hz), 6.70 (1H, d, J = 5 Hz), 7.30 (1H, dd, J = 5,1 Hz), 7.41 (1H, br s), 8.49 (1H, d, J = 5 Hz). MS (ES1+): m/z 344 (M + H).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 76. Example 434<br>
4-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]butanoicacid1H NMR (CDCl3) 5 1.37 (1H, t, J= 7 Hz), 1.72-1.84 (2H, m), 2.33 (2H, t, J= 7 Hz), 2.47-2.57 (2H, m), 2.58 (1H, s), 3.03 (2H, q, J= 7 Hz), 5.88 (1H, d, J= 4 Hz), 6.53 (1H, d, J= 4 Hz), 7.27 (1H, m), 7.38 (1H, s), 8.53 (1H, d, J= 5 Hz). MS (ESI-): m/z 356, MS (ES1+): m/z 358.<br>
Example 435<br>
3-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l ,2-b]pyridazin-3-yl]propanoic acid 1H NMR (CDCl3) 6 137 (1H, t, J= 7 Hz), 2.36-2.47 (2H, m), 2.58 (1H, s), 2.76-2.88<br>
(2H, m), 3.03 (2H, q, J= 7 Hz), 5.89 (1H, d, J= 4 Hz), 6.55 (1H, d, J= 4 Hz), 7.25<br>
(1H, d, J= 5 Hz), 7.35 (1H, s), 8.53 (1H, d, J= 5 Hz).<br><br>
Example 436<br>
4-[4-(2-chloro-4-pyridiny])-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]butanoicacid1H NMR (CDCl3) 6 1.24 (1H, t, J= 7 Hz), 1.30-1.42 (2H, m), 1.35 (9H, s), 1.63-1.76 (2H, m), 2.22-2.37 (4H, m), 3.93 (1H, d, J= 17 Hz), 4.12 (2H, q, J= 7 Hz), 4.29 (1H, d, J= 17 Hz), 7.22 (2H, d, J= 8 Hz), 7.26-7.36 (4H, m), 7.50 (1H, s), 8.42 (lH,d,J=z). MS (ESF): m/z 418, MS (ESI+): m/z 420.<br>
Example 437<br>
3-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2'b]pyridazin-3-yl]propanoicacid1H NMR (CDCl3) 6 1.36 (1H, t, J= 7 Hz), 2.06 (2H, t, J= 7 Hz), 2.78 (2H, t, J= 7 Hz), 3.04 (2H, q, J= 7 Hz), 5.99 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.28 (1H, d, J= 5 Hz), 7.41 (1H, s), 7.45-7.55 (, m), 8.53 (1H, d, J= 5 Hz). MS (ESf): m/z 404, MS (ESI+): m/z 406.<br>
Example 438<br>
5-[2-benzyl-4-(2-chloro-4-pyridinyl)-7-ethylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid  NMR (CDCl3) 6 1.16-1.32 (2H, m), 1.39 (1H, t, J= 7 Hz), 1.38-1.53 (2H, m), 2.15 (2H, 1, J= 7 Hz), 2.30-2.40 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.21 (2H, s), 5.88 (1H, d, J= 4 Hz), 6.58 (lH,d, J= 4 Hz), 7.18-7.35 (7H,m), 8.49 (1H, d, J= 5 Hz). MS (ESI-): m/z 446, MS (ESf): m/z 448.<br>
Example 439 {2-[7-ethyl-2-methyl-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]ethoxy}acetic<br>
acid<br>
1H NMR (CDCh) 5 137 (1H, t, J= 7 Hz), 2.44 (1H, s), 2.59 (1H, s), 2.74-2.92 (2H, m),3.02(2H,q,J=7Hz),3.54-3.66(2H,m),3.93(2H,m),5.82(lH,d,J=4Hz),<br>
6.53 (1H, d, J= 4 Hz), 7.63 (1H, s), 8.52 (1H, s), 8.56 (1H, s).<br>
F.-x ample 440 {2-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]ethoxy}acetic<br>
acid<br>
,H NMR (CDCl3) 6 137 (1H, (, J= 7 Hz), 2.80 (2H, t, J= 7 Hz), 3.03 (2H, q, J= 7 Hz),<br><br>
3.20 (2H, t, J= 7 Hz), 3.72 (1H, s), 6.01 (1H, d, .1= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.42 (1H, d, J= 5 Hz), 7.45-7.60 (6H, m), 8.57 (J H, d, J= 5 Hz).<br>
Example 441 [4-(5-bromo-3-pyridiny])-7-e{hyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]aceticacid<br>
1H NMR (CDC1.0 6 1 -37 (1H, t, J= 7 Hz), 2.55 (1H, s), 2.97-3.10 (2H, m), 3.30-3.62 (2H, m), 5.97 (1H, m), 6.57 (1H, m), 8.03 (1H, s), 8.69 (1H, s), 8.77 (1H, s).<br>
MS(ESl+):m/z374 376.<br>
Example 442<br>
3-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(4-pyridinylmethoxy)methyl]pyrro]o[l,2-b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDCfe) 6 1.38 (1H, t, J= 7 Hz), 2.33-2.50 (2H, m), 2.42 (1H, s), 2.80-3.00 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.72 (2H, s), 4.83 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.36 (2H, d, J= 7 Hz), 7.55 (1H, s), 8.41 (1H, s), 8.44 (2H, d,J=7Hz),8.53(lH,s). MS(ESl+):m/z429 431.<br>
Example 443<br>
3-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(2-pyrazinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDC13) 6 1.38 (1H, t, J= 7 Hz), 2.42 (1H, s), 2.40-2.55 (2H, m), 2.83-3.12 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.84 (2H, s), 4.91 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.57 (1H, s), 8.42 (1H, s), 8.48-8.55 (1H, m), 8.76 (1H, s). MS (ES1+): m/z 432.<br>
Example 444<br>
3-{7-ethyl-4-(5-methyl-3-pyridinyl)-2-[(2-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDCl3) 6 1.37 (1H, t, J= 7 Hz), 2.43 (1H, s), 2.50-2.60 (2H, m), 2.88-3.05 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.81 (2H, s), 4.87 (2H, s), 5.82 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.27 (1H, m), 7.48 (1H, d, J= 8 Hz), 7.56 (1H, s), 7.77 (1H, t, J= 8 Hz), 8.43 (1H, s), 8.54 (2H, m).<br><br>
Example 445<br>
4-{7-elhyl-4-(5-methyl-3-pyridinyl)-2-[(4-pyridinylinelhoxy)melhyl]pyrro]o[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDCl3) 6 1.40 (1H, t, J= 7 Hz), 1.70-1.85 (2H, m), 2.16-2.31 (2H, m), 2.44 (1H, s), 2.53-2.83 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.72 (2H, s), 4.83-4.98 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.30 (2H, d, J= 7 Hz), 7.57 (1H, s), 8.38-8.55 (4H,m). MS (ESI-): m/z 443, MS (ESI+): m/z 445.<br>
Example 446<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-pyridiny]melhoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J= 7 Hz), 1.40-1.63 (4H, m), 2.20 (2H, t, J= 7 Hz), 2.52-2.68 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.69 (2H, s), 4.78 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.35 (2H, d, J= 6 Hz), 7.88 (1H, m), 8.54 (2H, d, J= 6 Hz), 8.55 (1H, m), 8.79 (1H, m).<br>
Example 447<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethy]-2-[(3-pyridiny]methoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDC13) 6 1.38 (1H, t, J= 7 Hz), 1.40-1.62 (4H, m), 2.17 (2H, t, J= 7 Hz), 2.50-2.67 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.69 (2H, s), 4.76 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.61 (1H, d, i= 4 Hz), 7.32-7.38 (1H, m), 7.77 (1H, d, J= 8 Hz), 7.88 (1H, m), 8.55 (2H, m), 8.65 (1H, m), 8.78 (1H, m). MS (ESI-): m/z 521 523, MS (ESI+): m/z 523 525.<br>
Example 448<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-pyridinylmethoxy)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}penlanoic acid<br>
1H NMR (CDCl3) 6 1.37 (1H, t, J= 7 Hz), 1.48-1.67 (4H, m), 2.26 (2H, t, J= 7 Hz), 2.53-2.75 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.82 (2H, s), 4.83 (2H, s), 5.90 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.26-7.34 (1H, m), 7.53 (1H, d, J= 8 Hz), 7.75-<br><br>
7.83 (1H, m), 7.87 (1H, m), 8.55 (] H, d, J= 2 Hz), 8.62 (1H, m), 8.77 (1H, d, J= 2 Hz). MS(ESI+):m/z523 525.<br>
Example 449<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-pyrazinylmethoxy)methy]]pynolo[J,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDC13) 5 1 -38 (1H51, J= 7 Hz), 1.45-1.64 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.53-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.83 (2H, s), 4.87 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.53 (1H, m), 8.77 (2H, m). MS (ESI˚): m/z 522 524, MS (ESI+): m/z 524 526.<br>
Example 450<br>
4-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-pyridinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDCl3) 6 1.39 (1H, t, J= 7 Hz), 1.69-1.84 (2H, m), 2.27 (2H, t, J= 7 Hz), 2.56-2.80 (2H, m), 3.02 (2H, q, J= 7 Hz), 4.73 (2H, s), 4.92 (2H, m), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.31 (2H, d, J= 6 Hz), 7.90 (1H, m), 8.46 (2H, d, J= 6 Hz), 8.57 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS (ESI-): m/z 507 509, MS (ES1+): m/z 509 511.<br>
Example 451<br>
4-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(3-pyridinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
 NMR (CDCl3) 6 1.38 (1H, t, J= 7 Hz), 1.66-1.83 (2H, m), 2.26 (2H, t, J= 7 Hz), 2.53-2.77 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.71 (2H, s), 4.86 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.33 (1H, m), 7.78 (1H, d, J= 8 Hz), 7.90 (1H, m), 8.50 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.60 (1H, s), 8.78 (1H, d, J= 2 Hz).<br>
MS(ES]+):m/z509 511.<br>
Example 452<br>
4-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-pyridinylmelhoxy)methyl]pyrroIo[l,2-b]pyridazin-3-yl}butanoic acid<br><br>
f<br>
1H NMR (CDCl3) 5 1.37 (1H, t, J= 7 Hz), 1.70-1.85 (2H, m), 2.23-2.34 (2H, m), 2.57-2.76 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.81 (2H, s), 4.90 (2H, m), 5.91 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.28 (1H, m), 7.49 (1H, d, J= 7 Hz), 7.77 (1H, t, J= 8 Hz), 7.88 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.57 (1H, m), 8.74 (1H, d, J= 2 Hz).<br>
MS(ESl+):m/z509 511.<br>
Example 453<br>
4-{4-(5-bromo-3-pyridinyl)-2-[(cyclopropylmethoxy)methyl]-7-ethylpynolo[l,2-,]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDC13) 6 0.22 (2H, m), 0.57 (2H, m), 1.07-1.22 (1H, m), 1.37 (1H, t, J= 7 Hz), 1.72-1.87 (2H, m), 2.28 (2H, t, J= 7 Hz), 2.58-2.77 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.41 (2H, d, J= 7 Hz), 4.72 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.93 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ESI'): m/z 470 472, MS (ESI+): m/z 472 474.<br>
Example 454<br>
4-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-pyrazinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDCl3) 6 1.38 (1H, t, J= 7 Hz), 1.68-1.83 (2H, m), 2.27 (2H, t, J= 7 Hz), 2.56-2.78 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.84 (2H, s), 4.92 (2H, m), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.91 (1H, m), 8.51 (2H, m), 8.56 (1H, d, J= 2 Hz), 8.76 (2H,m). MS (ESI'): m/z 508 510, MS (ES1+): m/z 510 512.<br>
Example 455<br>
3-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-pyridinylmelhoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl} propanoic acid<br>
 NMR (CDCl3) 5 1.39 (1H, t, J= 7 Hz), 2.38 (2H, t, J= 7 Hz), 2.83-2.98 (2H, m), 3.07 (2H, q, J= 7 Hz), 4.74 (2H, s), 4.83 (2H, s), 5.95 (1H, d, J= 4 Hz), 6.65 (1H, d, J= 4 Hz), 7.38 (2H, d, J= 6 Hz), 7.88 (1H, s), 8.43 (2H, d, J= 6 Hz), 8.55 (1H, s),8.78(lH,s). MS (ESI'): m/z 493 495, MS (ESI+): m/z 495 497.<br><br>
Example 456<br>
4-{4-(5-bi-omo-3-pyriclinyJ)-7-ethyl-2-[(2-hydroxyethoxy)methyl]pyrro]o[l,2-<br>
b]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDCl3) 5 1.37 (1H, t, J= 7 Hz), 1.68-1.83 (2H, m), 2.28 (2H, t, J= 7 Hz), 2.53-2.76 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.75 (2H, m), 3.79 (2H, m), 4.78 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.90 (1H, s), 8.56 (1H, s), 8.78 (JH,<br>
s). MS (ESI'): m/z 460 462, MS (ESI+): m/z 462 464.<br>
Example 457<br>
3-[2-[(cyclohexylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pynolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDCl3) 6 0.88-1.06 (2H, m), 1.10-1.36 (1H, m), 1.37 (1H, t, J= 7 Hz), 1.58-1.85 (6H, m), 2.42 (1H, s), 2.48-2.60 (2H, m), 2.80-3.02 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.39 (2H, d, J= 7 Hz), 4.67 (2H, m), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.57 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS (ESI˚): m/z 434, MS (ES1+): m/z 436.<br>
Example 458<br>
3-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexy]methoxy)methyl]-7-ethylpyrrolo[l,2-b]pyridazin-3-yl}propanoic acid<br>
JH NMR (CDCl3) 6 0.88-1.05 (2H, m), 1.10-1.36 (1H,m), 1.37 (1H, t, J= 7 Hz),<br>
1.56-1.83 (6H, m), 2.51 (2H, t, J= 7 Hz), 2.80-3.07 (2H, m), 3.06 (2H, q, J= 7 Hz), 3.37 (2H, d, J= 7 Hz), 4.67 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.55 (1H, s), 8.79 (1H, s). MS (ESI-): m/z 498 500, MS (ESI+): m/z 500 502.<br>
Example 459<br>
4-{4-(5-bromo-3-pyridinyl)-2-[(cyclohexylmethoxy)methyl]-7-ethylpyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (CDCl3) 6 0.86-1.03 (2H, m), 1.10-1.35 (1H, m), 1.37 (1H, t, J= 7 Hz),<br>
1.60-1.82 (8H, m), 2.28 (2H, t, J= 7 Hz), 2.55-2.76 (2H, m), 3.05 (2H, q, J= 7 Hz), 3.36 (2H, d, J= 7 Hz), 4.67 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz),<br><br>
7.91 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.76 (1H, d, J= 2 Hz). MS (ESI'): m/z 512 514, MS (ES1+): m/z 514 516.<br>
Example 460<br>
4-[2-[(cyclopropylmethoxy)methyl]-7-elhyl-4-(5-methyI-3-pyridinyJ)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (CDC13) 6 0.22-0.32 (2H,m), 0.55-0.63 (2H,m), 1.10-1.22 (lH,m), 1.37 (1H, t, J= 7 Hz), 1.73-1.86 (2H, m), 2.20-2.35 (2H, m), 2.46 (1H, s), 2.55-2.86 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.43 (2H, d, J= 7 Hz), 4.70-4.85 (2H, m), 5.88 (1H, d, J= 4 Hz), 6.57 (1H, d, J= 4 Hz), 7.62 (1H, s), 8.42 (1H, s), 8.46 (1H, s). MS (ESI+): m/z 408.<br>
Example 461<br>
3-[2-[(cyclopropylmethoxy)methyl]-7-ethyl-4-(5-methyl-3-pyridinyl)pyrro]o[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDC13) 5 0.23-0.35 (2H, m), 0.54-0.65 (2H, m), 1.08-1.24 (1H, m), 1.37 (1H, t, J= 7 Hz), 2.43 (1H, s), 2.50-2.65 (2H, m), 2.70-3.05 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.44 (2H, d, J= 7 Hz), 4.74 (2H, s), 5.89 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.56 (1H, s), 8.42 (1H, s), 8.53 (1H, s). MS (ESI-): m/z 392, MS (ESI+): m/z 394.<br>
Example 462<br>
3-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-methoxyethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDC13) 6 1.37 (1H, t, J= 7 Hz), 2.48-2.62 (2H, m), 2.83-3.02 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.37 (1H, s), 3.60 (2H, m), 3.73 (2H, m), 4.75 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78 (1H, d,J=2Hz). MS (ESI-): m/z 460 462, MS (ES1+): m/z 462 464.<br>
Example 463<br>
5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(4-moiphoIinylcarbonyl)oxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid<br><br>
1H NMR (CDCl3) 6 1.37 (1H, 1, J= 7 Hz), 1.35-1.65 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.40-2.56 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.48-3.57 (4H, m), 3.60-3.78 (4H, m), 5.33 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.79 (1H, d, J= 2 Hz).<br>
Example 464<br>
5-[4-(5-bromo-3-pyridinyl)-2-({[(dimethylamino)carbonyl]oxy}methyl)-7-elhy]pyrrolo[l ,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCl3) 5 1.36 (1H, t, J= 7 Hz), 1.45-1.65 (4H, m), 2.22 (2H, t, J= 7 Hz), 2.42-257 (2H, m), 2.97 (6H, s), 3.03 (2H, q, J= 7 Hz), 5.30 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.89 (1H, s), 8.54 (1H, s), 8.78 (1H, s). MS(ESl+):m/z503 505.<br>
Example 465<br>
5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(l-pyrrolidinylcarbonyl)oxy]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (CDCl3) 5 1.36 (1H, t, J= 7 Hz), 1.40-1.63 (4H, m), 1.82-1.97 (4H, m), 2.23 (2H, t, J= 7 Hz), 2.43-2.58 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.37-3.52 (4H, m), 5.31 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS (ESI-): m/z 527 529, MS (ES1+): m/z 529 531.<br>
Example 466<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-<br>
[({[methyl(phenyl)amino]carbonyl}oxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}penlanoic<br>
acid<br>
1H NMR (CDCl3) 6 1.38 (1H, t, J= 7 Hz), 1.40-1.58 (4H, m), 2.18 (2H, t, J= 7 Hz), 2.32-2.53 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.37 (1H, s), 5.36 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.16-7.40 (, m), 7.87 (1H, s), 8.52 (1H, s), 8.79 (lH.s).<br>
Example 467 4-(4-(5-bromo-3-pyiidl3iyl)-7-ethyl-2-{[(4-morpholinylcarbonyr)oxy]melhyl}pyrrolo[l,2-<br><br>
b]pyiidazin-3-yI)butanoic acid<br>
1H NMR (CDC13) 5 J .37 (1H, t, J= 7 Hz), J .65-1.84 (2H, m), 2.27 (2H, t, J= 7 Hz), 2.45-2.68 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.53 (4H, m), 3.69 (4H, m), 5.36 (2H, s), 5.95(lH,d,J=4Hz),6.63(lH,d,J=4Hz),7.91 (lH,m), 8.55 (1H, d, J= 2 Hz), 8.78(lH,d,J=2Hz).<br>
Example 468<br>
4-[4-(5-bromo-3-pyridinyl)-2-({[(dimethylamino)carbonyl]oxy}methyl)-7-<br>
ethylpyrrolo[l ,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (CDC13) 5 1.36 (1H, t, J= 7 Hz), 1.66-1.82 (2H, m), 2.27 (2H, t, J= 7 Hz), 2.46-2.68 (2H, m), 2.97 (6H, s), 3.04 (2H, q, J= 7 Hz), 5.33 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz).<br>
Example 469<br>
3-[4-(5-bromo-3-pyridinyl)-2-({[(dimethylamino)carbonyl]oxy}methyl)-7-ethylpyrroIo[l ,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (CDC13) 6 1.36 (1H, t, J= 7 Hz), 2.45 (2H, t, J= 7 Hz), 2.82-2.96 (2H, m), 2.97 (6H, s), 3.03 (2H, q, J= 7 Hz), 5.33 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS (ESI-): m/z 473 475, MS (ESI+): m/z 475 477.<br>
Example 470<br>
5-{4-(5-bromo-3-pyridinyl)-2-[(l,l-dioxido-4-thiori-»orpholinyl)methy]]-7-ethylpyrrolo[l ,2-b]pyridazin-3-yl}pentanoic acid<br>
JH NMR (300 MHz, CDC13) 5 1.36 (1H, t, J = 7 Hz), 1.42-1.56 (4H, m), 2.26 (2H, l, J = 7 Hz), 2.48-2.61 (2H, m), 3.01 (2H, q, J = 7 Hz), 3.10 (4H, t, J = 6 Hz), 3.19 (4H, t, J = 6 Hz), 3.85 (2H, s), 5.92 (1H, d, J = 4 Hz), 6.61 (1H, d, J = 4 Hz), 7.89 (1H, dd, J = 2, 2 Hz), 8.56 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz). MS(m/z)550(M+H).<br>
Example 471 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(4-thiomO]pho]iny]melhy])pyrrolo[l,2-b]pyridazin-<br><br>
3-y]]penlanoic acid<br>
1H NMR (300 MHz, CDCl3) 6 ] .37 (1H, t, J = 7 Hz), ] .43-1.58 (4H, m), 2.24 (2H, t, J = 7 Hz), 2.49-2.61 (2H, m), 2.66 (4H, t, J = 4 Hz), 2.86 (4H, 1, J = 4 Hz), 3.02 (2H, q, J = 7 Hz), 3.68 (2H, s), 5.89 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 7.90 (lH,s), 8.56 (lH,s), 8.79 (lH,s).<br>
MS(m/z)518(M+H).<br>
Example 472<br>
5-(4-(5-bromo-3-pyridinyI)-7-ethyl-2-{[4-(2-hydroxyethy])-l-<br>
piperazinyl]methyl}pyrrolo[l,2-b]pyridazin-3-y])pentanoicacid<br>
1H NMR (300 MHz, CDCl3) 6 1.34 (1H, t, J = 7 Hz), 1.41-1.57 (4H, m), 2.21 (2H, t, J = 6 Hz), 2.43-2.57 (2H, m), 2.80-2.84 (4H, m), 2.91-3.00 (6H, m), 3.65 (2H, s), 3.83 (2H, m), 5.88 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.88 (1H, s), 8.55 (1H,s),8.77(lH,s). MS (m/z) 545 (M+H).<br>
Example 473<br>
4-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(4-thiomorpholiny]melhy])pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (300 MHz, CDCl3) 6 1.37 (1H, t, J = 7 Hz), 1.72 (2H, tt, J = 7, 7 Hz), 2.26 (2H, t, J = 7 Hz), 2.53-2.68 (6H, m), 2.87-2.90 (4H, m), 3.02 (2H, q, J = 7 Hz), 3.72 (2H, s), 5.91 (1H, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.78 (1H, dd, J = 2,2 Hz), 8.52 (1H, d, J = 2 Hz), 8.68 (1H, d, J = 2 Hz). MS (m/z) 460 (M+H).<br>
Example 474<br>
4-{4.(5-chloro-3-pyridinyl)-7-ethyl-2-[(4-pyridinyImethoxy)methy]]pyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoic acid<br>
 NMR (300 MHz, CDC13) § 1.38 (1H, t, J = 7 Hz), 1.73 (2H, tt, J = 7, 7 Hz), 2.25 (2H, t, J = 7 Hz), 2.57-2.73 (2H, m), 3.04 (2H, q, J = 7 Hz), 4.72 (2H, s), 4.89 (2H, s), 5.93 (1H, d, J =5 Hz), 6.63 (1H, d, J =5 Hz), 7.31 (2H, d, J = 6 Hz), 7.76 (1H, dd, J = 2,2 Hz), 8.46 (2H, d, J = 6 Hz), 8.53 (1H, d, J = 2 Hz), 8.67 (1H, d, J = 2 Hz).<br><br>
MS (m/z) 465 (M+H).<br>
Example 475<br>
4-[4-(5-chloro-3-pyridinyl)-7-ethy]-2-(4-morpholiny]methyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoic acid<br>
1H NMR (300 MHz, CDC13) 6 1.37 (1H, I, J = 7 Hz), 1.73 (2H, tl, J = 7, 7 Hz), 2.26<br>
(2H, l, J = 7 Hz), 2.54-2.72 (6H, m), 3.03 (2H, q, J = 7 Hz), 3.66-3.73 (6H, m),<br>
5.90 (1H, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.79 (1H, s), 8.53 (1H, s), 8.67 (JH,<br>
s). MS (m/z) 443 (M+H).<br>
Example 476<br>
5-{4-(5-chloro-3-pyridinyl)-2-[(cyc]opropylmethoxy)methyl]-7-ethylpynolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (300 MHz, CDC13) 8 0.24 (2H, dt, J = 7, 7 Hz), 0.57 (2H, dt, J = 7, 7 Hz), 1.07-1.17 (lH,m), 1.38 (1H, t, J = 7 Hz), 1.45-1.61 (4H,m), 2.23 (2H, 1, J = 7 Hz), 2.52-2.66 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.41 (2H, d, J = 7 Hz), 4.70 (2H, s), 5.90 (1H, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.74 (1H, dd, J = 2, 2 Hz), 8.52 (1H, d, J = 2 Hz), 8.68 (1H, d, J = 2 Hz). MS (m/z) 442 (M+H).<br>
Example 477<br>
4-{4-(5-chloro-3-pyridinyl)-2-[(cyclopropylmethoxy)methyl]-7-ethy3pyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (300 MHz, CDCl3) 8 0.23 (2H, dt, J = 6, 6 Hz), 0.56 (2H, dt, J = 6, 6 Hz), 1.05-1.17 (1H, m), 1.37 (1H, t, J = 7 Hz), 1.75 (2H, tt, J = 7, 7 Hz), 2.28 (2H, t, J = 7 Hz), 2.57-2.70 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.42 (2H, d, J = 7 Hz), 4.73 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.77 (1H, dd, J = 2,2 Hz), 8.52 (1H, d, J = 2 Hz), 8.66 (1H, d, J = 2 Hz). MS (m/z) 428 (M+H).<br>
Example 478 5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(isobutoxymethyl)pynolo[l,2-b]pyridazin-3-<br><br>
yl]pentanoic acid<br>
1H NMR (300 MHz, CDC13) 5 0.93 (6H, d, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.42-<br>
1.59	(4H, m), 1.92 (1H, qt, J = 7,7 Hz), 2.24 (2H, 1, J = 7 Hz), 2.48-2.69 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.33 (2H, d, J = 7 Hz), 4.66 (2H, s), 5.91 (1H, d, J = 4 Hz),<br>
6.59	(1H, d, J = 4 Hz), 7.90 (1H, dd, J = 2,2 Hz), 8.56 (1H, d, J = 2 Hz), 8.77 (1H, d,J = 2Hz).<br>
MS(m/z)489(M+H).<br>
Example 479<br>
3-[4-(5-ch]oro-3-pyridinyl)-7-ethyl-2-(isobutoxymelhyl)pyrrolo[l,2-b]pyridazin-3-y]]propanoic acid<br>
 NMR (300 MHz, CDGh) 5 0.92 (6H, d, J = 7 Hz), 1.37 (1H, 1, J = 7 Hz), 1.91 (1H, qt, J = 7, 7 Hz), 2.49 (2H, t, J = 8 Hz), 2.82-2.98 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.35 (2H, d, J = 7 Hz), 4.69 (2H, s), 5.92 (1H, d, J = 4 Hz), 6.61 (1H, d, J = 4 Hz), 7.72 (1H, dd, J = 2, 2 Hz), 8.51 (1H, d, J = 2 Hz), 8.69 (1H, d, J = 2 Hz).<br>
MS (m/z) 416 (M+H).<br>
Example 480<br>
3-[4-(5-bromo-3-pyridinyI)-7-ethyl-2-(4-moipholinylmethyl)pyrroIo[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H NMR (300 MHz, CDC13) 5 1.36 (1H, 1, J = 7 Hz), 2.55 (2H, t, J = 8 Hz), 2.66 (4H, br s), 2.79-2.97 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.70-3.74 (6H, m), 5.92 (1H, d, J = 4 Hz), 6.61 (1H, d, J = 4 Hz), 7.90 (1H, dd, J = 2, 2 Hz), 8.55 (1H, d, J = 2 Hz), 8.79(lH,d,J = 2Hz). MS (m/z) 474 (M+H).<br>
Example 481<br>
4-[4-(5-bromo-3-pyridinyl)-7-e(hyl-2-(4-moipholinylmethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoic acid<br>
1H NMR (300 MHz, CDC13) 6 1.36 (1H, 1, J = 7 Hz), 1.73 (2H, tt, J = 7, 7 Hz), 2.26 (2H, t, J = 7 Hz), 2.57-2.70 (6H,m), 3.02 (2H, q, J = 7 Hz), 3.69 (6H, m), 5.90 (1H, d, J = 4 Hz), 6.58 (1H, d, J = 4 Hz), 7.93 (1H, dd, J = 2, 2 Hz), 8.57 (1H, d, J = 2Hz),8.77(lH,d,J = 2Hz).<br><br>
MS (m/z) 488 (M+H).<br>
Example 482<br>
4-{4-(5-ch]oro-3-pyricliny])-2-[(cyclopropylamino)methy]]-7-cthy]pyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H NMR (300 MHz, CDC13) 6 0.54-0.60 (2H, m), 0.74-0.79 (2H, m), 1.38 (1H, t, J = 7 Hz), 1.65 (2H, tt, J = 6, 6 Hz), 2.21 (2H, t, J = 6 Hz), 2.45-2.55 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.30 (2H, s), 5.04 (1H, br s), 5.93 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.73 (1H, dd, J = 2,2 Hz), 8.52 (1H, d, J = 2 Hz), 8.69 (1H, d, J = 2 Hz).<br>
MS (m/z) 413 (M+H).<br>
Example 483<br>
5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(2-phenoxyethyl)amino]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (300 MHz, CDCl3) 6 1.36 (1H, t, J = 7 Hz), 1.42-1.56 (4H, m), 2.22 (2H, br s), 2.34-2.48 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.38-3.43 (2H, br s), 4.23-4.50 (4H, m), 5.93 (1H, d, J = 4 Hz), 6.60 (1H, d, J = 4 Hz), 6.89-6.97 (1H, m), 7.23-7.30 (2H, m), 7.85 (1H, s), 8.52 (1H, s), 8.78 (1H, s).<br>
MS (m/z) 552 (M+H).<br>
Example 484<br>
5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(2-<br>
hydroxyethyl)(methyl)amino]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid 1H NMR (300 MHz, CDC13) 6 1.36 (1H, t, J = 7 Hz), 1.34-1.54 (4H, m), 2.15-2.26 (2H, m), 2.33-2.52 (2H, m), 2.98 (2H, q, J = 7 Hz), 3.16 (1H, s), 3.59-3.72 (2H, m), 3.99-4.10 (2H, m), 4.70 (2H, s), 5.94 (1H, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.85 (1H, s), 8.51 (1H, s), 8.73 (1H, s). MS (m/z) 490 (M+H).<br>
Example 485<br>
5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(l-piperidinylmethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br><br>
1H NMR (300 MHz, CDCl3) 6 1.36 (1H, t, J = 7 Hz), 1.39-1.51 (6H,m), 1.62-1.71 (4H, m), 2.19 (2H, I, J = 6 Hz), 2.52-2.65 (2H, m), 2.78-2.91 (4H, m), 3.10 (2H, q, J = 7 Hz), 3.65 (2H, s), 5.89 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 7.88 (JH, s), 8.55 (lH,s), 8.76 (lH,s).<br>
MS(m/z)5()0(M+H).<br>
Example 486<br>
3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(4-lhiomoq')holinylmethyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid<br>
]U NMR (300 MHz, CDCl3) 6 1.37 (1H, t, J = 7 Hz), 2.52 (2H, t, J = 8 Hz), 2.68 (4H, t, J = 5 Hz), 2.81-2.95 (6H, m), 3.02 (2H, q, J = 7 Hz), 3.74 (2H, s), 5.92 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 7.89 (1H, dd, J = 2,2 Hz), 8.55 (1H, d, J = 2 Hz), 8.79(lH,d,J = 2Hz). MS(m/z)490(M+H).<br>
Example 487<br>
3-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[4-(2-hydroxyethyl)-l-piperazinyl]methyl}pyrrolo[l,2-b]pyridazin-3-yl)propanoic acid<br>
1H NMR (300 MHz, DMSO-d6) 5 1.32 (1H, t, J = 7 Hz), 2.40-2.56 (12H, m), 2.58-2.65 (2H, m), 2.94 (2H, q, J = 7 Hz), 3.52 (2H, t, J = 5 Hz), 3.67 (2H, s), 5.83 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 8.25 (1H, dd, J = 2,2 Hz), 8.63 (1H, d, J = 2 Hz),8.86(lH,d,J = 2Hz). MS (m/z) 517 (M+H).<br>
Example 488<br>
4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(isobutoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (300 MHz, CDC13) 8 0.91 (6H, d, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.74 (2H, tt, J = 8, 8 Hz), 1.91 (1H, qt, J = 7,7 Hz), 2.27 (2H, t, J = 8 Hz), 2.56-2.73 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.33 (2H, d, J = 7 Hz), 4.68 (2H, s), 5.92 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.92 (1H, dd, J = 7, 7 Hz), 8.56 (1H, d, J = 2 Hz), 8.77(lH,d,J=2Hz). MS (m/z) 475 (M+H).<br><br>
Example 489<br>
5-[2-{[2-(benzylamino)-2-oxoethoxy]methyl}-7-ethyl-4-(5-methyl-3-pyridiny])pyrrolo[l ,2-b]pyridazin-3-y]]penlanoic acid<br>
1H NMR (CDCl3) 6 1 -33 (1H, t, J= 7 Hz), 1.39-1.60 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.42 (1H, s), 2.40-2.58 (2H, m), 2.95 (2H, q, J= 7 Hz), 4.19 (2H, s), 4.50 (2H, d, J= 7 Hz), 4.75 (2H, m), 5.91 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.07 (1H, br), 7.22-7.34 (, m), 7.54 (1H, s), 8.40 (1H, s), 8.53 (1H, s). MS (ESI): m/z 513, MS (ESI+): m/z 515.<br>
Example 490<br>
5-(7-ethyl-4-(5-methyl-3-pyridinyl)-2-{[(phenylsulfonyl)amino]methyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (CDCb) 6 1.36 (1H, t, J= 7 Hz), 1.23-1.60 (4H, m), 2.19 (2H, t, J= 7 Hz), 2.28-2.46 (2H, m), 2.42 (1H, s), 2.97 (2H, q, J= 7 Hz), 4.37 (2H, m), 5.89 (1H, d, J= 4 Hz), 5.90 (1H, m), 6.57 (1H, d, J= 4 Hz), 7.42-7.53 (4H, m), 7.90 (2H, d, J= 8 Hz), 8.34 (1H, s), 8.53 (1H, s). MS (ESI): m/z 505, MS (ESI+): m/z 507.<br>
Example 491<br>
5-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(l-pyrrolidinylmethyl)pyrrolo[l,2-b]pyridazin-3-yl]penlanoic acid<br>
1H NMR (300 MHz, CDCl3) 6 1.35 (1H, t, J = 7 Hz), 1.39-1.57 (4H, m), 1.79-1.88 (4H, m), 2.18 (2H, t, J = 7 Hz), 2.84-2.89 (6H, m), 3.00 (2H, q, J = 7 Hz), 3.89-<br>
4.02	(2H, m), 5.88 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.87 (1H, s), 8.55<br>
(1H,S),8.75(1H,S).<br>
MS (m/z) 486 (M+H).<br>
Example 492 3-[4-(3-chlorophenyl)-7-ethyl-2-(methoxymethyl)pynolo[l,2-b]pyridazin-3-yl]propanoic<br>
acid<br>
1H NMR (CDCl3) 8 1.37 (1H, t, J = 8 Hz), 2.39-2.48 (2H, m), 2.83-2.94 (2H, m),<br>
3.03	(2H, q, J = 8 Hz), 3.45 (1H, s), 4.65 (2H, s), 5.95 (1H, d, J = 5 Hz), 6.60 (1H,<br><br>
d, J = 5 Hz), 7.24 (1H, m), 7.35 (1H, br s), 7.40-7.46 (2H, m). MS(ESl+):m/z373(M + H).<br>
Example 493<br>
4-[4-(3-chlorophenyl)-7-elhyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]bulanoic<br>
acid<br>
1H NMR (CDC13) 6 1.37 (1H, t, J = 8 Hz), 1.64-1.78 (2H, m), 2.24 (2H, t, J = 8 Hz), 2.56-2.66 (2H, m), 3.04 (2H, q, J = 8 Hz), 3.45 (1H, s), 4.65 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.21-7.29 (1H, overlapped with CDCl3), 7.36 (lH.br s), 7.39-7.46 (2H,m).<br>
MS (ESI+): m/z 387 (M + H).<br>
Example 494<br>
5-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(4-phenyl-l-piperazinyl)methyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (300 MHz, CDC13) 6 1.37 (1H, t, J = 7 Hz), 1.41-1.61 (4H, m), 2.22 (2H, t, J = 7 Hz), 2.49-2.67 (2H, m), 2.76 (4H, t, J = 5 Hz), 3.03 (2H, q, J = 7 Hz), 3.20 (4H, t, J = 5 Hz), 3.73 (2H, s), 5.89 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 6.85 (1H, dd, J = 8,8 Hz), 6.93 (2H, J = 8 Hz), 7.25 (2H, J = 8 Hz), 7.90 (1H, dd, J = 2, 2 Hz), 8.56 (1H, d, J = 2 Hz), 8.77 (1H, d, J = 2 Hz).<br>
Example 495<br>
5-(4-(5-bromo-3-pyridinyl)-7-ethyl-2-{[(2-methoxyethyl)amino]melhyl}pyrrolo[l,2-<br>
b]pyridazin-3-yl)pentanoic acid<br>
1H NMR (300 MHz, CDCl3) 6 1.28 (1H, t, J = 7 Hz), 1.32-1.43 (4H, m), 2.03-2.17 (2H, m), 2.23-2.41 (2H, m), 2.49-2.88 (2H, m), 2.98 (2H, q, J = 7 Hz), 3.37 (1H, s), 3.89-3.99 (2H, m), 4.51 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.82 (1H, s), 8.47 (1H, s), 8.72 (1H, s).<br>
Example 496<br>
5-[7-ethyl-2-(methoxymethyl)-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid mp 111-112°C<br><br>
1H NMR (CDCl3) 6 1.37 (1H, t, J = 8 Hz), J .41-1.60 (4H, m), 2.21 (2H, br 1, J = 8 Hz), 2.30-2.70 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.46 (1H, s), 3.90 (1H, s), 4.63 (2H, br d, J = 5 Hz), 5.92 (1H, d, J = 5 Hz), 6.58 (2H, d, J = 8 Hz), 7.25 (1H, m), 8.22 (1H, d, J = 1 Hz), 8.40 (1H, d, J = 3 Hz).<br>
MS (ESI+): m/z 398 (M + H).<br>
Example 497<br>
5-[7-ethyl-4-(5-methoxy-3-pyridinyl)-2-methylpynolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
mp 133-134°C<br>
1H NMR (CDCl3) 6 1.37 (1H, 1, J = 8 Hz), 1.40-1.62 (7H, m), 2.24 (2H, t, J = 8 Hz), 2.35-2.49 (2H, m), 2.56 (1H, s), 3.01 (2H, q, J = 8 Hz), 3.89 (1H, s), 5.87 (1H, d, J = 5 Hz), 6.51 (1H, d, J = 5 Hz), 7.23 (1H, m), 8.20 (1H, d, J = 1 Hz), 8.39 (1H, d,J = 1Hz).<br>
MS (ESI+): m/z 369 (M + H).<br>
Example 498<br>
3-[7-ethyl-2-(methoxymethyl)-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoic acid mp 164-165°C<br>
1H NMR (CDCl3) 5 1.37 (1H, t, J = 8 Hz), 2.44-2.54 (2H, m), 2.80-3.00 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 3.89 (1H, s), 4.66 (2H, br s), 5.95 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.25 (1H, m), 8.22 (1H, d, J = 1 Hz), 8.38 (1H, d, J = 3 Hz).<br>
MS (ES1+): m/z 370 (M + H).<br>
Example 499<br>
4-[7-ethyl-2-(methoxymethyl)-4-(5-methoxy-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]bulanoic acid mp 140-141°C<br>
1H NMR (CDClj) 6 1.38 (1H, t, J = 8 Hz), 1.68-1.82 (2H, m), 2.25 (2H, t, J = 8 Hz), 2.52-2.75 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.46 (1H, s), 3.92 (1H, s), 4.65 (2H, br<br><br>
d, J = 7 Hz), 5.94 OH, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.29 (1H, m), 8.23 (lH,d,J = l Hz),8.37(lH,d,J = 1Hz). MS (ESI+): m/z 384 (M + H).<br>
Example 500<br>
5-[7-ethyl-2-(methoxymethyl)-4-(5-pyrimidinyl)pyrro]o[l,2-b]pyridazin-3-y]]pentanoic<br>
acid<br>
1H NMR (CDC13) 5 1.38 (1H, t, J = 8 Hz), 1.40-1.64 (4H, m), 2.25 (2H, t, J = 8 Hz), 2.49-2.61 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 4.65 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 8.82 (2H, s), 9.32 (1H, s). MS(ESI+):m/z369(M + H).<br>
Example 501<br>
4-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(methoxymethy])pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
mp 112-113˚0<br>
1H NMR (CDCl3) 6 1.38 (1H, t, J = 8 Hz), 1.66-1.79 (2H, m), 2.28 (2H, t, J = 8 Hz), 2.52-2.71 (2H, m), 3.05 (2H, d, J = 8 Hz), 3.46 (1H, s), 4.66 (2H, br s), 5.92 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 7.77 (1H, m), 8.53 (1H, d, J = 1 Hz), 8.67 (lH,d,J = 2Hz).<br>
MS(ESl+):m/z388(M + H).<br>
Example 502<br>
3-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yljpropanoic acid<br>
mp 159-16CC<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J = 8 Hz), 2.47 (2H, br t, J = 8 Hz), 2.79-2.98 (2H, m), 3.04 (2H, d, J = 8 Hz), 3.47 (1H, s), 4.66 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 5 Hz), 7.74 (1H, m), 8.51 (1H, d, J = 1 Hz), 8.68 (1H, d, J = 3 Hz).<br>
MS (ESI+): m/z 374,376 (M + H).<br>
Example 503 5-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(methoxymelhyl)pyrrolo[l,2-b]pyridazin-3-<br><br>
yl]penlanoic acid mp 118-]19°C<br>
1H NMR (CDCl3) 6 1.37 (1H, t, J = 8 Hz), 1.40-1.62 (7H, m), 2.24 (2H, t, J = 8 Hz), 2.45-2.64 (2H, in), 3.04 (2H, d, J = 8 Hz), 3.45 (1H, s), 4.63 (2H, s), 5.91 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.74 (1H, m),8.51 (lH,d, J = 1 Hz), 8.67 (1H, d,J = 2Hz).<br>
MS (ES1+): m/z 402,404 (M + H).<br>
Example 504<br>
4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(4H-l,2,4-triazol-4-ylmethyl)pyrrolo[l,2-<br>
b]pyridazin-3-yI]bulanoic acid<br>
1H-NMR (CDC)3) 6 1.36 (1H, t, J = 7 Hz), 1.60 (2H, m), 2.32 (2H, m), 2.46 (2H, m), 3.01 (2H, q, J = 7 Hz), 5.75 (2H, m), 5.97 (1H, d, J = 5 Hz), 6.66 (1H, d, J = 5 Hz), 7.87 (1H, m), 7.97 (1H, s), 8.53 (1H, s), 8.65 (1H, s), 8.69 (1H, s).<br>
Example 505<br>
4-{4-(5-bromo-3-pyridinyl)-2-[(cyclopropylamino)methyl]-7-ethylpyrrolo[l,2-b]pyridazin-3-yl}butanoic acid<br>
1H-NMR (CDCl3) 6 0.56 (2H, m), 0.75 (2H, m), 1.38 (1H, t, J = 7 Hz), 1.65 (2H, m), 2.21 (2H, m), 2.50 (2H, m), 3.01 (2H,q, J = 7 Hz), 3.27 (1H, br), 4.29 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.98 (1H, m), 8.55 (1H, m), 8.78 (lH,m). MS (ESf) m/z: 457 and 459 (M + H)<br>
Example 506<br>
4-{4-(5-bromo-3-pyridinyl)-7-ethyl-2-[(2-oxo-l,3-oxazolidin-3-y])methyl]pyrrolo[l,2-<br>
b]pyridazin-3-y]}butanoic acid<br>
1H-NMR (CDC13) 5 1.37 (1H, t, J = 7 Hz), 1.68 (2H, m), 2.31 (2H, m), 2.53 (2H, m), 2.98 (2H, q, J = 7 Hz), 3.77 (2H, m), 4.42 (2H, t,J = 7 Hz), 4.67 (2H, m), 5.94 (1H, d J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.89(1H, m), 8.55 (1H, m), 8.78 (1H, m).<br>
Example 507 2-bromo-4-[3-(elhoxycarbonyI)-7-ethyl-2-me(hyIpyrrolo[l,2-b]pyridazin-4-yl]benzoic<br><br>
acid<br>
1H-NMR (CDCl3) 6 1.00 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 2.62 (1H, s), 3.04 (2H, q, J = 7 Hz), 4.06 (2H, q, J = 7 Hz), 6.29 (1H, d, J = 5 Hz), 6.68 (1H, d, J = 5 Hz), 7.49 (2H, dd, J = 2 and 8 Hz), 7.82 (1H, d, J = 2 Hz), 8.07 (1H, d, J = 8 Hz). MS (ESI+) m/z: 431 and 433 (M + H)<br>
Example 508<br>
5-[4-(3-cyanophenyl)-7-ethyl-2-(phenoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic<br>
acid<br>
1H-NMR (CDCl3) 6 1.25-1.49 (7H, m), 2.15 (2H, m), 2.54 (2H, m), 3.02 (2H, q, J = 7 Hz), 5.23 (2H, s), 5.86 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 6.98 (1H, 1, J = 8 Hz), 7.06 (2H, d, J = 8 Hz), 7.28 (2H, t, J = 8 Hz), 7.60 (2H, m), 7.67 (1H, s), 7.77 (lH,m).<br>
Example 509<br>
5-[4-(3-cyanophenyl)-7-ethyl-2-(3-methyl-2-thienyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoic acid<br>
JH-NMR (CDCl3) 6 1.14-1.28 (4H, m), 1.37 (1H, t, J = 7 Hz), 2.01 (2H, t, J = 7 Hz), 2.23 (1H, s), 2.40 (2H, m), 3.02 (2H, q, J = 7 Hz), 5.92 (1J, d, J = 5 Hz)(, 6.64 (1H, d, J = 5 Hz), 6.94 (U, d, J = 5 Hz), 7.33 (1H, d, J = 5 Hz), 7.57-7.66 (2H, m), 7.73-7.76 (2H,m).<br>
Example 510<br>
(2E)-4-[4-(3-cyanophenyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]-2-butenoic acid1H-NMR (CDCl3) 6 1.38 (1H, t, J = 7 Hz), 2.55 (1H, s), 3.03 (2H, q, J = 7 Hz), 3.09 (2H, d, J = 7 Hz), 5.45 (1H, dt, J = 7 and 16 Hz), 6.05 (1H, d, J = 5 Hz), 6.25 (1H, d, J = 16 Hz), 6.57 (1H, d, J = 5 Hz), 7.55 (1H, t, J = 8 Hz), 7.66+-7.72 (1H, m). MS (ES1+): m/z 345 (M+H)<br>
Example 511<br>
4-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoic acid<br>
1H NMR (CDCl3) 5 1 -37 (1H, t, J= 7 Hz), 1.68-1.84 (2H, m), 2.28 (2H, t, J= 7 Hz),<br><br>
2.56-2.74 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.46 (1H, s), 4.66 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.57 (1H, d, J= 2 Hz), 8.78 (1H, d, J=2Hz). MS (ESI'): m/z 430 432, MS (ESI+): m/z 432 434.<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 159. Example 512<br>
ethyl 4-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]butanoale 1H NMR (CDC13) 6 1.26 (1H,t, J= 7 Hz), 1.36 (1H, t, J= 7 Hz), 1.35-1.45 (2H,m), 1.88 (2H, t, J= 7 Hz), 2.43-2.55 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 5.98 (1H, d, J= 4 Hz), 6.65 (1H, d, J= 4 Hz), 7.33 (1H, d, J= 5 Hz), 7.42-7.55 (6H,m),8.55QH,d,J=z). MS(ESI+):m/z448.<br>
Example 513<br>
ethyl 3-[4-(2-chloio-4-pyridinyl)-7-ethyl-2-phenyIpyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDCl3) 6 1.09 (1H, t, J= 7 Hz), 1.36 (1H, t, J= 7 Hz), 1.98-2.08 (2H, m), 2.75-2.85 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.92 (2H, q, J= 7 Hz), 6.00 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.32 (1H, d, J= 5 Hz), 7.42 (1H, s), 7.43-7.57 (, m), 8.55(lH,d,J=z). MS (ESI+): m/z 434.<br>
Example 514<br>
methyl {2-[4-(2-chloro-4-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-<br>
yl]ethoxy} acetate<br>
1H NMR (CDCl3) 5 1.36 (1H, t, J= 7 Hz), 2.73-2.85 (2H, t, J= 7 Hz), 3.03 (2H, t, J= 7 Hz), 3.15 (2H, t, J= 7 Hz), 3.74 (2H, s), 4.09 (1H, s), 6.02 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.39 (1H, m), 7.42-7.60 (6H, m), 8.53 (1H, d, J= 5 Hz). MS (ESI+): m/z 450.<br>
Example 515<br><br>
ethyl 5-[4-(3-cyanophenyl)-7-elhy]-2-(3-methyl-2-thieriyl)py]'rolo[l52-b]pyiidazin-3-<br>
yl]propanoate<br>
1H-NMR (CDCl3) 5 1.09-1.26 (7H, m), 1.36 (1H, t, J = 7 Hz), 1.93 (2H, t, J = 7 Hz), 2.23 (1H, s), 2.39 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.03 (2H, q, J = 7 Hz), 5.93 (1H, d, J = 5 Hz), 6.64 (1H, d, J = 7 Hz), 6.96 (1H, d, J = 5 Hz), 7.33 (1H, d, J = 5 Hz), 7.60-7.67 (2H, m), 7.72-7.79 (2H, m).<br>
Example 5J6<br>
methyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(2-lhienyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H-NMR (CDCl3) 5 1.21-1.47 (7H, m), 2.04 (2H, t, J = 7 Hz), 2.60 (2H, m), 3.05 (2H,<br>
q, J = 7 Hz), 3.61 (1H, s), 5.37 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.13 (1H,<br>
m), 7.36 (1H, m), 7.44 (1H, m), 7.62-7.78 (4H, m).<br>
Example 517<br>
ethyl 3-[4-(3-cyanophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]propanoate<br>
1H-NMR (CDCl3) 6 1.08 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.98 (2H, m), 2.75 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.89 (2H, q, J = 7 Hz), 5.93 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.41-7.55 (, m), 7.57-7.78 (4H, m).<br>
MS(ESI+):m/z424(M + H)<br>
Example 518<br>
ethyl 5-[4-(3-chlorophenyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate 1H-NMR (CDCl3) 6 1.02-1.25 (7H, m), 1.37 (1H, t, J = 7 Hz), 1.88 (2H, t, J = 7 Hz), 2.43 (2H, m), 3.01 (2H, q, J = 7 Hz), 4.00 (2H, q, J = 7 Hz), 5.96 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.29 (1H, m), 7.37-7.54 (8H, m). MS (ESI+): m/z 461<br>
Example 519 4-(5-bromo-3-pyridinyl)-7-ethyl-2-phenylpyrrolo[l,2-b]pyridazine-3-carbonitrile<br>
1H NMR (CDC13) 5 1.42 (1H, t, J = 8 Hz), 3.12 (2H, t, J = 8 Hz), 6.65 (1H, d, J = 5 Hz), 6.94 (1H, d, J = 5 Hz), 7.51-7.59 (1H, m), 7.83-7.91 (2H, m), 8.19 (1H, m), 8.85-8.92 (2H,m).<br><br>
MS (ESf): m/z 403,405 (M + H).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 175. Example 520<br>
5-{4-(3-cyanophenyl)-7-ethyl-2-[(4-pyridinylmethoxy)metliyl]pyrrolo[l,2-b]pyridazin-3-yljpentanoicacid<br>
1H NMR (CDCb) 6 1.38 (1H, t, J= 7 Hz), 1.36-1.57 (4H, m), 2.16 (2H, t, J= 7 Hz), 2.51-2.62 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.69 (2H, s), 4.78 (2H, s), 5.87 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.35 (2H, d, J= 5 Hz), 7.61 (2H, d, J= 5 Hz), 7.67 (1H, s), 7.77 (1H, m), 8.54 (2H, d, J= 5 Hz).<br>
MS (ESI˚): m/z 467, MS (ES1+): m/z 469.<br>
Example 521<br>
5-{4-[3-(aminocarbonyl)phenyl]-7-ethyl-2-[(4-pyridinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoic acid<br>
1H NMR (CDC13) 6 1.38 (1H, t, J= 7 Hz), 1.47-1.68 (4H, m), 2.15-2.40 (2H, m), 2.40-2.56 (1H, m), 2.82-2.96 (1H, m), 3.05 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.72 (1H, d, J= 17 Hz), 4.93 (1H, d,J= 17 Hz), 5.83 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.31 (2H, d, J= 5 Hz), 7.39 (1H, br), 7.45 (1H, d, J= 8 Hz), 7.58 (1H, t, J= 8 Hz), 7.69 (1H, br), 7.77 (1H, br), 7.98 (1H, d, J= 8 Hz), 8.57 (2H, d, J= 5 Hz). MS (ESF): m/z 485, MS (ES1+): m/z 487.<br>
Example 522<br>
5-{4-(3-cyanophenyl)-7-ethyl-2-[(2-pyrazinylmethoxy)methyl]pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDC13) 0 1 -38 (1H, t, J= 7 Hz), 1.30-1.57 (4H, m), 2.18 (2H, m), 2.48-2.65 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.83 (2H, s), 4.85 (2H, s), 5.86 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.61 (2H, d, J= 5 Hz), 7.68 (1H, s), 7.77 (1H, m), 8.53 (2H, d,J=z),8.76(lH,s). MS (ESF): m/z 468, MS (ESI+): m/z 470.<br>
Example 523<br><br>
5-{4-(3-cyanophenyl)-7-elhyl-2-[(3-pyricliny]methoxy)methy]]pynolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H NMR (CDCl3) 6 1.38 (1H, 1, J= 7 Hz), 1.38-1.57 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.49-2.62 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.69 (2H, s), 4.76 (2H, s), 5.85 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.33 (1H, m), 7.62 (2H, m), 7.67 (1H, s), 7.73-7.82 (2H, m), 8.53 (1H, d, J= 5 Hz), 8.67 (1H, s).<br>
MS (ESI-): m/z 467, MS (ESI+): m/z 469.<br>
Example 524<br>
5-[4-(3-cyanopheny])-7-ethyl-2-(5-methyI-3-isoxazolyI)pyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H-NMR (CDCl3) 6 1.34-1.52 (7H, m), 2.17 (2H, t, J = 7 Hz), 2.53 (1H, s), 2.77 (2H, m), 3.03 (2H, q, J = 7 Hz), 5.89 (1H, d, J = 5 Hz), 6.54 (1H, s), 6.67 (1H, d, J = 5 Hz), 7.63 (2H, m), 7.68 (1H, s), 7.78 (1H, m).<br>
Example 525<br>
5-[4-(3-cyanophenyl)-7-ethy]-2-(2-thienyl)pyrrolo[ 1,2-b]pyridazin-3-yl]penlanoic acid 1H-NMR (CDCl3) 5 1.23-1.42 (7H, m), 2.07 (2H, t, J = 7 Hz), 2.58 (2H, m), 3.03 (2H, q, J = 7 Hz), 5.87 (1H, d, J = 5 hz), 6.56 (1H, d, J = 5 Hz), 7.13 (1H, m), 7.36 (1H, m), 7.43 (1H, d, J = 5 Hz), 7.62 (2H, m), 7.70 (1H, s), 7.76 (1H, m).<br>
Example 526 3-[4-(3-cyanophenyl)-7-ethyl-2-pheny]pyno]o[l,2-b]pyridazin-3-yl]propanoic acid<br>
1H-NMR (CDCl3) 6 1.36 (1H, t, J = 7 Hz), 1.99 (2H, m), 2.75 (2H, m), 3.00 (2H, q, J<br>
= 7 Hz), 5.93 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.42-7.55 (, m), 7.57-<br>
7.78 (4H,m).<br>
Example 527 5-[4-(3-chlorophenyl)-7-elhyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid<br>
1H-NMR (CDCl3) S 1 -03-1.25 (4H, m), 1.36 (1H, t, J = 7 Hz), 1.90 (2H, t, J = 7 Hz), 2.41 (2H, m), 3.00 (2H, q, J = 7 Hz), 5.97 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.28 (1H, m), 7.35-7.54 (8H, m).<br>
MS(ESl+):m/z433(M+H)<br><br>
The following compound(s) was(were) obtained in a similar manner to thai of Example 180. Example 528<br>
ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(5-methyl-3-isoxazoIyI)pyrrolo[],2-b]pyridazin-3-yl]propanoate<br>
1H-NMR (CDCl3) 5 1.22 (1H, t, J = 7 Hz), 1.32-1.46 (, m), 1.72 (2H, m), 2.10 (2H, 1, J = 7 Hz), 2.54 (1H, s), 2.78 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.06 (2H, q, J = 7 Hz), 5.89 (1H, d, J = 5 Hz), 6.54 (1H, s), 6.66 (1H, d, J = 5 Hz), 7.62 (2H, m), 7.67 (lH,s), 7.77 (lH,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Preparation 176. Example 529<br>
ethyl 4-[4-(aminocarbonyl)-3-bromophenyl]-7-ethyl-2-methylpyrrolo[l,2-b]pyridazine-3-carboxylate<br>
1H-NMR (CDCl3) 6 1.03 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 2.60 (1H, s), 3.03 (2H, q, J = 7 Hz), 4.07 (2H, q, J = 7 Hz), 5.83 (1H, s, br), 6.19 (1H, s, br), 6.28 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 5 Hz), 7.46 (1H, d, J = 8 Hz), 7.72 (1H, s), 7.77 (lH,d,J = 8Hz).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 184. Example 530<br>
3-[2-(cyclopentylamino)-7-ethyl-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
1H-NMR (CDCb) 6 1.36 (1H, t, J = 7 Hz), 1.51-1.80 (6H, m), 2.15 (2H, m), 2.96 (2H, q, J = 7 Hz), 3.05 (1H, s), 4.27 (1H, m), 5.94 (1H, d, J = 5 Hz), 6.47-6.53 (2H, m), 7.53-7.59 (1H, m), 7.74 (1H, m).<br>
Example 531 3-[7-ethyl-2-(methylamino)-3-(methylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
1H-NMR (CDCl3) 6 1.37 (1H, t, J = 7 Hz), 2.94-3.07 (8H, m), 5.95 (1H, d, J = 5 Hz),<br><br>
6.50 (2H, m), 7.54-7.59 (1H, m), 7.74 (J H, m).<br>
The following compound(s) was(were) obtained in a similar manner lo that of Example 225. Example 532<br>
(2R,3R,4S,5S,6R)-2-({3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(methoxymelhyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoyl}amino)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}tetrydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)<br>
1H-NMR (CDC13) 5 1.07 (9H, s), 1.11 (9H, s), 1.16 (9H, s), 1.18 (9H, s), 1.37 (1H, t, J = 7 Hz), 2.23 (2H, m), 2.84 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.48 (1H, s), 3.91-4.21 (1H, m), 4.62-4.67 (2H, m), 5.00-5.26 (1H, m), 5.43 (2H, m), 5.91 (1H, d, J = 5 Hz), 6.55 (1H, m, br), 6.62 (1H, d, J = 5 Hz), 7.84 (1H, m), 8.51 (1H, m), 8.77 (lH,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 226. Example 533 [4-(3-chlorophenyl)-7-ethyl-2-(2-furyl)pyrrolo[l,2-b]pyridazin-3-yl]methanol<br>
1H-NMR (CDCl3) 5 1.40 (1H, t, J = 7 Hz), 2.53 (1H, t, J = 7 Hz), 3.07 (2H, q, J = 7 Hz), 4.48 (2H, m), 6.23 (1H, d, J = 5 Hz), 6.62 (1H, m), 6.71 (1H, d, J = 5 Hz), 7.10 (1H, d, J = 5 Hz), 7.46-7.52 (1H, m), 7.61 (1H, m), 7.64 (1H, m).<br>
Example 534 [4-(2-chloro-4-pyridinyl)-7-ethyl-2-methylpyrrolo[l,2-b]pyridazin-3-yl]methanol<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J = 8 Hz), 3.05 (2H, q, J = 8 Hz), 3.45-3.55 (4H, m), 4.40 (2H, br d, J = 7 Hz), 4.77 (2H, br s), 6.22 (1H, d, J = 5 Hz), 6.70 (1H, d, J = 5 Hz), 8.11 (1H, m), 8.74 (1H, br s), 8.80 (1H, d, J = 2 Hz). MS(ESI+):m/z302(M + H).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 227. Example 535<br><br>
(2R,3S,4S,5R,6R)-2-[(acetyloxy)melhyl]-6-({5-[4-(3-cyanophenyl)-7-elhyl-2-phenylpynolo[l,2-b]pyridazin-3-yl]pentyl}oxy)tetrydro-2H-pyran-3,4,5-triyl triacetate1H-NMR (CDCl3) 6 0.82-1 .18 (6H, m), 1.37 (1H, t, J = 7 Hz), 1.92-2.17 (14H, m), 2.35 (2H, m), 3.01 (2H, q, J = 7 Hz), 3.16 (1H, m), 3.62 (1H, m), 3.85 (1H, m), 4.11 (2H, m), 4.10 (2H, m), 4.30 (1H, d, J = 8.1 Hz), 4.96 (1H, m), 5.11 (1H, m), 5.35 (1H, m), 5.90 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 7.44-7.53 (, m), 7.60-7.80 (4H,m).<br>
The following compound(s) was(were) obtained in a similar manner to that of Example 228. Example 536<br>
ethyl 3-[7-ethyl-2-(hydroxymethyl)-4-(5-melhyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoate<br>
1H NMR (CDCl3) 6 1.19 (1H, t, J= 7 Hz), 1.39 (1H, t, J= 7 Hz), 2.33 (2H, t, J= 7 Hz), 2.43 (1H, s), 2.70-2.82 (2H, m), 3.04 (2H, q, J= 7 Hz), 3.71 (1H, t, J= 5 Hz), 4.05 (2H, q, J= 7 Hz), 4.89 (2H, d, J= 5 Hz), 5.98 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.52 (1H, s), 8.42 (1H, d, J= 2 Hz), 8.56 (1H, d, J= 2 Hz). MS(ESl+):m/z368.<br>
Example 537<br>
ethyl 4-[7-ethyl-2-(hydroxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCb) 6 1.24 (1H, t, J= 7 Hz), 1.39 (1H, t, J= 7 Hz), 1.62-1.78 (2H, m), 2.16-2.28 (2H, m), 2.36-2.53 (2H, m), 2.44 (1H, s), 3.06 (2H, q, J= 7 Hz), 3.86 (1H, t, J= 7 Hz), 4.12 (2H, q, J= 7 Hz), 4.90 (2H, m), 5.96 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.44 (1H, s), 8.56 (1H, s). MS (ES1+): m/z 382.<br>
Example 538<br>
ethyl 5-[4-(3-cyanophenyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]pentanoate<br>
1H NMR (CDCl3) 6 1.26 (1H, t, J= 7 Hz), 1.39 (1H, t, J= 7 Hz), 1.46-1.65 (4H, m), 2.16 (2H, t, J= 7 Hz), 2.32-2.44 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.12 (2H, q, J= 7<br><br>
Hz), 4.86 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 758-7.68 (1H, m), 7.75-7.82 (lH,m). MS(ESI+):m/z406.<br>
Example 539<br>
ethyl 4-[4-(5-bromo-3-pyridinyl)-7-elhyl-2-(hydroxymelhyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljbulanoate<br>
1H NMR (CDC13) 6 1.25 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.64-1.79 (2H, m), 2.23 (2H, t, J= 7 Hz), 2.42-2.53 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.91 (2H, s), 5.97 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.80 (1H, d, J= 2 Hz). MS(ESI+):m/z446 448.<br>
Example 540<br>
ethyl 3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDCl3) 6 1.20 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.32 (2H, m), 2.68-2.90 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.10 (2H, m), 4.89 (2H, s), 6.03 (1H, m), 6.65 (1H, m), 7.90 (1H, m), 8.58 (1H, m), 8.83 (1H, m). MS(ESI+):m/z432 434.<br>
Example 541<br>
ethyl 4-[4-(5-chloro-3-pyridinyl)-7-ethyl-2-(hydroxymethyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (300 MHz, CDCl3) 5 1.22 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 1.67 (2H, tt, J = 7, 7 Hz), 2.20 (2H, t, J = 7 Hz), 2.37-2.79 (2H, m), 3.04 (2H, q, J = 7 Hz), 3.77 (1H, t, J = 4 Hz), 4.07 (2H, q, J = 7 Hz), 4.91 (2H, d, J = 4 Hz), 5.96 (1H, d, J = 4 Hz), 6.61 (1H, d, J = 4 Hz), 7.73 (1H, dd, J = 2, 2 Hz), 8.52 (1H, d, J = 2 Hz),8.70(lH,d,J = 2Hz).<br>
Example 542<br>
ethyl 3-[4-(3-chlorophenyl)-7-ethyl-2-(hydroxymethyl)pynolo[l,2-b]pyridazin-3-<br>
yl]propanoate<br><br>
1H NMR (300 MHz, CDCl3) 6 1.20 (1H, 1, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 2.31 (2H, t, J = 8 Hz), 2.85 (2H, I, J = 8 Hz), 3.04 (2H, q, J = 7 Hz), 3.69-3.75 (1H, br s), 4.06 (2H, q, J = 7 Hz), 4.88 (2H, s), 6.00 (1H, d,J =4 Hz), 6.59 (1H, d, J = 4 Hz), 7.23-7.26 (1H, m), 7.36 (1H, s), 7.44-7.46 (2H, m).<br>
Example 543<br>
ethyl 4-[4-(3-chlorophenyl)-7-ethyl-2-(hydroxymelhyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCb) 5 1.21 (1H, t, J = 8 Hz), 1.38 (1H, t, J = 8 Hz), 1.57 (1H, s), 1.59-1.74 (2H, m), 2.20 (2H, t, J = 8 Hz), 2.37-2.47 (2H, m), 3.03 (2H, q, J = 8 Hz), 3.84 (1H, t, J = 5 Hz), 4.06 (2H, q, J = 8 Hz),4.39 (2H, d, J = 5 Hz), 5.32 (2H, s), 5.96 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.21-7.29 (1H, overlappled with CDCl3), 7.36 (1H, br s), 7.39-7.47 (2H, m).<br>
Example 544 9-(5-bromo-3-pyridinyl)-6-ethyl-lH,1H-furo[3,4-e]pyrrolo[l,2-b]pyridazin-l-one<br>
1H NMR (CDCl3) 6 1.42 (1H, t, J = 8 Hz), 3.11 (2H, q, J = 8 Hz), 5.32 (2H, s), 6.87 (1H, d, i = 5 Hz), 6.99 (1H, d, J = 5 Hz), 8.20 (1H, m), 8.83-8.87 (2H, m).<br>
MS (ESI+): m/z 358, 360 (M + H).<br>
4-(5-bromo-3-pyridinyl)-7-ethyl-2-(hydroxymethy])pyrrolo[l,2-b]pyridazine-3-carboxylic acid<br>
1H NMR (CDC13-CD30D) 6 1.40 (1H, t, J = 8 Hz), 3.09 (2H, q, J = 8 Hz), 4.93 (2H, s), 6.34 (1H, d,J = 5 Hz), 6.79 (1H, d, J = 5 Hz), 7.96 (1H, m), 8.55 (1H, br s), 8.73(lH,brs). MS (ESI+): m/z 376,378 (M + H).<br>
Example 545<br>
3-[4-(5-bromo-3-pyridinyl)-7-ethyl-2-(melhoxymethyl)pyrrolo[l,2-b]pyridazin-3-yl]-N-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrydro-2H-pyran-2-yljpropanamide<br>
1H-NMR (DMSO-d6) 6 1.30 (1H, t ,J = 7 Hz), 2.21 (1H, m), 2.96 (2H, q, J = 7 Hz),<br><br>
3.25-3.45 (8H, m), 3.66 (1H, m), 4.40 (1H, m), 4.55-4.67 (, m), 4.75 (1H, m), 5.85(lH,d,J = z),6.66(1H,d,J=z),8.23(lH,m),8.33(lH,d,br,J = 7 Hz), 8.61 (1H, m), 8.84 (1H, m).<br>
Example 546<br>
3-[7-e1Hy]-2-phenyl-3-(5-{[(2R,3R,4S1HR,6R)-3,41H-trihydroxy-6-<br>
(hydroxynie1Hyl)tetiydro-2H-pyran-2-yl]oxy}pentyl)pyrrolo[J,2-b]pyridazin-4-<br>
y]]benzonitrile<br>
1H-NMR (CDC13) 6 0.85-1.38 (6H, m), 1.46 (1H, t, J = 7 Hz), 2.13 (2H, m), 2.38 (2H, m), 2.65 (1H, m), 2.73 (1H, m), 3.02 (2H, q, J = 7 Hz), 3.23 (1H, m), 3.48-3.70 (4H, m), 3.80-4.01 (1H, m), 4.13 (1H, m), 5.90 (1H, d, J = 5 Hz), 663 (1H, d, J = 5 Hz), 7.42-7.55 (, m), 7.60-7.79 (4H, m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 235. Example 547<br>
N-(2-aminoe1Hyl)-3-[4-(5-bromo-3-pyridinyl)-7-elhyl-2-(me1Hoxymelhyl)pyrrolo[l,2-b]pyridazin-3-yl]propanamide<br>
1H-NMR (CDC13) 6 1.37 (1H, t, J = 7 Hz), 2.29 (2H, m), 2.72-3.07 (6H, m), 3.33 (2H, q, J = 7 Hz), 3.49 (1H, s), 4.68 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.06 (1H, m, br), 6.62 (1H, d, J = 5 Hz), 7.89 (1H, m), 8.55 (1H, m), 8.77 (1H, m). MS (ESf) m/z: 460 and 462 (M + H)<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 268. Example 548<br>
e1Hyl 3-{7-e1Hyl-4-(5-me1Hyl-3-pyridinyl)-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoate<br>
1H NMR (CDCl3) 5 1.15 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.37 (2H, t, J= 7 Hz), 2.43 (1H, s), 2.86-3.01 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.99 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.81 (2H, s), 5.95 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.27 (2H, d, J= 7 Hz), 7.51 (1H, s), 8.43 (1H, s), 8.56 (1H, s), 8.57 (2H, d, J= 7 Hz). MS (ES1+): m/z 459.<br><br>
Example 549<br>
e1Hyl 3-{7-e1Hyl-4-(5-me1Hyl-3-pyriclinyl)-2-[(2-pyrazinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoate<br>
1H NMR (CDC1.0 6 1.16 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.39 (2H, t, J= 7 Hz), 2.43 (1H, s), 2.88-3.03 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.01 (2H, q, J= 7 Hz), 4.83 (2H, s), 4.90 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.53 (1H, s), 8.42 (1H, m), 8.48-8.55 (1H, m), 8.76 (1H, s). MS (ESI+): m/z 460.<br>
Example 550<br>
e1Hyl 3-{7-e1Hyl-4-(5-me1Hyl-3-pyridinyl)-2-[(2-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoate<br>
1H NMR (CDCl3) 6 1.15 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.40 (2H, t, J= 7 Hz), 2.42 (1H, s), 2.88-3.00 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.99 (2H, q, J= 7 Hz), 4.79 (2H, s), 4.86 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.16-7.23 (1H, m), 7.45-7.53 (2H, m), 7.68 (1H, m), 8.42 (1H, m), 8.53 (2H, m). MS (ES1+): m/z 459.<br>
Example 551<br>
e1Hyl 4-{7-e1Hyl-4-(5-me1Hyl-3-pyridinyl)-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDCl3) 6 1.18 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.60-1.80 (2H, m), 2.13-2.25 (2H, m), 2.43 (1H, s), 2.53-2.76 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.03 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.83 (2H, m), 5.92 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.27 (2H, d, J= 5 Hz), 7.53 (1H, s), 8.42 (1H, s), 8.53 (1H, s), 8.55 (2H, d,J=z). MS(ESI+):m/z473.<br>
Example 552<br>
e1Hyl 5-{4-(3-cyanophenyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCl3) 5 1.22 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.35-1.57 (4H, m),<br><br>
2.11 (2H, t, J= 7 Hz), 2.53-2.65 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.03 (2H, q,J= 7 Hz), 4.67 (2H, s), 4.78 (2H, s), 5.87 (1H, d, J= 4 Hz), 6.61 (1H, ci, J= 4 Hz), 7.28 (2H, d, J= 5 Hz), 7.61 (2H, m), 7.66 (1H, s), 7.78 (1H, m), 8.58 (2H, d, J= 5 Hz). MS(ESI+):m/z497.<br>
Example 553<br>
e1Hyl 5-{4-(3-cyanopheny])-7-e1Hyl-2-[(2-pyrazinylme1Hoxy)me1Hy]]pyrro]o[l,2-b]pyridazin-3-y]}pentanoate<br>
1H NMR (CDC13) 5 1 -22 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.35-1.58 (4H, m), 2.11 (2H, 1, J= 7 Hz), 2.55-2.65 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.82 (2H, s), 4.86 (2H, s), 5.86 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.62 (2H, m), 7.67 (1H, s), 7.78 (1H, m), 8.51 (2H, m), 8.74 (1H, s).<br>
MS(ESl+):m/z498.<br>
Example 554<br>
e1Hyl 5-{4-(3-cyanophenyl)-7-e1Hyl-2-[(3-pyridinylme1Hoxy)me1HyI]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCl3) 6 1.22 (1H, t, J= 7 Hz), 1.39 (1H, t, J= 7 Hz), 1.32-1.66 (4H, m), 2.10 (2H, t, J= 7 Hz), 2.48-2.60 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.66 (2H, s), 4.75 (2H, s), 5.86 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.28 (1H, m), 7.58-7.63 (2H, m), 7.66 (1H, s), 7.66-7.80 (2H, m), 8.54 (1H, m), 8.62 (lH,m). MS(ESI+):m/z497.<br>
Example 555<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCl3) 5 1.23 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.40-1.62 (4H, m), 2.16 (2H, t, J= 7 Hz), 2.53-2.71 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.09 (2H, q, J= 7 Hz), 4.67 (2H, s), 4.78 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.31 (2H, d, J= 5 Hz), 7.88 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.58 (2H, d, J= 5 Hz), 8.79 (lH,d,J=2Hz).<br><br>
Example 556<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-7-elhyl-2-[(3-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCl3) 6 1 -23 (1H, t, J= 7 Hz), 1.40 (1H, 1, J= 7 Hz), 1.30-1.60 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.50-2.68 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.12 (2H, q, .1= 7 Hz), 4.68 (2H, s), 4.78 (2H, s), 5.95 (1H, m), 6.63 (1H, m), 7.24-7.38 (1H, m), 7.75 (1H, m), 7.89 (1H, m), 8.58 (2H, s), 8.64 (1H, s), 8.80 (1H, s).<br>
MS(ESf):m/z551553.<br>
Example 557<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCl3) 6 1.24 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.40-1.58 (4H, m), 2.12 (2H, t, J= 7 Hz), 2.53-2.68 (2H, m), 3.03 (2H, q, J= 7 Hz), 4.10 (2H, q, J= 7 Hz), 4.78 (2H, s), 4.84 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.22 (1H, m), 7.48 (1H, d, J= 8 Hz), 7.68-7.75 (1H, m), 7.88 (1H, m), 8.57 (2H, m), 8.78(lH,d,J=2Hz).<br>
Example 558<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-pyrazinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (CDCb) 6 1.22 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.40-1.62 (4H, m), 2.15 (2H, t, J= 7 Hz), 2.53-2.72 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.08 (2H, q, J= 7 Hz), 4.82 (2H, s), 4.86 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.88 (1H, m), 8.52 (2H, m), 8.55 (1H, d, J= 2 Hz), 8.74 (1H, m), 8.79 (1H, d, J= 2 Hz). MS (ES1+): m/z 552 554.<br>
Example 559<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pynolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDCl3) 5 1.19 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.60-1.80 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.55-2.74 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.06 (2H, q, J= 7<br><br>
Hz), 4.69 (2H, s), 4.83 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.30 (2H, d, J= 6 Hz), 7.88 (1H, m), 8.56 (2H, d, J= 6 Hz), 8.57 (1H, m), 8.80 (1H, m). MS (ES1+): m/z 537 539.<br>
Example 560<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(3-pyridinylmelhoxy)me1Hyl]pyrrolo[ 1,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDC13) 6 1.26 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.55-1.82 (2H, m), 2.18 (2H, t, J= 7 Hz), 2.52-2.72 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.05 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.83 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.28 (1H, m), 7.73 (1H, d, J= 8 Hz), 7.88 (1H, m), 8.54 (2H, m), 8.62 (1H, s), 8.79 (1H,<br>
s)<br>
Example 561<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDC13) 6 1.26 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.63-1.82 (2H, m), 2.18 (2H, t, J= 7 Hz), 2.55-2.75 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.00 (2H, q, J= 7 Hz), 4.80 (2H, s), 4.88 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.22 (1H, m), 7.48 (1H, d, J= 8 Hz), 7.71 (1H, t, J= 8 Hz), 7.89 (1H, m), 8.55 (2H, m), 8.78(lH,d,J=2Hz). MS(ESI+):m/z537 539.<br>
Example 562<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-2-[(cyclopropylme1Hoxy)me1Hyl]-7-e1Hylpyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDCl3) 6 0.25 (2H, m),0.60 (2H, m), 1.08-1.22 (1H, m), 1.22 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.69-1.82 (2H, m), 2.21 (2H, t, J= 7 Hz), 2.56-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.42 (2H, d, J= 7 Hz), 4.04 (2H, q, J= 7 Hz), 4.73 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J=2Hz),8.79(lH,d,J=2Hz). MS (ESf): m/z 500 502.<br><br>
Example 563<br>
e1Hyl 4-{4-(5-biomo-3-pyridiny])-7-e1Hyl-2-[(2-pyrazinylme1Hoxy)mc1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (CDCl3) 6 1-19 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 1.70-1.82 (2H, m), 2.23 (2H, t, J= 7 Hz), 2.56-2.76 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.04 (2H, q, J= 7 Hz), 4.84 (2H, s), 4.95 (2H, m), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.50 (2H, m), 8.56 (1H, s), 8.74 (1H, s), 8.79 (1H, m). MS (ESI+): m/z 538 540.<br>
Example 564<br>
e1Hyl 3-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoate<br>
1H NMR (CDC13) &amp; 1.16 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.41 (2H, t, J= 7 Hz), 2.85-3.07 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.02 (2H, q, J= 7 Hz), 4.68 (2H, s), 4.81 (2H, s), 5.95 (1H, d, J= 4 Hz), 6.65 (1H, d, J= 4 Hz), 7.31 (2H, d, J= 6 Hz), 7.87 (1H, m), 8.55 (1H, m), 8.56 (2H, d, J= 6 Hz), 8.79 (1H, d, J= 2 Hz). MS(ESI+):m/z523 525.<br>
Example 565<br>
e1Hyl 4-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{ [2-(tetrydro-2H-pyran-2-<br>
yloxy)e1Hoxy]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)butanoate<br>
1H NMR (CDCl3) 5 1.20 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.46-1.93 (8H, m), 2.21 (2H, t, J= 7 Hz), 2.55-2.76 (2H, m), 3.02 (2H, q, J= 7 Hz), 3.46-3.56 (1H, m), 3.60-3.68 (1H, m), 3.74-3.82 (2H, m), 3.83-3.96 (2H, m), 4.03 (2H, q, J= 7 Hz), 4.63 (1H, m), 4.77 (2H, s), 5.91 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz).<br>
Example 566<br>
e1Hyl 4-{4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (300 MHz, CDCl3) 6 1.19 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 1.70 (2H, t, J = 7 Hz), 2.19 (2H, t, J = 7 Hz), 2.55-2.67 (2H, m), 3.04 (2H, q, J = 7 Hz), 4.03 (2H, q, J = 7 Hz), 4.69 (2H, s), 4.83 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.63 (1H, d, J<br><br>
= 5 Hz), 7.29 (2H, d, J = 6 Hz), 7.73 (1H, dd, J = 2, 2 Hz), 8.52 (1H, d, J = 2 Hz), 8.58 (2H, d, J = 6 Hz), 8.69 (1H, d, J = 2 Hz).<br>
Example 567<br>
e1Hyl 3-[4-(3-chlorophenyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[ 1,2-b]pyridazin-3-<br>
yl]propanoate<br>
1H NMR (CDCl-0 5 1.20 (1H, t, J = 8 Hz), 1.37 (1H, t, J = 8 Hz), 2.33-2.44 (2H, m), 2.84-2.94 (2H, m), 3.03 (2H, q, J = 8 Hz), 3.45 (1H, s), 4.05 (2H, q, J = 8 Hz), 4.64 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 7.21-7.29 (1H, overlappled wi1H CDC13), 7.36 (1H, br s), 7.38-7.46 (2H,m).<br>
Example 568<br>
e1Hyl 4-[4-(3-chlorophenyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoate<br>
1H NMR (CDCl3) 5 1.20 (1H, t, J = 8 Hz), 1.37 (1H, t, J = 8 Hz), 1.62-1.78 (2H, m), 2.14-2.28 (2H, m), 2.53-2.66 (2H, m), 3.04 (2H, q, J = 8 Hz), 3.46 (1H, s), 4.04<br>
˚<br>
(2H, q, J = 8 Hz), 4.65 (2H, s), 5.93 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 721-7.29 (1H, overlappled wi1H CDC13), 7.36 (IH, br s), 7.39-7.46 (2H, rn).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of<br>
Example 272.<br>
Example 569<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-2-[(l,l-dioxido-4-1Hiomorpholinyl)me1Hyl]-7-<br>
e1Hylpyrrolo[l,2-b]pyridazin-3-yl}pentanoate<br>
1H NMR (300 MHz, CDC13) 5 1.23 (1H, t, J = 7 Hz), 1.36 (1H, t, J = 7 Hz), 1.39-1.53 (4H, m), 2.19 (2H, t, J = 7 Hz), 2.50-2.61 (2H, m), 3.00 (2H, q, J = 7 Hz), 3.10 (4H, t, J = 6 Hz), 3.21 (4H, t, J = 6 Hz), 3.85 (2H, s), 4.10 (2H, q, J = 7 Hz), 5.92 (IH, d, J = 4 Hz), 6.61 (IH, d, J = 4 Hz), 7.88 (IH, dd, J = 2,2 Hz), 8.55 (IH, d,J = 2Hz),8.80(lH,d,J=2Hz).<br>
Example 570<br>
e1Hyl 5-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(4-1Hiomorpholinylme1Hyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]pentanoate<br><br>
1H NMR (300 MHz, CDC13) 8 1.23 (1H, t, J = 7 Hz), .1.37 (1H, t, J = 7 Hz), 1.41-<br>
1.54	(4H, m), 2.19 (2H, t, J = 7 Hz), 2.50-2.61 (2H, m), 2.66 (4H, t, J = 4 Hz),<br>
2.85 (4H, t, J = 4 Hz), 3.01 (2H, q, J = 7 Hz), 3.67 (2H, s), 4.10 (2H, q, J = 7 H),<br>
5.88 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.88 (1H, dd, J = 2, 2 Hz), 8.55 (1H,<br>
d, J = 2 Hz), 8.79 (1H, d, J = 2 Hz).<br>
Example 571<br>
e1Hyl 5-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{[4-(2-hydroxye1Hyl)-l-<br>
piperazinyl]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoa1e<br>
1H NMR (300 MHz, CDC13) 6 1.23 (1H, t, J = 7 Hz), 1.36 (1H, t, J = 7 Hz), 1.40-<br>
1.55	(4H, m), 2.18 (2H, t, J = 7 Hz), 2.48-2.66 (12H, in), 3.02 (2H, q, J = 7 Hz),<br>
3.61 (2H, t, J = 5 Hz), 3.66 (2H, s), 4.10 (2H, q, J = 7 Hz), 5.88 (1H, d, J = 4 Hz),<br>
6.57	(1H, d, J = 4 Hz), 7.88 (1H, dd, J = 2,2 Hz), 8.55 (1H, d, J = 2 Hz), 8.78 (1H,<br>
d,J = 2Hz).<br>
Example 572<br>
e1Hyl 4-[4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(4-1Hiomorpholinylme1Hyl)pyirolo[l,2-<br>
b]pyridazin-3-yl]butanoate<br>
 NMR (300 MHz, CDCl3) 6 1.21 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.70 (2H, tt, J = 7, 7 Hz), 2.19 (2H, t, J = 7 Hz), 2.50-2.67 (6H, m), 2.86 (4H, t, J = 5 Hz), 3.02 (2H, q, J = 7 Hz), 3.70 (2H, s), 4.05 (2H, q, J = 5 Hz), 5.89 (1H, d, J = 4 Hz),<br>
6.58	(1H, d, J = 4 Hz), 7.74 (1H, dd, J = 2,2 Hz), 8.52 (1H, d, J = 2 Hz), 8.68 (1H,<br>
d,J = 2Hz).<br>
Example 573<br>
e1Hyl 4-[4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(4-moipholinylme1Hyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]butanoate<br>
1H NMR (300 MHz, CDCl3) 8 1.21 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.72 (2H, tt, J = 7,7 Hz), 2.20 (2H, t, J = 7 Hz), 2.56-2.69 (6H, m), 3.02 (2H, q, J = 7 Hz), 3.68-3.71 (6H, m), 4.05 (2H, q, J = 7 Hz) 5.89 (1H, d, J = 4 Hz), 6.58 (1H, d, J = 4 Hz), 7.74 (1H, dd, J = 2, 2 Hz), 8.53 (1H, d, J = 2 Hz), 8.69 (1H, d, J = 2 Hz).<br>
Example 574<br><br>
e1Hyl 3-[4-(5-brono-3-pyridinyl)-7-e1Hyl-2-(4-moipho]iny]me1Hyl)pyiTolo[l,2-b]pyridazin-3-y]]propanoale<br>
1H NMR (300 MHz, CDC1-0 5 1.21 (1H, t, J = 7 Hz), 1.34 (1H, t, J = 7 Hz), 2.47-2.54 (2H, m), 2.59 (4H, l, J = 5 Hz), 2.81-2.95 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.67 (4H, t, J = 5 Hz), 3.69 (2H, s), 4.07 (2H, q, J = 7 Hz), 5.90 (IH, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.88 (1H, dd, J = 2,2 Hz), 8.55 (1H, d, J = 2 Hz), 8.79 (1H, d, J = 2 Hz).<br>
Example 575<br>
e1Hyl 4-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(4-morpholinylme1Hyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]butanoate<br>
1H NMR (300 MHz, CDC13) 6 1.21 (1H, t, J = 7 Hz), 1.36 (1H, t, J = 7 Hz), 1.73 (2H, tt, J = 7,7 Hz), 2.20 (2H, t, J = 7 Hz), 255-2.69 (6H, m), 3.02 (2H, q, J = 7 Hz), 3.69 (4H, t, J = 5 Hz), 4.05 (2H, q, J = 7 Hz), 5.89 (1H, d, J = 4 Hz), 6.58 (1H, d, J = 4 Hz), 7.89 (1H, dd, J = 2,2 Hz), 8.57 (1H, d, J = 2 Hz), 8.79 (1H, d, J = 2 Hz).<br>
Example 576<br>
e1Hyl 4-{4-(5-chloro-3-pyridinyl)-2-[(cyclopropylamirio)me1Hyl]-7-e1Hylpyrrolo[l,2-<br>
b]pyridazin-3-yl}butanoate<br>
1H NMR (300 MHz, CDC13) 6 0.46-0.52 (4H, m), 1.21 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 1.71 (2H, tt, J = 8,8 Hz), 2.21 (2H, t, J = 8 Hz), 2.32-2.39 (1H, m), 2.45-2.54 (2H, m), 3.04 (2H, q, J = 7 Hz), 4.06 (2H, q, J = 7 Hz), 4.07 (2H, s), 5.89 (1H, d, J = 4 Hz), 6.57 (1H, d, J = 4 Hz), 7.72 (1H, dd, J = 2,2 Hz), 8.50 (1H, d,J = 2Hz),8.68(lH,d,J=2Hz).<br>
Example 577<br>
e1Hyl 5-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{[(2-<br>
phenoxye1Hyl)amino]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br>
1H NMR (300 MHz, CDC13) 6 1.23 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.40-1.56 (4H, m), 2.18 (2H, t, J = 8 Hz), 2.41-2.52 (2H, m), 3.04 (2H, q, J = 7 Hz), 3.19 (2H, t, J = 5 Hz), 4.07 (2H, s), 4.09 (2H, q, J = 7 Hz), 4.17 (2H, t, J = 5 Hz), 5.90 (1H, d, J = 4 Hz), 6.57 (1H, d, J = 4 Hz), 6.92-6.98 (1H, m), 7.29-7.32 (2H, m),<br><br>
7.86 (1H, dd, J = 2,2 Hz), 8.54 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz).<br>
Example 578<br>
e1Hyl 5-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{[(2-<br>
hydroxyetliyl)(me1Hyl)amino]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoale<br>
1H NMR (300 MHz, CDC13) b 1.23 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.42-1.63 (4H, m), 2.20 (2H, t J = 8 Hz), 2.38 (1H, s), 2.53-2.64 (2H, m), 2.75 (2H, I, J = 5 Hz), 3.02 (2H, q, J = 7 Hz), 3.66 (2H, t, J = 5 Hz), 3.77 (2H, s), 4.10 (2H, q, J = 7 Hz), 5.90 (1H, d, J = 4 Hz), 6.59 (1H, d, J = 4 Hz), 7.88 (1H, dd, J = 2,2 Hz), 8.55 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz).<br>
Example 579<br>
e1Hyl 5-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(l-piperidinylme1Hyl)pyrrolo[l,2-b]pyridazin-<br>
3-yl]pentanoate<br>
1H NMR (300 MHz, CDCl3) 8 1.23 (1H, t, J = 7 Hz), 1.36 (1H, t, J = 7 Hz), 1.42-1.58 (6H, m), 1.69 (4H, tt, J = 5,5 Hz), 2.18 (2H, t, J = 8 Hz), 2.53-2.64 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.19 (4H, t, J = 5 Hz), 3.60 (2H, s), 4.07 (2H, q, J = 7 Hz), 5.86 (1H, d, J = 5 Hz), 6.54 (1H, d, J = 5 Hz), 7.89 (1H, dd, J = 2,2 Hz), 8.56 (1H, d, J = 2Hz),8.75(lH,d,J = 2Hz).<br>
Example 580<br>
e1Hyl 3-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(4-1Hiomorpholinylme1Hyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]propanoate<br>
1H NMR (300 MHz, CDCl3) 6 1.23 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 2.46 (2H, t, J = 8 Hz), 2.64 (4H, t, J = 5 Hz), 2.86 (6H, m), 3.02 (2H, q, J = 7 Hz), 3.69 (2H, s), 4.06 (2H, q, J = 7 Hz), 5.91 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.88 (1H, dd, J = 2, 2 Hz), 8.56 (1H, d, J = 2 Hz), 8.80 (1H, d, J = 2 Hz).<br>
Example 581<br>
e1Hyl 3-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{ [4-(2-hydroxye1Hyl)-l -<br>
piperazinyl]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)propanoate<br>
1H NMR (300 MHz, CDCl3) 6 1.21 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 2.46-2.63 (12H, m), 2.80-2.94 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.61 (2H, t, J = 5 Hz), 3.70<br><br>
(2H, s), 4.08 (2H, q,J = 7 Hz), 5.90 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.88 (1H, dd, J = 2,2 Hz), 8.56 (1H, d, J = 2 Hz), 8.79 (1H, d, J = 2 Hz).<br>
Example 582<br>
e1Hyl 5-[4-(5-biomo-3-pyridinyl)-7-e1Hyl-2-(l-pyrro]idinylme1Hyl)pyrrolo[l,2-<br>
]pyridazin-3-yl]pentanoate<br>
1H NMR (300 MHz, CDC13) 8 1 -23 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.40-1.55 (4H, m), 1.75-1.80 (4H, m), 2.19 (2H, t, J = 7 Hz), 2.54-2.66 (6H, m), 3.02 (2H, q, J = 7 Hz), 3.76-3.81 (2H,m), 4.10 (2H, q, J = 7 Hz), 5.87 (1H, d, J = 5 Hz), 6.55 (1H, d, J = 5 Hz), 7.89 (1H, dd, J = 2, 2 Hz), 8.56 (1H, d, J = 2 Hz), 8.77 (1H, d, J = 2 Hz).<br>
Example 583<br>
e1Hyl 5-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(4-phenyl-l-piperazinyl)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}pentanoate<br>
1H NMR (300 MHz, CDC13) 6 1.21 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 1.41-1.54 (4H, m), 2.17 (2H, t, J = 7 Hz), 2.53-2.68 (2H, m), 2.75 (4H, t, J = 5 Hz), 3.03 (2H, q, J = 7 Hz), 3.19 (4H, t, J = 5 Hz), 3.73 (2H, s), 4.07 (2H, q, J = 7 Hz), 5.89 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 5 Hz), 6.85 (1H, dd, J = 8, 8 Hz), 6.93 (2H, J = 8 Hz), 7.25 (2H, J = 8 Hz), 7.89 (1H, dd, J = 2,2 Hz), 8.56 (1H, d, J = 2 Hz), 8.78 (lH,d,J = 2Hz).<br>
Example 584<br>
e1Hyl5-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{[(2-<br>
me1Hoxye1Hyl)amino]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br>
}U NMR (300 MHz, CDCl3) 5 1.23 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.41-1.60 (4H, m), 2.19 (2H, t, J = 7 Hz), 2.43-2.52 (2H, m), 2.96 (2H, t, J = 5 Hz), 3.03 (2H, q, J = 7 Hz), 3.40 (1H, s), 3.58 (2H, t, J = 5 Hz), 3.99 (2H, s), 4.10 (2H, q, J = 7 Hz), 5.89 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.87 (1H, dd, J = 2,2 Hz), 8.54 (1H, d, J = 2 Hz), 8.78 (1H, d, J = 2 Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 385.<br><br>
Example 585<br>
3-[4-(5-bromo-3-pyridiny])-7-elhy]-2-(me1Hoxymelhyl)pyrroIo[l,2-b]pyridazin-3-yl]-N-[2-hydroxy-l,l-bis(hydroxymelhyl)e1Hyl]propanamide<br>
1H-NMR (CDCl3) 6 137 (1H,t, J = 7 Hz), 2.25-3.10 (6H, m), 3.49 (1H, s), 3.58 (4H, m),3.81 (2H,m),455(2H,s),5.97(lH,d,J=z),61H4(IH,s),6.64(lH,d,J = 5 Hz), 7.93 (1H, m), 8.52 (1H, m), 8.78 (1H, m).<br>
Example 586<br>
tert-butyl [2-({3-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrro]o[l,2-<br>
b]pyridazin-3-yl]propanoyl}amino)e1HyI]carbamate<br>
1H-NMR (CDCl3) 6 1.37 (1H, t, J = 7 Hz), 1.43 (9H, s), 2.26 (2H, m), 2.88 (2H, m), 3.04 (2H, q, J = 7 Hz), 3.20 (2H, m), 3.28 (2H, m), 3.48 (1H, s), 4.67 (2H, s), 4.85 (1H, s, br), 5.93 (1H, d, J = 5 Hz), 6.20 (1H, s, br), 6.63 (1H, d, J = 5 Hz), 7.88 (1H, m), 8.53 (1H, m), 8.79 (1H, m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 330. Example 587<br>
e1Hyl 5-[2-{[2-(benzylamino)-2-oxoe1Hoxy]me1Hyl}-7-e1Hyl-4-(5-me1Hyl-3-pyridinyl)pyrrolo[ 1 ,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDCl3) 6 1.22 (1H, t, J= 7 Hz), 1.34 (1H, t, J= 7 Hz), 1.33-1.55 (4H; m), 2.12 (2H, t, J= 7 Hz), 2.43 (1H, s), 2.40-2.56 (2H, m), 2.96 (2H, q, J= 7 Hz), 4.07 (2H, q, J= 7 Hz), 4.19 (2H, s), 4.52 (2H, d, J= 7 Hz), 4.76 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.59 (1H, d, J= 4 Hz), 7.06 (1H, br), 7.23-7.38 (, m), 7.49 (1H, s), 8.40 (1H,S),8.54(1H,S). MS (ESI+): m/z 543.<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 333. Example 588<br>
e1Hyl4-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(4H-l,2,4-triazol-4-ylme1Hyl)pyrro]o[l,2-b]pyridazin-3-yl]butanoate<br>
1H-NMR (CDCl3) 8 1.22-1.34 (6H, m), 1.67 (2H, m), 2.23 (2H, m), 2.51 (2H, m),<br><br>
2.98(2H,q,J = 7Hz),4.21 (2H, q, J = 7 Hz), 5.67 (2H, m), 5.97 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 7.85 (1H, m), 7.96 (1H, s), 8.34 (1H, s), 8.53 (1H, m), 8.79 (1H, m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 336. Example 589<br>
e1Hyl 5-(7-e1Hyl-4-(5-me1Hyl-3-pyridinyl)-2-{[(phenylsulfonyl)araino]me1Hyl}pyrrolo[l,2-b]pyridazin-3-yl)pentanoate<br>
1H NMR (CDC13) 6 1.23 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.26-1.57 (4H, m), 2.16 (2H, t, J= 7 Hz), 2.33-2.46 (2H, m), 2.42 (1H, s), 2.98 (2H, q, J= 7 Hz), 4.11 (2H, q, J= 7 Hz), 4.38 (2H, m), 5.91 (1H, br), 5.92 (1H, d, J= 4 Hz), 6.58 (1H, d, J= 4 Hz), 7.43-7.55 (4H, m), 7.93 (2H, d, J= 8 Hz), 8.33 (1H, d, J= 2 Hz), 8.54 (lH,dsJ=2Hz).<br>
MS(ESI+):m/z 535.<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 340. Example 590<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-2-[(cyclopropylamino)me1Hyl]-7-e1Hylpyrrolo[l,2-b]pyridazin-3-yl}butanoate<br>
1H-NMR (CDCl3) 5 0.48 (4H, m), 1.19 (1H, t, J = 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.70 (2H, t, J = 7 Hz), 2.22 (2H, m), 2.50 (2H, m), 2.95-3.07 (1H, m), 3.96-4.12 (4H, m), 5.90 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.88 (1H, m), 8.54 (1H, m), 8.77 (lH,m).<br>
Example 591<br>
To a suspension of L1A1H4 (113 mg) in 1HF (10 mL) was added e1Hyl [4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]acetate (600 mg) under ice-water cooling and 1He mixture was stirred at 0 °C for 2 hours. To 1He mixture was added potassium sodium tartrate solution and 1He insolubles were filterred off. After evaporation of solvent, 1He residue was partitioned between AcOEt and water. 1He organic layer was separated, washed wi1H brine, dried over MgSO4, and evaporated in<br><br>
vacuo. 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of hexane and AcOEt (5:1 - 1:1) to give 2-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-mclhylpyrrolo['1 ,2-b]pyridazin-3-yl]e1Hanol as yellow oil (246 mg).<br>
2-[4-(5-bromo-3'pyridinyl)-7-e1HyI-2-meihylpyrrolo[l,2-b]pyridazin-3-yl]e1Hanol<br>
1H NMR (CDC13) 5 137 (1H, t, 3= 7 Hz), 2.60 (1H, s), 2.72-2.84 (2H, m), 3.03 (2H, q,J=7Hz),3.65(2H,t,J=7Hz),5.89(1H,d,J=4Hz),655(lH,d,J=4Hz), 7.91 (1H, t, J= 2 Hz), 8.56 (1H, d, J= 2 Hz), 8.76 (1H, d, J= 2 Hz).<br>
MS(ESI+):m/z360 362.<br>
Example 592<br>
A mixture of 3-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]propanoic acid (1.07 g), diphenylphosphoryl azide (1.14 g) and Et3N (0.576 mL) in BuOH (30 mL) was heated under reflux for 2 hours. After evaporation of solvent, 1He residue was partitioned between AcOEt and water. 1He organic layer was separated, washed wi1H aq NC03 solution and brine, dried over MgS04, and evaporated in vacuo. 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of hexane and AcOEt (20:1 - 3:1) to give tert-butyl {2-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]e1Hyl}carbamate as yellow oil (450 mg).<br>
tert-butyl {2-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-<br>
yl]e1Hyl} carbamate<br>
1H NMR (CDCb) 6 1.37 (9H5 s), 1.37 (1H, t, J= 7 Hz), 2.64 (1H, s), 2.62-2.75 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.10-3.27 (2H, m), 4.40-4.52 (1H, m), 5.89 (1H, d, J= 4 Hz), 6.55 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.53 (1H, m), 8.77 (1H, m).<br>
Example 593<br>
To a suspension of 60% N (74 mg) in DMF (3 mL) was added e1Hyl 3-[4-(5-bromo-3-pyridinyl)-7-e1Hy]-2-(hydroxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoate (200 mg) under ice-water cooling, and 1He mixture was stirred at 0 °C for 0.5 hour. To 1His was added 3-(bromomelbyl)pyridine hydrobromide (234 mg) under ice-water cooling, and 1He mixture was stirred at ambient temperature for 2 hours. 1He mixture was<br><br>
partitioned between AcOEt and water. 1He aqueous layer was separated, acidified to pH 3-4 wi1H HC1 and extracted wi1H AcOEt. 1He organic layer was washed wi1H water and brine, dried over MgS04, and evaporated in vacuo. 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of CHCl3 and MeOH (100:1 - 20: J) to give 3-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(3~pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoic acid as a yellow powder (110 mg).<br>
3-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(3-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-<br>
b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDCb) 5 1.39 (1H,1, J= 7 Hz), 2.41 (2H, t, J= 7 Hz), 2.80-2.98 (2H, m), 3.04 (2H, q, J= 7 Hz), 4.70 (2H, s), 4.83 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d5 J= 4 Hz), 7.32-7.38 (1H, m), 7.81 (1H, d, J= 8 Hz), 7.87 (1H, m), 8.52 (1H, d, J= 8 Hz), 8.53 (1H, d, J= 2 Hz), 8.63 (1H, s), 8.77 (1H, d, J= 2 Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 593. Example 594<br>
4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-me1Hoxye1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3~yl}butanoic acid<br>
]U NMR (CDCl3) 5 1.37 (1H, t, J= 7 Hz), 1.72-1.83 (2H, m), 2.28 (2H, t, J= 7 Hz), 2.60-2.77 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.39 (1H, s), 3.62 (2H, m), 3.77 (2H, m), 4.75 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.92 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz). MS (ESI-): m/z 474 476, MS (ESf): m/z 476 478.<br>
Example 595<br>
3-{4_(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoic acid<br>
1H NMR (CDCb) 6 1.38 (1H, t, J= 7 Hz), 2.48-2.62 (2H, m), 2.98-3.10 (2H, m), 3.05 (2H, q, J= 7 Hz), 4.82 (2H, s), 4.88 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.27 (1H, m), 7.48 (1H, d, J= 8 Hz), 7.77 (1H, t, J= 8 Hz), 7.90 (1H, m), 8.56 (2H,m), 8.80 (lH,m). MS(ESl+):m/z495 497.<br><br>
Example 596<br>
3-{45-bromo-3-pyridiny])-2-[(cycIopropylme1Hoxy)melhyl]-7-e1Hy]pyrro]o[l,2-b]pyridazin-3-yl}propanoic acid<br>
1HNMR(CDa3)6 0.25(2H,m),058(2H,m),1.12(lH,m), 1.37 (1H, t, J= 7 Hz), 2.40-2.63 (2H, m), 2.85-3.05 (2H, m), 3.02 (2H, q, J= 7 Hz), 342 (2H, d, J= 7 Hz), 4.73 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.77 (1H, d, J= 2 Hz).<br>
MS (ESF): m/z 456 458, MS (ESI+): m/z 458 460.<br>
Example 597<br>
3-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2'pyrazinylmelhoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3~yl}propanoic acid<br>
1H NMR (CDC13) 5 1.38 (1H, t, J= 7 Hz), 2.48 (2H, t, J= 7 Hz), 2.85-3.09 (2H, m), 3.06 (2H, q, J= 7 Hz), 4.84 (2H, s), 4.92 (2H, s), 5.96 (1H, d, J= 4 Hz), 6.65 (1H, d, J= 4 Hz), 7.90 (1H, m), 8.48-8.62 (1H, m), 8.77 (2H, m).<br>
Example 598<br>
A mixture of e1Hyl 4-(4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-{[2-(tetrydro-2H-pyran-2-yloxy)e1Hoxy]me1Hyl}pyrro]o[l,2-b]pyridazin-3-yl)butanoate (89 mg) and pyridinium p-toluenesulfonate (0.8 mg) in MeOH (5 mL) was heated under reflux for 2 hours. After evaporation of solvent, 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of hexane and AcOEt (10:1 - 1:1) to give e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-hydroxye1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}butanoate as yellow oil (69 mg).<br>
e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-[(2-hydroxye1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}butanoate<br>
1HNMR(CDCl3)5l.22(1H,lJ=7Hz),1.37(1H,t,J=7Hz), 1.69-1.84 (2H,m), 2.22 (2H,1, J= 7 Hz), 2.53-2.72 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.76 (2H, m), 3.83 (2H, m), 4.07 (2H, q, J= 7 Hz), 4.79 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.79 (1H, d, J= 2 Hz). MS(ESI+):ni/z490 492.<br><br>
Example 599<br>
To a suspension of 60% N (69.5 mg) in DMF (3 mL) was added e1Hyl 5-[4-(5-bromo-3-pyridinyl)-7-e1HyI-2-(hydroxyme1Hyl)pyrrolo[J,2-b]pyridazin-3-yl]pentanoate (200 nig) under ice-water cooling and 1He mixture was stirred at 0 °C for 0.5 hour. To 1His was added 4-morpholinecarbonyl chloride (659 mg) and 1He mixture was stirred at ambient temperature for 15 hours. 1He mixture was partitioned between AcOEt and water. 1He organic layer was separated, washed wi1H water and brine, dried over MgSO1H, and evaporated in vacuo. 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of hexane and AcOEt (20:1 -1:1) to give [4-(5-bromo-3-pyridinyl)-3-(5-e1Hoxy-5-oxopentyl)-7-e1Hylpyrrolo[l,2-b]pyridazin-2-yl]me1Hyl 4-morpholinecarboxylate as yellow oil (75 mg).<br>
[4-(5-bromo-3-pyridinyl)-3-(5-e1Hoxy-5-oxopentyl)-7-e1Hylpyrrolo[l,2-b]pyridazin-2-yljme1Hyl 4-morpholinecarboxylate<br>
1H NMR(CDC13) 6 1.23 (1H, t, J= 7 Hz), 1.37 (1H,t, J= 7 Hz), 1.40-1.60 (4H,m), 2.18 (2H, t, J= 7 Hz), 2.42-2.54 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.53-3.57 (4H, m), 3.63-3.78(4H,m),4.09(2H,q,J=7Hz),5.33(2H,s),5.93(lH,d,J=4Hz),6.62 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS (ESI˚): m/z 573 575.<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 599. Example 600<br>
e1Hyl 5-[4-(5-bromo-3-pyridinyl)-2-({[(dime1Hylamino)carbonyl]oxy}me1Hyl)˚-7-e1Hylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate<br>
1H NMR (CDC13) 6 1.23 (1H, t, J= 7 Hz), 1.36 (1H, t, J= 7 Hz), 1.35-1.60 (4H, m), 2.17 (2H, t, J= 7 Hz), 2.44-2.57 (2H, m), 2.98 (6H, s), 3.03 (2H, q, J= 7 Hz), 4.09 (2H, q, J= 7 Hz), 5.30 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.54 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS(ESl+):m/z531533.<br>
Example 601<br><br>
[4-(5-bromo-3-pyridiny])-3-(5-elhoxy-5-oxopentyl)-7-e1Hy]pyrrolo[J,2-b]pyridazin-2-<br>
yl]me1Hyl J -pyrrolidinecarboxylate<br>
1H NMR (CDC1.0 6 1.23 (1H, t, J= 7 Hz), 1.36 (1H, t, J= 7 Hz), 1.38-1.60 (4H, m), J .86-1.98 (4H, m), 2.J7 (2H, t, J= 7 Hz), 2.44-2.57 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.36-3.52 (4H, m), 4.1 J (2H, q, J= 7 Hz), 5.32 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.61 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz).<br>
Example 602<br>
elhyl 5-{4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-<br>
[({[me1Hyl(phenyl)amino]carbonyl}oxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}pentanoate1H NMR (CDCl3) 6 1.20 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.32-1.57 (4H, m), 2.13 (2H, t, J= 7 Hz), 2.33-2.48 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.38 (1H, s), 4.08 (2H, q, J= 7 Hz), 5.34 (2H, s), 5.92 (1H, d, J= 4 Hz), 6.60 (1H, d, J= 4 Hz), 7.20-7.38 (, m), 7.83 (1H, s), 8.49 (1H, s), 8.77 (1H, s).<br>
Example 603<br>
[4-(5-bromo-3-pyridinyl)-3-(4-e1Hoxy-4-oxobutyl)-7-e1Hylpyrrolo[l,2-b]pyridazin-2-yl]me1Hyl 4-morpholinecarboxylate<br>
1H NMR (CDC13) 6 1 -20 (1H, t, J= 7 Hz), 1.37 (1H, t, J= 7 Hz), 1.63-1.80 (2H, m), 2.22 (2H, t, J= 7 Hz), 2.44-2.65 (2H, m), 3.03 (2H, q, J= 7 Hz), 3.54 (4H, m), 3.68 (4H, m), 4.05 (2H, q, J= 7 Hz), 5.37 (2H, s), 5.94 (1H, d, J= 4 Hz), 6.62 (1H, d, J= 4 Hz), 7.87 (1H, m), 8.55 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS(ESI+):m/z559 561.<br>
Example 604<br>
e1Hyl 4-[4-(5-bromo-3-pyridinyl)-2-({[(dime1Hylamino)carbonyl]oxy}me1Hyl)-7-<br>
e1Hylpyrrolo[ 1,2-b]pyridazin-3-yl]butanoate<br>
1H NMR (CDCl3) 6 1.20 (1H,t, J= 7 Hz), 1.36 (1H,t, J= 7 Hz), 1.66-1.79 (2H,m), 2.20 (2H, t, J= 7 Hz), 2.46-2.62 (2H, m), 2.97 (6H, s), 3.03 (2H, q, J= 7 Hz), 4.04 (2H, q, J= 7 Hz), 5.34 (2H, s), 5.93 (1H, d, J= 4 Hz), 6.63 (1H, d, J= 4 Hz), 7.89 (1H, m), 8.56 (1H, d, J= 2 Hz), 8.78 (1H, d, J= 2 Hz). MS(ESl+):m/z517 519.<br><br>
Example 605<br>
e1Hyl 3-[4-(51Hromo-3-pyridiny])-2-({[(dime1Hy]amino)carbonyl]oxy}niclhyl)-7-e1Hylpyrrolo[3,2-b]pyridazin-3-yl]propanoate<br>
1H NMR (CDCl3) 5 1.20 (1H, t, J= 7 Hz), 1.36 (1H, t, J= 7 Hz), 2.37 (2H, t, J= 7 Hz), 2.82-2.93 (2H, m), 2.97 (6H, s), 3.03 (2H, q, J= 7 Hz), 4.05 (2H, q, J= 7 Hz), 5.32<br>
(2H,s),5.96(1H,d,J=4Hz),6.63(lH,d,J=4Hz),7.88(1H,m),854(lH,d,<br>
J=2Hz),8.78(lH,d,J=2Hz).<br>
Example 606<br>
To a solution of sodium hydride (93.1 mg) in DMF (4 mL) was added e1Hyl 3-[4-(3-chlorophenyl)-7-e1Hyl-2-(hydroxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoate (150 mg) under ice water cooling and 1He mixture was stirred at 1His temperature for 1 hour. To 1His was added 4-(bromome1Hyl)pyridine hydrobromide (196 mg) and 1He mixture was stirred for 1 hour at ambient temperature. 1He reaction was quenched by adding water. 1He mixture was extracted wi1H CHQ3. 1He organic layer was washed wi1H water and brine, dried over MgS04 and evaporated in vacuo. 1He residue was purified by silica gel column chromatography eluting wi1H a mixture of CHO3-MeOH = 30-1 to give 3-{4-(3-chlorophenyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-yl}propanoic acid (18 mg) as a yellow solid.<br>
3-{4-(3-chlorophenyl)-7-e1Hyl-2-[(4-pyridinylme1Hoxy)me1Hyl]pyrroIo[l,2-b]pyridazin-3-yl}propanoicacid<br>
1H NMR (300 MHz, CDCfe) 5 1.39 (1H, t, J = 7 Hz), 2.33 (2H, t, J = 7 Hz), 2.84-2.91 (2H, m), 3.04 (2H, q, J = 7 Hz), 4.73 (2H, s), 4.82 (2H, s), 5.96 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 7.23-7.26 (1H, m), 7.36-7.38 (1H, m), 7.42-7.44 (2H, m), 8.41(2H,d,J = z). MS(m/z)450(M+H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 606. Example 607 3_{4_(3_chlorophenyl)-7-e1Hyl-2-[(3-pyridinylme1Hoxy)me1Hyl]pyrrolo[l,2-b]pyridazin-3-<br>
yljpropanoic acid<br><br>
1H NMR (300 MHz, CDC13) 5 1.39 (1H, t, J = 7 Hz), 2.32-2.38 (2H,m), 2.84-2.92 (2H, m), 3.04 (2H, q, J = 7 Hz), 4.70 (2H, s), 4.82 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.60 (1H, d, J = 5 Hz), 7.2J-7.24 (1H, m), 7.31-7.36 (2H, m), 7.40-7.42 (2H, m), 7.80 (2H, d, J = 8 Hz), 8.51 (1H, d, J = 5 Hz), 8.64 (1H, s).<br>
Example 608<br>
3-{4-(3-chloropheny])-7-e1Hy]-2-[(2-pyraziny]me1Hoxy)rne1Hyl]pyrrolo[l,2-b]pyridazin-3-yljpropanoic acid<br>
1H NMR (300 MHz, CDCl3) 5 1.38 (1H, t, J = 7 Hz), 2.42 (2H, t, J = 7 Hz), 2.91-2.97 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.83 (2H, s), 4.90 (2H, s), 5.96 (2H, d, J = 5 Hz), 6.62 (2H, d, J = 5 Hz), 7.23-7.26 (1H, m), 7.36 (1H, s), 7.43-7.44 (2H, m), 8.51-8.53 (2H,m), 8.75 (lH,s).<br>
Example 609<br>
A solution of 5-[7-e1Hyl-2-me1Hyl-4-(2-vinyl-4-pyridinyl)pyrrolo[l ,2-b]pyridazin-3-yl]pentanoic acid (15 mg) in MeOH was added 10% Pd/C (2 rng). 1He mixture was stirred under under hydrogen atomosphere (1 atm) for 6 h. 1He reaction mixture was filtered 1Hrough Celite and 1He filtrate was concentrarted in vacuo. 1He residue was triturated wi1H hexane to give 5-[7-e1Hyl-4-(2-e1Hyl-4-pyridinyl)-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid (14 mg) as an yellow solid.<br>
5-[7-e1Hyl-4-(2-e1Hyl-4-pyridinyl)-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]pentanoicacid 1H NMR (CDCl3) 5 1.29-1.64 (10H, m), 2.18-2.30 (2H, m), 2.45-2.48 (2H, m), 2.56 (1H, s), 2.91-3.06 (4H, m), 5.84 (1H, d, J = 5 Hz), 6.53 (1H, d, J = 16 Hz), 6.51 (1H, d, J = 5 Hz), 7.25-7.32 (2H, m), 8.69 (1H, br s).<br>
Example 610<br>
To a solution of e1Hyl 4-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(hydroxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoate (70.0 mg) in toluene (1 mL) was added tributylphosphine (0.098 mL), l,3-oxazolidin-2-one (34.1 mg) in 1Hat order in an ice ba1H. After stirring for 5 minutes, to 1He mixture was added 1,1-(azodicarbonyl)dipiperidine (98.9 mg). 1He mixture was stirred for 10 minutes in 1He ba1H, and 8 hours at room temperature. Hexane (5 mL) was added, and 1He mixture was<br><br>
filtered. 1He filtrate was evaporated. Preparative 1Hin layer chromatography (e1Hyl<br>
acetale-hexane = 1-1) afforded e1Hyl 4-{4-(5-bromo-3-pyridinyl)-7-e1Hy]-2-[(2-oxo-'J,3-oxazoIidin-3-y])mc1Hy)]pyrro]o['l,2-b]pyridazin-3-yl}butanoate as an yellow gum (25.0 vng).<br>
e1Hyl 4-{4-(5-bromo-3-pyridiny])-7-e1Hyl-2-[(2-oxo-l,3-oxazoIidin-3-<br>
yl)me1HyI]pyrroIo[ 1,2-b]pyridazin-3-yl}butanoate<br>
1H-NMR (CDC13) 6 1.20 (1H, t, J = 7 Hz), 1.369 (1H, t, J = 7 Hz), 1.65 (1H, t, J = 7 Hz), 2.25 (2H, t, J = 7 Hz), 2.51 (2H, m), 2.99 (2H, q, J = 7 Hz), 3.79 (2H, t, J = 7 Hz), 4.04 (2H, q, J = 7 Hz), 4.43 (2H, t, J = 7 Hz), 4.69 (2H, m), 5.95 (1H, d, J = 5 Hz), 6.61 (1H, d, J = 5 Hz), 7.87 (1H, m), 8.55 (1H, m), 8.80 (1H, m).<br>
Example 611<br>
To a solution of 2-bromo-4-[3-(e1Hoxycarbonyl)-7-e1HyI-2-me1Hylpyrrolo[l,2-b]pyridazin-4-yl]benzoic acid (50.0 rng) in tetrydrofuran (1 mL) was added a solution of 1 M borane-tetrydrofuran complex (0.348 mL) in an ice ba1H. After stirring for 2 hours at room temperature, additional solution of 1He borane-tetrydrofuran complex (0.348 mL) was added. 1He mixture was stirred for 15 hours at room temperature. 1He mixture was parititioned between e1Hyl acetate and 1 N hydrochloric acid. 1He organic layer was washed wi1H water, saturated sodium bicarbonate, and brine, dried over magnesium sulfate, and evaporated to give e1Hyl 4-[3-bromo-4-(hydroxyme1HyJ)phenyl]-7-e1HyI-2-me1Hylpyrrolo[l,2-b]pyridazine-3-carboxylate as an yellow oil (54.2 mg).<br>
e1Hyl 4-[3-bromo-4-(hydroxyme1Hyl)phenyl]-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazine-3-<br>
carboxylate<br>
1H-NMR (CDCl3) 5 0.99 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 2.59 (1H, s), 3.03 (2H, q, J = 7 Hz), 4.07 (2H, q, J = 7 Hz),4.82 (2H, s), 6.33 (1H, d, J = 5 Hz), 6.66 (1H, d, J = 5 Hz), 7.44 (1H, d, J = 8 Hz), 7.58 (1H, d, J = 8 Hz), 7.67 (1H, s).<br>
Example 612<br>
To a solution of 2-(2-{2-[7-e1Hyl-2-me1Hyl-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l32-b]pyridazin-3-yl]e1Hoxy}e1Hoxy)e1Hyl acetate (62.0 mg) in me1Hanol (1 mL) was added potassium carbonate (22.2 mg). After stirring for 1.5 hour, 1He solvent was evaporated<br><br>
off. Preparative 1Hin layer chromatography (CHCh-MeOH = 20-1) affroded 1He desired product as an yellow gum (54.J mg). 1He gum was dissolved in 1 N HC1 (1 mL), and 1He solution was lyophilized to give a dark green gum, which was crystalyzed upon standing. 1He crystal was triturated in diisopropyl e1Her to give 2-(2-{2-[7-e1Hyl-2-me1Hyl-4-(5-me1Hyl-3-pyridinyl)pyrrolo[],2-b]pyridazin-3-yl]e1Hoxy}e1Hoxy)e1Hanol hydrochloride as an yellow powder (40.3 mg).<br>
2-(2-{2-[7-e1Hyl-2-me1Hyl-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]e1Hoxy}e1Hoxy)e1Hanol hydrochloride<br>
1H-NMR (DMSO-d6): 1.29 (1H, t, J = 7 Hz), 2.51 (1H, s), 2.56 (1H, s), 2.62 (2H, m),<br>
2.94 (2H, q, J = 7 Hz), 3.30-3.47 (10H, m), 5.84 (1H, d, J = 5 Hz), 6.59 (1H, d, J<br>
= 5 Hz), 8.26 (1H, m), 8.77 (1H, m), 8..85 (1H, m).<br>
Example 613<br>
A mixture of e1Hyl 5-[2-(bromome1Hyl)-4-(3-cyanophenyl)-7-e1Hylpyrrolo[l,2-b]pyridazin-3-yl]pentanoate (70.0 mg), phenol (21.1 mg), and pottassium carbonate (31.0 mg) in N,N-dime1Hylformamide was stirred for 2.5 hours at room temperature. 1He mixture was partitioned between e1Hyl acetate and 1 N hydrochloric acid. 1He organic layer was washed wi1H water, saturated sodium bicarbonate, and brine, dried over magnesium sulfate, and evaporated to give e1Hyl 5-[4-(3-cyanophenyl)-7-e1Hyl-2-(phenoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]pentanoate as an yellow gum (77.5 mg, 108%).<br>
e1Hyl 5-[4-(3-cyanophenyl)-7-e1Hyl-2-(phenoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]propanoate<br>
1H-NMR (CDC13) 6 1.21 (1H, t, J = 7 Hz), 1.35-1.53 (7H, m), 2.07 (2H, m), 2.54 (2H, m), 3.03 (2H, q, J = 7 Hz), 4.05 (2H, q, J = 7 Hz), 5.24 (2H, s), 5.86 (1H, d, J = 5 Hz), 6.65 (1H, d, J = 5 Hz), 6.80-7.01 (1H, m), 7.03 (2H, d, J = 9 Hz), 7.32 (2H, t, J = 9 Hz), 7.55-7.63 (2H, m), 7.67 (1H, s), 7.76 (1H, m). MS(ESl+):m/z482(M + H)<br>
Example 614<br>
A mixture of 4-(3-cyanophenyl)-7-e1Hyl-3-(me1Hylsulfonyl)pyrrolo[J,2-<br><br>
b]pyridazin-2-yl Irifluoromelhanesulfonate (50.0 mg), 3-furylboronic acid (23.6 nig), dichlorobis(triphenylphosphine)palladium (3.71 mg), and 2 N sodium carbonate (44.8 mg in 0.2 mL of water) in dioxane was stirred for 20 minutes at 85°C. 1He mixture was partitioned between EtOAc and water, and 1He organic layer was washed wi1H brine, dried, and evaporated. Preparative 1Hin layer chromatography (EtOAc-hexane = 1-1) afforded 3-[7-e1Hy]-2-(2-furyl)-3-(me1Hylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an orange solid (11.5 mg).<br>
3-[7-e1Hyl-2-(2-furyl)-3-(me1Hylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
1H-NMR (CDC13) 6 1.40 (1H, t, J = 7 Hz), 3.10 (2H, q, J = 7 Hz), 3.20 (1H, s), 6.30 (1H, d, J = 5 Hz), 6.63 (1H, m), 6.87 (1H, d, J = 5 Hz), 6.95 (1H, m), 7.60-7.73 (4H,m),8.79(lH,m).<br>
Example 615<br>
To a solution of 5-[4-(3-cyanophenyl)-7-e1Hyl-2-phenylpyrrolo[l,2-b]pyridazin-3-yl]pentanoic acid(100 mg) in tetrydrofurane (1 mL) was added 1 M borane-tetrydrofurane comples (0.708 mL,) in an ice ba1H under a nitrogen atmosphere. 1He mixture was stirred for 4 hours in 1He ba1H and 1 hour at room temperature. 1He reaction was quenched by adding 1 N hydrochloric acid (1 mL). 1He mixture was partitioned between EtOAc (10 mL) and 1 N hydrochloric acid (5 mL). 1He organic layer was washed wi1H water and brine, dried over magnesium sulfate, and evaporated. Preparative 1Hin layer chromatography elutingwi1H acetone-hexane = 1-2 afforded 3-[7-e1Hyl-3-(5-hydroxypentyl)-2-phenylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile as an yellow gum (104<br>
mg).<br>
3-[7-e1Hyl-3-(5-hydroxypentyl)-2-phenylpyrrolo[l,2-b]pyridazin-4-yl]benzonitrile<br>
1H-NMR (CDCl3) 5 0.98-1.17 (6H, m), 1.36 (1H, t, J = 7 Hz), 2.38 (2H, m), 258 (2H,<br>
m), 3.34 (2H, m), 5.89 (1H, d, J = 5 Hz), 6.62 (1H, d, J = 5 Hz), 7.45-7.53 (,<br>
m), 7.55-7.67 (4H,m). MS(ESI+):m/z410(M + H)<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 24.<br><br>
Preparation 343<br>
e1Hyl 2-[(5-bromo-3-pyridiny])carbonyl]-4-melhoxy-3-oxobutanoate<br>
1H NMR (CDC13) 6 0.96-1.10 (1H, m), 3.23 (1,, s), 3.49 (1., s), 4.00-4.34 (4H, m), 4.57 (1H, s), 8.00 (0., br s), 8.23 (0., br s), 8.60-8.91 (2H, m).<br>
Preparation 344<br>
1-lert-butyl 8-e1Hyl 2-acetyl-2-[(6-cyano-3-pyridinyl)carbonyl]octanedioate<br>
1H NMR (CDC13) 6 1.22-1.46 (16H,m), 1.55-1.70 (2H,m), 2.17-2.34 (4H,m),2.48<br>
(1H, s), 4.14 (2H, q, J = 8 Hz), 7.77 (1H, br d, J = 8 Hz), 8.17 (1H, dd, J = 8, 2<br>
Hz),8.97(lH,d,J = 2Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 78. Preparation 345 e1Hyl 7-[(6-cyano-3-pyridinyl)carbonyl]-8-oxononanoate<br>
1H NMR (CDCb) 5 1.20-1.45 (7H, m), 1.52-1.70 (2H, m), 1.92-2.14 (2H, m), 2.17-2.39 (, m), 4.11 (2H, q, J = 8 Hz), 4.40 (1H, t, J = 8 Hz), 7.84 (1H, br d, J = 8 Hz), 8.39 (1H, m), 9.23 (1H, br s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 130. Preparation 346 e1Hyl 4-melhoxy-3-oxobutanoate<br>
1H NMR (CDCb) 6 1.28 (1H, t, J = 8 Hz), 3.42 (1H, s), 3.51 (2H, s), 4.09 (2H, s), 4.20(2H,q,J = 8Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 338. Preparation 347 benzyl 3-[(l-amino-5-e1Hyl-lH-pyrrol-2-yl)carbonyl]-5-bromobenzoate<br>
1H-NMR (CDCl3) 8 1.28 (1H, t, J = 7 Hz), 2.75 (2H, q, J = 7 Hz), 5.37 (2H, s), 5.73 (2H, s), 5.94 (1H, d, J = 5 Hz), 6.66 (1H, d, J = 5 Hz), 7.35-7.48 (, m), 7.99 (lH,s), 8.33 (lH,s), 8.38 (lH,s).<br><br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 321. Preparation 348 benzyl 3-bromo-5-[(5-e1Hyl-1H-pyrrol-2-yl)carbonyl]benzoate<br>
1H-NMR (CDCl3) 5 1.29 (1H, t, J = 7 Hz), 2.72 (2H, q, J = 7 Hz), 5.37 (2H, s), 6.09 (1H, m), 6.78 (1H, m), 7.33-7.45 (, m), 8.15 (1H, s), 8.33 (1H, s), 8.45 (1H, s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of<br>
Preparation 310.<br>
Preparation 349<br>
benzyl 3-bromo-5-(chlorocarbonyI)benzoate<br>
Preparation 350<br>
To a solution of benzyl 3-bromo-5-iodobenzoate (1.00 g) in 1HF (10 mL) was added 0.76 M isopropyl magnesium bromide (3.16 mL) in an ice ba1H under a nitrogen atmosphere. After stirring for 0.5 hour, 1He mixture was poured onto dryice. 1He mixture was warmed to room temperature over 1 hour. 1He mixture was partitioned between EtOAc and 1 N HC1. 1He organic layer was washed wi1H brine, dried over MgSCXi, and evaporated. Flash silicagel column chromatography (chloroform-me1Hanol = 50-0 to 50-2) afforded 3-benzyloxycarbonyl-5-bromobenzoic acid as a white solid (273 mg).<br>
3-[(benzyloxy)carbonyl]-5-bromobenzoic acid<br>
1H-NMR (DMSO-d6) 6 5.39 (2H, s), 7.30-7.52 (, m), 8.29 (2H, s), 8.43 (1H, s).<br>
Preparation 351<br>
A mixture of 3-bromo-5-iodobenzoic aicd (5.00 g) and N,N-dime1Hylformamide (0.059 mL) in dichlorome1Hane (50 mL) was added oxalyl chloride (1.47 mL) in an ice ba1H under a nitrogen atmosphere. After stirring for 1 hour, 1He volatile was evaporated off. 1He residue was dissolved in dichlorome1Hane (50 mL), and to 1He solution was added bensyl alcohol (1.82 g) followe by trie1Hyl amine (3.2 mL) in 1He ice ba1H. 1He mixture was stirred for 2 hours at room temperature. 1He mixture was partitioned<br><br>
between EtOAc and water. 1He organic layer was washed wi1H water (two times), satd. NCO1H, and brine, dried over MgS04 and evaporated. Flash silicagel columnc hromatography (EtOAc-hexanes = 1/200 to 20/200) afforded benzyl 3-bromo-5-iodobenzoate as white crystals (5.95 g).<br>
benzyl 3-bromo-5-iodobenzoate<br>
1H-NMR (CDCb) 6 535 (1H,s), 7.35-7.68 (,m), 8.04 (lH,s), 8.16 (lH,m), 8.30 (lH,s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hai of Example 1. Example 615<br>
benzyl 3-bromo-5-[7-e1Hyl-2-me1Hyl-3-(me1Hylsulfonyl)pyrrolo[ 1,2-b]pyridazin-4-yljbenzoate<br>
1H-NMR (CDC13) 6 1.38 (1H, t, J = 7 Hz), 2.88 (1H, s), 3.05 (1H, s), 3.06 (2H, q, J = 7 Hz), 5.35 (2H, s), 6.15 (1H, d, J = 5 Hz), 6.72 (1H, d, J = 5 Hz), 7.33-7.45 (, m), 7.68 (1H, m), 7.94 (1H, m), 8.28 (1H, m).<br>
Example 616 4-(3-cyanophenyl)-7-e1Hyl-2-phenylpyrrolo[l,2-b]pyridazine-3-carbonitrile<br>
1H NMR (CDCl3) 8 1.42 (1H, t, J = 8 Hz), 3.12 (2H, q, J = 8 Hz), 6.60 (1H, d, J = 5<br>
Hz), 6.92 (1H, d, J = 5 Hz), 7.50-7.58 (1H, m), 7.73 (1H, t, J = 8 Hz), 7.82-7.91<br>
(1H, m), 7.93-8.01 (2H,m).<br>
Example 617 2-tert-butyl-4-(3-chlorophenyl)-7-e1Hylpyrrolo[l,2-b]pyridazine-3-carbonitrile<br>
1H NMR (CDCl3) 8 1.38 (1H, t, J = 8 Hz), 1.60 (9H, s), 3,05 (2H, q, J = 8 Hz), 6.48 (1H, d, J = 5 Hz), 6.77 (1H, d, J = 5 Hz), 7.45-7.54 (1H, m), 7.60 (1H, br s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 78. Example 618 e1Hyl 6-[4-(6-cyano-3-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[ 1,2-b]pyridazin-3-yl1Hexanoate<br><br>
1H NMR (CDC1.-,) 6 1.15-1.64 (12H, m), 2.21 (1H, t, J = 8 Hz), 2.32-2.44 (2H, m), 2.56 (1H, s), 3.01 (2H, q, J = 8 Hz), 4.10 (2H, q, J = 8 Hz), 5.79 (1H, d, J = 5 Hz), 6.54 (1H, d, J = 5 Hz), 7.85 (1H, br s), 8.30 (1H, br d, J = 8 Hz), 8.72 (1H, br s).<br>
MS(ESI+):m/z405(M + H).<br>
1He following compound(s) was(were) obtained in a similar manner 1o 1Hai of Example 21. Example 619<br>
e1Hyl 4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazine-3-carboxylate<br>
1H NMR (CDCl3) 6 1.04 (1H, t, J = 8 Hz), 1.38 (1H, t, J = 8 Hz), 3.06 (2H, q, J = 8 Hz), 3.39 (1H, s), 4.10 (2H, q, J = 8 Hz), 4.76 (2H, s), 6.33 (1H, d, J = 5 Hz), 6.74 (1H, d, J = 5 Hz), 7.96 (1H, br s), 8.61 (1H, br s), 8.78 (1H, d, J = 2 Hz). MS (ESI+): m/z 418, 420 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 76. Example 620<br>
3-bromo-5-[7-e1Hyl-2-me1Hyl-3-(me1Hylsulfonyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoic acid<br>
1H-NMR (CDCl3 + CD30D) 6 1.38 (1H, t, J = 7 Hz), 2.86 (1H, s), 3.05 (1H, s), 3.06 (2H, q, J = 7 Hz), 6.19 (1H, d, J = 5 Hz), 6.71 (1H, d, J = 5 Hz), 7.53 (1H, s), 7.90 (1H,S),8.23(1H,S).<br>
Example 621<br>
(2E)-3-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]acrylic acid<br>
1H NMR (CDCl3) 5 1.39 (1H, t, J = 8 Hz), 3.07 (2H, q, J = 8 Hz), 3.51 (1H, s), 4.65 (2H, s), 5.96 (1H, d, J = 15 Hz), 6.27 (1H, d, J = 5 Hz), 6.74 (1H, d, J = 5 Hz), 7.68 (1H, d, J = 15 Hz), 7.93 (1H, m), 8.57 (1H, d, J = 1 Hz), 8.70 (1H, d, J = 2 Hz). MS (ESI+): m/z 416,418 (M + H).<br><br>
Example 622<br>
6-[4-(6-cyano-3-pyridiny])-7-e1Hy]-2-me1Hy]pyrro]o[ 1,2-b]pyridazin-3-y]1Hexanoic acid 1H NMR (CDCh) 5 1.15-1.69 (9H, m),l .90-2.50 (4H, m), 2.56 (1H, s), 3.01 (2H, q, J = 8 Hz), 5.80 (1H, d, J = 5 Hz), 6.51 (1H, d, J = 5 Hz), 7.84 (1H, dd, J = 8,2 Hz), 8.28 (1H, d, J = 8 Hz), 8.51 (1H, d, J = 2 Hz). MS (ESf): m/z 377 (M + H). Example 622-2<br>
6-{4-[6-(aminocarbonyl)-3-pyridinyl]-7-e1Hyl-2-me1Hy]pynolo[l,2-b]pyridazin-3~ yl1Hexanoic acid<br>
1H NMR (CDCl3) 6 1.16-1.51 (9H, m), 2.10-2.24 (2H, m), 2.35-2.47 (2H, m), 2.58 (1H, s), 3.01 (2H, q, J = 8 Hz), 5.85 (1H, d, J = 5 Hz), 6.54 (1H, d, J = 5 Hz), 7.22 (1H, br s), 7.90 (1H, dd, J = 8,1 Hz), 8.01 (1H, br s), 8.34 (1H, d, J = 8 Hz), 8.61 (lH,d,J = lHz). MS (ESI+): m/z 395 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 147. Example 623<br>
e1Hyl (2E)-3-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]acrylate<br>
1H NMR (CDCl3) 6 1 -27 (1H, t, J = 8 Hz), 1.39 (1H, t, J = 8 Hz), 3.06 (2H, q, J = 8 Hz), 3.51 (1H, s), 4.17 (2H, q, J = 8 Hz), 4.64 (2H, s), 5.97 (1H, d, J = 15 Hz), 6.24 (1H, d, J = 5 Hz), 6.73 (1H, d, J = 5 Hz), 7.51 (1H, d, J = 15 Hz), 7.91 (1H, br s), 8.57 (1H, br s), 8.70 (1H, br s). MS (ESI+): m/z 444,446 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 200. Example 624<br>
[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]me1Hanol<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J = 8 Hz), 3.05 (2H, q, J = 8 Hz), 3.45-3.55 (4H, m), 4.40 (2H, br d, J = 7 Hz), 4.77 (2H, br s), 6.22 (1H, d, J = 5 Hz), 6.70 (1H, d, J =<br><br>
5 Hz), 8.11 (1H, m), 8.74 (1H, br s), 8.80 (1H, d, J = 2 Hz). MS (ESI+): m/z 376,378 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 205. Example 625<br>
(4E)-5-[4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]-4-pentenoic acid<br>
1H NMR (CDCb) 6 1.37 (1H, l, J = 8 Hz), 2.26-2.43 (4H, m), 2.50 (1H, s), 3.01 (2H, q, J = 8 Hz), 5.40 (1H, dt, J = 15, 7 Hz), 6.05 (1H, d, J = 5 Hz), 6.20 (1H, d, J = 15 Hz), 6.56 (1H, d, J = 5 Hz), 7.28 (1H, br d, J = 5 Hz), 7.39 (1H, br s), 8.47 (1H, brd,J = z).<br>
MS (ESI+): m/z 370 (M + H).<br>
Example 625-2<br>
(4Z)-5-[4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yl]-4-pentenoic acid<br>
1H NMR (CDC13) 6 1.39 (1H, t, J = 8 Hz), 1.87-2.00 (2H, m), 2.12 (2H, t, J = 8 Hz), 2.42 (1H, s), 3.03 (2H, q, J = 8 Hz), 5.58 (1H, dt, J = 10, 8 Hz), 6.17 (1H, d, J = 5 Hz), 6.26 (1H, br d, J = 10 Hz), 6.60 (1H, d, J = 5 Hz), 7.35 (1H, br d, J = 5 Hz), 7.44 (1H, br s), 8.48 (1H, br d, J = 5 Hz). MS (ESI+): m/z 370 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 220. Example 626<br>
4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazine-3-carboxylic acid<br>
1H NMR (CDCl3) 6 1.39 (1H, t, J = 8 Hz), 3.06 (2H, q, J = 8 Hz), 3.44 (1H, s), 4.82 (2H, s), 6.36 (1H, d, J = 5 Hz), 6.77 (1H, d, J = 5 Hz), 8.09 (1H, br s), 8.65 (1H, brs),8.72(lH,brs). MS (ES1+): m/z 390, 392 (M + H).<br><br>
Example 627<br>
4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1HyIpyrroIo[l ,2-b]pyridazine˚3-carboxyIic acid 1H NMR (CDCl3) 6 138 (1H,t, J = 8 Hz), 2.70 (1H, s), 3.06 (2H, q, J = 8 Hz), 6.26<br>
(lH,d,J = z),6.72(lH,d,J=z),7.32(lH,dd,J = 5J Hz),7.43 (lH,br s),8.50(lH,d,J=z). MS(ESI+):m/z316(M+H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 244. Example 628<br>
4-(2-chloro-4-pyridinyl)-7-elhyl-2-me1Hylpyrrolo[l,2-b]pyridazine-3-carbaldehyde 1H NMR (CDCl3) 6 1.39 (1H, t, J = 8 Hz), 2.81 (1H, s), 3.09 (2H, q, J = 8 Hz), 6.43 (1H, d, J = 5 Hz), 6.78 (1H, d, J = 5 Hz), 7.34 (1H, br d, J = 5 Hz), 7.46 (1H, br s), 8.56 (1H, d, J = 5 Hz), 9.76 (1H, s). MS (ESI˚): m/z 300 (M + H).<br>
Example 629<br>
4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazine-3-<br>
carbaldehyde<br>
1H NMR (CDCl3) 6 1.41 (1H, t, J = 8 Hz), 3.14 (2H, q, J = 8 Hz), 3.55 (1H, s), 4.94 (2H, s), 6.50 (1H, d, J = 5 Hz), 6.84 (1H, d, J = 5 Hz), 7.95 (1H, br s), 8.12 (1H, br s), 8.84 (1H, br s), 9.85 (1H, s).<br>
MS (ESf): m/z 374,376 (M + H).<br>
Example 630<br>
A solution of phosphorus oxychloride (241 mg, 1.57 mmol) in N,N-dime1Hylformamide (4 mL) was stirred for 10 min at room temperature. 1He resulting mixture was cooled to 0°C, and a solution of e1Hyl 4-(4~fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate (428 mg, 1.31 mmol) in N,N-dime1Hylformamide (0.7 mL) was added. 1He resulting mixture was warmed to 50°C, and stirred for 45 min. Since 1He startimg material was remained, a solution of phosphorus oxychloride (621 mg, 0.67 mmol) in N,N-dime1Hylformamide (0.2 mL) was added, and 1He mixture was stirred for 15 min. 1He resulting mixture was poured into<br><br>
ice-cooled water (10 mL), and extracted wi1H e1Hyl acetate (30 mL). 1He organic layer was washed wi1H water and saturated sodium bicarbonate. All 1He aqueous layer was extracted wi1H e1Hyl acetate. 1He combined organic extract was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give a blue oil. Flash silica gel column chromatography eluting wi1H e1Hyl acetate-hexane = 1-20 to 1-10 afforded e1Hyl 4-(4-fluorophenyl)-7-formyl-2-isopropyIpyrroIo[ 1,2-b]pyridazine-3-carboxylate as an yellow oil, which was crystalized upon standing (360 mg, 77.5%).<br>
1H-NMR (CDC13) 5 1.02 (1H, t, J = 7 Hz), 1.41 (6H, d, J = 7 Hz), 3.29 (1H, septet, J = 7 Hz,), 4.10 (2H5 q, J = 7 Hz), 6.42 (1H, d, J = 5 Hz), 7.20 (2H, t, J = 9 Hz), 7.45 - 7.51 (1H, m), 10.56 (1H ,s).<br>
MS(ESI+):m/z355(M + H)<br>
Example 631<br>
To a solution of N,N-dime1Hylacetamide (80.1 mg, 0.919 mmol) in dichloroe1Hane (1 mL) was added phosphorus oxychloride (141 mg, 0.919 mmol) in dichloroe1Hane (0.5 mL) at 0°C. After stirring for 0.5 h, a solution of e1Hyl 4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate (200 mg, 0.613 mmol) in dichloroe1Hane(0.5 mL) was added. 1He resulting mixture was stirred for 3 days at room temperature. 1He mixture was partitioned between e1Hyl acetate (30 mL) and water (5 mL), and 1He organic layer was washed wi1H saturated sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, and evaporated to give an orange gum. Flash silica gel column chromatography eluting wi1H e1Hyl acetate-hexane = 1-20 to 1-10 afforded e1Hyl 7-acetyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l ,2-b]pyridazine-3-carboxylate as an yellow gum (144 mg, 63.8%).<br>
1H-NMR (CDCl3) 6 1.00 (1H, t, J = 7 Hz), 1.41 (6H, d, J = 7 Hz), 2.88 (1H, s), 3.09 (1H, septet, J = 7 Hz), 4.09 (2H, q, J = 7 Hz), 6.40 (1H, d, J = 5 Hz), 7.19 (2H, t, J = 9 Hz), 7.46 (2H, dd, J = 3 and 9 Hz), 7.57 (2H, d, J = 7 Hz).<br>
MS(ESf):m/z369(M + H)<br>
Example 632<br>
A solution of e1Hyl 4-(4-fluorophenyl)-7-formyl-2-isopropy]pyrrolo[l,2-<br><br>
b]pyridazine-3-carboxyIale (100 mg, 0.282 mmol) and sodium borohydride (10.7 mg, 0.282 mmol) in e1Hanol (1 roL) was stirred for 0.5 h under an ice ba1H. 1He mixture was partitioned between e1Hyl acetate (10 mL) and water (5 mL), and 1He organic layer was cashed wi1H brine, dried over anhydrous magnesium sulfate, and evaporateed to give s1Hyl 4-(4-fluorophenyl)-7-hydroxyme1Hyl-2-isopropylpyrrolo[l,2-b]pyridazine-3-1Harboxylate as an yellow gum (89.1 mg, 89.1%).<br>
1H-NMR (CDC13) 5 0.97 (1H, t, J = 7 Hz), 1.37 (6H,, J = 7 Hz), 3.25-3.37 (2H, m), 4.04 (2H, q, J = 7 Hz), 5.06 (1H, d, J = 7 Hz), 6.32 (1H, d, J = 5 Hz), 6.78 (1H, d, J = 5 Hz), 7.19 (2H, t, J = 9 Hz), 7.46 (2H, d, J = 4 and 9 Hz).<br>
Example 633<br>
To a solution of e1Hyl 4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate (80.0 mg, 0.245 mmol) and N,N-dime1Hylaminopyridine (29.9 mg, 0.245 mmol) in N,N-dime1Hylformamide (0.5 mL) was added 3,7-dinitro-5-(trifluorome1Hyl)dibenzo[b,d]1Hiophenium trifluorome1Hanesulfonate (120 mg, 0.245 mmol) at -20°C. 1He resulting mixture was stirred for 45 min at 0°C and 12 h at room<br>
temperatue. Water (5 mL) and e1Hyl acetate (10 mL) were added, and 1He resulting mixture was filtered. 1He organic layer was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give a brown gum. Flash silica gel column chromatography eluting wi1H toluene-hexane = 1-5 to 4-5 afforded e1Hyl 4-(4-fluorophenyl)-2-isopropyl-7-trifluorome1Hylpyrrolo[l,2-b]pyridazine-3-carboxylate product as an yellow gum (46.7 mg, 48.3%).<br>
1H-NMR (CDCl3) 6 1.00 (1H, t, J = 7 Hz), 1.38 (6H, d, J = 7 Hz), 3.26 (1H, septet, J = 7 Hz), 4.08 (2H, q, J = 7 Hz), 6.33 (1H, d, J = 5 Hz), 7.12 (1H, d, J = 5 Hz), 7.19 (2H, t, J = 9 Hz), 747 (2H, d, J = 4 and 9 Hz).<br>
MS (ESf): m/z 395 (M + H)<br>
Example 634<br>
A solution of e1Hyl 4-(4-fluorophenyl)-7-formyl-2-isopropyIpyrroIo[l ,2-b]pyridazine-3-carboxylate (200 mg, 0.564 mmol), hydroxylamine hydrochloride (51.0 mg, 0.734 mmol), and sodium formate (69.1 mg, 1.02 mmol) in formic acid (2 mL) were<br><br>
refluxcd for 2 h. 1He mixture was evaporated to give a green gum. 1He gum was partitioned between e1Hyl acetate (10 mL) and saturated sodium bicarbonate (5 mL). 1He organic layer was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give a green gum. Flash silica gel column chromatography eluting wi1H e1Hyl acetate-hexane = 1-10 to 1-8 gave e1Hyl 7-cyano-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate as an yellow crystal (144 mg, 72.6%).<br>
1HNMR (CDCb) 5 1.01 (1H, t, J = 7 Hz), 1.41 (6H, d, J = 7 Hz), 3.26 (1H, septet, J = 7 Hz), 4.09 (2H, q, J = 7 Hz), 636 (1H, d, J = 5 Hz), 7.20 (2H, t, J = 9 Hz), 7.28 (1H, d, J = 5 Hz), 7.47 (2H, d, J = 4 and 9 Hz).<br>
MS (ESI+): m/z 398 (M + HCOOH + H)<br>
Example 635<br>
A solution of e1Hyl 7-cyano-4-(4-fluorophenyl)-2-isopropylpyrrolo[l ,2-b]pyridazine-3-carboxylate (70.4 mg, 0.200 mmol) in sulfuric acid (1 mL) was stirred for 50 min at 70°C. 1He solution was partitioned between e1Hyl acetate and water. 1He organic layer was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give a brown gum. Preparative silica gel 1Hin layer chromatography eluting wi1H e1Hyl acetate-hexane = 1-1 afforded e1Hyl 7-aminocarbonyl-4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate as an orange solid (5.2 mg, 7.0%).<br>
1H-NMR (CDC13) 6 0.99 (1H, t, J = 7 Hz), 1.41 (6H, d, J = 7 Hz), 3.41 (1H, septet, J = 7 Hz), 4.08 (2H, q, J = 7 Hz), 5.93 (1H, br s), 6.46 (1H, d, J = 5 Hz), 7.45 (2H, t, J = 9 Hz), 7.28 (1H, d, J = 5 Hz), 8.90 (1H, br s).<br>
Example 636<br>
To a mixture of e1Hyl 4-(4-fluorophenyl)-2-isopropylpyrrolo[l,2-b]pyridazine-3-carboxylate (100 mg, 0.306 mmol) and ammonium 1Hiocyanate (28.0 mg, 0.368 mmol) in me1Hanol (100 mL) was added cerium ammonium nitrate (386 mg, 0.705 mmol) under an ice ba1H. 1He mixture was stirred for 30 min. 1He mixture was stirred for additional 10 min after adding ammonium 1Hiocyanate (8.2 mg, 0.107 mmol). Water (5 mL) was added, and 1He mixture was extracted wi1H e1Hyl acetate (20 mL). 1He organic extract was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give a<br><br>
deep green gum. Flash silica gel column chromatography eluting wi1H e1Hyl acetate-hexane = 1-10 to 3-20 afforded e1Hyl e1Hyl 4-(4-fluorophenyl)-2-isopropyl-7-1Hiocyanatopyrrolo[l,2-b]pyridazine3-carboxylale as an yellow gum (89.6 mg, 82.3%).<br>
1H-NMR (CDCb) 5 1.01 (1H, t, J = 7 Hz), 1.46 (6H, d, J = 7 Hz), 3.36 (1H, septet, J = 7Hz),4.08(2H,q,J = 7Hz),6.23(1H,d,J = 5 Hz), 7.14-7.22 (1H,m), 7.16 (2H, t, J = 9 Hz), 7.46 (2H, dd, J = 4 and 9 Hz).<br>
Example 637<br>
To a solution of e1Hyl 4-(4-fluorophenyl)-2-isopropyl-7-1Hiocyanatopyrrolo[l,2-b]pyridazine-3-carboxylate (77.7 mg, 0219 mmol) in me1Hanol (0.7 mL) was added 85% potassium hydroxide (0.3 mg, 0.004 mmol) at room temperature. After stirring for 5 min, 1He mixture was partitioned between e1Hyl acetate (20 mL) and water (5 mL). 1He organic layer was washed wi1H brine, dried over anhydrous magnesium sulfate, and evaporated to give an yellow gum. Preparative silica gel 1Hin layer chromatography eluting wi1H e1Hyl acetate-hexane = 1-7 afforded e1Hyl 4-(4-fluorophenyl)-2-isopropyl-7-(me1Hyl1Hio)pyrrolo[l32-b]pyridazine-3-carboxylate as an yellow gum (35.9 mg, 44.1%).<br>
1H-NMR (CDC13) 5 0.98 (1H, t, J = 7 Hz), 1.41 (6H, d, J = 7 Hz), 2.52 (1H, s), 3.32 (1H, septet, J = 7 Hz), 4.05 (2H, q, J = 7 Hz), 6.35 (1H, d, J = 5 Hz), 6.89 (1H, d, J = 5 Hz), 7.16 (2H, t, J = 9 Hz), 7.44 (2H, d, J = 4 and 9 Hz).<br>
MS (ESf): m/z 373 (M + H)<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 1 Example 638 3-(9-e1Hyl-3-me1Hoxy-5,6-dihydrobenzo[f]pyrrolo[l,2-b]cinnolin-12-yl)benzonitrile<br>
1HNMRCCDCL3) 6 1-41 (1H,t,J = 8 Hz), 2.91-3.11 (6H,m), 3.78 (1H,s), 6.09 (1H, d, J = 5 Hz), 6.38 (1H, dd, J = 8,3 Hz), 6.52 (1H, d, J = 8 Hz), 6.59 (1H, d, J = 5 Hz), 6.77 (1H, br s), 7.56 (1H, t, J = 8 Hz), 7.67 (1H, br d, J = 8 Hz), 7.70-7.77 (2H,m).<br>
Example 639<br><br>
4-(3-e1Hy]-6H-indeno[l,2-e]pyrrolo[J,2-b]pyridazin-ll-y])benzonitri]e<br>
1H NMR (CDCl3) 6 1.43 (1H, t, J = 8 Hz), 3.09 (2H, q, J = 8 Hz), 4.11 (1H, s), 6.14 (1H, d, J = 5 Hz), 6.64 (1H, d, J = 5 Hz), 6.71 (1H, d, J = 8 Hz), 7.07 (1H, I, J = 8 Hz), 7.20-7.30 (1H, overlapped wi1H CDCl3), 7.49 (1H, d, J = 8 Hz), 7.69 (2H, d, J = 8Hz),7.88(2H,d,J = 8Hz). MS(ESl+):m/z336(M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hai of Preparation 24. Preparation 352 e1Hyl 4-me1Hoxy-2-[(5-me1Hyl-3-pyridinyl)carbonyl]-3-oxobutanoate<br>
1H NMR (CDCl3) 6 0.97,1.26 (1H, t, J= 7 Hz), 2.40 (1H, s), 3.24,3.35,3.49 (1H, s),<br>
3.98-4.20 (2H, m), 4.11,4.20,4.54 (2H, s), 5.70 (1H, s), 7.67,7.92,8.02, 8.50-<br>
8.66, 8.77, 8.89 (1H,m).<br>
Preparation 353<br>
e1Hyl 2-[(5-chloro-3-pyridinyl)carbonyl]-4-me1Hoxy-3-oxobutanoate<br>
1H NMR (CDCl3) 5 1.00,1.06, 1.28,1.35 (1H, t, J= 7 Hz), 3.23, 3.43,3.49 (1H, s),<br>
4.05-4.33 (2H, m), 4.56 (2H, s), 7.85, 8.05, 8.22, 8.29, 8.58-8.82,8.85,9.01, 9.10<br>
(1H,m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 176. Preparation 354 tert-butyl 3-bromo-5-({l-[(cyanoacetyl)amino]-5-e1Hyl-lH-pyrrol-2-yl}carbonyl)benzoate<br>
1HNMR (CDCl3) 6 1.29 (34H, t, J = 7 Hz), 1.60 (9H, s), 2.61 (2H, q, J = 7 Hz), 3.64 (2H, s), 6.00 (1H, m), 6.80 (1H, m), 8.03 (1H, m), 8.26 (1H, m), 8.28 (1H, m).<br>
Preparation 355<br>
tert-butyl 3-bromo-5-[(5-e1Hyl-l-{[(me1Hylsulfonyl)acetyl]amino}-lH-pyrrol-2-<br>
yl)carbonyl]benzoate<br>
1H-NMR(CDCl3)6 1.29(1H,t,J=7Hz), 1.60(9H,s),2.60(2H,q,J = 7 Hz),2.92<br><br>
(1H, s), 4.04 (2H,s), 6.11 (1H,m), 6.78 (lH,m), 8.03 (lH,m), 8.25 (J H,m), 8.27 (lH,m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 153. Preparation 356 tert-butyl 3-bromo-5-(chlorocarbonyl)benzoate<br>
1He following cornpound(s) was(were) obtained in a similar manner to 1Hat of Preparation 164. Preparation 357 tert-butyl 3-bromo-5-[(5-e1Hyl-lH-pyrrol-2-yl)carbonyl]benzoate<br>
1H-NMR (CDC13) 6 1.32 (1H, t, J = 7 Hz), 1.61 (9H, s), 2.74 (2H, q, J = 7 Hz), 6.10<br>
(1H, m), 6.80 (1H, m), 8.13 (1H, m), 8.26 (1H, m), 8.39 (1H, m), 9.34 (1H, s, br).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 338. Preparation 358 tert-butyl 3-[(l1HaMIo-5-e1Hyl-lH-pyrrol-2-yl)carbonyl]-5-bromobenzoate<br>
1H -NMR (CDCb) 5 1.29 (1H, t, J = 7 Hz), 1.61 (9H, s), 2.76 (2H, q, J = 7 Hz), 5.74<br>
(2H, s, br), 5.93 (1H, d, J = 5 Hz), 6.63 (1H, d, J = 5 Hz), 8.05 (1H, m), 8.25 (1H,<br>
m),8.29(lH,m).<br>
Preparation 359<br>
To a solution of tert-butyl 3-bromo-5-iodobenzoate (4.00 g) in tetrydrofuran (30 mL) was added 0.76 M isopropylmagnesium bromide (13.7 mL) in an ice-me1Hanol ba1H under a nitrogen atmosphere. After stirring for 0.5 hour, 1He mixture was poured onto dryice. 1He mixture was warmed to room temperature over 1 hour. 1He mixture was partitioned between EtOAc and 1 N hydrochloric acid. 1He organic layer was back extracted wi1H 1 N sodium hydroxide (two times). 1He extract was acidified by adding concentrated hydrochloric acid, and extracted wi1H chloroform (two times). 1He organic extract was washed wi1H brine, dried over MgSO4, and evaporated to give 3-bromo-5-(lert-butoxycarbonyl)benzoic acid as a pale brown solid (529 mg).<br><br>
5-bromo-5-(tert-butoxycarbonyl)bcnzoic acid<br>
1H -NMR (DMSOd6) 6 1.57 (9H, s), 8.21 (1H, s), 8.25 (1H, s), 837 (1H, s).<br>
Preparation 360<br>
To a vigirously stirred suspension of pondered MgSO4 (7.36 g) in dichlorome1Hane (50 mL) was added sulfuric acid (0.758 mL) at room temperature. After stirring for 15 minutes, to 1He mixture was added 3-bromo-5-iodobenzoic acid (5.00 g) followed by tert-butanol (7.31 mL). 1He mixture was stirred for 3 days at room temperature. 1He mixture was partitioned between EtOAc and water. 1He organic layer was washed wi1H satd. NCCb and brine, dried over MgS04, and evaporated to give tert-butyl 3-bromo-5-iodobenzoate as pale purple crystals (4.44 g).<br>
tert-butyl 3brorno-5-iodobenzoate<br>
1H-NMR (CDC13) 6 1.58 (9H, s), 8.00 (1H, m), 8.06 (1H, m), 8.22 (1H, m).<br>
Preparation 361<br>
To a suspension of li1Hium (316 rng) in e1Her (10 mL) was added cyclopropylbromide (2.50 g) in e1Her (10 mL) over 20 min in a me1Hanol-ice ba1H under a nitrogen atmosphere. 1He mixture was stirred for 0.5 hour in an ice ba1H. 1He mixture was cooled in a dryice-acetone ba1H. To 1He mixture was added a solution of triisopropoxyborane (5.05 g) in tetrydrofuran (5 mL) over 15 minutes. 1He mixture was alowed to warme to room temperature over 2 hours. 1He reaction was quenced by adding hydrochloric acid. 1He organic solvent was evaporated off, and 1He residual   solution was extracted wi1H e1Her (30 mL, five times). 1He combined extract was dried over MgS04, and evaporated to give a white solid (968 mg). 1He solid was triturated in cold hexanes to give cyclopropylboronic acid as a white powder (789 mg).<br>
cyclopropylboronic acid<br>
1H-NMR (DMSO-d6) 6 -0.40 (1H, m), 032 (2H, m), 0.39 (2H, m), 7.28 (2H, s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 21.<br><br>
Example 640<br>
e1Hyl 7-e1Hyl-2-(me1Hoxymelhyl)-4-(5-melhyl-3-pyridinyl)pynolofl,2-b]pyritlazine-3-<br>
carboxylate<br>
1H NMR (CDC1..) 5 0.99 (1H, t, J= 7 Hz), 1.38 (1H, t, J= 7 Hz), 2.41 (1H, s), 3.06 (2H, q, J= 7 Hz), 3.38 (1H, s), 4.06 (2H, q, J= 7 Hz), 4.75 (2H, s), 6.33 (1H, d, J= 4 Hz), 6.71 (1H, d, J= 4 Hz), 7.61 (1H, s), 8.52 (1H, d, J= 2 Hz), 8.54 (1H, d, .1= 2 Hz). MS(ESI+):m/z354.<br>
Example 641<br>
e1Hyl 4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(me1HoxyjTie1Hyl)pyrrolo[l,2-b]pyridaziiie-3-<br>
carboxylate<br>
1H NMR (300 MHz, CDClj) 5 1.04 (1H, t, J = 7 Hz), 1.38 (1H, t, J = 7 Hz), 3.06 (2H, q, J = 7 Hz), 3.39 (1H, s), 4.09 (2H, q, J = 7 Hz), 4.76 (2H, s), 6.33 (1H, d, J = 4 Hz), 6.75 (1H, d, J = 4 Hz), 7.81 (1H, dd, J = 2, 2 Hz), 8.57 (1H, d, J = 2 Hz), 8.68(lH,d,J = 2Hz). MS(m/z)374(M+l).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 076. Example 642<br>
(2E)-3-[7-e1Hyl-2-(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]acrylic acid<br>
1H NMR (CDCl3) 6 1.39 (1H, t, J= 7 Hz), 2.43 (1H, s), 3.07 (2H, q, J= 7 Hz), 3.51 (1H, s), 4.65 (2H, s), 5.97 (1H, d, J= 16 Hz), 6.27 (1H, d, J= 4 Hz), 6.71 (1H, d, J= 4 Hz), 7.61 (1H, s), 7.72 (1H, d, J= 16 Hz), 8.46 (1H, d, J= 2 Hz), 8.57 (1H, d, J=2Hz). MS (ES1+): m/z 352.<br>
Example 643 (2E)-3-[4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]acrylic acid<br>
1H NMR (300 MHz, CDC13) 6 1.39 (1H, t, J = 7 Hz), 3.07 (2H, q, J = 7 Hz), 3.51<br><br>
(1H, s), 4.65 (2H, s), 5.97 (1H, d, J = 16 Hz), 6.27 (1H, d, J = 4 Hz), 6.75 (1H, d, J = 4 Hz), 7.69 (1H, d, J = 16 Hz), 7.78 (1H, dd, J = 2, 2 Hz), 8.54 (1H, d, J - 2 Hz), 8.71 (lH,d,J = 2Hz). MS(m/z)400(M+l).<br>
Example 644<br>
4-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxymc1Hyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]butanoic acid<br>
1H-NMR (CDC13) 6 0.78 (2H, m), 1.10 (2H, m), 1.37 (1H, t, J = 7 Hz), 1.73 (2H, m), 1.98 (1H, m), 2.23 (2H, m), 2.62 (2H, m), 3.02 (2H, q, J = 7 Hz9, 3.46 (1H, s), 4.65 (2H, q, J = 7 Hz), 5.88 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.36 (1H, m), 8.41 (lH,m), 8.47 (lH,m).<br>
Example 645<br>
5-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3'<br>
yl]pentanoic acid<br>
1H-NMR (CDCl3) 5 0.75 (2H, m), 1.08 (2H, m), 1.37 (1H, t, J = 7 Hz), 1.40-1.57 (4H, m), 1.96 (1H, m), 2.18 (2H, m), 2.51 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.45 (1H, s), 4.61 (2H, m), 5.87 (1H, d, J = 5 Hz), 6.56 (1H, d, J = 5 Hz), 7.34 (1H, m), 8.39 (lH,m),8.50(lH,m).<br>
Example 646<br>
3-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-<br>
yljpropanoic acid<br>
1H-NMR (DMS0-d6) 6 0.76 (2H,m) ,1.08 (2H, m), 1.37 (1H, t, J = 7 Hz), 1.95 (1H, m), 2.48 (2H, m), 2.87 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.47 (1H, s), 4.66 (2H, m), 5.90 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.35 (1H, m), 8.40 (1H, m), 8.48 (lH,m).<br>
Example 647<br>
5-[4-(2-chloio-4-pyridinyl)-7-e1Hyl-2-me1Hy]pyrrolo[l,2-b]pyridazin-3-yl]-5-oxopentanoic acid<br>
1H NMR (CDCb) 8 1.38 (1H, t, J = 8 Hz), 1.73-1.85 (2H, m), 2.26 (2H, t, J = 8 Hz),<br><br>
2.36 (2H, t, J = 8 Hz), 2.46 (1H, s), 3.04 (2H, q, J = 8 Hz), 6.33 (1H, d, J = 5 Hz), 6.70(lH,d,J=z),7.34(1H,brd),7,45(lH,brs),81H3(lH,d,J = 6Hz).<br>
Example 648<br>
(2E)-3-[4-(2-chloro-4-pyridiny])-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-y]Jacrylic<br>
acid<br>
1H NMR (CDC13) 6 1.38 (1H, t, J = 8 Hz), 2.67 (1H, s), 3.05 (2H, q, J = 8 Hz), 5.79 (1H, d, J = 15 Hz), 6.19 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 5 Hz), 7.24-7.29 (1H, overlapped wi1H CDC13), 7.40 (1H, br s), 7.51 (1H, d, J = 15 Hz), 8.55 (1H, d, J = 5 Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 146. Example 649<br>
e1Hyl (2E)-3-[4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-melhylpyrrolo[l,2-b]pyridazin-3-yljacrylate<br>
1H NMR (CDC13) 6 1.27 (1H, t, J = 8 Hz), 1.38 (1H, t, J = 8 Hz), 2.65 (1H, s), 3.04<br>
(2H,q,J = 8Hz),4.17(2H,q,J = 8Hz),5.76(lH,d,J = 15 Hz),6.16 (1H,d,J =<br>
5 Hz), 6.65 (1H, d, J = 5 Hz), 7.24-7.29 (1H, overlapped wi1H CDC13), 7.40 (1H,<br>
br s), 7.53 (1H, d, J = 15 Hz), 8.53 (1H, d, J = 5 Hz). MS (ES1+): m/z 370 (M + H).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 181. Example 650<br>
tert-butyl 3-bromo-5-(3-cyano-7-e1Hyl-2-oxo-l,2-dihydropyrrolo[l ,2-b]pyridazin-4-yl)benzoate<br>
1H-NMR (CDCl3) 6 1.36 (1H, t, J = 7 Hz), 2.94 (2H, q, J = 7 Hz), 6.57 (1H, d, J = 5<br>
Hz), 6.72 (1H, d, J = 5 Hz), 7.94 (1H, m), 8.20 (1H, m), 8.38 (1H, m).<br>
Example 651<br>
tert-butyl 3-bromo-5-[7-e1Hyl-3-(me1Hylsulfonyl)-2-oxo-l,2-dihydropyrrolo[l,2-<br>
b]pyridazin-4-yl]benzoate<br><br>
1H-NMR (CDCl3) 6 1.35 (1H, 1, J = 7 Hz), 3.02 (2H, q, J = 7 Hz), 3.06 (1H, s), 6.24 (1H, d, J = 5 Hz), 6.70 (J H,d,J = 5 Hz), 7.23 (1H, m), 7.94 (1H, m), 8.25 (1H, m).<br>
1He following compound(s) was(were) obtained in a similar manner lo 1Hat of Example 183. Example 652<br>
tert-butyl 3-bromo-5-(3-cyano-7-e1Hyl-2-{[(trifluorome1Hyl)sulfonyl]oxy}pyrrolo[l,2-b]pyridazin-4-yl)benzoate<br>
1H-NMR (CDCl3) 5 139 (1H, t, J = 7 Hz), 1.61 (9H, s), 3.02 (2H, q, J = 7 Hz), 6.81 (1H, d, J = 5 Hz), 700 (1H, d, J = 5 Hz), 7.96 (1H, m), 8.21 (1H, m), 8.33 (1H, m).<br>
Example 653<br>
tert-butyl 3-bromo-5-(7-e1Hyl-3-(me1Hylsulfonyl)-2-<br>
{[(trifluorome1Hyl)sulfonyl]oxy}pyirolo[l,2-b]pyridazin˚4»yl)benzoate<br>
1H-NMR (CDCl3) 5 1.38 (1H, t, J = 7 Hz), 1.59 (9H, s), 3.01 (2H, q, J = 7 Hz), 3.22<br>
(1H, s), 6.46 (1H, d, J = 5 Hz), 7.12 (1H, d, J = 5 Hz), 7.67 (1H, m), 7.90 (1H, m),<br>
8.23 (lH,m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 184. Example 654<br>
tert-butyl 3-bromo-5-[3-cyano-7-e1Hyl-2-(l -pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoate<br>
1H-NMR (CDCb) 5 1.35 (1H, t, J = 7 Hz), 1.60 (9H, s), 2.01 (4H, m), 2.93 (2H, q, J<br>
= 7 Hz), 3.73 (4H, m), 6.32 (1H, d, J = 5 Hz), 6.58 (1H, d, J = 7 Hz), 7.86 (1H, m),<br>
8.12 (lH,m), 8.24 QH,m).<br>
Example 655<br>
tert-butyl 3-bromo-5-[7-e1Hyl-3-(me1Hylsulfonyl)-2-(l-pyrrolidinyl)pyrrolo[l,2-<br>
b]pyridazin-4-yl]benzoate<br>
1H-NMR(CDCl3)51.37(1H,t,J = 7Hz),1.58(9H,s),1.99(4H,m),2.98(2H,q,J = 7 Hz), 3.21 (1H, s), 3.52 (4H, m), 6.30 (1H, d, J = 5 Hz), 6.66 (1H, d, J = 5 Hz),<br><br>
7.76 (lH,m), 8.00 (lH,m), 8.19 (1H,m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of<br>
Example 147.<br>
Example 656<br>
e1Hyl (2E)-3-[4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]acrylate<br>
1H NMR (300 MHz, CDCl3) 5  1.27 (1H, l, J = 7 Hz), 1.39 (1H, t, J = 7 Hz), 3.07 (2H, q,J =7Hz),31H1(1H,s),4.18(2H,q,J=7Hz),4.64(2H,s),5.97(lH,d,J = 16 Hz), 6.24 (1H, d, J = 4 Hz), 6.72 (1H, d, J = 4 Hz), 7.61 (1H, d, J = 16 Hz), 7.76 (1H, dd, J = 2,2 Hz), 8.54 (1H, d, J = 2 Hz), 8.68 (1H, d, J = 2 Hz).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 205. Example 657<br>
(4E)-5-[4'(5-chloro-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]-4-pentenoic acid<br>
1H NMR (300 MHz, CDC13) 6 138 (1H, t, J = 7 Hz), 2.25-2.41 (4H, m), 3.05 (2H, q,<br>
J = 7 Hz), 3.50 (1H, s), 4.57 (2H, s), 5.53 (1H, dd, J = 16,7 Hz), 6.13 (1H, d, J =<br>
4 Hz), 6.36 (1H, d, J = 16 Hz), 6.65 (1H, d, J = 4 Hz), 7.80 (1H, s), 8.54 (1H, br s),<br>
8.62(lH,brs). MS(m/z)400(M+l).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Preparation 153. Example 658 4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazine-3-carbonyl chloride<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 244. Example 659<br>
7-e1Hyl-2-(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carbaldehyde<br><br>
1H NMR (CDCl3) 0 1 -40 (1H, t, J= 7 Hz), 2.45 (1H, s), 3.12 (2H, q, J= 7 Hz), 3.56 (1H, s), 4.96 (2H, s), 6.51 (1H, d, J= 4 Hz), 6.80 (1H, d, J= 4 Hz), 7.62 (1H, s), 8.54 (lH,s), 8.61 (1H,S),9.79(1H,S).<br>
MS(ESl+):m/z310.<br>
ixample 660<br>
4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazine-3-<br>
:arbaldehyde<br>
1H NMR (300 MHz, CDC13) 6 1.41 (1H, t, J = 7 Hz), 3.12 (2H, q, J = 7 Hz), 3.54 (1H, s), 4.94 (2H, s), 6.50 (1H, d, J = 4 Hz), 6.84 (1H, d, J = 4 Hz), 7.81 (1H, dd, J = 2,2 Hz), 8.59 (1H, d, J = 2 Hz), 8.74 (1H, d, J = 2 Hz), 9.85 (1H, s).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 533. Example 661<br>
[7-e1Hyl-2-(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-b]pyridazin-3-yl]me1Hanol<br>
1H NMR (CDCl3) 5 1.38 (1H, t, J= 7 Hz), 2.43 (1H, s), 3.05 (2H, q, J= 7 Hz), 3.52 (1H, s), 4.37-4.51 (2H, br), 4.66-4.78 (2H, br), 6.20 (1H, d, J= 4 Hz), 6.67 (1H, d, J= 4 Hz), 7.75 (1H, s), 8.54 (1H, s), 8.60 (1H, s). MS(ESI+):m/z312.<br>
Example 662<br>
[4-(5-chloro-3-pyridinyl)-7-e1Hyl-2-(nie1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-<br>
yl]me1Hanol<br>
1H NMR (300 MHz, CDCl3) 6 1.38 (1H, t, J = 7 Hz), 3.05 (2H, q, J = 7 Hz), 3.53 (1H, s), 4.41 (2H, d, J = 6 Hz), 4.77 (2H, s), 6.22 (1H, d, J = 4 Hz), 6.70 (1H, d, J = 4 Hz), 7.97 (1H, dd, J = 2, 2 Hz), 8.69-8.71 (2H, m). MS (m/z) 332 (M+l).<br>
Example 663<br>
A mixture of 7-e1Hyl-2-(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-b]pyridazine-3-carbaldehyde (48 mg) and e1Hyl (triphenylphosphoranylidene)acetate<br><br>
(56.8 mg) in 1HF (3 mL) was stirred at ambient temperature for 2 hours. After<br>
evaporation of solvent, 1He residue was purified by silica gel column chromatography<br>
eluting wi1H a mixture of hexane and AcOEt (5:1 - 2:1) to give e1Hyl (2E)-3-[7-c1Hyl-2-<br>
(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[J,2-b]pyridazin-3-yl]aci7late as a<br>
yellow powder (30 mg).<br>
e1Hyl (2E)-3-[7-e1Hyl-2-(me1Hoxyme1Hyl)-4-(5-me1Hyl-3-pyridinyl)pyrrolo[l,2-<br>
b]pyridazin-3-yl]acrylate<br>
1H NMR (CDC13) 6 1 -26 (1H, t, J= 7 Hz), 1.39 (1H, t, J= 7 Hz), 242 (1H, s), 3.07 (2H, q, J= 7 Hz), 3.51 (1H, s), 4.12 (2H, q, J= 7 Hz), 4.64 (2H, s), 5.97 (1H, d, J= 16 Hz), 6.24 (1H, d, J= 4 Hz), 6.70 (1H, d, J= 4 Hz), 7.55 (1H, s), 7.63 (1H, d, J= 16 Hz), 8.47 (1H, d, J= 2 Hz), 8.55 (1H, d, J= 2 Hz). MS(ESI+):m/z380.<br>
Example 664<br>
To a mixture of e1Hyl 4-[4-(5-bromo-3-pyridinyl)-7-e1Hyl-2-(melhoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoate (75.0 mg), cyclopropylboronic acid (18.2 mg), tricyclohexylphosphine (4.57 mg), and potassium phosphate (104 mg) in toluene-water (1 mL-0.2 mL) was added palladium acetate (1.83 mg). 1He mixture was stirred for 2 hours at 100°C. 1He mixture was partitioned between EtOAc and water. 1He organic layer was washed wi1H brine, dried over MgS04, and evaporated. Preparative silicagel 1Hin layer chtomatography (EtOAc-hexanes = 1-3) afforded e1Hyl 4-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoateas an yellow gum (60.9 mg).<br>
e1Hyl 4-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[l,2-b]pyridazin-3-yl]butanoate<br>
1H-NMR (CDCl3) 5 0.76 (2H, m), 1.07 (2H, m), 1.20 (1H, t, J= 7 Hz), 1.37 (1H, t, J = 7 Hz), 1.68 (2H, m), 1.96 (1H, m), 2.17 (2H, m), 2.56 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.46 (1H, s), 4.03 (2H, q, J = 7 Hz), 4.65 (2H, m), 5.90 (1H, d, J = 5 Hz), 6.57 (1H, d, J = 5 Hz), 7.30 (1H, m), 8.40 (1H, m), 8.51 (1H, m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 664. Example 665<br><br>
e1Hyl 5-[4-(5-cyclopropyl-3-pyridiny])-7-e1Hy]-2-(me1Hoxyme1Hy])pyrrolofl,2-b]pyridazin-3-yI]pentanoate<br>
1H-NMR (CDC13) 6 0.76 (2H, m), J .08 (2H, m), 1.23 (1H, 1J = 7 Hz), 1.35-157 (7H, m), 1.96 (1H, m), 2.16 (2H, t, J = 7 Hz), 2.53 (2H, m), 3.03 (2H, q, J = 7 Hz), 3.46(1H,s),4.08(2H,q,J = 7Hz),4.62(2H,s),5.89OH,d,J = z),656(1H, d, J = 5 Hz), 7.29 OH, m), 8.40 (1H, m), 8.52 (1H, m).<br>
Example 666<br>
e1Hyl 3-[4-(5-cyclopropyl-3-pyridinyl)-7-e1Hyl-2-(me1Hoxyme1Hyl)pyrrolo[ 1,2-<br>
b]pyridazin-3-yl]propanoate<br>
1H-NMR(CDCl3)5 0.76(2H,m), 1.08 (2H,m), 1.19 (1H, t, J = 7 Hz), 1.37(1H,t,J = 7 Hz), 1.97 (1H, m), 2.38 (2H, m), 2.85 (2H, m), 3.02 (2H, q, J = 7 Hz), 3.46 (1H, s), 4.04 (2H, q, J = 7 Hz), 4.64 (2H, s), 5.92 (1H, d, J = 5 Hz), 6.59 (1H, d, J = 5 Hz), 7.29 (1H, m), 8.40 (1H, m), 8.53 OH, m).<br>
Example 667<br>
tert-butyl 3-[3-cyano-7-e1Hyl-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]-5-<br>
cyclopropylbenzoate<br>
1H-NMR (CDC13) 6 0.81 (2H, m), 1.03 (2H, m), 1.35 (1H, t, J = 7 Hz), 1.59 (9H, s), 1.94-2.08 (, m), 2.94 (2H, q, J = 7 Hz), 3.68-3.77 (4H, m), 6.35 (1H, j, J = 5 Hz), 6.55 OH, d, J = 5 Hz), 7.43 (1H, s), 7.84 (1H, s), 7.97 (1H, s).<br>
Example 668<br>
A solution of tert-butyl 3-bromo-5-[3-cyano-7-e1Hyl-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoate (16.0 mg) in trifluoroacetic acid (05 mL) was stirred for 0.5 hour at room temperature. 1He reaction was quenched by adding water. 1He mixture was neutralized by adding NaOH (pH = 3). 1He mixture was extracted wi1H EtOAc. 1He extract was washed wi1H brine, dried over MgS04, and evaporated to give a greenish yellow solid. 1He solid was triturated in hexanes-CHCb (2-1) to afford 3-bromo-5-[3-cyano-7-e1Hyl-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoic acid as an yellow powder (10.8 mg).<br>
3-bromo-5-[3-cyano-7-e1Hyl-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoic acid<br><br>
M-I-NMR (CDCb + CD3OD) 5 136 (1H, t, J = 7 Hz), 2.0] (4H, m), 2.94 (2H, q, J = 7 Hz), 3.72 (4H, m), 6.36 (1H, d, J - 5 Hz), 6.60 (J H, d, J = 5 Hz), 7.92 (1H, m), 8.23(lH,m),835(1H,m).<br>
1He following compound(s) was(were) obtained in a similar manner to 1Hat of Example 668. Example 669<br>
3-[3-cyano-7-e1Hyl-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]-5-cyclopropylbenzoic acid<br>
1H-NMR (CDC13 + CD3OD) 6 0.81 (2H, m), 1.05 (2H, m), 1.35 (1H, t, J = 7 Hz),<br>
2.01 (, m), 2.94 (2H, q, J = 7 Hz), 7.73 (4H, m), 637 (1H, d, J = 5 Hz), 6.57<br>
(1H, d, J = 5 Hz), 6.98 (1H, s), 7.90 (1H, s), 8.08 (lH,s).<br>
Example 670<br>
3-bromo-5-[7-e1Hyl-3-(me1Hylsulfonyl)-2-(l-pyrrolidinyl)pyrrolo[l,2-b]pyridazin-4-yl]benzoic acid<br>
1H-NMR (CDCb + CD30D) 5 137 (1H, t, J = 7 Hz), 1.98 (4H, m), 2.99 (2H, q, J = 7<br>
Hz), 320 (1H, s), 3.56 (4H, m), 632 (1H, d, J = 5 Hz), 6.67 (1H, d, J = 5 Hz),<br>
7.80 (1H, m), 8.08 (1H, m), 830 (1H, m).<br>
Example 671<br>
To a 3-necked frask containing Zn-Cu couple was added a solution of e1Hyl 4-iodobutanoate (369 mg) in toluene (3 mL) and N,N-dime1Hylacetamide (0.2 mL) at ambient temperature under N2. 1He mixture was stirred at 1He temperature for 1 h and 1Hen at 601H for 3 h. A suspension of tetrakis(triphenylphosphine)palladium (44 mg) in toluene (0.5 mL) was added and stirred for 5 min. After removal of an oil ba1H, 1He mixture was cooled in an ice-water ba1H. To 1His mixture was added a solution of 4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazine-3-carbonyl chloride (212 mg) in DCM (1 mL) dropwise. After 10 min, 1He reaction mixture was stirred at ambient temperature for 2 h. 1He reaction mixture was partitioned between AcOEt and H2O. 1He organic layer was washed wi1H sat. NCO3 and brine, dried over MgS04, and evaporated in vacuo. 1He residue was purified by flash silica gel chromatography (silica gel, 80 mL) eluled wi1H hexane-AcOEt = 10-1 and 5-1 to give e1Hyl 5-[4-(2-chloro-4-<br><br>
pyridiny])-7-e1Hyl-2-me1Hylpyrrolo[l,2-b]pyridazin-3-yI]-5-oxopentanoate as yellow amorphous (J43 mg).<br>
e1Hyl 5-[4-(2-ch]oro-4-pyridiny])-7-elhy]-2-me1Hy]pyrroIo[l,2-b]pyridazin-3-yl]-5-oxopenlanoate<br>
1HNMR(CDC13)&amp; l.23(1H,t,J = 8H2),138(1H,t,J = 8Hz),l.7l-l.84(2H,m), 2.17 (1H, t, J = 8 Hz), 2.32 (1H, t, J = 8 Hz), 2.46 (1H, s), 3.04 (2H, q, J = 8 Hz), 4.06(2H,q,J = 8Hz),6.32(1H,d,J = z),6.70(lH,d,J = 5 Hz), 7.32 (1H, dd, J = 5, 1), 7.46 (1H, br s), 8.53 (1H, d, J = 5 Hz).<br>
Example 672<br>
To a solution of 5-[4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hylpyrro]ofl,2-b]pyridazin-3-yl]-5-oxopentanoic acid (47 mg) in EtOH (1 mL) was added sodium borohydride (5 mg) in an ice-water ba1H under N2. After 10 min, 1He mixture was stirred at ambient temperature. After 1 h, ano1Her odium borohydride (5 mg) was added. After 2 h, 1He reaction mixture was partitioned between CHCl3 and H2O. 1He aqueous layer was extracted wi1H CHCl3 twice. 1He combined organic layer was dried over MgS04 and evaporated in vacuo. 1He residue was purified by p-TLC (CHCl3-MeOH = 10-1) to give 5-[4-(2-chloro-4-pyridiny])-7-e1Hy]-2-me1Hy]pyrrolo[l,2-b]pyridazin-3-yl]-5-hydroxypentanoic acid as yellow amorphous (28 mg).<br>
5-[4-(2-chloro-4-pyridinyl)-7-e1Hyl-2-me1Hy]pyrro]o[l,2-b]pyridazin-3-yl]-5-hydroxypentanoic acid<br>
1H NMR (CDCl3) 6 1.36 (1H, t, J = 8 Hz), 1.46-1.83 (1H, m), 1.95 (1H, m), 2.70 (1H, br s), 3.01 (2H, q, J = 8 Hz), 4.63 (1H, m), 5.85 (1H, m), 6.55 (1H, d, J = 5 Hz), 7.18-7.29 (1H, overlapped wi1H CDCl3), 7.34 (1H, d, J = 2 Hz), 8.49 (1H, d, J = 5 Hz).<br><br>
WE CLAIM:<br>
1.       A compound of 1He formula<br><br><br>
R7is<br>
(1)	hydrogen,<br>
(2)	substituted or unsubstituted aryl,<br>
(3)	substituted or unsubstituted heterocyclic groups, containing 1 to 2 nitrogen atom(s)<br>
(4)	carboxy, protected carboxy or CONRIORU,<br>
(5)	acyl or halocarbonyl,<br>
(6)	cyano,<br>
(7)	amino, protected amino, or mono- or di(C1-6)alkylamino,<br>
(8)	hydroxy, aryloxy, acyloxy or C1-6 alkyl optionally substituted by hydroxy or acyloxy,<br>
(9)	C1-6alkyl1Hio, C1-6alkylsulfinyl or C1-6alkylsulfonyl, or<br>
(10)	-O-R12,<br>
or<br>
R' and Rz are combined toge1Her to form C1-6 alkylene or C2-6 alkenylene<br>
group   which  is   optionally  interrupted  by  amino  or  sulfonyl  and<br>
optionally fuse wi1H benzene ring, and also is optionally substituted by<br>
1He group consisting of C1-6alkyl, hydroxy, oxo and C1-6alkoxy,<br>
R3 is substituted aryl, or substituted or unsubstituted heterocyclic group,<br>
R4 is hydrogen, halogen, cyano, carbamoyl, acyl, 1Hiocyanate, C1-6<br>
alkyl1Hio, C2-6 alkenyl, hydroxyl(C1-6)alkyl, trihalo(C1-6)alkyl or C1-6<br>
alkyl,<br>
R5,  R6, R10 and R11  each independently represents hydrogen,  C1-6<br>
alkylsulfonyl, heterocyclic group or C1-6 alkyl optionally substituted by<br>
hydroxy, alkoxy, sulfo, carboxy, protected carboxy or -R<br>
or alternatively R5 and R6 or R10 and R11 toge1Her wi1H 1He nitrogen atom<br>
to which 1Hey are attached, represent N-containing heterocyclic group,<br>
and R12 and R17 are each independently a group derived from protected<br>
or unprotected sugar by removal of 1He hydroxy group 1Herefrom,<br>
or a pharmaceutical1H acceptable salt 1Hereof, or prodrug 1Hereof.<br><br>
2.       A compound as claimed in claim 1, wherein R1 is (1) carboxy or protected caxboxy,<br>
(2)-CONR5R6 [wherein R5 and R6 each independently represents C1-6 alkyl, or alternatively R5 and R6, toge1Her wi1H nitrogen atom to which 1Hey are attached represents saturated 5- or 6-membered heteromonocyclic group containing I to 2 nitrogen atom(s)],<br>
(3)	hydroxy or C1-6alkoxy,<br>
(4)	amino, cyclo(C3_7)alkylamino, or mono- or di(C1-6)alkylamino optionally substituted by C1-6 alkoxy,<br>
(5) trihalo (O3alkyl,<br>
(6)trihalo (C1-6)alkylsulfonyloxy or arylsulfonylamino, (7) C1-6 alkyl optionally substituted by (i) halogen; (ii) carboxy; (iii) protected carboxy; (iv) cyano; (v)carbamoyl; (vi) -OCONR15R16 [wherein R15 and R16 each independently represents hydrogen, aryl or C1-6 alkyl optionally substituted by aryl, or R15 and R16, toge1Her wi1H 1He nitrogen atom to which 1Hey are attached, represents saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom,]; (vii) C1-6 alkyltihio.; (viii) C1-6alkylsulfonyl; (ix) C1-6Halkylsulfonyloxy; (x)C1-6alkylsulfonylamino; (xi) mono- or di(C1-6)alkylamino optionally substituted by hydroxy, C1-6 alkoxy, aryloxy, or substituted or unsubstituted aryl; (xii) amino; (xiii) acylamino; (xiv) protected amino; (xv) hydroxy; (xvi) acyloxy; (xvii) cyclo(C3-7)alkyloxy; (xviii) aryloxy; (xix) aryl; (xx) saturated or unsaturated 5- or 6-meinbered heteromonocyclic group containing 1 to 3 nitrogen atom(s) and also optionally containing oxygen atom or sulfur atom which is optionally substituted by C1-6 alkyl, hydroxy1H _6)alkyl, aryl or oxo; or (xxi) C1-6 alkoxy optionally substituted by carboxy, protected carboxy, hydroxy, protected hydroxy, C]_6 alkoxy, cyclo(C3_7) alkyl, substituted or unsubstituted aryl, saturated or unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s)<br><br>
optionally substituted by C 1-6 alkyl, or -CONR13R14 [wherein R13 and R14 each independently represents hydrogen or C1-6 alkyl optionally substituted by aryl, or R13 and R14, toge1Her wi1H 1He nitrogen atom to which 1Hey are attached, represents saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom.],<br>
(8) aryl optionally substituted by 1He substituent(s) selected from 1He group consisting of halogen, or<br>
(9) saturated or unsaturated 5- or 6-membered heteromonocyclic group optionally substituted by C1-6 alkyl or halogen.<br>
R2isR7or-(AVX-A2-R7<br>
wherein<br>
p is Oor 1;<br>
A1 is (CrC2)alkylene or—CH=CH-;<br>
A is —(CH2)n- or -(CH=CH)m- [wherein n is integer which may range<br>
from 1 to 6 and m is integer which may range from I to 3];<br>
X is single bond, -0-, -NR8-, -C(=0)-, -C(=NR9)- or hydroxy(Cr C2) alkylene; [wherein R8 is hydrogen or O3 alkyl, and R9 is substituted or unsubstituted pyrrolyl] R7is<br>
(1)	hydrogen<br>
(2)	aryl optionally substituted by C1-6 alkoxy,<br><br>
(3)	unsaturated heteromonocyclic group containing 1 to 2 nitrogen atom(s),<br>
(4)	carboxy, esterified carboxy or -CONR10RU [wherein R10 and R1 ˚each independently represents hydrogen, Cj_6 alkylsulfonyl, unsaturated heteromonocyclic group containing 1 to 2 nitrogen atom(s) or C1-6 alkyl optionally substituted by hydroxy, alkoxy, carboxy, protected carboxy, sulfo or-R17 alternatively RI0and R11 toge1Her wi1H<br><br>
1He nitrogen atom to which 1Hey are attached, represents saturated 5- or 6-membered heteromonocyclic group containing 1 to 2 nitrogen atom(s) and also optionally containing oxygen atom such as morpholinyl],<br>
(5)	acyl or halocarbonyl,<br>
(6)	cyano,<br>
(7)amino, protected amino or mono- or di(C1-6)alkylamino, (8)hydroxy, aryloxy, acyloxy or C1-6 alkoxy optionally substituted by hydroxy or acyloxy,<br>
(9)	C1-6 alkyl1Hio, C1-6 alkylsulfinyl or C1-6 alkylsulfonyl, or<br>
(10)	-OR12, or<br><br><br>
R3 is (1) aryl substituted by at least one substituent(s) selected from 1He group consisting of(i) halogen, (ii) carboxy, (iii) protected carboxy, (iv) cyano, (v) -CONR15R16 [wherein R15 and R16 each independently represents hydrogen, C1-6 alkyl optionally substituted by hydroxy], (vi) C1-6 alkyl, (vii) cyclo(C3_7)alkyl, (viii) hydroxy(C1-6)alkyl, (ix) C1-6alkoxy, (x) trihalo(C1-6)alkyl, (xi) unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 2 nitrogen atom(s), (xii) C1-6 alkylsulfonyl, (xiii) nitro, (xiv) sulfamoyl, and (xv) protected sulfamoyl; or (2) heterocyclic group selected from 1He group consisting of pyridinyl, pyrazinyl, oxazolyl, isooxazolyl, furanyl, 1Hienyl, quinolinyl, benzofuranyl and benzo1Hienyl, wherein said heterocyclic group is optionally substituted by at least one substituent(s) selected from 1He group consisting of (i) C1-6 alkyl, (ii) cyclo(C3-7)alkyl, (iii) C1-6 alkoxy, (iv) acyl, (v) amino, (vi) mono- or di(C1-6)alkylamino, (vii) protected amino, (viii) cyano, (ix) carboxy, (x) protected carboxy, (xi) -CONR15R16 [wherein R15 and R16 each independently represents hydrogen, C1-6 alkyl optionally substituted by hydroxy], (xii) C2-6alkenyl optionally substituted by C1-6 alkoxy, (xiii) halogen, (xiv) C1-6 aikyl1Hio and (xv) hydroxyl;<br>
R4 is hydrogen, halogen, cyano, carbamoyl, acyl, 1Hiocyanate, O3 aikyl1Hio, C2-6 alkenyl, hydroxyl(C1-6 )alkyl, trihalo(C1-6)alkyl or C1-6 alkyl,<br>
R12 and R17 are each  independently a group derived from protected or<br>
unprotected  sugar  such as  galactose by removal  of 1He  hydroxy  group<br>
1Herefrom.<br>
3.       A compound as claimed in claim 2, wherein R4 is d.6 alkyl.<br><br>
4.	A compound as claimed in claim 3, wherein<br>
R1 is   (1) mono- or di(C1-6)alkylamino,<br>
(2)	phenyl,<br>
(3)	saturated or unsaturated 5 to 6 membered heteromonocyclic group selected from 1He group consisting of pyrrolidinyl, pyrrolyl, oxazolyl, isooxazoiyl, 1Hiazolyl, furanyl, 1Hienyl and pyridinyl, or<br>
(4)	C1-6 alkyl optionally substituted by (i) C1-6 alkoxy or (ii) saturated 5-or 6-membered heteromonocyclic group selected from 1He group consisting of piperazinyl and morpholinyl, wherein C1-6 alkoxy is optionally substituted by cyclo(C3-7) alkyl or pyridinyl.<br>
5.	A compound as claimed in claim 4, wherein<br>
R2 is R7 or -A2-R7, wherein<br>
A   is —(CH2)n- or —(CH=CH)m- [wherein n is integer which may<br>
range 2 to 6 and m is integer of 1 or 2, and<br>
R   is hydrogen, C1-6 alkyl sulfonyl., carboxy, esterified carboxy or<br>
pyridinyl, R3 is (1) phenyl substituted by C1-6 alkyl, cyclo(C3-7) alkyl, C1-6 alkoxy,<br>
halogen, cyano or carbamoyl; or<br>
(2) quinolinyl; or pyridinyl substituted by C1-6 alkyl, cyclo(C3-7)alkyl,<br>
C1-6 alkoxy, carbamoyl or halogen.<br>
6.	A compound as claimed in claim 5, wherein<br>
R1       is phenyl, pyrrolyl, isooxazolyl, furanyl, 1Hienyl,C1-6 alkyl optionally substituted by C1-6   alkoxy, piperazinyl or morpholinyl, wherein O3 alkoxy is optionally substituted by cyclo(C3-7)alkyl or pyridinyl, R2      is -(CH2)n-R7,wherein n is integer which may range 2 to 5, and R7 is<br>
carboxy or esterified carboxy, and R3      is (1) phenyl substituted by O3 alkyl; cyclo(C3-7)alkyl, C1-6 alkoxy, halogen, cyano or carbamoyl; or (2) pyridinyl substituted by C1-6 alkyl, cyclo(C3-7)alkyl, C1-6 alkoxy, carbamoyl or halogen.<br><br><br><br><br><br><br><br><br><br>
(TNF).<br>
12,	A pharmaceutical composition of claim 10, for prevention or treatment of diseases<br>
for which 1Herapy by a PDE-IV inhibitor or TNF produxtion inhibitor is relevant,<br>
13.	A pharmaceutical composition of cJaira 10, for prevention or treatment of as1Hma,<br>
chronic obstructive pulmonary disease (CGPD), fibrotic disease, acute and fulminant<br>
hepatitis, hepatic steatosis (alcoholic or non-alcoholic steatohepatitis), chronic (viral or<br>
non-viral) hepatitis, hepatic cinhosis, autoimmune hepatitis, autoimmune inflammatory<br>
bowel disease, atopic dermatitis, Alzheimer's diseases and viral infection.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-correspondnece-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWNvcnJlc3BvbmRuZWNlLXBvLnBkZg==" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-correspondnece-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWRlc2NyaXB0aW9uKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWZvcm0gMjYucGRm" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-form 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTUxNi1jaGVucC0yMDA1LXBjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1516-chenp-2005-pct.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="220955-a-method-to-reproduce-av-data-in-an-interactive-mode.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="220957-cable-support-system.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>220956</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1516/CHENP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>31/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>01-Aug-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>11-Jun-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>05-Jul-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ASTELLAS PHARMA INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SAWADA, KOZO</td>
											<td></td>
										</tr>
										<tr>
											<td>2</td>
											<td>IMAMURA, KENICHIRO</td>
											<td></td>
										</tr>
										<tr>
											<td>3</td>
											<td>OHNE, KAZUHIKO</td>
											<td></td>
										</tr>
										<tr>
											<td>4</td>
											<td>ABE YOSHITO</td>
											<td></td>
										</tr>
										<tr>
											<td>5</td>
											<td>OKUMURA, MITSUAKI</td>
											<td></td>
										</tr>
										<tr>
											<td>6</td>
											<td>INQUE, MAKOTO</td>
											<td></td>
										</tr>
										<tr>
											<td>7</td>
											<td>MIZUTANI, TSUYOSHI</td>
											<td></td>
										</tr>
										<tr>
											<td>8</td>
											<td>SAWADA, YUKI</td>
											<td></td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D487/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/JP2003/017091</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-12-26</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>2003903628</td>
									<td>2003-07-14</td>
								    <td>Australia</td>
								</tr>
								<tr>
									<td>2</td>
									<td>2003900189</td>
									<td>2003-01-09</td>
								    <td>Australia</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/220956-pyrrolopyridazine-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 10:10:25 GMT -->
</html>
